Document:

exv10w103

Exhibit 10.103

***Text Omitted and Filed Separately

with the Securities and Exchange Commission.

Confidential Treatment Requested

Under 17 C.F.R. Sections 200.80(b)(4)

and 240.24b-2.

RESTATED AGREEMENT

between

GEN-PROBE INCORPORATED

and

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Dated as of July 24, 2009

 

 

RESTATED AGREEMENT

     THIS RESTATED AGREEMENT (the “Agreement”), dated as of July 24, 2009 (the “Effective Date”),
is entered into between GEN-PROBE INCORPORATED, a Delaware corporation (“Gen-Probe”), having a
place of business at 10210 Genetic Center Drive, San Diego, California 92121, and NOVARTIS VACCINES
AND DIAGNOSTICS, INC., a Delaware corporation (“Novartis”), having a place of business at 4560
Horton Street, Emeryville, California 94608.

RECITALS

     WHEREAS, Gen-Probe owns or has rights in certain patent rights, other intellectual property
rights and technology regarding in vitro diagnostic assays based on or utilizing transcription
mediated amplification and regarding certain instruments to conduct such assays.

     WHEREAS, Novartis owns or has rights in certain patent rights, other intellectual property
rights and technology regarding hepatitis C virus and type 1 human immunodeficiency virus and the
detection thereof.

     WHEREAS, Gen-Probe has developed certain assays and instruments, which utilize inter alia such
Gen-Probe patent rights, other intellectual property rights and technology which Novartis wishes to
distribute and sell, for use in the blood screening field, on the terms and subject to the
conditions of this Agreement.

     WHEREAS, Novartis was formerly Chiron Corporation, and Gen-Probe and Chiron Corporation
previously entered into that certain Agreement dated June 11, 1998, relating to the development,
manufacture, marketing and distribution of products in the blood screening and clinical diagnostic
fields, as amended, supplemented, and modified by various written agreements between Gen-Probe and
Chiron Corporation or Novartis, as applicable (collectively, as so amended, supplemented, and
modified, the “1998 Agreement”). Novartis succeeded Chiron Corporation as a party to the 1998
Agreement and, accordingly, all references in the 1998 Agreement to “Chiron” shall be interpreted
to refer to Novartis.

     WHEREAS, subsequent to the execution of the 1998 Agreement, Chiron Corporation, succeeded by
Novartis, assigned its rights and obligations under the 1998 Agreement with respect to Clinical
Diagnostic Assays, Clinical Diagnostic Instruments, and the Clinical Diagnostic Field (as such
terms are defined in the 1998 Agreement) to Chiron Diagnostics Corporation, which was subsequently
acquired by Bayer Corporation. Chiron Corporation, succeeded by Novartis, retained all rights and
obligations under the 1998 Agreement with respect to Blood Screening Assays, Blood Screening
Instruments and the Blood Screening Field (as such terms are defined in the 1998 Agreement).

     WHEREAS, in connection with recent discussions between the parties and in accordance with that
certain Amendment No. 11 to the 1998 Agreement dated as of January 1, 2009, the parties now desire
to restate and clarify their agreement as of the Effective Date, solely with respect to the Blood
Screening Field (as defined in the 1998 Agreement), as provided herein.

1

 

     NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth
below, the Parties hereby agree as set forth herein:

ARTICLE 1

DEFINITIONS

     For purposes of this Agreement, the terms defined in this ARTICLE 1 shall have the respective
meanings set forth below:

     1.1 “Affiliate” shall mean, with respect to any Person, any other Person which
directly or indirectly controls, is controlled by, or is under common control with, such Person. A
Person shall be regarded as in control of another Person if it owns, or directly or indirectly
controls, more than fifty percent (50%) of the voting stock or other ownership interest of the
other Person (or such lesser percentage as is the maximum percentage permitted under applicable law
for foreign ownership where control is exercised by contract or otherwise), or if it directly or
indirectly possesses the power to direct or cause the direction of the management and policies of
the other Person by any means whatsoever.

     1.2 “Ancillary Product” means an item that is necessary for the use of Blood Screening
Assays with Blood Screening Instruments and that is sold by Gen-Probe to Novartis for resale by
Novartis for use with a Blood Screening Assay or a Blood Screening Instrument.

     1.3 “Applicable Purchase Price” shall mean, with respect to any Blood Screening Assay
on a per unit basis, the following price:

          1.3.1 With respect to each HCV Blood Screening Assay, an amount equal to the sum of:

               (a) Fifty percent (50%) of Gen-Probe’s Manufacturing Cost of such HCV Blood Screening Assay,
plus

               (b) The percentage specified below for the calendar year in which such HCV Blood Screening
Assay is sold, multiplied by the Net Sales of such HCV Blood Screening Assay for the applicable
period pursuant to Section 6.1.1.

	 	 	 	 	 
	Calendar Year	 	Applicable Percentage
	2009
	 	 	44	%
	2010
	 	 	46	%
	2011
	 	 	46	%
	2012
	 	 	47	%
	2013
	 	 	47	%
	2014
	 	 	48	%
	2015 and all subsequent years
during the Blood Screening Term
	 	 	50	%

2

 

          1.3.2 With respect to each Non-HCV Blood Screening Assay, an amount equal to the sum of:

               (a) Fifty percent (50%) of Gen-Probe’s Manufacturing Cost of such Non-HCV Blood Screening
Assay, plus

               (b) Fifty percent (50%) of Net Sales of such Non-HCV Blood Screening Assay for the applicable
period pursuant to Section 6.1.1.

          provided, however, that the percentage referred to in (b) above shall be
adjusted to reflect the value of patent rights contributed by either party covering the marker
which is the subject of any such Non-HCV Blood Screening Assay approved by the parties for
development following the Effective Date, with the amount of the adjustment determined by the
Supervisory Board pursuant to ARTICLE 4, based on the value of such patent rights and the degree of
exclusivity which is provided for the Non-HCV Blood Screening Assay; and

          provided, further, that the Supervisory Board may modify the allowable deductions from
Net Sales for Non-HCV Blood Screening Assays approved by the parties for development following the
Effective Date.

          1.3.3 Notwithstanding any other provision of this Agreement, except as agreed to otherwise in
writing by the parties, the Applicable Purchase Price for any Blood Screening Assay shall not be
less than Gen-Probe’s Manufacturing Cost for such Assay.

     1.4 “Blood Screening Assays” shall mean, collectively, all blood screening assays
developed or commercialized under this Agreement, including both HCV Blood Screening Assays and
Non-HCV Blood Screening Assays.

     1.5 “Blood Screening Field” shall mean the nucleic acid probe based testing of human
blood, plasma or other blood products intended for direct transfusion or other administration to
humans.

     1.6 “Blood Screening Instruments” shall mean the Tigris Instrument, the ESAS
Instrument, the ESAS2 Instrument, the reagent preparation incubator, and the Panther Instrument for
use in the Blood Screening Field, and any modifications and any such other instrument(s) for use in
the Blood Screening Field as are developed by Gen-Probe after the Effective Date and offered to and
accepted by Novartis (all pursuant to Section 3.1 below).

3

 

     1.7 “Blood Screening Term” shall mean the period commencing on the Effective Date and
expiring on June 30, 2025, subject to earlier termination pursuant to and in accordance with the
provisions of this Agreement.

     1.8 “CBER” shall mean the Center for Biologics Evaluation and Research.

     1.9 “Change in Control” shall mean, with respect to a party, (a) the acquisition of
such party by another entity by means of any transaction or series of related transactions
(including, without limitation, any reorganization, merger or consolidation, but excluding any
merger effected exclusively for the purpose of changing the domicile of such party); (b) the sale,
transfer or other disposition of all or substantially all of the assets of such party (including
without limitation all of its assets relating to this Agreement); or (c) the sale of all or
substantially all of the capital stock of such party; unless in each of clauses (a) through (c)
above, such party’s stockholders of record immediately prior to such acquisition or sale hold (by
virtue of the securities issued in consideration for such party’s acquisition or sale or otherwise)
greater than fifty percent (50%) of the total voting power of the surviving or acquiring entity.

     1.10 “Clinical Diagnostic Field” shall mean the nucleic acid probe based testing of
samples taken from a human patient for the purpose of detecting, identifying or quantifying, or
testing for drug susceptibility of, hepatitis virus, other viral organisms, or cancer (including
markers of early disease stages), for the purpose of research, diagnosis or medical care; provided,
however, that the Clinical Diagnostic Field shall exclude the Blood Screening Field. For purposes
of clarity and to avoid uncertainty, the Clinical Diagnostic Field shall exclude testing for
genetic predisposition to disease. For purposes of clarity and to avoid uncertainty, the Clinical
Diagnostic Field shall include the use in connection with the testing described above of standards
and controls which are not taken from a human patient.

     1.11 “Commercially Reasonable Efforts” shall mean:

          1.11.1 With respect to a party’s efforts under this Agreement to develop, manufacture (or have
manufactured), supply, promote, market, or sell a Product, that level of effort devoted by such
party to develop, manufacture (or have manufactured), supply, promote, market or sell products of
similar market size and market character, and in the absence of/without consideration of revenue
from any licensee (other than the other party) of such party’s intellectual property rights (i.e.,
the Gen-Probe IP Rights or the Novartis IP Rights, as applicable).

          1.11.2 In all other instances that level of effort which would be devoted by an independent
entity reasonably seeking to pursue its own business efforts in light of all relevant
circumstances.

     1.12 “Competitive Probe Assay” shall have the meaning given to such term in Section
8.1.1(b)(ii).

     1.13 “Component Instruments” shall mean, as of the Effective Date, the ESAS
Instruments and the reagent preparation incubator.

4

 

     1.14 “Confidential Information” shall mean, with respect to a party, all information of any
kind whatsoever (including without limitation, compilations, data, formulae, models, patent
disclosures, procedures, processes, projections, protocols, results of experimentation and testing,
specifications, strategies, and techniques), and all tangible and intangible embodiments thereof of
any kind whatsoever (including without limitation, apparatus, compositions, documents, drawings,
machinery, patent applications, records, and reports), which is (i) not generally known and (ii)
disclosed by such party to the other party pursuant to and in accordance with the terms of ARTICLE
7 of this Agreement.

     Notwithstanding the foregoing, Confidential Information of a party shall not include
information which the other party can establish by written documentation (a) to have been publicly
known prior to disclosure of such information by the disclosing party to the other party, (b) to
have become publicly known, without fault on the part of the other party, subsequent to disclosure
of such information by the disclosing party to the other party, (c) to have been received by the
other party at any time from a source, other than the disclosing party, rightfully having
possession of and the right to disclose such information, (d) to have been otherwise known by the
other party prior to disclosure of such information by the disclosing party to the other party, or
(e) to have been independently developed by employees or agents of the other party without access
to or use of such information disclosed by the disclosing party to the other party.

     1.15 “Customer” shall mean the Third Party to whom Products are sold, transferred or
otherwise conveyed by Novartis or its Affiliates.

     1.16 “Development Costs” shall mean, with respect to any Product, the fully-burdened
cost to a party of conducting the research and development (including clinical trials and
regulatory submissions) of such Product, including the cost of materials, direct labor and
overhead, all as determined in accordance with such party’s standard accounting practices for other
products researched and developed by such party pursuant to and in accordance with the applicable
Development Program (including the applicable budget).

     1.17 “Development Program” shall mean, with respect to each Blood Screening Assay or
Blood Screening Instrument developed pursuant to this Agreement, the product development program as
described in ARTICLE 3 below to develop such Blood Screening Assay or Blood Screening Instrument.

     1.18 “ESAS Instrument” shall mean the Enhanced Semi-Automated System developed by
Gen-Probe, and related software and appropriate repair parts, for DNA/RNA amplified assay
processing incorporating a separate magnetic wash station and a chemiluminescent detection system
(Leader HC) required to perform the following steps: (a) magnetic separation of the captured target
RNA/DNA, (b) washing and aspiration of the captured target RNA/DNA, and (c) chemiluminescent
detection steps needed to support Gen-Probe’s patented Hybridization Protection Assay (HPA) and TMA
Assay processes and associated reagent product lines. For purposes of this Agreement, “ESAS
Instrument” does not include Tecan automated pipetting stations such as the Genesis or EVO
instrument.

5

 

     1.19 “ESAS 2 Instrument” shall mean the instrument developed pursuant to the Modified Blood
Screening Instrument — eSAS 2 Addendum, dated January 1, 2002, under the 1998 Agreement. As of
the Effective Date, the eSAS 2 Instrument consists of the ESAS Instrument plus the front-end
pipettor (FEP) and/or the reagent addition station (RAS).

     1.20 “FDA” shall mean the United States Food and Drug Administration, or the successor
thereto.

     1.21 “First Commercial Sale” shall mean, with respect to any Product, the first sale
of such Product in the United States, for use by a Third Party, after FDA license approval or
clearance of such Product (and without considering product transfers made pursuant to an
Investigational New Drug application).

     1.22 “Forecast” shall mean the twelve-month rolling forecast of Novartis’s estimated
purchase requirements of Blood Screening Assays or the fifteen-month rolling forecast of Novartis’s
estimated purchase requirements of Blood Screening Instruments, as applicable, over the period
covered by the forecast, as set forth in Sections 5.3.1 and 5.4.1 of the Agreement, respectively
set forth on a product-by-product basis.

     1.23 “Gen-Probe Copyrights” shall mean all rights under the copyright laws of any
jurisdiction in the world, together with all rights commonly referred to as “moral rights,” in and
to the Blood Screening Instruments in which Gen-Probe has an ownership or other licensable interest
during the Blood Screening Term; all to the extent and only to the extent that Gen-Probe has the
right to grant licenses, immunities or other rights thereunder.

     1.24 “Gen-Probe IP Rights” shall mean, collectively, the Gen-Probe Copyrights,
Gen-Probe Know-How and Gen-Probe Patent Rights.

     1.25 “Gen-Probe Know-How” shall mean all information of any type whatsoever (including
without limitation, formulae, procedures, protocols, techniques, data and results of
experimentation and testing), which is Confidential Information of Gen-Probe and which (i) relates
to the Gen-Probe Patent Rights and which is necessary to exploit the Gen-Probe Patent Rights for
use in the Blood Screening Field or (ii) is disclosed by Gen-Probe pursuant to ARTICLE 7, all to
the extent and only to the extent that Gen-Probe has the right to grant licenses, immunities or
other rights thereunder.

     1.26 “Gen-Probe Marks” shall mean those trademarks owned by or licensed to Gen-Probe
(other than pursuant to this Agreement) which are used to market any Product in accordance with the
provisions of this Agreement.

     1.27 “Gen-Probe Patent Rights” shall mean (a) all the patents and patent applications
which cover nucleic acid probe assays and instrument technologies, to the extent necessary for use
in the Blood Screening Assays or Blood Screening Instruments, but only to the extent in each case
(i) of the design of the Products as of the Effective Date and (ii) that Gen-Probe has an ownership
or other licensable interest therein; (b) such other Gen-Probe patent rights which claim markers or
their uses as may become subject to this Agreement pursuant to the terms hereof with respect to
Blood Screening Assays developed hereunder, (c) all other patents and patent applications which
cover nucleic acid probe assays and instrument technologies, to the

6

 

extent necessary for use in the Blood Screening Assays or Blood Screening Instruments but only
to the extent in each case of the design of the Products as of the Effective Date and any future
modifications to any such designs and/or any new Products approved for development by Gen-Probe
after the Effective Date (subject to Section 6.2); (d) such Gen-Probe patent rights with respect to
any future modifications to any Blood Screening Instrument as become subject to this Agreement
pursuant to Section 3.1, and such Gen-Probe patent rights with respect to any future Blood
Screening Instrument as are developed by Gen-Probe after the Effective Date and offered to and
accepted by Novartis (all pursuant to Section 3.1); or (e) such other Gen-Probe patent rights which
become subject to this Agreement pursuant to ARTICLE 8; (f) all patents that have issued or in the
future issue from any of the foregoing, including without limitation utility, model and design
patents and certificates of invention; and (g) all divisional, continuations,
continuations-in-part, reissues, renewals, extensions or additions to any of the foregoing patent
applications and patents; but in each case only to the extent that Gen-Probe has or hereafter
acquires an ownership or other licensable interest as of the date (1) Gen-Probe approves a Product
for development or (2) a modification to an existing Product is made, considered on a
product-by-product basis, and all to the extent and only to the extent that Gen-Probe has the right
to grant licenses, immunities or other rights thereunder.

     1.28 “HCV Blood Screening Assays” shall mean those Blood Screening Assays which
include as a constituent element an assay for HCV, including, as of the Effective Date, the
original duplex Blood Screening Assay for HIV-1 and HCV, the Ultrio Assay Product, and the Ultrio
Plus Assay Product (subject to the terms of the Future Blood Screening Assay — Ultrio 2 Addendum,
dated October 1, 2008, under the 1998 Agreement).

     1.29 “HCV” shall mean hepatitis C virus.

     1.30 “HIV-1” shall mean type 1 human immunodeficiency virus.

     1.31 [Intentionally left blank.]

     1.32 “Manufacturing Cost” shall mean, with respect to any Product, the fully-burdened
cost to a party (expressed on a per unit basis) of manufacturing or having manufactured such
Product, together with the packaging thereof, including the cost of materials, direct labor,
quality control, warranty parts and labor (only as to Blood Screening Instruments manufactured by
Gen-Probe), and overhead (but excluding royalties paid or payable to Third Parties), all as
determined in accordance with such party’s standard accounting practices for other products
manufactured. For the avoidance of doubt, Manufacturing Cost shall include the cost of dry ice for
frozen or refrigerated products. An estimate of Manufacturing Cost for each Product shall be
established by the manufacturing party and provided to the other party on an annual basis. Within
seventy-five (75) days of the close of each calendar year the manufacturing party will provide the
other party with a detailed report of the aggregate of all actual Manufacturing Costs incurred for
Products, on a product-by-product basis. In the event the aggregate of all actual Manufacturing
Costs for a Product manufactured in the calendar year exceeds, or is less than, the estimate set
and used to determine the Applicable Purchase Price paid for such Products sold during such
calendar year, the parties will “true up” the aggregate Applicable Purchase Price paid for such
Products accordingly.

7

 

     1.33 “Net Sales” shall mean with respect to any Product(s), except as otherwise provided in
this Section 1.33, on a per unit basis where applicable and in the aggregate where applicable, the
gross sales price of such Product(s) invoiced by any of (i) Novartis, (ii) Novartis’s Affiliates,
(iii) Gen-Probe, or (iv) or any distributor for Novartis in Japan, Germany, Italy, France, or the
United Kingdom (all of which are individually referred to hereafter in this Section 1.33 as
“Seller”), following shipment to unaffiliated Third Parties less, to the extent actually paid or
accrued by such Seller: (a) discounts, rebates or chargebacks actually allowed and taken, to the
extent consistent with industry practices and price reductions given for similar products by such
Seller; and/or (b) amounts repaid or credited by reason of rejection, spoilage, expiration or
return; and/or (c) to the extent separately stated on purchase orders, invoices or other documents
of sale, taxes levied on and/or other governmental charges made as to production, or transportation
or insurance charges; and/or (d) charges for freight, handling and transportation; and/or (f)
sales, use and value-added taxes and other similar taxes incurred and separately stated on
invoices; and/or (g) customs duties, surcharges and other governmental charges incurred in
exporting or importing such Product. Transfer to any unaffiliated Third Party of a Blood Screening
Instrument qualifying for sale treatment under generally accepted accounting principles (GAAP) will
be deemed to be a “sale” for purposes of this Agreement, including without limitation the
calculation of “Net Sales” under this Section 1.33 and the compensation due Gen-Probe on account of
sales under Section 6.1.2 (including Sections 6.1.2(b) and 6.1.2(c)). With respect to sales of
Blood Screening Assays, the “per unit” basis of calculating Net Sales may be either a “per test” or
“per donation” basis, in the same manner as which Novartis derives revenues from the sale of such
assays.

          1.33.1 In the event that a Product is sold in combination with another product other than as
addressed in Section 6.1.2(d), (a “Combination Product”) for a single price in a particular period,
Net Sales from sales of a Combination Product for that period, for purposes of this Agreement,
shall be calculated by multiplying the Net Sales of that Combination Product for that period by the
fraction A/(A+B), where A is the average per unit Net Sales of the Product sold separately in the
country of sale in that period and B is the average per unit Net Sales of the other product(s) sold
separately in the country of sale in that period. This calculation shall be made for each Product
comprising the Combination Product and the results added. In the event that no such separate sales
are made in the applicable period, Net Sales of such Combination Product shall be determined based
on a reasonable apportionment of the gross amount invoiced therefor based upon the relative
contribution of the Product to the price of the Combination Product. Such apportionment shall be
negotiated in good faith between the parties and resolved pursuant to ARTICLE 11 if they are unable
to agree.

          1.33.2 For purposes of calculating Net Sales, the Seller may, at its option, determine the
allowable deductions from gross sales based on accruals estimated reasonably and consistently with
such party’s standard accounting practices, which shall be notified to the other party on an annual
basis. If such accruals are used, within seventy-five (75) days of the close of each calendar year
the Seller will provide the other party with a reasonably detailed report of all actual deductible
expenses incurred. In the event the aggregate of all actual deductible expenses for sales in the
calendar year exceeds, or is less than, the estimate set and used to determine Net Sales during
such calendar year, the parties will “true up” Net Sales accordingly.

8

 

     1.34 “Non-HCV Blood Screening Assays” shall mean those Blood Screening Assays which do not
include as a constituent element an assay for HCV, including as of the Effective Date the WNV Assay
Product.

     1.35 “Novartis Copyrights” shall mean all rights under the copyright laws of any
jurisdiction in the world, together with all rights commonly referred to as “moral rights,” in and
to the Blood Screening Assays or Blood Screening Instruments in which Novartis has an ownership or
other licensable interest during the Blood Screening Term; all to the extent and only to the extent
that Novartis has the right to grant licenses, immunities or other rights thereunder.

     1.36 “Novartis Know-How” shall mean all information of any type whatsoever (including
without limitation, formulae, procedures, protocols, techniques, data and results of
experimentation and testing), which is Confidential Information of Novartis and which (i) relates
to the Novartis Patent Rights and which is necessary to exploit the Novartis Patent Rights for use
in the Blood Screening Field or (ii) is disclosed by Novartis pursuant to ARTICLE 7, all to the
extent and only to the extent that Novartis has the right to grant licenses, immunities or other
rights thereunder.

     1.37 “Novartis Marks” shall mean those trademarks owned by or licensed to Novartis
(other than pursuant to this Agreement) which are used to market any Product in accordance with the
provisions of this Agreement.

     1.38 “Novartis Patent Rights” shall mean (a) all United States and foreign patent
applications covering (i) the composition of matter of HCV or HIV-1, or, in each case of the
foregoing, any nucleotide sequence thereof or (ii) the use thereof in the Blood Screening Field;
(b) such other Novartis patent rights which claim markers or their uses as may become subject to
this Agreement pursuant to the terms hereof with respect to Blood Screening Assays developed
hereunder and sold by Novartis or pursuant to ARTICLE 8; (c) all other patents and patent
applications which cover nucleic acid probe assays and instrument technologies, to the extent
necessary for use in the Blood Screening Assays or Blood Screening Instruments but only to the
extent in each case of the design of the Products as of the Effective Date and any future
modifications to any such designs and/or any new Products approved for development by Novartis
after the Effective Date (subject to Section 6.2); (d) all patents that have issued or in the
future issue from any of the foregoing, including without limitation utility, model and design
patents and certificates of invention; and (e) all divisional, continuations,
continuations-in-part; reissues, renewals, extensions or additions to any of the foregoing patent
applications and patents; but in each case only to the extent Novartis has an ownership or other
licensable interest as of the date (1) Novartis approves a Product for development or (2) a
modification to an existing Product is made, considered on a product-by product basis, and all to
the extent and only to the extent that Novartis has or hereafter acquires the right to grant
licenses, immunities or other rights thereunder.

     1.39 “Novartis IP Rights” shall mean, collectively, the Novartis Copyrights, Novartis
Know-How and Novartis Patent Rights.

9

 

     1.40 “Panther Instrument” shall mean an integrated, fully-automated low to mid volume
molecular diagnostic instrument system to be developed by Gen-Probe in accordance with Attachment B
to Amendment No. 11 and pursuant to a new product development addendum to be negotiated in good
faith and to conclusion by the parties immediately following the Effective Date. The parties
intend that the Panther Instrument will be designed to be able to process the Blood Screening
Assays, with an anticipated throughput of [...***...] tests in [...***...] hours; continuous access
to samples and reagents; and an estimated transfer price from the manufacturer of approximately
$[...***...].

     1.41 “Person” shall mean an individual, corporation, partnership, limited liability
company, trust, business trust, association, joint stock company, joint venture, pool, syndicate,
sole proprietorship, unincorporated organization, governmental authority or any other form of
entity not specifically listed herein.

     1.42 “Product” shall mean a Blood Screening Assay or Blood Screening Instrument.

     1.43 “Purchase Order” shall mean the binding purchase order of Blood Screening Assays
or Blood Screening Instruments delivered in accordance with the provisions of Section 5.3.3 or
Section 5.4.2 of the Agreement, respectively.

     1.44 “Registration Trial” means the clinical trial activity required by a governmental
regulatory authority to be completed as a prerequisite to the sale of a Product within the
regulatory authority’s jurisdiction. Clinical trial activity intended solely to foster customer
acceptance (i.e., a “market trial”), rather than intended to generate approval by a regulatory
authority, shall not be considered a Registration Trial.

     1.45 “Roche Promoter-Primer Patent Claims” means claims contained in EP 505012 or in
any F. Hoffman-La Roche, Ltd. and Roche Molecular Systems, Inc. (collectively “Roche”) patent drawn
to compositions or methods claimed therein having a priority date on or before the Effective Date
(as such term is defined in the HCV Probe License Agreement and HIV Probe License Agreement by and
among Chiron, F. Hoffman-La Roche, Ltd. and Roche Molecular Systems, Inc. and dated October 10,
2000) or in any Roche patent issued or application that claims priority, at least in part, from
USSN 716,975 filed March 3, 1985 or USSN 791,308 filed October 25, 1985 or USSN 818,127 filed
January 10, 1986 or USSN 935,587 filed November 26, 1986, including without limitation US Patent
5,176,995 or foreign counterparts thereof, but excluding the Roche Optioned Patents (as such term
is defined in the HCV Probe License Agreement and HIV Probe License Agreement by and among Chiron,
F. Hoffman-La Roche, Ltd. and Roche Molecular Systems, Inc. and dated October 10, 2000).

     1.46 “Spare Part” means any field replaceable part required to ensure that a Blood
Screening Instrument performs as intended.

     1.47 “Supervisory Board” shall mean the committees comprising representatives of
Gen-Probe and Novartis as described in Section 4.1 below.

     1.48 “Territory” shall mean the entire world.

***Confidential Treatment Requested

10

 

     1.49 “Third Party” shall mean any Person other than Gen-Probe, Novartis and their
respective Affiliates.

     1.50 “Tigris Instrument” shall mean the integrated, automated instrument, and related
software and appropriate repair parts, for DNA/RNA amplified assay processing incorporating all
systems required to perform the following steps: (a) lysis/annealing, (b) enzymatic amplification,
(c) hybridization/selection, and (d) detection/decontamination, which utilize processing steps that
include heating/cooling, reagent addition, mixing, chemiluminescent detection and aspiration needed
to support Gen-Probe’s patented Hybridization Protection Assay (HPA) and TMA Assay processes and
associated reagent product lines.

     1.51 “TMA Assay” shall mean an in vitro diagnostic assay based on or utilizing
transcription-based nucleic acid amplification, but excluding the “Teknika Version” of
transcription-based amplification (as that term is defined in Schedule 1.51).

     1.52 “Transfer Price” shall mean, with respect to any Product, on a per unit basis,
the following price:

          1.52.1 For each Blood Screening Assay sold as of the Effective Date, the transfer price
previously approved by the Supervisory Board. For each Blood Screening Assay approved for
development following the Effective Date, the transfer price shall be established by the new
product development addendum for such assay and is expected to range between [...***...] of the
Applicable Purchase Price. The Transfer Price for each Blood Screening Assay shall be reviewed by
the Supervisory Board on an annual basis and shall be reasonably adjusted to reflect material
changes in Manufacturing Costs.

          1.52.2 The Transfer Price for each Tigris Instrument shall be equal to the amount actually
invoiced to Gen-Probe by its manufacturer.

          1.52.3 The Transfer Price for each ESAS Instrument shall be an amount equal to the lesser of
(a) [...***...], reasonably adjusted for inflation from June 11, 1998, and (b) [...***...] of the
Manufacturing Cost of such Blood Screening Instrument. Should CBER mandate modifications to any
Blood Screening Instrument which results in extraordinary increases in the cost of the Blood
Screening Instrument, the parties shall negotiate in good faith with respect to adjusting the
amounts set forth herein.

          1.52.4 The Transfer Price for each reagent preparation incubator shall be an amount equal to
[...***...] of the Manufacturing Cost of such Blood Screening Instrument.

          1.52.5 The Transfer Price for any Blood Screening Instrument, other than the Tigris
Instrument, the ESAS Instrument, and the reagent preparation incubator shall be negotiated between
the parties concurrently with the negotiation of any development program for such other Blood
Screening Instrument pursuant to Section 3.1.3 (Development Program) or as part of the offer
described in Section 3.2.4 (Other Blood Screening Instruments).

***Confidential Treatment Requested

          
11

 

          1.52.6 The Transfer Price for Spare Parts and Ancillary Parts delivered to Novartis by
Gen-Probe shall be equal to (i) [...***...] of the amount actually invoiced to Gen-Probe by a Third
Party manufacturer or (ii) Gen-Probe’s Manufacturing Cost, as applicable.

          1.52.7 Gen-Probe shall promptly notify Novartis upon Gen-Probe’s receipt of notice of a
proposed or actual increase in the price of any Spare Part or Ancillary Product supplied by a Third
Party and use reasonable commercial efforts to extend to Novartis, if made available by the
manufacturer, the benefit of any opportunity to acquire additional quantities of impacted Spare
Parts or Ancillary Products prior to the noticed date of the increase. In no event shall Gen-Probe
ship to Novartis any Spare Part or Ancillary Product for which there has been a price increase
without first notifying Novartis of the price increase.

     1.53 “Ultrio Assay Product” shall mean the assay developed pursuant to the Future
Blood Screening Assay  — Ultrio Addendum, dated January 1, 2001, under the 1998 Agreement.

     1.54 “Ultrio Plus Assay Product” shall mean the assay under development pursuant to
the Future Blood Screening Assay — Ultrio 2 Addendum, dated October 1, 2008, under the 1998
Agreement.

     1.55 “Valid Claim” shall mean (a) a claim of an issued patent that has not been held
unenforceable or invalid by an agency or a court of competent jurisdiction in any final judgment as
to which the owner or rights holder has no further right of appeal and, in addition (b) a claim of
a patent application which is being prosecuted or pursued in good faith for the United States and
which meets the requirements for patentability under applicable law and that has not been abandoned
or finally rejected without the possibility of appeal or refiling. Either party may contest
whether a claim in a pending patent application for the United States meets the requirements for
patentability under applicable law. Such contest shall be made pursuant to the procedures
established by ARTICLE 11 except that (i) in lieu of submitting the issue to a single arbitrator,
the issue shall be submitted to a panel of three patent attorneys with experience in the subject
matter for binding determination and (ii) there shall be no appeal from the decision of the
majority of such panel. The burden of proof before the arbitrators shall be a preponderance of the
evidence.

     1.56 “WNV Assay Product” shall mean the assay developed pursuant to the Future Blood
Screening Assay  — West Nile Virus Addendum, dated June 1, 2003, under the 1998 Agreement.

ARTICLE 2

REPRESENTATIONS AND WARRANTIES

     2.1 By Each Party. Each party hereby represents and warrants to the other party as of
the date of the execution of this Agreement (except as specifically otherwise indicated below) as
follows:

***Confidential Treatment Requested

12

 

          2.1.1 Corporate Existence and Power. Such party (a) is a corporation duly organized,
validly existing and in good standing under the laws of the state in which it is incorporated; (b)
has the corporate power and authority and the legal right to own and operate its property and
assets, to lease the property and assets it operates under lease, and to carry on its business as
it is now being conducted; and (c) is in compliance with all requirements of applicable law, except
to the extent that any noncompliance would not have a material adverse effect on the properties,
business, financial or other condition of such party and would not materially adversely affect such
party’s ability to perform its obligations under this Agreement.

          2.1.2 Authorization and Enforcement of Obligations. Such party (a) has the corporate
power and authority and the legal right to enter into this Agreement and to perform its obligations
hereunder, and (b) has taken all necessary corporate action on its part to authorize the execution
and delivery of this Agreement and the performance of its obligations hereunder. This Agreement
has been duly executed and delivered on behalf of such party, and constitutes a legal, valid,
binding obligation, enforceable against such party in accordance with its terms.

          2.1.3 Consents. All necessary consents, approvals and authorizations of all
governmental authorities and other Persons required to be obtained by such party in connection with
this Agreement have been obtained on or before the Effective Date.

          2.1.4 No Conflict. The execution and delivery of this Agreement and the performance
of such party’s obligations hereunder (a) do not conflict with or violate any requirement of
applicable laws or regulations, and (b) do not conflict with, or constitute a default under, any
contractual obligation of such party.

     2.2 DISCLAIMER OF WARRANTIES. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A
REPRESENTATION MADE, OR WARRANTY GIVEN, BY EITHER PARTY THAT ANY PATENT WILL ISSUE BASED UPON ANY
PENDING PATENT APPLICATION WITHIN THE GEN-PROBE PATENT RIGHTS OR NOVARTIS PATENT RIGHTS, THAT ANY
PATENT WITHIN THE GEN-PROBE PATENT RIGHTS OR NOVARTIS PATENT RIGHTS WHICH ISSUES WILL BE VALID, OR
THAT THE USE OF ANY LICENSE GRANTED HEREUNDER OR THAT THE USE OF ANY GEN-PROBE PATENT RIGHTS OR
NOVARTIS PATENT RIGHTS WILL NOT INFRINGE THE PATENT OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY
OTHER PERSON. FURTHERMORE (EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN SECTION 5.7 BELOW), NEITHER
PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE GEN-PROBE
PATENT RIGHTS OR NOVARTIS PATENT RIGHTS OR THE PRODUCTS, INCLUDING WITHOUT LIMITATION, ANY WARRANTY
OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT.

13

 

ARTICLE 3

BLOOD SCREENING PRODUCTS

     3.1 Blood Screening Assays; Blood Screening Instruments.

          3.1.1 Current Products. Prior to the Effective Date, the parties have developed
Products for use in the Blood Screening Field, including Blood Screening Assays and Blood Screening
Instruments. The Blood Screening Assays developed prior to the Effective Date are: the duplex
Blood Screening Assay for HIV-1 and HCV; the Ultrio Assay Product, the Ultrio Plus Assay Product,
and the WNV Assay Product. The Blood Screening Instruments developed prior to the Effective Date
are: the ESAS Instrument, the ESAS2 Instrument, and the Tigris Instrument.

          3.1.2 New Product Development.

               (a) From time to time during the Blood Screening Term, the Supervisory Board may discuss the
selection and establishment of development programs for one or more new Products, including without
limitation the development of modifications to the then-existing Products (which modifications
shall in and of themselves be considered Products). The rights granted by each party to the other
with respect to any of the Products during the Blood Screening Term shall extend to and include any
and all modifications to such Product as are developed during the Blood Screening Term to improve
the sample processing, amplification, detection, analysis, or reliability of such Product which
utilize the same base technologies and which do not change the fundamental character of such
Product, to the extent that Gen-Probe is not prohibited as of the Effective Date from granting such
rights. From time to time during the Blood Screening Term, the Supervisory Board shall consider
potential modifications to the Products.

               (b) If both parties wish to develop a Product, the Supervisory Board shall discuss in good
faith and propose a mutually acceptable written Development Program and a budget for such
development (both of which shall be updated at least annually) for such Product which shall set
forth (i) the specifications for such Product, and (ii) the parties’ respective obligations to
develop such Product and to conduct such clinical trials and apply for such regulatory approvals as
necessary or appropriate to make and sell the Products in the Territory for use in the Blood
Screening Field. If a Blood Screening Assay or Blood Screening Instrument is selected for
development by both parties in accordance with this Section, then the parties shall develop such
Blood Screening Assay or Blood Screening Instrument as set forth in Section 3.1.3.

               (c) If one party wishes to develop the Product and the other party does not, the party wishing
to conduct such development shall have the right to proceed at its sole expense, in accordance with
a Development Program, including a budget, to be updated annually, approved by the Supervisory
Board (which approval shall not be unreasonably withheld or delayed), provided that such developing
party may elect to cease such development at any time in its discretion. The other party shall
have no obligation to fund any of the Development Costs of conducting the Development Program for
such Product. In any event,

14

 

subject to all terms of this Agreement, Novartis shall have the exclusive right and obligation
to market and sell all Products for use in the Blood Screening Field pursuant to Section 3.1.9.

          3.1.3 Development Programs.

               (a) Establishment. For each Product selected for development by both parties in
accordance with Section 3.1.2, the parties shall prepare and agree upon a final written Development
Program and budget for each Product, which shall set forth (i) the specifications for such Product,
(ii) a proposed schedule for the Development Program, and (iii) the parties’ respective obligations
to develop such Product and to conduct such clinical trials and apply for such regulatory approvals
as necessary or appropriate to make and sell in the Territory such Product for use in the Blood
Screening Field. The Development Program as agreed by the parties for each Product may not be
modified except by the action of the Supervisory Board.

               (b) Responsibilities. Each party shall develop each Product in accordance with its
respective responsibilities as set forth in and assigned by the applicable Development Program
documents. In accordance with Section 3.1.6, the parties shall conduct such clinical trials and
apply for and endeavor to obtain such regulatory approvals as necessary or appropriate to make and
sell each Product in the Territory for use in the Blood Screening Field. Each party shall consult
with the other party on such matters and each party shall reasonably consider the other party’s
advice and recommendations on all matters relating to such Development Program.

               (c) Conduct of Development. Each party shall conduct its respective obligations under
the Development Program for each Product in compliance in all material respects with all
requirements of applicable laws and regulations and all applicable good laboratory, clinical and
manufacturing practices. Gen-Probe and Novartis each shall proceed diligently with their
respective obligations under each such Development Program and shall use their respective
Commercially Reasonable Efforts to achieve its objectives efficiently and expeditiously. Gen-Probe
and Novartis each shall allocate sufficient personnel, equipment, facilities and other resources to
each such Development Program to carry out their respective obligations and to accomplish the
objectives thereof.

               (d) Subcontracts. Upon approval of the Supervisory Board which shall not be
unreasonably withheld by either party (and except as to such subcontracts which exist as of the
Effective Date), Gen-Probe and Novartis each may subcontract portions of the Development Program
for each Product to be performed by it in the normal course of its business; provided, however,
that (i) unless the other party gives its prior written consent, such subcontracting shall not
involve the transfer (including but not limited to any sublicense) of any intellectual property
rights of the other party or Confidential Information of the other party to Third Parties; (ii) if
the other party consents to the subcontractor’s access to Confidential Information of the other
party, the subcontracted party shall enter into a confidentiality agreement with the subcontracting
party incorporating the terms of ARTICLE 7 below; (iii) the subcontracting party shall supervise
such subcontract work; (iv) the subcontracted party shall be in compliance in all material respects
with all requirements of applicable laws and regulations, together with all applicable good
laboratory, clinical and manufacturing practices; (v) prior to subcontracting any portion of the
Development Program to a Third Party, each party will offer

15

 

the other party the opportunity to perform such portion on terms which, taken as a whole, are
equal to or better than those which could be obtained from a Third Party; and (vi) if required by
the Supervisory Board, the subcontracted party shall enter into an agreement with the
subcontracting party to effectuate the provisions of ARTICLE 8 below, and which shall include a
provision for assignment of inventions arising from the subcontracted work.

          3.1.4 Funding.

               (a) Subject to Section 3.1.4(b) below, unless the parties agree in writing otherwise,
Gen-Probe and Novartis each shall pay one-half (1/2) of the aggregate Development Costs of conducting
the Development Program for each Product which they mutually agree to develop. Within thirty (30)
days after the end of each calendar quarter, each party shall report to the other all Development
Costs incurred by such party (if any) during such calendar quarter in conducting the Development
Program for each Product. Within thirty (30) days after receiving such reports, the parties shall
make such payments to each other as are necessary to cause each party to have paid its appropriate
share under this Section of the aggregate budgeted Development Costs incurred with respect to the
Development Program for such Product during such calendar quarter.

               (b) In the case of a Product which is funded by one party pursuant to Section 3.1.2(c), such
party shall be solely responsible for all Development Costs of such Product.

               (i) If the funding party is Gen-Probe, Novartis shall pay an additional royalty to
Gen-Probe equal to a percentage, established by the Supervisory Board at the time of
approval of the Development Program, of Net Sales of such Product, until the aggregate
royalty paid to Gen-Probe solely under this sentence effectively reimburses Gen-Probe for
disproportionate budgeted Development Costs incurred by Gen-Probe with respect to the
Development Program for such Product.

               (ii) If the funding party is Novartis, Novartis shall be entitled to offset against
amounts owing to Gen-Probe solely with respect to such Product an amount equal to a
percentage, established by the Supervisory Board at the time of approval of the Development
Program, of Net Sales of such Product, until the aggregate offset taken solely under this
sentence effectively reimburses Novartis for disproportionate budgeted Development Costs
incurred by Novartis with respect to the Development Program for such Product. Novartis
shall report the amount of any such offsets in each report pursuant to Section 6.4.

               (iii) The additional royalty or offset established by the Supervisory Board shall be
intended to enable the funding party to recover such Development Costs for such Development
Program within the longer of (i) three (3) years or (ii) a period equal to the duration of
such Development Program. The additional royalty or offset shall be set based on the
information available to the Supervisory Board at the time of its initial approval of the
Development Program and shall not be adjusted thereafter except at the sole discretion of
the Supervisory Board.

16

 

          3.1.5 Records and Reports for Development Programs.

               (a) Records. Gen-Probe and Novartis each shall maintain records, in sufficient detail
appropriate for regulatory or patent purposes, which shall be complete and accurate and shall fully
and properly reflect all work done and results achieved in the performance of the Development
Programs for Blood Screening Assays and Blood Screening Instruments (including all data in the form
required under all applicable laws and regulations).

               (b) Inspection of Records. Gen-Probe and Novartis each shall have the right, during
normal business hours and upon reasonable notice, to inspect the records of the other party
relating to the Development Programs for any Blood Screening Assay and Blood Screening Instrument,
to the extent reasonably required for the performance of the Development Program. The parties
shall develop reasonable procedures for requesting and delivering copies of such records to each
other as may be necessary for the performance of the Development Programs for Blood Screening
Assays and Blood Screening Instruments. Each party shall maintain such records and the information
of the other party contained therein in confidence incorporating the terms of ARTICLE 7 below and
shall not use such records or information except to the extent otherwise permitted by this
Agreement.

               (c) Development Reports and Information. Gen-Probe and Novartis each shall keep the
other informed of the progress of such party under the Development Programs for Blood Screening
Assays and Blood Screening Instruments.

          3.1.6 Regulatory Matters.

               (a) Gen-Probe and Novartis will share equal responsibility for clinical trials for all
Products. Disagreements on clinical trial issues shall be resolved by the Supervisory Board, and
if necessary through the dispute resolution procedures set forth in ARTICLE 11.

               (b) Gen-Probe and Novartis will share equal responsibility for regulatory and licensure
strategy and management of regulatory submissions for all Products, subject to all terms of this
paragraph. Gen-Probe shall be the licensed party for all Products manufactured by Gen-Probe and
shall maintain its status as the primary point of contact with the FDA. Schedule 3.1.6 sets forth
a list of licensed manufacturers for each Product as of the Effective Date. Except as set forth
herein or in the Quality Agreement dated May 28, 2009, Novartis shall remain the primary point of
contact with all regulatory and licensing authorities outside the United States for submission and
registration of Products. Each party shall use its best efforts to execute its regulatory and
licensure responsibilities with appropriate timing and urgency pursuant to the approved Development
Program. Disagreements on regulatory and licensing issues shall be resolved by the Supervisory
Board, and if necessary through the dispute resolution procedures set forth in ARTICLE 11,
excluding arbitration. For regulatory and licensing disputes that cannot be otherwise resolved,
Gen-Probe’s CEO shall have the right to make the final decision.

17

 

          3.1.7 Initiation of “Companion Diagnostic” Program. The parties will work together,
on a non-exclusive basis, to research and develop molecular diagnostic assays that could be used to
help identify patients who are likely to particularly benefit from medicines that Novartis or any
of its Affiliates is developing or marketing. To develop these potential “companion diagnostic”
tests, Novartis may contribute biomarkers discovered through its research efforts, and Gen-Probe
will provide its molecular diagnostics technologies and assay development expertise. Novartis will
also provide at least [...***...] in aggregate research funding to Gen-Probe in 2009 and 2010 in
support of initial research and development. The parties will establish development agreements on
a case-by-case basis, with the parties expecting to share revenues associated with any companion
diagnostic tests that are successfully commercialized.

          3.1.8 Manufacturing.

               (a) Subject to Section 3.1.8(b) below, Gen-Probe shall have the exclusive right and the
obligation to manufacture (or to have manufactured) and supply Novartis with its requirements of
the Blood Screening Assays and Blood Screening Instruments in the Territory for use in the Blood
Screening Field in accordance with ARTICLE 5 below.

               (b) Step-In Manufacturing Rights.

               (i) Assays. If Gen-Probe (i) fails at any time during the Blood Screening Term
to maintain the applicable FDA (CBER) license for the facility used to manufacture a Blood
Screening Assay (unless Gen-Probe is approved by CBER to manufacture from an alternative
location or the Supervisory Board agrees within fifteen (15) days of such event that
Gen-Probe shall retain the manufacturing responsibility hereunder); or (ii) fails to supply
Novartis within forty-five (45) days after the requested delivery date with Novartis’s
monthly requirements for a Blood Screening Assay ordered in accordance with Section 5.3
below, for any three (3) months in any nine-month period (unless the Supervisory Board
agrees within fifteen (15) days of such event that Gen-Probe shall retain the manufacturing
responsibility hereunder), then Novartis shall have the right to, and if Novartis elects to
manufacture or have manufactured, the obligation to use Commercially Reasonable Efforts to,
manufacture (or to have manufactured) its requirements of such Blood Screening Assay, to be
conducted by the Blood Screening Instruments in the Territory for use in the Blood Screening
Field; provided, however, such right of Novartis shall be on an assay-by-assay basis for a
failure to supply. In such event, Novartis shall consider in good faith, as its preferred
alternative upon Gen-Probe’s request, to take over control of and responsibility for the
facility used by Gen-Probe to manufacture the Blood Screening Assays, and Gen-Probe promptly
shall provide such reasonable technical assistance, at Gen-Probe’s sole cost, as necessary
to enable Novartis to exercise its rights to manufacture (or have manufactured) such Blood
Screening Assay.

               (ii) Instruments. If Gen-Probe fails to supply Novartis within forty-five (45)
days after the requested delivery date with Novartis’s monthly requirements for a Blood Screening Instrument ordered in accordance with Section 5.4 below,
for any three (3) months in any nine-month period (unless the Supervisory Board agrees
within fifteen (15) days of such event that Gen-Probe shall retain the manufacturing

***Confidential Treatment Requested

18

 

responsibility hereunder), then Novartis shall have the right to, and if Novartis elects to
manufacture or have manufactured, the obligation to use Commercially Reasonable Efforts to,
manufacture (or to have manufactured) its requirements of such Blood Screening Instrument in
the Territory for use in the Blood Screening Field. In such event, Gen-Probe promptly shall
provide such reasonable technical assistance, at Gen-Probe’s sole cost, as necessary to
enable Novartis to exercise its rights to manufacture (or have manufactured) such Blood
Screening Instrument for use in the Blood Screening Field and Gen-Probe shall provide to
Novartis, directly or indirectly, to the greatest possible extent, all remedies available to
Gen-Probe against any Blood Screening Instrument manufacturer which has failed to supply
Gen-Probe in accordance with the applicable manufacturing contract.

               (c) If Gen-Probe desires to subcontract with any Third Party (except as to such subcontracts
which exist as of the Effective Date) to manufacture any of the Blood Screening Instruments,
Gen-Probe shall grant to Novartis the first right of negotiation for the right to manufacture such
Blood Screening Instrument, provided that Novartis is able to do so on commercially reasonable and
competitive terms and conditions, before Gen-Probe may offer such opportunity to any Third Party.
Any such subcontracts for the manufacture of any of the Blood Screening Instruments (in whole), or
any of the major functional components or disposables thereof, shall be subject to the approval of
the Supervisory Board which shall not be unreasonably withheld by either party.

               (d) If either party exercises any right granted hereunder to have any Blood Screening Assay or
Blood Screening Instrument manufactured, then (i) such party shall first require that the
subcontracted party shall enter into a confidentiality agreement with such party incorporating the
terms of ARTICLE 7 below; (ii) such party shall supervise such subcontract work; (iii) the
subcontracted party shall comply in all material respects with all requirements of applicable laws
and regulations, together with all applicable good laboratory, clinical and manufacturing
practices; and (iv) the subcontracted party shall enter into an agreement with such party to the
extent necessary to effectuate the provisions of ARTICLE 8 below.

     3.1.9 Commercialization.

               (a) Except as otherwise set forth in Sections 3.1.9(b) and Section 3.2 below, during the Blood
Screening Term, Gen-Probe hereby grants to Novartis the exclusive distribution right in the
Territory, at Novartis’s sole cost, directly or through distributors, to promote, market and sell
the Blood Screening Assays to be conducted by the Blood Screening Instruments for use in the Blood
Screening Field (recognizing the lack of clear distinction between blood screening and clinical
diagnostic markets in certain countries). Except as otherwise set forth in Sections 3.1.9(b) and
Section 3.2 below, during the Blood Screening Term, Gen-Probe hereby grants to Novartis the
exclusive distribution right in the Territory, at Novartis’s sole cost, directly or through
distributors, to promote, market and sell the Blood Screening Instruments to conduct Blood
Screening Assays for use in the Blood Screening Field. Novartis shall, use its Commercially
Reasonable Efforts to promote, market, sell and meet the reasonably foreseeable market demands for
the Blood Screening Assays and Blood Screening Instruments in the Territory for use in the Blood
Screening Field. No nucleic acid probe based

19

 

assays other than the Blood Screening Assays shall be conducted on the Blood Screening
Instruments purchased by Novartis.

               (b) Subject to regulatory requirements, the Products shall be marketed under such trademarks
as may be determined by the Supervisory Board to give adequate recognition to the respective
contributions and interests of the parties. It is the intention of the parties that both parties’
contributions and interests will be recognized.

               (c) Novartis shall have the right, and the obligation, at its sole expense, to maintain and
service all Blood Screening Instruments placed in the Territory for use in the Blood Screening
Field. Novartis shall be a party to all service contracts for all such Blood Screening
Instruments. Novartis shall have the right to charge a fee to the users of such Blood Screening
Instruments for such service. Novartis may exclude from Net Sales all revenues received by
Novartis in consideration for providing instrument maintenance and repair service for Blood
Screening Instruments, including TECAN Genesis automatic pipetting stations or any successor
pipetting instrument (e.g., TECAN EVO) (whether deemed part of a Blood Screening Instrument or
not), regardless of the form of the instrument transfer (sale, lease, or rental), location
(U.S./Canada or foreign), party providing instrument (Novartis or Third Party), or party providing
service (Novartis or Third Party service provider). Novartis shall charge no more for such
services than commercially reasonable values for the diagnostic and/or blood screening markets
consistent with standard industry practice in those markets.

               (d) New Market Entry. The parties agree to create a process for the approval of
business cases concerning the proposed registration of Products in new geographic markets. Where
such business cases are approved pursuant to this process, Registration Trial costs shall be split
equally between the parties. If Gen-Probe declines to approve a business case for a Product,
Novartis may proceed to enter the new market by paying all of the essential costs for a
Registration Trial for such Product. The essential costs for a Registration Trial shall include
(i) the actual costs of the Registration Trial and (ii) to the extent included in a budget
pre-approved by the other party, consent not to be unreasonably withheld, all financial obligations
incurred by a party to Third Parties or to the other party for services that are essential to the
Registration Trial (by way of example, mandatory product modifications such as local country
translations of software or documents or fees charged for regulatory submissions). Novartis shall
be entitled to recover one-half of the essential costs incurred by Novartis for such a Registration
Trial by deducting such amounts from the Applicable Purchase Price paid to Gen-Probe for sales of
the applicable Product made in such country in the first two years following its registration and
approval for sale, provided that the resulting Applicable Purchase Price to be paid to Gen-Probe
shall not be less than the sum of (i) twenty-five percent (25%) of Net Sales of such Product in
such country in the applicable period and (ii) fifty percent (50%) of Gen-Probe’s Manufacturing
Costs for such Product sold in such country in the applicable period. For each payment period as
to which Novartis makes such deduction Novartis shall report the amount and basis of the deduction
in its report pursuant to Section 6.4.

               (e) For each Product to be commercially introduced after the Effective Date, the parties shall
agree upon the timing and amounts of appropriate initial purchases of such Product by Novartis, in
order to establish initial inventory in accordance with the terms of this Agreement and reasonable
commercial practices.

20

 

               (f) For each Product that the parties agree should not be offered for sale beyond a specified
date due to commercial obsolescence (“end-of-life”), the parties shall agree upon an appropriate
end-of-life plan for such Product. The parties generally intend that they will share equally all
end-of-life costs incurred in accordance with the agreed plan. Each party shall use its best
efforts to minimize end-of-life costs, including scrap costs.

          3.1.10 Licenses.

               (a) During the Blood Screening Term, Novartis hereby grants to Gen-Probe a nonexclusive
license in the Territory under the Novartis IP Rights (i) to conduct Gen-Probe’s obligations under
each Development Program to develop the Blood Screening Assays, and (ii) to manufacture or have
manufactured the Blood Screening Assays. Gen-Probe shall not have the right to grant sublicenses
under such license, without the prior express written consent of Novartis.

               (b) During the Blood Screening Term, Gen-Probe hereby grants to Novartis a nonexclusive
license in the Territory under the Gen-Probe IP Rights to conduct Novartis’s obligations, if any,
under each Development Program to develop the Blood Screening Assays and the Blood Screening
Instruments. Novartis shall not have the right to grant sublicenses under such license, without
the prior express written consent of Gen-Probe.

               (c) If Novartis exercises its option to acquire the right to manufacture (or have
manufactured) any Blood Screening Assays or Blood Screening Instruments under Section 3.1.8 above,
during the balance of the Blood Screening Term, Gen-Probe shall grant to Novartis a nonexclusive
license in the Territory under the Gen-Probe IP Rights to exercise its rights under Section 3.1.8
above to manufacture (or have manufactured) such Blood Screening Assays and Blood Screening
Instruments for use in the Blood Screening Field. Novartis shall not have the right to grant
sublicenses under such license, without the prior express written consent of Gen-Probe.

               (d) Gen-Probe’s Rights in Japan in the Clinical Diagnostic Field. Notwithstanding
anything in the Ultrio Addendum, the WNV Addendum or this Agreement to the contrary, Gen-Probe
shall have the right to manufacture and sell the hepatitis B discriminatory probe assay portion of
the Ultrio Assay Product (the “HBV Discriminatory Assay”) and the WNV Assay Product for use in the
Clinical Diagnostic Field within the territory of Japan. Gen-Probe may acquire the right to
manufacture and sell the WNV Assay Product for use in the Clinical Diagnostic Field in the
remainder of the world by payment to Novartis of [...***...]. Gen-Probe may acquire the right to
manufacture and sell the HBV Discriminatory Assay for use in the Clinical Diagnostic Field in the
remainder of the world by payment to Novartis of a commensurate amount.

               (e) Immunity Under Roche Promoter-Primer Patent Claims. Novartis agrees that
Gen-Probe shall be entitled to the benefit of the immunity from suit previously granted to Chiron
Corporation, and subject to the limitations as granted to Chiron Corporation, by F. Hoffman-La
Roche and Roche Molecular Systems, Inc. under the Roche Promoter-Primer Patent Claims, which
immunity was previously granted to Chiron Corporation (and a party to be designated by Chiron
Corporation) by F. Hoffman-La Roche and Roche Molecular Systems, Inc.

***Confidential Treatment Requested

21

 

     3.2 Noncompetition.

          3.2.1 Subject to the provisions of Section 1.3, during the Blood Screening Term, Novartis
shall have the right, in its sole discretion, to grant licenses to Third Parties under the Novartis
Patent Rights, with the following limitations. With respect to the patent rights for each virus,
and in the United States and Japan only, once Novartis has granted one license in each such country
with respect to such virus for use in the Blood Screening Field, upon the grant of a second license
to such patent rights for such virus in such country for use in the Blood Screening Field, Novartis
shall pay to Gen-Probe [...***...] of all consideration received by Novartis in return for the
grant of such license for such virus, including upfront fees, royalties and non-cash consideration.
Any further licenses of such patent rights for such virus in such country for use in the Blood
Screening Field may be granted only with the prior written consent of Gen-Probe which shall not be
unreasonably withheld so long as Novartis adequately compensates Gen-Probe. A license by Novartis
for an HIV-1 or HCV assay for the sole purpose of confirming or supplementing the results of a
Blood Screening Assay shall not be considered as a license subject to the terms and restrictions of
this Section, so long as such confirmatory or supplemental assay is mandated by applicable
regulatory authorities or demanded by the market.

          3.2.2 During the Blood Screening Term, neither party shall grant to any Third Party any
license or other rights to develop or commercialize any nucleic acid probe-based assay for any
virus or marker for which there is no Blood Screening Assay then being developed or commercialized
under this Agreement for use in the Blood Screening Field (including an assay for the sole purpose
of confirming or supplementing the results of a Blood Screening Assay), unless such party has first
presented to the Supervisory Board the opportunity to develop and commercialize a TMA Assay for
such virus or marker under this Agreement for use in the Blood Screening Field. Such opportunity
may involve nonexclusive or exclusive rights to the virus or marker, as negotiated by the parties
through the Supervisory Board. Such negotiation shall include a determination of the Applicable
Purchase Price pursuant to Section 1.3.2, which shall take into account the extent to which the
opportunity is exclusive or nonexclusive. If the arrangement accepted by the Supervisory Board is
nonexclusive, the party holding the intellectual property for the virus or marker shall be free to
license rights to such virus or marker to Third Parties for use in the Blood Screening Field; and
if not, licensing shall be subject to such restrictions as are then agreed upon.

          3.2.3 During the Blood Screening Term, Gen-Probe shall not grant to any Third Party a license
under the Gen-Probe IP Rights to develop or commercialize (i) a TMA assay for use in the Blood
Screening Field or (ii) an assay utilizing Gen-Probe’s “Hybridization Protection Assay” (“HPA”) for
use in the Blood Screening Field.

          3.2.4 Other Blood Screening Instruments. If Gen-Probe develops any new instrument for
use in the Blood Screening Field, it shall offer to grant to Novartis, during the Blood Screening
Term and on reasonable terms to be negotiated, rights to such instrument comparable to the rights
granted under this Agreement as to the Blood Screening Instruments existing on the Effective Date,
to the extent that Gen-Probe reasonably concludes that it is not prohibited as of the Effective
Date from granting such rights.

***Confidential Treatment Requested

22

 

          3.2.5 New Technology; Alternative Technology. During the Blood Screening Term,
neither party shall develop, manufacture or sell (whether alone, with or by its Affiliate, or in
collaboration with any Third Party) any nucleic acid probe based assay or other Product
specifically intended for use in the Blood Screening Field (recognizing the lack of clear
distinction between blood screening and clinical diagnostic markets in some countries), other than
pursuant to this Agreement and except as provided in Sections 3.2.1, 3.2.2, or 3.2.6, and except as
follows:

               (a) New Technology. If a party or its Affiliate becomes aware of any new or improved
nucleic acid probe based assay method or products incorporating such method, and/or instrumentation
therefor, (collectively the “New Technology”) which may reasonably be expected to offer
technological advantages over the TMA Assays provided for by this Agreement, and such party or its
Affiliate desires to develop or commercialize assay products for use in the Blood Screening Field
using such New Technology, then such party shall inform the other party in writing and the parties
shall discuss such New Technology and shall use good faith efforts to reach agreement for the joint
development and/or commercialization of assay products in the Blood Screening Field incorporating
the New Technology, which agreement may include an adjustment of the Applicable Purchase Price for
such products.

               (b) If the parties cannot reach agreement for the joint development and/or commercialization
of any assay product incorporating New Technology following good faith negotiations in accordance
with Section (a) above, and Novartis or its Affiliate is the person desiring to develop or
commercialize assay products incorporating the New Technology, Novartis or its Affiliate may
proceed with product development or commercialization only if Novartis grants Gen-Probe a license
of the Novartis IP Rights, on reasonable commercial terms similar to those granted Third Parties,
permitting Gen-Probe and its Affiliates to make, have made, use, sell, and import under Gen-Probe’s
brands and trademarks the Blood Screening Assays and Blood Screening Instruments for use in the
Blood Screening Field (but solely with respect to that portion of the Blood Screening Field that is
likely to be adversely impacted — for example, with respect to platelets or plasma or red blood
cells only (such portion, the “Impacted Field”)) that are likely to be adversely impacted by the
introduction of such products (collectively, but only for use in the Impacted Field, the “Impacted
Products”). The license to Gen-Probe for an Impacted Product shall be effective, on a
country-by-country basis and Impacted Product-by-Impacted Product basis, on the date that is six
(6) months prior to the anticipated first commercial sale by Novartis of an assay product
incorporating the New Technology, provided that the license shall also permit Gen-Probe and its
Affiliates to undertake activities prior to such date that are necessary to enable Gen-Probe to
sell the Impacted Product as of such date. Upon the effective date of Gen-Probe’s right to sell
under the license, Novartis’s rights under this Agreement with respect to the Impacted Products
shall be modified to be co-exclusive with the right of Gen-Probe and its Affiliates to promote,
market and sell the Impacted Products for use in the Blood Screening Field. Gen-Probe and its
Affiliates shall not have any right to develop or commercialize Blood Screening Assays
incorporating New Technology and/or Blood Screening Instruments incorporating New Technology for
use in the Blood Screening Field during the Blood Screening Term except in collaboration with
Novartis.

23

 

               (c) Alternative Technology Identified by Gen-Probe. If Gen-Probe or its Affiliate
become aware of an alternative technology or product that is reasonably expected to substitute for
or significantly reduce the need for nucleic acid probe based assay methods in the Blood Screening
Field (such as, by way of example and not limitation, pathogen reduction or inactivation
technology) (collectively the “Alternative Technology”), and Gen-Probe or its Affiliate desires to
develop or commercialize products for use in the Blood Screening Field using such Alternative
Technology, then Gen-Probe shall inform Novartis in writing and the parties shall discuss such
Alternative Technology and shall use good faith efforts to reach agreement on reasonable commercial
terms for the joint development and/or commercialization of products in the Blood Screening Field
incorporating such Alternative Technology pursuant to the collaboration established by this
Agreement. Gen-Probe or its Affiliate shall not have any right to develop or commercialize
products for use in the Blood Screening Field incorporating Alternative Technology unless it has
first offered Novartis the opportunity to jointly participate in the development and
commercialization of such products on reasonable commercial terms.

               (d) Alternative Technology Identified by Novartis. If Novartis or its Affiliate
become aware of an Alternative Technology and Novartis or its Affiliate desires to develop or
commercialize products for use in the Blood Screening Field using such Alternative Technology, then
Novartis shall inform Gen-Probe in writing. (For the avoidance of doubt, therapeutic and
prophylactic drugs and/or vaccines shall not be considered Alternative Technology for purposes of
this Agreement.) Novartis shall have the option, at its sole discretion, of either: (i) offering
Gen-Probe the opportunity to jointly participate in the development and commercialization of such
products on reasonable commercial terms (Option 1); or (ii) commercializing the Alternative
Technology by itself, without first offering Gen-Probe the opportunity to jointly participate in
the development and commercialization of such products (Option 2). Novartis shall notify Gen-Probe
of its election in writing when notifying Gen-Probe of the Alternative Technology. Any notice of
Novartis’s election of Option 2 shall be delivered not less than one hundred and twenty (120) days
prior to the first commercial sale by Novartis or its Affiliate of the Alternative Technology
product. If Novartis elects Option 1, the parties shall discuss such Alternative Technology and
shall use good faith efforts to reach agreement on reasonable commercial terms for the joint
development and/or commercialization of products in the Blood Screening Field incorporating such
Alternative Technology pursuant to the collaboration established by this Agreement.

               (e) If Novartis or its Affiliate elects Option 1 with respect to the Alternative Technology,
but the parties are unable to reach agreement on commercially reasonable terms for the joint
development and/or commercialization of any product following good faith negotiations, Novartis or
its Affiliate may proceed with product development or commercialization only if Novartis grants
Gen-Probe a license of the Novartis IP Rights, on reasonable commercial terms similar to those
granted Third Parties, permitting Gen-Probe and its Affiliates to make, have made, use, sell, and
import under Gen-Probe’s brands and trademarks the Impacted Products. The license to Gen-Probe for
an Impacted Product shall be effective on a country-by-country basis and Impacted
Product-by-Impacted Product basis as of the first date on which (i) Novartis or its Affiliate has
commenced sales in such country of the Alternative Technology product and (ii) the number of blood
donations screened with an Impacted Product in such country for any calendar quarter have declined
as a result of the introduction of the Alternative Technology product by at least [...***...] (the
“Option 1 Threshold

***Confidential Treatment Requested

24

 

Decline”) from the number of donations screened with such Impacted Product in either (x) the
quarter immediately proceeding Novartis’s written notice to Gen-Probe of the Alternative Technology
or (y) the corresponding quarter for the prior calendar year. Upon the effective date of
Gen-Probe’s right to sell under the license, Novartis’s rights under the Agreement with respect to
the Impacted Product shall be modified to be co-exclusive with the right of Gen-Probe and its
Affiliates to promote, market and sell the Impacted Product for use in the Blood Screening Field.

               (f) If Novartis or its Affiliate elects Option 2 with respect to an Alternative Technology
other than viral reduction or viral inactivation, Novartis or its Affiliate may proceed with
product development or commercialization only if Novartis grants Gen-Probe a license of the
Novartis IP Rights, on reasonable commercial terms similar to those granted Third Parties,
permitting Gen-Probe and its Affiliates to make, have made, use, sell, and import under Gen-Probe’s
brands and trademarks the Impacted Products. The license to Gen-Probe for an Impacted Product
shall be effective on a country-by-country basis and Impacted Product-by-Impacted Product basis as
of the first date on which (i) Novartis or its Affiliate has commenced sales in such country of the
Alternative Technology product and (ii) the number of blood donations screened with an Impacted
Product in such country for any calendar quarter has declined as a result of the introduction of
the Alternative Technology product by at least [...***...] from the number of donations screened
with such Impacted Product in either (x) the quarter immediately proceeding Novartis’s written
notice to Gen-Probe of the Alternative Technology or (y) the corresponding quarter for the prior
calendar year (the “Option 2 [...***...] Threshold”); provided that the license shall permit
Gen-Probe and its Affiliates to undertake activities prior to such date that are necessary to
enable Gen-Probe and its Affiliates to sell the Impacted Product as of such date. If Novartis or
its Affiliate elects Option 2 with respect to an Alternative Technology for viral reduction or
viral inactivation, the license to Gen-Probe shall be effective on a country-by-country basis and
Impacted Product-by-Impacted Product basis as of the first date on which (iii) Novartis or its
Affiliate has commenced sales in such country of the Alternative Technology product and (iv) the
number of blood donations screened with an Impacted Product in such country for any calendar
quarter has declined as a result of the introduction of the Alternative Technology product (the
“Option 2 Viral Reduction Threshold”), and the Option 2 [...***...] Threshold shall not apply.
Upon the effective date of Gen- Probe’s right to sell under a license, Novartis’s rights under this
Agreement with respect to the Impacted Product shall be modified to be co-exclusive with the right
of Gen-Probe and its Affiliates to promote, market and sell the Impacted Product for use in the
Blood Screening Field.

               (g) For purposes of this Section 3.2, “country-by-country” shall mean, with respect to
Germany, the United Kingdom, France, and Italy (the “Major European Markets”), each country
individually and/or the four countries considered in the aggregate. By way of example, the Option
2 [...***...] Threshold would be triggered as to France as a result of the requisite percentage
decline in the number of screened blood donations in France and would also be triggered in France
(and the other Major European Markets) as a result of the requisite percentage decline in the
number of screened blood donations in the Major European Markets considered in the aggregate.

***Confidential Treatment Requested

25

 

          3.2.6 Nothing contained in this Section 3.2 shall preclude Gen-Probe from developing,
manufacturing, using or selling nucleic acid probes to ribosomal RNA pursuant to U.S. Patent No.
4,851,330, or U.S. Patent No. 5,288,611 and divisional, continuations, continuations-in-part,
reissues, renewals, extensions or additions. Gen-Probe shall be entitled to use Hybridization
Protection Assays (HPA) in connection with any such nucleic acid probes to ribosomal RNA. In the
event that Gen-Probe commercializes any such product for the Blood Screening Field, Gen-Probe shall
grant Novartis a right of first refusal to elect to become, on reasonable commercial terms to be
negotiated in good faith, the exclusive distributor for such product for the Blood Screening Field
in the United States and/or in Japan. Gen-Probe shall reasonably consider extending such a right
of first refusal as to other countries for which it has a right to do so.

ARTICLE 4

SUPERVISORY BOARD

     4.1 Supervisory Board.

          4.1.1 Generally; Composition. The Development Programs for the Products in the Blood
Screening Field shall be overseen by the Supervisory Board. The Supervisory Board shall be
available to address escalated unresolved conflicts between the parties under this Agreement and
shall provide executive-level strategy assessments regarding the subject matter of this Agreement.
The Supervisory Board shall be comprised of three (3) named representatives of Gen-Probe and three
(3) named representatives of Novartis. Each party shall appoint its respective representatives to
each Supervisory Board from time to time, and may substitute one or more of its representatives, in
its sole discretion, effective upon notice to the other party of such change.

          4.1.2 Meetings. Each Supervisory Board shall meet not less than once each calendar
quarter during the term of this Agreement, on such dates and at such times and places as agreed to
by Gen-Probe and Novartis, alternating between San Diego and Emeryville, or such other locations as
the parties shall agree. All meetings shall be set at times and places to be mutually agreed.

          4.1.3 Actions. Each party’s representatives shall collectively have one vote as to
all matters. Any approval, determination or other action agreed to by both parties’
representatives shall be the approval, determination or other action of the Supervisory Board. All
board actions require a unanimous vote. Any matters as to which the Supervisory Board cannot reach
a unanimous vote shall be presented to the parties’ respective presidents for consideration, in
accordance with ARTICLE 11.

          4.1.4 Reports. Within thirty (30) days following each Supervisory Board meeting
during the term of this Agreement, the Supervisory Board shall prepare and provide to each party a
reasonably detailed written summary report which shall describe any approval, determination or
other action by the Supervisory Board.

26

 

     4.2 Operating Committee.

          4.2.1 Purpose. The Novartis/Gen-Probe operating committee (“Operating Committee”) has
been established by the Supervisory Board to oversee Development Programs and related operations to
ensure effective execution and alignment such that the collaboration can endeavor to act as one
business. The Operating Committee will recommend prioritization of activities and initiate, review
and report on projects designed to increase shareholder value within both parties.

          4.2.2 Activities. Expected Operating Committee activities will include: (a) oversight
of day-to-day operations and related decision making; (b) increasing efficiencies and reducing
unnecessary redundant activities through techniques such as value stream mapping and other relevant
processes; (c) project review and reporting; (d) issue resolution; (e) selection of appropriate
business metrics; (f) oversight of preparation for Supervisory Board topics; and (g) making
recommendations to the Supervisory Board.

          4.2.3 Composition. The Operating Committee will be comprised of functional
representatives of both parties representing core activities, such as: Marketing, Finance, Supply
Chain, Quality, Regulatory, R&D, and Alliance Management. Each party may appoint its respective
representatives and may substitute one or more of its representatives in its sole discretion,
effective upon notice to the other party.

          4.2.4 Operation. The Operating Committee will establish its own charter and committee
rules of operation, but will perform all activities at the behest of and subject to the overall
authority of the Supervisory Board.

ARTICLE 5

SUPPLY TERMS

     5.1 Manufacture and Sale. On the terms and subject to the conditions of this ARTICLE
5, Gen-Probe shall manufacture, or have manufactured, sell and deliver to Novartis, and Novartis
shall purchase from Gen-Probe, such amounts of the Products, as Novartis orders pursuant to Section
5.3 and Section 5.4 below. Gen-Probe shall cause its subcontract manufacturers, if any, to comply
with the provisions of this ARTICLE 5. Gen-Probe acknowledges that Affiliates of Novartis have the
right to purchase Products pursuant to the terms of this Agreement. Gen-Probe shall use
Commercially Reasonable Efforts to meet the market demand for the Products as to which it has
undertaken an obligation to manufacture.

     5.2 Manufacturing Practices.

          5.2.1 Specifications. Gen-Probe shall manufacture all the Products under this
Agreement in accordance with all applicable laws and regulations and in conformity with the product
specifications.

27

 

          5.2.2 Audit. Novartis shall have the right, at its sole expense, to audit Gen-Probe for
compliance with Section 5.2.1 upon reasonable notice during normal business hours and not more than
once in each calendar year (or such additional times as may be necessary to ensure compliance with
all material requirements).

          5.2.3 Certificates of Analysis. Gen-Probe shall provide certificates of analysis to
Novartis for all the Blood Screening Assays manufactured and supplied hereunder based upon a
reference standard reasonably proposed by Gen-Probe and acceptable to Novartis.

          5.2.4 Quality Control Information. Upon the reasonable request of Novartis, Gen-Probe
shall provide Novartis with such reasonable information, including analytical and manufacturing
documentation, requested by Novartis regarding quality control, stability data and shipping
validation for Products. Novartis shall treat all such information disclosed pursuant to this
Section as confidential information of Gen-Probe subject to the provisions of ARTICLE 7 below.

     5.3 Blood Screening Assays: Forecasts and Orders; Purchase Obligation; Purchase Orders;
Inventory; Supply Obligation; Delivery and Acceptance.

          5.3.1 Blood Screening Assays Forecasts.

               (a) On or before the first (1st) day of each calendar month during the term of this Agreement,
Novartis shall provide to Gen-Probe a Forecast, covering the period commencing the calendar month
immediately succeeding the month in which the Forecast is delivered (for example, on January 1,
Novartis will deliver a rolling twelve (12) month Forecast commencing February 1), showing
Novartis’s estimated purchase requirements over the period covered by the Forecast. The Forecast
shall include purchase requirements, at the following level of detail:

               (i) for the first (1st), second (2nd), and third (3rd) calendar months covered by the
Forecast, the Forecast shall specify the Blood Screening Assays by packaging configuration,
including kit size and/or catalogue part number, and associated quantities for purchase from
Gen-Probe by Novartis in such three-month period;

               (ii) for the fourth (4th), fifth (5th), and sixth (6th) calendar months covered by the
Forecast, the Forecast shall specify the Blood Screening Assays and ancillary materials, by
labeling requirement detailed according to the provisions of Schedule 5.3.1(a), attached
hereto, and associated quantities that Novartis expects to order from Gen-Probe by Novartis
in such period; and

               (iii) for the seventh (7th) through twelfth (12th) calendar months covered by the
Forecast, the Forecast shall specify the estimated purchase requirements, by test, and
associated quantities that Novartis expects to order from Gen-Probe by Novartis in such
period.

28

 

               (iv) Subject to the additional provisions set forth in subparagraph (v) below, in each
Forecast delivered, Novartis may not (A) amend the quantities of Blood Screening Assays from
the quantities specified for the first (1st), second (2nd) and third
(3rd) calendar months in the immediately preceding Forecast; (B) amend the
quantities of Blood Screening Assays specified in the Forecast for the fourth
(4th), fifth (5th) and sixth (6th) calendar months in the
immediately preceding Forecast to an amount that is less than ninety percent (90%) nor more
than one hundred-ten percent (110%) of the amount forecasted when the month being amended
was the sixth (6th) calendar month; (C) amend the quantities of Blood Screening
Assays specified in the Forecast for the seventh (7th) calendar month in the
immediately preceding Forecast as it transitions to the sixth (6th) calendar
month in the delivered Forecast to an amount that is less than eighty percent (80%) nor more
than one hundred thirty percent (130%) of the quantity of Blood Screening Assays specified
in the previous Forecast when the month in question was the seventh (7th)
calendar month; or (D) amend the quantities of Blood Screening Assays specified in the
Forecast for the eighth (8th) calendar month in the immediately preceding
Forecast as it transitions to the seventh (7th) calendar month in the delivered
Forecast to an amount that is less than eighty percent (80%) nor more than one hundred forty
percent (140%) of the quantity of Blood Screening Assays specified in the previous Forecast
when the month in question was the eighth (8th) calendar month. For example, on
January 1, Novartis will deliver a Forecast in which February is the first (1st)
calendar month and September is the eighth (8th) calendar month of the Forecast.
If Novartis estimates in such Forecast that in August, the seventh (7th) calendar
month, it will require 100,000 tests, Novartis may not decrease its Forecast below 80,000
tests nor increase it above 130,000 tests as that month transitions to the sixth
(6th) calendar month in the next Forecast. Similarly, if Novartis estimates in a
Forecast that in September, the eighth (8th) calendar month, it will require
100,000 tests, then in the subsequent Forecast Novartis may not decrease its Forecast below
80,000 tests nor increase it above 140,000 tests when that month transitions to the seventh
(7th) calendar month. For purpose of the convenience of reference hereafter, the
Forecast delivered in which the applicable calendar month is the eighth (8th)
month is referred to as the “original Forecast”; and the quantity as forecast in any
subsequent Forecast, amended as permitted under this Section (i.e., the Forecast delivered
in which the applicable month transitions to the next lower month, such as from the eighth
(8th) month to the seventh (7th)), is referred to as the “amended
Forecast.”

               (v) Notwithstanding the provisions of subparagraph (iv) above, the parties acknowledge
that Gen-Probe incurs substantial expense ramping up production and otherwise preparing to
meet quantities forecasted by Novartis, even in periods commencing the seventh
(7th) calendar month and beyond in the then-current Forecast. Therefore, the
parties agree that Novartis may not reduce the Forecast down under subparagraph (iv)(B) and
(C), above, in the aggregate to an amount that is less than eighty percent (80%) of the
highest quantity of Blood Screening Assays specified in any Forecast. (For example, on
January 1, Novartis will deliver a Forecast in which February 1 is the first
(1st) month and September is the eighth (8th) month of the Forecast.
If Novartis estimates in such Forecast that in September it will require 100,000 tests, then
Novartis may not amend the Forecast, at any time or in the aggregate, to an amount that is
less than 80,000 tests deliverable in September. In addition, if, in the subsequent

29

 

Forecast when the month in question transitions from the eighth (8th) to the
seventh (7th) month, Novartis increases the Forecast of the month in question
from 100,000 tests to 120,000 tests, then Novartis may not amend the Forecast to an amount
that is less than 96,000 tests deliverable in September (i.e., 80% of 120,000). Similarly,
if in the next Forecast, when the month in question transitions from the seventh
(7th) to the sixth (6th) month, Novartis further increases the
Forecast to 150,000 tests, then Novartis may not amend the Forecast to an amount that is
less than 120,000 tests deliverable in September (i.e., 80% of 150,000).

               (b) Commencing in the first full month following the Effective Date, the parties shall meet
monthly, on or before the twenty-third (23rd) day of each calendar month, to review the previous
month’s performance and the current Forecast and production plan for the purpose of making
production planning and inventory management decisions necessary to meet Customer supply needs in a
cost-efficient manner. Such production planning meetings shall be attended by qualified members of
each party, and shall be sponsored by each party’s senior supply chain executive.

               (c) In the event that any disagreement arises between the parties pursuant to the obligations
imposed in this Section 5.3.1, the parties shall submit such dispute first to a discussion between
responsible managers, and if they cannot agree, then to the Supervisory Board for resolution as
soon as is reasonably achievable. In the event that the Supervisory Board is (i) unable to resolve
the issue at its next meeting, or (ii) is unable or unwilling to meet within the thirty (30) day
period after submittal of the issue to the Supervisory Board, then the issue shall be referred by
the parties for resolution in accordance with the terms of ARTICLE 11 herein.

          5.3.2 Blood Screening Assays Purchase Obligation.

               (a) Novartis shall be required to purchase, in the respective month, the quantity of Blood
Screening Assays, by part number, specified in each Forecast for the first (1st), second (2nd) and
third (3rd) calendar months covered by each Forecast. If any Forecast fails to conform with the
provisions of Section 5.3.1, considered in the aggregate, then for purposes of determining
Novartis’s purchase obligation under this Section 5.3.2(a) such non-conforming Forecast shall be
revised to comply with such provisions of Section 5.3.1.

               (b) Notwithstanding anything in this Agreement to the contrary, the expiration or sooner
termination of this Agreement, other than a termination by Novartis for default of Gen-Probe in
accordance with the provisions of Section 10.2.1 and subject to the provisions of Section 12.2
governing force majeure events, shall not operate to extinguish Novartis’s obligation to purchase
the quantity of Blood Screening Assays specified in accordance with Section 5.3.1 through the
eighth (8th) calendar month covered by the Forecast in effect as of the effective date of
expiration or sooner termination.

               (c) In the event that any disagreement arises between the parties pursuant to the obligations
imposed in this Section 5.3.2, the parties shall submit such dispute first to a discussion between
responsible managers, and if they cannot agree, then to the Supervisory Board for resolution as
soon as is reasonably achievable. In the event that the

30

 

Supervisory Board is (i) unable to resolve the issue at its next meeting, or (ii) is unable or
unwilling to meet within the thirty (30) day period after submittal of the issue to the Supervisory
Board, then the issue shall be referred by the parties for resolution in accordance with the terms
of ARTICLE 11 herein.

          5.3.3 Blood Screening Assays Purchase Orders.

               (a) Novartis or its Affiliates shall submit to Gen-Probe binding Purchase Orders on or before
the fifth (5th) day of each calendar month during the term hereof covering the Blood Screening
Assays forecasted by Novartis for the third (3rd) calendar month covered by the then-current
Forecast (for example, on January 5, Novartis or its Affiliates will submit Purchase Orders for
Blood Screening Assays to be delivered in April). Each Purchase Order shall be in writing and
reasonably similar to the sample Purchase Order attached hereto as Schedule 5.3.3. Each
Purchase Order shall specify the quantity of Blood Screening Assays ordered (by packaging
configuration, including kit size and/or catalogue part number), the place of delivery, the
requested delivery date, and such other information as Gen-Probe reasonably requests. Novartis or
its Affiliates may not request a delivery date for any Blood Screening Assays that is less than
eighty-five (85) days or more than ninety-five (95) days after the date of the applicable Purchase
Order (for example, a Purchase Order submitted to Gen-Probe on January 5 may only specify a
delivery date between the first and the tenth of April).

               (b) Purchase Orders submitted to Gen-Probe by Novartis or its Affiliates shall be binding on
Gen-Probe as to that quantity of Blood Screening Assays set forth in the then-current Forecast for
such calendar month. If the quantity of any Blood Screening Assays ordered by Novartis and its
Affiliates in aggregate for any calendar month exceeds the quantity of such Blood Screening Assays
set forth in the then-current Forecast for such month, then Gen-Probe shall use Commercially
Reasonable Efforts to deliver the amount of Blood Screening Assays in excess of the forecasted
amount. Gen-Probe shall provide Novartis and its Affiliates with written notice of the anticipated
delivery date for such additional Blood Screening Assays.

               (c) In the event that the Purchase Orders received from Novartis and its Affiliates herein
fail to order in aggregate Blood Screening Assays of the types and in the amounts specified in the
then-current Forecast for the applicable calendar month, Gen-Probe shall have the right to reject
such Purchase Order(s). Gen-Probe shall notify Novartis in writing within ten (10) days of receipt
of such Purchase Order(s). If not rejected by Gen-Probe within ten (10) days of receipt, such
Purchase Order(s) shall be deemed accepted by Gen-Probe. In the event that Gen-Probe rejects a
Purchase Order Novartis or its Affiliate shall have five (5) days to correct the Purchase Order and
resubmit it to Gen-Probe.

               (d) In the event that any disagreement arises between the parties pursuant to the obligations
imposed in this Section 5.3.3, the parties shall submit such dispute first to a discussion between
responsible managers, and if they cannot agree, then to the Supervisory Board for resolution as
soon as is reasonably achievable. In the event that the Supervisory Board is (i) unable to resolve
the issue at its next meeting, or (ii) is unable or unwilling to meet within the thirty (30) day
period after submittal of the issue to the Supervisory

31

 

Board, then the issue shall be referred by the parties for resolution in accordance with the
terms of ARTICLE 11 herein.

               (e) In the event of a conflict between the terms and conditions of any Purchase Order and this
Agreement, the terms and conditions of this Agreement shall prevail.

          5.3.4 Blood Screening Assays Inventory.

               (a) The parties agree that the amount of inventory sufficient to ensure uninterrupted testing
by Customers in the event of a disruption of supply of Blood Screening Assays from Gen-Probe is a
minimum of (5) months’ forward demand for such Blood Screening Assays, as determined by the most
current Forecast. Accordingly, Novartis shall purchase and maintain a minimum of a five (5)
months’ inventory of Blood Screening Assays based on the latest Forecast. Compliance with this
inventory requirement shall be determined by comparing the five (5) months’ forward demand as
determined by the most current Forecast against the aggregate of the following: (i) inventory
maintained at Novartis or its Affiliate’s warehousing facilities; (ii) finished goods inventory on
hand at Gen-Probe or in-transit from Gen-Probe; and (iii) a reasonable estimate of inventory held
by Third Party or Affiliated distributors, all of (i) through (iii) measured for each Blood
Screening Assay on a global basis.

               (b) Notwithstanding the foregoing, Gen-Probe shall maintain sufficient inventory of raw
materials and work in progress as necessary to meet the production requirements for Novartis’s
commitments for the first through eighth months of Novartis’s most current Forecast.

               (c) Each party shall give an independent certified public accounting firm selected by the
other party access to the applicable records (and the applicable records of any Affiliate) for the
purpose of permitting the audit, at the auditing party’s expense and in accordance with Section 6.6
of this Agreement, of compliance with this Section 5.3.4.

          5.3.5 Blood Screening Assays Supply Obligation.

               (a) Gen-Probe shall be required to supply in any given month the quantity of Blood Screening
Assays ordered by Novartis or its Affiliates pursuant to Purchase Orders as to that quantity of
Blood Screening Assays set forth in the then-current Forecast for such month, as the forecasted
demand may be amended as permitted in Section 5.3.1(a)(iv) above. If Gen-Probe becomes aware of
any fact indicating that Gen-Probe may be unable to meet Novartis’s forecasted demand as specified
in the original Forecast as to any Blood Screening Assay or indicating that Gen-Probe may be unable
to meet Novartis’s forecasted demand as specified in an amended Forecast permitted under Section
5.3.1(a)(iv), Gen-Probe shall promptly provide written notice of such fact to Novartis’s senior
supply chain executive. The parties’ senior supply chain executives shall meet and attempt to agree
upon a resolution, including exploring ways to meet such increased demand. If the parties cannot
agree on such a resolution, then the issue will be referred to the Supervisory Board for resolution
no later than the later to occur of (i) thirty (30) days after such referral, or (ii) the next
regularly scheduled Supervisory Board meeting. If the Supervisory Board fails to resolve the
issue, the parties may invoke the provisions of ARTICLE 11 herein. The failure of Gen-Probe to
supply that quantity

32

 

of Blood Screening Assays in a Novartis Purchase Order in excess of Novartis’s forecasted
demand as specified in the then-current Forecast or amended Forecast, as permitted under Section
5.3.1(a)(iv) for such month, shall not trigger the Novartis manufacturing rights set forth in
Section 3.1.8(b) of the Agreement.

               (b) As of the Effective Date, and except as otherwise stated below or as may be otherwise
agreed by the parties subject to Sections 3.1.9(e) and (f) of this Agreement, Gen-Probe shall
ensure that the expiration date for Blood Screening Assays and Ancillary Products supplied to
Novartis shall be no earlier than (i) eleven (11) months after the date of shipment to Novartis or
its Affiliate if designated for export; and (ii) eight (8) months after the date of shipment to
Novartis or its Affiliate if designated for sale by Novartis in the United States. Recognizing
that expiration dating is directly related to order volume, manufacturing lot size, and
Manufacturing Costs, the parties shall work together in an effort to increase the minimum
expiration dating for Blood Screening Assays delivered to Novartis to twelve (12) months. The
Syscheck, Flashcheck, and System Fluid Preservative Ancillary Products shall not be subject to the
minimum expiration dating requirement set forth above, but the expiration date for such Ancillary
Products shall be no earlier than five (5) months after the date of shipment to Novartis. Novartis
shall not be required to hold any minimum amount of inventory of such Ancillary Products and the
parties shall work together in an effort to increase the minimum expiration dating for such
Ancillary Products to six (6) months when delivered to Novartis.

          5.3.6 Blood Screening Assays Delivery and Acceptance.

               (a) All Blood Screening Assays purchased by Novartis or its Affiliates under this Agreement
shall be shipped f.o.b. place of manufacture to such location as designated by Novartis or its
Affiliates in the applicable Purchase Order. Novartis or its Affiliates shall have the right to
select the carrier.

               (b) Novartis or its Affiliates shall be responsible for all freight, insurance charges, taxes,
import and export duties, inspection fees and other charges applicable to the sale and transport of
Blood Screening Assays purchased by Novartis or its Affiliates to such location designated by
Novartis or its Affiliates in the applicable Purchase Order. Gen-Probe shall, to the extent
possible, charge such expenses to Novartis’s carrier accounts or pre-pay such charges. When
Gen-Probe pre-pays such charges, it shall invoice such charges to Novartis in reasonable detail,
specifying the Blood Screening Assays to which such charges apply. Novartis shall pay all such
invoices within thirty (30) days of date of invoice.

     5.4 Blood Screening Instruments: Forecasts; Purchase Orders and Purchase Obligation;
Supply Obligation; Shipping and Delivery; Engineering Change Notification.

          5.4.1 Blood Screening Instrument Forecasts. With respect to Forecasts of Blood
Screening Instruments: (i) Novartis shall submit Forecasts for Tigris Instruments to Gen-Probe in
accordance with the provisions set forth in this Section 5.4.1 and (ii) Novartis shall not be
required to submit Forecasts for Component Instruments and for Spare Parts, but Novartis shall
place orders for Component Instruments and for Spare Parts in accordance with Section 5.4.2(b) and
Section 5.4.2(c) below, respectively.

33

 

               (a) On or before the first (1st) day of the first month of each calendar quarter (i.e., January,
April, July and October) during the term of this Agreement, Novartis shall provide to Gen-Probe a
fifteen (15) month rolling Forecast for delivery of Tigris Instruments, covering the period
commencing on the first calendar month of the quarter. For example, on or before January 1, 2009,
Novartis will deliver a Forecast showing Novartis’s estimated purchase requirements for the period
covering January 1, 2009 through April 1, 2010. This Forecast may be provided more frequently, upon
mutual written agreement by the parties. The first twelve (12) months of each rolling Forecast
submitted to Gen-Probe by Novartis shall be fixed and binding upon the parties.

               (b) The parties shall meet monthly, on or before the twenty-third day of each calendar month,
to review the most recent Forecast submitted by Novartis, the status of prior Blood Screening
Instrument forecasts and allocations, and production planning for future deliveries of Tigris
Instruments. The purpose of these meetings will be to make decisions concerning ordering Blood
Screening Instruments, production planning, and inventory allocation, as necessary to meet
Novartis’s and Gen-Probe’s supply chain needs in a cost efficient manner. Such meetings shall be
attended by qualified members of each party and shall be sponsored by the parties’ senior supply
chain executives. The meeting agenda shall include a review of Novartis’s Forecasts for Tigris
Instrument deliveries, the Blood Screening Instrument production schedule, and the allocation, as
between Novartis and Gen-Probe, of Tigris Instruments to be delivered during each month of the
remaining Forecast period following the meeting. Once the allocation described in the foregoing
sentence is agreed upon, neither party may change its allocation of Tigris Instruments for the
period covered by the plan without the express written consent of both parties. This agreed plan
is henceforth referred to as the “Tigris Instrument Allocation Plan.”

               (c) Both parties acknowledge that Gen-Probe incurs substantial expense involved in purchasing
the parts required to manufacture Tigris Instruments for use by Gen-Probe in the Clinical
Diagnostic Field and for use by Novartis in the Blood Screening Field in that these parts must be
purchased nine (9) months in advance of the delivery of a Tigris Instrument. At the monthly
meetings mentioned in the paragraph above, Novartis and Gen-Probe will review the inventory of
Blood Screening Instrument parts required for Tigris Instrument production. Novartis and Gen-Probe
participants in such meeting will jointly confirm the amount of Tigris Instrument parts to be
purchased to cover forecasted deliveries of manufactured Blood Screening Instruments as scheduled
in the Tigris Instrument Allocation Plan, recognizing the nine (9) month lead time between ordering
parts and the delivery of manufactured Blood Screening Instruments. The parties acknowledge that
purchases of Spare Parts and other Ancillary Products may be reasonably increased to facilitate
economical order quantities.

34

 

          5.4.2 Blood Screening Instruments Purchase Orders and Purchase Obligation.

               (a) Tigris Instruments. Novartis or its Affiliates shall place binding purchase
orders for Tigris Instruments (“Tigris Instrument Purchase Orders”) as set forth in this Section
5.4.2(a).

               (i) Novartis or its Affiliates shall submit Tigris Instrument Purchase Orders in
writing by registered mail, facsimile or email, addressed to the attention of the Gen-Probe
Customer Service Department. Each Tigris Instrument Purchase Order shall specify the
quantity of Tigris Instruments ordered, the place of delivery for completed Tigris
Instruments, and such other information as Gen-Probe reasonably requests in writing.
Gen-Probe shall confirm acceptance or rejection of each Novartis Tigris Instrument Purchase
Order within five (5) business days of receipt of such Tigris Instrument Purchase Order. In
the event of a conflict between the terms and conditions of any Tigris Instrument Purchase
Order and this Agreement, the terms and conditions of this Agreement shall prevail. Each
Tigris Instrument Purchase Order for manufactured Tigris Instruments shall include Novartis
or its Affiliate’s shipping instructions, which may require shipment by Gen-Probe or its
designee to multiple locations.

               (ii) Novartis or its Affiliates shall submit, on or before the first day of the current
calendar quarter, binding Tigris Instrument Purchase Orders for Tigris Instruments to cover
the fixed twelve (12) month period commencing on the first day of the current calendar
quarter, for delivery to Novartis or its Affiliates pursuant to the most recent Tigris
Instrument Allocation Plan. For example, on or before January 1, 2009, Novartis or its
Affiliates shall submit to Gen-Probe Tigris Instrument Purchase Orders for all Tigris
Instruments represented in the current Tigris Instrument Allocation Plan for the period
covering January 1, 2009 through December 31, 2009. If such Tigris Instrument Purchase
Orders do not match the then-current Tigris Instrument Allocation Plan, Gen-Probe’s
acceptance of deviations to such Tigris Instrument Allocation Plan will be at Gen-Probe’s
discretion.

               (iii) Each Novartis Tigris Instrument Purchase Order for completed Tigris Instruments
shall be submitted no less than (12) twelve months prior to the month in which delivery was
requested in the most recent Tigris Instrument Allocation Plan. Each Tigris Instrument
Purchase Order shall be for no less then the number of Tigris Instruments specified for the
applicable month in the most recent Tigris Instrument Allocation Plan.

               (b) Component Instruments. Novartis or its Affiliates shall place binding Purchase
Orders for Component Instruments (“Component Instrument Purchase Orders”) with Gen-Probe as set
forth in this Section 5.4.2(b).

               (i) Novartis or its Affiliates shall submit such Component Instrument Purchase Orders
in writing by registered mail, facsimile or email, addressed to the attention of the
Gen-Probe Customer Service Department. Each Component Instrument Purchase Order shall
specify the quantity of each Component Instrument

35

 

ordered, the place of delivery, and such other information as Gen-Probe reasonably
requests. As of the Effective Date, Gen-Probe has provided Novartis with the minimum lead
times required for deliveries of Component Instruments, which may be adjusted upon
reasonable notice to the extent any manufacturer of Component Instruments changes its lead
time requirements. If the Component Instrument Purchase Order specifies a delivery date
that complies with the minimum required lead time, Gen-Probe shall confirm acceptance or
rejection of each Novartis Component Instrument Purchase Order within five (5) business days
of receipt of such Component Instrument Purchase Order. If the Component Instrument
Purchase Order specifies a delivery date that complies with the minimum required lead time
and if Gen-Probe fails to respond to Novartis or its Affiliates within said five (5)
business days, the Component Instrument Purchase Order shall be deemed accepted by Gen-Probe
as issued by Novartis or its Affiliates with respect to the quantity, shipping schedule, and
shipping instructions. Likewise, if Novartis or its Affiliates fail to respond to
Gen-Probe’s written response within five (5) business days of Novartis or its Affiliate’s
receipt of such written response, then the modifications to the Component Instrument
Purchase Order set forth in such Gen-Probe written response shall be deemed accepted by
Novartis. In the event of a conflict between the terms and conditions of any Component
Instrument Purchase Order and this Agreement, the terms and conditions of this Agreement
shall prevail.

               (ii) Component Instrument Purchase Orders for each Blood Screening Instrument must be
placed with a requested delivery date far enough in advance to allow the manufacturer the
time required to manufacture and release the Blood Screening Instrument. Component
Instrument Purchase Orders for Blood Screening Instruments that do not meet the lead time
requirements must be submitted to Gen-Probe for review and approval; Gen-Probe shall have no
obligation with respect to any such Component Instrument Purchase Order until Gen-Probe has
affirmatively approved quantities and delivery dates. Once the quantities and delivery
dates are agreed upon, Gen-Probe will forward the short lead time Component Instrument
Purchase Order to the manufacturer or supplier.

               (c) Spare Parts. Novartis or its Affiliates shall order Spare Parts for Tigris
Instruments directly from the supplier/manufacturer, (e.g., KMC Systems, Inc) and Novartis shall
order Spare Parts for the front-end pipettor and the reagent addition station components of the
ESAS2 Instrument directly from STRATEC Biomedical Systems AG. Novartis shall place binding
Purchase Orders for Spare Parts for Component Instruments (“Spare Parts Purchase Orders”) as set
forth in this Section 5.4.2(c).

               (i) Novartis or its Affiliates shall submit Spare Parts Purchase Orders in writing by
registered mail, telefax or email, addressed to the attention of the Gen-Probe Customer
Service Department. Each Spare Parts Purchase Order shall specify (A) the quantity of each
Spare Part ordered, (B) the requested shipping schedule for such Spare Parts, (C) shipment
instructions for such Spare Parts, which may require shipment by Gen-Probe or its designee
to multiple locations, and (D) such other information as Gen-Probe reasonably requests.
With the exception of such quantity, shipping schedule, shipping instructions, and
information requested by Gen-Probe, and unless otherwise mutually agreed in writing by the
parties, all other terms and conditions of any Spare

36

 

Parts Purchase Order shall be null and void. In the event of a conflict between the
terms and conditions of any Spare Parts Purchase Order and this Agreement, the terms and
conditions of this Agreement shall prevail.

               (ii) Gen-Probe will provide to Novartis or its Affiliates a written response to each
Spare Parts Purchase Order within five (5) business days of Gen-Probe’s receipt of such
Spare Parts Purchase Order, indicating either that the terms of the Spare Parts Purchase
Order are acceptable as stated, or setting forth necessary adjustments. As of the Effective
Date, Gen-Probe has provided Novartis with the minimum lead times required for deliveries of
Spare Parts for Component Instruments, which may be adjusted upon reasonable notice to the
extent any manufacturer of Spare Parts for Component Instruments changes its lead time
requirements. If the Spare Parts Purchase Order specifies a delivery date that complies
with the minimum required lead time and if Gen-Probe fails to respond to Novartis or its
Affiliates within said five (5) business days, the Spare Parts Purchase Order shall be
deemed accepted by Gen-Probe as issued by Novartis or its Affiliates with respect to the
quantity, shipping schedule, and shipping instructions. Likewise, if Novartis or its
Affiliates fail to respond to Gen-Probe’s written response within five (5) business days of
Novartis or its Affiliate’s receipt of such written response, then the modifications to the
Spare Parts Purchase Order set forth in such Gen-Probe written response shall be deemed
accepted by Novartis.

               (iii) Spare Parts Purchase Orders that do not meet the lead time requirements must be
submitted to Gen-Probe for review and approval. Gen-Probe shall have no obligation with
respect to any such Spare Parts Purchase Order until Gen-Probe has affirmatively approved
quantities and delivery dates. Once the quantities and delivery dates are agreed upon,
Gen-Probe will forward the short lead time Spare Parts Purchase Order to the manufacturer or
supplier.

               (iv) Novartis shall pay Gen-Probe the amount of each accepted Spare Parts Purchase
Order for Spare Parts within thirty (30) days following delivery and receipt of the invoice
for such Spare Parts.

               (d) Emergency Purchase Orders. Either party may submit a purchase order for expedited
shipment for a part or parts of a Blood Screening Instrument in response to an “instrument down”
situation in which the party submitting the purchase order does not have a required part(s) in
inventory in a stock location(s) from which the part(s) could be obtained within the time required
to meet the customer requirements for repair of the applicable Blood Screening Instrument (such
purchase order, an “Emergency Purchase Order”). If the other party has the required part(s) in
inventory, it will make every commercially reasonable effort to supply the needed part(s) as soon
as possible.

37

 

          5.4.3 Blood Screening Instruments Supply Obligation

               (a) Tigris Instruments.

               (i) Gen-Probe shall use its best efforts to obtain from the supplier/manufacturer and
supply to Novartis or its Affiliates in any given month, the quantity of Tigris Instruments
ordered by Novartis or its Affiliates pursuant to a Tigris Instrument Purchase Order in
accordance with the quantity of Tigris Instruments set forth in the then-current Tigris
Instrument Allocation Plan for such month. If Gen-Probe becomes aware of any fact
indicating that Gen-Probe may be unable to meet Novartis or its Affiliate’s demand as
specified in an agreed upon Tigris Instrument Allocation Plan, Gen-Probe will immediately
notify Novartis. The parties shall communicate and attempt to agree upon a resolution,
including exploring ways to meet such demand.

               (ii) Gen-Probe will make every commercially reasonable effort to deliver the latest
version of each Tigris Instrument at the time of manufacturing.

               (iii) Gen-Probe will use Commercially Reasonable Efforts to supply Tigris Instruments
that Novartis or its Affiliates may request that are in addition to those agreed upon in the
Tigris Instrument Allocation Plan. Novartis or its Affiliates shall provide Gen-Probe with
as much notice as possible if and when Novartis or its Affiliates requests additional Tigris
Instruments. Gen-Probe shall provide Novartis or its Affiliates with notice of the
anticipated delivery date for such additional Tigris Instruments.

               (iv) If for any three (3) months in any twelve-month period Gen-Probe fails to supply
Novartis with Novartis or its Affiliates’ aggregate monthly requirements of a Blood
Screening Instrument, ordered by Novartis or its Affiliates in accordance with this
Agreement, within forty-five (45) days after the requested delivery date, then Novartis or
its Affiliates shall have the right to place orders directly with the Blood Screening
Instrument manufacturer, unless Gen-Probe’s failure to supply was caused by the
manufacturer.

               (b) Component Instruments. Gen-Probe shall use its best efforts to obtain from the
manufacturer and supply to Novartis or its Affiliates in any given month the quantity of Component
Instruments ordered by Novartis or its Affiliates pursuant to a Component Instrument Purchase
Order. If Gen-Probe becomes aware of any fact indicating that Gen-Probe may be unable to meet
Novartis or its Affiliates’ demand as specified in a Component Instrument Purchase Order, Gen-Probe
will immediately notify Novartis. The parties shall communicate and attempt to agree upon a
resolution, including exploring ways to meet such demand.

               (c) Spare Parts

               (i) For those Spare Parts properly and timely identified on Spare Parts Purchase Orders
submitted to Gen-Probe by Novartis or its Affiliates, Gen-Probe shall use its best efforts
to obtain from the supplier/manufacturer and supply to Novartis or its Affiliates in any
given month the quantity of Spare Parts ordered by Novartis or its Affiliates. Gen-Probe
will routinely monitor overdue Spare Parts

38

 

Purchase Orders and work with their suppliers to assign new delivery dates. If
Gen-Probe becomes aware of any fact indicating that Gen-Probe may be unable to meet the
terms of a Novartis Spare Parts Purchase Order for any Spare Part, Gen-Probe will
immediately notify Novartis Purchasing. The parties shall communicate and attempt to agree
upon a resolution, including exploring ways to meet such demand.

               (ii) If Novartis or its Affiliates requires Spare Parts to be delivered earlier than
the lead times specified in this Agreement for such Spare Parts, Gen-Probe shall use its
Commercially Reasonable Efforts to supply in accordance with Novartis or its Affiliates’
requested delivery dates, and shall provide Novartis or its Affiliates with notice of the
anticipated delivery date for such Spare Parts. Novartis or its Affiliates shall provide
Gen-Probe with as much advance notice as possible if and when Novartis or its Affiliates so
requests early delivery of Spare Parts. The parties hereby acknowledge and agree that in
any event, Gen-Probe shall not be in breach of its obligations hereunder for not satisfying
delivery requests that do not meet the lead times specified in this Agreement.

               (iii) If Gen-Probe terminates its agreement with any of the manufacturers of Spare
Parts required to maintain Gen-Probe supplied Blood Screening Instruments, Gen-Probe shall
promptly notify Novartis and use Commercially Reasonable Efforts to provide Spare Parts to
Novartis from an alternative manufacturer. If Gen-Probe fails to secure a supply of Spare
Parts from an alternative manufacturer within ninety (90) days of the termination of the
prior Spare Parts agreement, Novartis may manufacture or have manufactured the necessary
Spare Parts. In such event, Gen-Probe promptly shall provide such reasonable technical
assistance, at Gen-Probe’s sole cost, as necessary to enable Novartis to manufacture (or
have manufactured) such Spare Parts.

               (d) Five Year Support and Parts Availability. Gen-Probe will provide applicable
support and Spare Parts availability for at least five (5) years after a given Blood Screening
Instrument falls out of production. Gen-Probe will provide written notification if Gen-Probe
expects any Blood Screening Instrument to fall out of production with sufficient lead time to
consider and potentially place orders for last-time purchases of such Blood Screening Instrument.
With respect to Spare Parts obsolescence, Gen-Probe will: (i) notify Novartis in writing of any
planned Spare Part obsolescence, and any plan to initiate a design change will be communicated in
advance in writing to Novartis; (ii) purchase material for last-time Spare Part purchases that
include quantities designated for all released Novartis Blood Screening Instruments; and (iii) bear
the cost of such last-time purchases, including any field instrument upgrades that are required due
to Spare Part obsolescence, as well as storage costs to hold such materials.

          5.4.4 Blood Screening Instruments Shipping and Delivery

               (a) Tigris Instruments. Gen-Probe shall release Tigris Instruments to Novartis or its
Affiliates according to Tigris Instrument Purchase Order delivery dates. Gen-Probe shall supply a
Certificate of Compliance, a Declaration of Conformity, and a Configuration List when a Tigris
Instrument is released by Gen-Probe Quality Control.

39

 

Novartis or its Affiliates shall be responsible for all outbound freight, insurance charges,
taxes, import and export duties, and other charges applicable to the sale and transport of Tigris
Instruments purchased by Novartis or its Affiliates to such location designated by Novartis or its
Affiliates in the applicable Tigris Instrument Purchase Order. Novartis or its Affiliates will
make arrangements for the shipment of released Tigris Instruments to customers of Novartis or its
Affiliates or Novartis-approved third parties for storage. Shipping terms shall be FCA the
supplier/manufacturer’s facility or other storage facility utilized by Gen-Probe, as governed by
Incoterms 2000. Proof of delivery shall be upon receipt by Novartis or its Affiliates of a faxed
copy of a packing slip from Gen-Probe or its designee indicating the Tigris Instrument is available
for shipment. Novartis or its Affiliates agree to accept ownership of the Tigris Instrument upon
receipt of such a packing slip.

               (b) Component Instruments. With respect to Component Instruments, Gen-Probe shall
supply a Certificate of Compliance for those Component Instruments released by Gen-Probe Quality
Control. Novartis or its Affiliates shall be responsible for all outbound freight, insurance
charges, taxes, import and export duties, and other charges applicable to the sale and transport of
such Component Instruments purchased by Novartis or its Affiliates to such location designated by
Novartis or its Affiliates in the applicable Component Purchase Order. Shipment and receipt of
such Component Instruments shall be FCA Gen-Probe, 10210 Genetic Center Drive, San Diego,
California 92101, as governed by Incoterms 2000.

               (c) Spare Parts. Shipping terms for software, manuals and Component Instrument Spare
Parts shall be FCA Gen-Probe, 10210 Genetic Center Drive, San Diego, California 92101, as governed
by Incoterms 2000.

          5.4.5 Blood Screening Instruments Engineering Change Notification

               (a) Tigris Instruments. Unless otherwise agreed by the parties in writing, Gen-Probe
shall be the owner of the design of the Tigris Instruments and, as such, only Gen-Probe has the
right to effect any change to the design of a Tigris Instrument. Gen-Probe shall notify Novartis
in writing of any change to a Tigris Instrument within five (5) business days after such change has
been approved by Gen-Probe. Gen-Probe shall bear the cost of any and all parts required to
implement Tigris Instrument modifications that are 1) mandated by the FDA or any comparable foreign
regulatory body or 2) mandated by Gen-Probe to assure or increase Tigris Instrument safety or
reliability, or ensure proper Tigris Instrument performance according to the Tigris Instrument
specifications. This shall include replacing or upgrading any Spare Parts in Novartis’s inventory
that can no longer be used as a result of a change, at no additional cost to Novartis. Novartis
shall bear the cost of parts required to implement all other changes not mandated by the FDA or
Gen-Probe. When changes to Tigris Instruments in the field or in inventory will be performed at the
expense of Novartis, Novartis retains the right to determine if and when a change to the Tigris
Instruments in the field will be implemented, dependent upon availability of the parts and other
internal business conditions necessary to implement the change.

               (b) Component Instruments. Unless otherwise agreed by the parties in writing, with
respect to Component Instruments, Gen-Probe shall be the owner of the design of such Component
Instruments and, as such, only Gen-Probe has the right to effect any change to

40

 

the design of such Component Instrument. Gen-Probe shall notify Novartis in writing of any
change to such Component Instrument within five (5) business days after such change has been
approved by Gen-Probe.

               (c) Spare Parts. Unless otherwise agreed by the parties in writing, Gen-Probe shall
be the owner of the design of the Spare Parts and, as such, only Gen-Probe has the right to effect
any change to the design of a Spare Part. Gen-Probe shall notify Novartis in writing of any change
to a Spare Part within five (5) business days after such change has been approved by Gen-Probe.

     5.5 Packaging. All Products supplied under this Agreement shall be packaged in such
manner as Novartis reasonably determines and Gen-Probe does not reasonably object.

     5.6 Rejection and Cure

          5.6.1 Blood Screening Assays. If a shipment of Blood Screening Assays or any portion
thereof is spoiled, damaged or defective, or fails to have the appropriate remaining life, then
Novartis or its Affiliates shall have the right to reject such shipment or the portion thereof that
fails to so conform, as the case may be. Novartis or its Affiliates shall give written notice to
Gen-Probe of its rejection hereunder, within thirty (30) days after Novartis or its Affiliates’
receipt of such shipment, specifying the grounds for such rejection and requesting a return
material authorization. All or any part of any shipment may be held for Gen-Probe’s disposition,
at Gen-Probe’s expense if found to be not in conformance with the applicable specifications.
Gen-Probe shall use its Commercially Reasonable Efforts to cure such rejection or replace such
rejected shipment (or portion of shipment) after receipt of notice of rejection thereof.

          5.6.2 Blood Screening Instruments. If any Blood Screening Instrument is damaged,
defective or fails to conform to the specifications therefor, then Novartis or its Affiliates shall
have the right to reject such damaged, defective or nonconforming Blood Screening Instrument.
Novartis or its Affiliates shall give written notice to both Gen-Probe and any manufacturer
designated by Gen-Probe of its rejection hereunder, within ten (10) days after installation of such
Instrument, specifying the grounds for such rejection and requesting a return material
authorization. The Blood Screening Instrument shall be held for Gen-Probe’s disposition, at
Gen-Probe’s expense, if found to be damaged, defective or nonconforming. Gen-Probe shall use its
Commercially Reasonable Efforts to replace such rejected Blood Screening Instrument after receipt
of notice of rejection thereof.

          5.6.3 LIMITATION OF LIABILITY. EXCEPT AS OTHERWISE SPECIFICALLY SET FORTH IN THIS
AGREEMENT, GEN-PROBE’S SOLE LIABILITY TO NOVARTIS, AND NOVARTIS’S SOLE REMEDY, WITH RESPECT TO THE
SPECIFIC MATTERS ADDRESSED UNDER SECTION 5.6 ABOVE SHALL BE THE REJECTION AND REPLACEMENT OF
NON-CONFORMING PRODUCTS. NOTHING IN THIS SECTION SHALL LIMIT ANY RIGHTS OR REMEDIES UNDER ARTICLE
9 OR ANY RIGHT OF NOVARTIS TO ASSUME RESPONSIBILITY FOR THE MANUFACTURE OF THE PRODUCTS UNDER
ARTICLE 3.

41

 

     5.7 Warranty. Gen-Probe warrants that all the Products delivered to Novartis pursuant to
this Agreement shall conform with the applicable specifications, shall be free from defects in
material and workmanship, and shall be manufactured in compliance with applicable laws and
regulations. Any and all warranties by subcontract manufacturers of the Blood Screening
Instruments shall inure to the benefit of Novartis, to the extent permitted by such subcontract
manufacturer.

          5.7.1 LIMITATION OF LIABILITY. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS
AGREEMENT, GEN-PROBE MAKES NO OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE PRODUCTS.
GEN-PROBE DISCLAIMS ALL OTHER WARRANTIES, EXPRESS AND IMPLIED, INCLUDING WITHOUT LIMITATION THE
IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT.

          5.7.2 Complaint Resolution. The parties agree that prompt investigation is required
of any complaint concerning product quality, in order to minimize product scrap and provide optimal
customer service. The parties shall use best efforts to respond promptly to any complaint that
potentially implicates product quality, in accordance with the May 28, 2009 Quality Agreement and
the parties’ “Complaint Handling Plan.”

     5.8 Independent Purchaser Status. Novartis and its Affiliates shall be independent
purchasers and resellers of the Products. Novartis and its Affiliates shall be free to use and
resell the Products on such terms as each may, in its sole discretion, determine, including price,
returns, credits and discounts.

     5.9 Non-Commercial Products. Gen-Probe agrees to provide to Novartis or its
Affiliates reasonable quantities of Blood Screening Assays manufactured by Gen-Probe for uses other
than sale to customers, including without limitation research studies, marketing studies, internal
research and development, and troubleshooting (all for Novartis or its Affiliate’s use only in
direct furtherance of the express purposes of this Agreement and without any implied license for
any purpose other than such express purposes), to the extent such Products are specifically ordered
by Novartis or its Affiliates for such purposes (“Non-commercial Products”). The entire
compensation to Gen-Probe for Non-commercial Products shall be not greater than one hundred twenty
percent (120%) of Gen-Probe’s Manufacturing Cost. The quantities of Non-commercial Products
ordered by Novartis or its Affiliates shall be subject to review by the Supervisory Board.

     5.10 Internal Commercial Use. For all Products which are used commercially by
Novartis or its Affiliates, Novartis shall pay to Gen-Probe the compensation which would be due
Gen-Probe had such Products been the subject of an arm’s length commercial sale by Novartis.

42

 

ARTICLE 6

PAYMENTS AND REPORTS

     6.1 Compensation

          6.1.1 Compensation to Gen-Probe for Blood Screening Assays. In consideration for the
rights granted, and the obligations accepted, by Gen-Probe, Novartis or its Affiliates, as
applicable, shall pay to Gen-Probe the following amounts:

               (a) Transfer Price. Within thirty (30) days after receipt of invoice, Novartis shall
pay to Gen-Probe the Transfer Price for each Blood Screening Assay purchased by Novartis or its
Affiliates.

               (b) Applicable Purchase Price. Novartis shall pay to Gen-Probe the Applicable
Purchase Price for each Blood Screening Assay sold by a Seller to a Third Party in a calendar
month, less the Transfer Price actually paid to Gen-Probe for such Blood Screening Assay, within
thirty (30) days after the end of each calendar month and concurrently with the written report
required by Section 6.4.

          6.1.2 Compensation to Gen-Probe for Blood Screening Instruments. In consideration for
the rights granted, and the obligations accepted, by Gen-Probe, Novartis or its Affiliates, as
applicable, shall pay to Gen-Probe the following amounts:

               (a) Transfer Price. Within thirty (30) days of invoice, Novartis shall pay to
Gen-Probe the Transfer Price for each Blood Screening Instrument purchased by Novartis or its
Affiliates.

               (b) Instrument Sales in the United States and Canada. Within thirty (30) days after
the end of each calendar month, Novartis shall pay to Gen-Probe an amount equal to fifty percent
(50%) of the difference of (A) Net Sales of each Blood Screening Instrument sold by Novartis or its
Affiliates to independent customers in the United States and Canada during such calendar month, and
(B) the Transfer Price actually paid to Gen-Probe for each Blood Screening Instrument included with
the calculation of Net Sales for such calendar month.

               (i) If Novartis or its Affiliates places an instrument with a customer in the United
States or Canada and receives revenue for Blood Screening Instruments and Blood Screening
Assays on a combined basis (such arrangement, a “Reagent Rental”), such revenue shall be
allocated to the Blood Screening Assays and in determining Net Sales for the Blood Screening
Assays Novartis shall not be entitled to deduct any amount allocated to an imputed charge
for instruments. Nothing contained in this subsection shall limit Novartis’ right to
deduct, in accordance with Section 3.1.9(c), instrument service revenue received pursuant to
a Reagent Rental arrangement.

               (ii) This Section expressly excludes from Net Sales all revenues received in connection
with the sale of TECANs, whether deemed part of a Blood Screening Instrument or not, so long
as the transfer qualifies as a sale under generally accepted accounting principles (GAAP).
For the avoidance of doubt, such

43

 

exclusion from Net Sales shall be taken by Novartis only for TECANs purchased from
Gen-Probe. Further, Novartis agrees to transfer such TECANs at no more than commercially
reasonable values for the diagnostic and/or blood screening markets consistent with standard
industry practice in those markets.

               (c) Instrument Sales Outside the United States and Canada. Except as otherwise agreed
by the parties in writing, Novartis shall retain the aggregate revenues received by it or its
Affiliates from sales of Blood Screening Instruments outside the United States and Canada.

               (d) Reagent Rentals Outside the United States and Canada. If Novartis or its
Affiliates leases or intends to lease a Blood Screening Instrument to an independent customer
outside the U.S. and Canada in combination with the sale of Blood Screening Assays, and Novartis is
to receive revenues for the Blood Screening Instruments, Blood Screening Assays and maintenance and
repair service on a combined, unallocated basis, Novartis shall be entitled to deduct from the
gross revenue received, prior to determining Net Sales for the Blood Screening Assays, an amount
equal to one hundred percent (100%) of the actual, out-of-pocket cost of the instrument, reasonably
allocated for the applicable period, assuming a five year life for the instrument, together with a
reasonable allocation of the actual, out-of-pocket costs of service. Once Novartis has deducted
an amount equal to its total, actual, out-of-pocket cost for the instrument, no further deductions
shall be allowed. If Novartis or its Affiliates leases or intends to lease a Blood Screening
Instrument to an independent customer outside the U.S. and Canada in combination with the sale of
Blood Screening Assays, and Novartis is to receive revenues for the Blood Screening Instruments,
Blood Screening Assays and maintenance and repair service on an allocated basis, Novartis shall be
entitled to deduct from the gross revenue received, prior to determining Net Sales for the Blood
Screening Assays, only those portions allocated in the customer agreement for the Blood Screening
Instruments and the maintenance and repair services, each at no more than commercially reasonable
value consistent with standard industry practice in the diagnostic and/or blood screening markets.

               (e) Reimbursement of Development Costs for FEP and RAS Components of eSAS 2
Instrument. As set forth in Schedule 6.1.2(e), Novartis shall be entitled to reimbursement of
development costs for the FEP component and the RAS component of the eSAS2 Instrument solely from
revenues from sales of such components.

          6.1.3 Compensation to Gen-Probe for Ancillary Products. In consideration for the
rights granted, and the obligations accepted, by Gen-Probe, Novartis or its Affiliates, as
applicable, shall pay to Gen-Probe the following amounts:

               (a) Transfer Price; Shipping. Within thirty (30) days after receipt of invoice,
Novartis shall pay to Gen-Probe the Transfer Price for each Ancillary Product purchased by Novartis
or its Affiliates.

               (b) Additional Compensation. Ancillary Products shall generally be sold by Novartis at a
price that is approximately equal to Novartis’ cost. If in any month Novartis’ aggregate revenues
from the sale of Ancillary Products exceeds one hundred twenty percent (120%) of the aggregate
Transfer Price paid for such Products, then within thirty (30)

44

 

days after the end of such calendar month, Novartis shall pay to Gen-Probe an amount equal to fifty
percent (50%) of the excess amount. Where Ancillary Products are sold by Novartis on a combined,
unallocated basis with other Products, Novartis shall not be entitled to deduct from revenue any
amount in excess of the Transfer Price for such Ancillary Products in determining Net Sales of such
other Products.

     6.2 Gen-Probe’s Agreement To Contribute To HIV Patent Payments. Pursuant to Section
8.6 and subject to this Section 6.2, the parties agree to share the payment obligation of Novartis
and Gen-Probe for the license of HIV-1 intellectual property rights owned by the National
Institutes of Health and Institut Pasteur as follows: Novartis will pay two-thirds of the
obligation and Gen-Probe shall pay one-third of the obligation. Gen-Probe shall make all payments
due hereunder to Novartis.

          6.2.1 The terms of a proposed agreement between the U.S. National Institutes of Health (“NIH”)
and Novartis (the “NIH-Novartis Agreement”) will require payments to NIH for the sale of Blood
Screening Assays not to exceed the following:

               (a) Five annual payments of [...***...], beginning in the first quarter of [...***...],
increasing in amount to [...***...] annually if and when [...***...]; and

               (b) A sales royalty of [...***...] percent [...***...] beginning upon the earlier of (i)
[...***...] or (ii) [...***...].

          6.2.2 [...***...].

               (a) [...***...]:

                    (i) [...***...];

                    (ii) [...***...];

                    (iii) [...***...]

***Confidential Treatment Requested

45

 

                    (iv) [...***...]

               (b) [...***...]

          6.2.3 Novartis and Gen-Probe will work together and will use their best efforts to minimize
the aggregate payments to NIH and Institut Pasteur. Novartis will invoice Gen-Probe for any amount
properly due to Novartis as Gen-Probe’s share of a payment made by Novartis under the NIH-Novartis
Agreement. If not paid within thirty (30) days of the date the invoice is delivered to Gen-Probe,
Novartis may immediately deduct from payments due Gen-Probe under this Agreement the amount due
Novartis. [...***...] At least annually, the parties will retrospectively “true-up” their
obligations under the agreements with [...***...] to be consistent with the parties’ agreement to
share such obligations two-thirds by Novartis and one-third by Gen-Probe, subject to all provisions
of this Agreement, including all limitations of the immediately preceding sentence.

     6.3 Invoicing. Upon shipment of the Products to Novartis, Gen-Probe shall submit
invoices therefor indicating the applicable Transfer Price to Novartis.

     6.4 Reports. Within thirty (30) days after the end of each calendar month during the
Blood Screening Term, as applicable in connection with Novartis’s payment obligations hereunder,
Novartis shall furnish to Gen-Probe a written report showing in reasonably specific detail (a) the
gross sales, on a Product-by-Product and country-by-country basis, of all Products sold by Novartis
and its Affiliates to independent customers in the Territory during such period as to which
Novartis is obligated to make payments hereunder based on Product sales and the calculation of Net
Sales on a worldwide basis from such gross sales; (b) the allowable deductions taken pursuant to
Section 1.33, Section 3.1.4(b)(ii), or Section 3.1.9(d) (each subject to the provisions of Section
1.33.2 concerning the use of accruals based upon estimates); (c) all amounts owing to Gen-Probe
hereunder payable in United States dollars, if any, which shall have accrued hereunder based upon
such sales of Products; (d) the withholding taxes, if any, required by law to be deducted in
respect of such sales; (e) the date of the First Commercial Sale of each Product in each country in
the Territory during such period; and (f) the exchange rates used in determining the amount of
United States dollars. Novartis shall keep complete and accurate records in sufficient detail to
properly reflect all gross sales and Net Sales and to enable all amounts payable hereunder to be
determined.

***Confidential Treatment Requested

46

 

               (a) Reagent Rental Reports. Novartis shall provide to Gen-Probe, no later than thirty
(30) days following the end of a calendar year, an annual report that (i) identifies with
specificity the number of Blood Screening Assays sold concurrently or in connection with the
placement of Blood Screening Instruments, and (ii) contains an accounting in reasonable detail of
the permitted deductions taken pursuant to Section 6.1.2(d) in the prior calendar year with regard
to such reagent rentals. Gen-Probe shall have the right to audit the books and records of Novartis
to determine the accuracy and sufficiency of any such report in accordance with this Agreement not
more than once every other year.

     6.5 Exchange Rates. With respect to sales of Products invoiced in United States
dollars, all such amounts calculated under this Agreement shall be expressed in United States
dollars. With respect to sales of Products invoiced in a currency other than United States
dollars, all such amounts calculated under this Agreement shall be expressed in the domestic
currency of the party making the sale together with the United States dollar equivalent of such
amounts calculated using Novartis’s standard accounting methods for calculating worldwide sales of
its other products.

     6.6 Audits.

          6.6.1 Upon the written request of either party (the “Requesting Party”) and not more than once
in each calendar year, the other party (the “Responding Party”) shall permit an independent
certified public accounting firm of nationally recognized standing, selected by the Requesting
Party and reasonably acceptable to the Responding Party, at the Requesting Party’s expense, to have
access during normal business hours to such of the records of the Responding Party as may be
reasonably necessary to verify the accuracy of the payment reports and invoices hereunder for any
year ending not more than thirty-six (36) months prior to the date of such request. The accounting
firm shall disclose to the Requesting Party only whether the payment reports and invoices are
correct or not and the specific details concerning any discrepancies. No other information shall
be shared.

          6.6.2 If such accounting firm concludes that undercharged or overcharged amounts are owing
from one party to the other for such period, the appropriate party shall pay such amounts within
thirty (30) days of the date the Requesting Party delivers to the Responding Party such accounting
firm’s written report so concluding. The fees charged by such accounting firm shall be paid by the
Requesting Party; provided, however, if the audit discloses either (a) that the amounts payable by
the Responding Party for the audited period are more than one hundred five percent (105%) of the
amounts actually paid for such period, or (b) that the amounts charged by the Responding Party for
the audited period are more than one hundred five percent (105%) of the amounts actually incurred
for such period, then the Responding Party shall pay the reasonable fees and expenses charged by
such accounting firm.

          6.6.3 The Requesting Party shall treat all financial information subject to review under this
Section 6.6 as confidential, and shall cause its accounting firm to retain all such financial
information in confidence with a confidentiality agreement reasonably acceptable to the Responding
Party.

47

 

     6.7 Payment Method. All payments by Novartis to Gen-Probe under this Agreement shall be
paid in United States dollars, and all such payments shall be originated from a United States bank
located in the United States and made by bank wire transfer in immediately available funds to such
account as Gen-Probe shall designate before such payment is due.

     6.8 Exchange Control. If at any time legal restrictions prevent the prompt remittance
of part or all royalties with respect to any country in the Territory where the Product is sold,
payment shall be made through such lawful means or methods as the parties reasonably shall
determine.

     6.9 Sales and Use Taxes. Any federal, state, county or municipal sales or use tax,
excise or similar charge, or other tax assessment (other than that assessed against income),
assessed or charged on the sale of the Products sold by Gen-Probe to Novartis pursuant to this
Agreement shall be paid by Novartis.

     6.10 Withholding Taxes. Novartis shall be entitled to deduct the amount of any
withholding taxes, value-added taxes or other taxes, levies or charges (other than United States
taxes) with respect to amounts payable by Novartis, its Affiliates or, in the case of Products for
the Blood Screening Field, by distributors in Japan, Germany, Italy, France, or the United Kingdom,
or any taxes required to be withheld by Novartis, its Affiliates, or such distributors, to the
extent Novartis, its Affiliates, or such distributors pay to the appropriate governmental authority
on behalf of Gen-Probe such taxes, levies or charges. Novartis shall use reasonable efforts to
minimize any such taxes, levies or charges required to be withheld on behalf of Gen-Probe by
Novartis, its Affiliates, or such distributors. Novartis promptly shall deliver to Gem-Probe proof
of payment of all such taxes, levies and other charges, together with copies of all communications
from or with such governmental authority with respect thereto.

     6.11 Late Payments. Unless otherwise provided in this Agreement, a party shall pay
interest to the other party on the aggregate amount of any amounts payable by such party that are
not paid on or before the date such amounts are due under this Agreement at a rate per annum equal
to the lesser of the prime rate of interest as reported by Bank of America NT&SA in San Francisco,
California, from time to time, plus two percent (2%), or the highest rate permitted by applicable
law, calculated on the number of days such payment is delinquent.

ARTICLE 7

CONFIDENTIALITY

     7.1 Confidential Information. For the period commencing on the date this Agreement is
first signed by both parties and ending seven (7) years following the expiration or earlier
termination hereof, a party (the “Receiving Party”) shall maintain in confidence the Confidential
Information of the other party, and shall not disclose, use, or grant the use of the Confidential
Information of the other party (the “Disclosing Party”) except on a need-to-know basis to its (and
its Affiliates’) directors, officers and employees, and to its consultants and to other Third
Parties, and then only to the extent that such disclosure or use is reasonably necessary in
connection with such party’s activities as expressly authorized by this Agreement. To the extent
that disclosure to any Person is authorized by this Agreement, prior to disclosure,

48

 

the Receiving Party shall obtain written agreement of such Person to hold in confidence and
not disclose, use or grant the use of the Confidential Information of the other party except as
expressly permitted under this Agreement. The parties agree that the term of the non-disclosure
and non-use obligations of a Third Party will end seven (7) years after the end of the contractual
arrangement with such Third Party. Each Receiving Party shall notify the Disclosing Party promptly
upon discovery of any unauthorized use or disclosure of the Disclosing Party’s Confidential
Information. Upon the expiration or earlier termination of this Agreement, each party shall return
to the other party all tangible items regarding the Confidential Information of the other party and
all copies thereof; provided, however, that each Receiving Party shall have the right to retain one
(1) copy for its legal files for the sole purpose of determining its obligations hereunder.

     7.2 Terms of this Agreement. The terms of this Agreement shall be considered
Confidential Information subject to the obligations of confidentiality, non-disclosure and non-use
in this ARTICLE 7. Notwithstanding the foregoing, either party may disclose the terms of this
Agreement in order to comply with applicable laws, rules and regulations (including those of the
United States Securities and Exchange Commission), provided, however, that reasonably in advance of
such disclosure the disclosing party shall provide written notice to the other party so that such
other party may review the proposed disclosure and provide comments to the disclosing party,
including by requesting confidential treatment of certain terms (such as the financial terms) of
this Agreement, and the disclosing party shall take into account the other party’s comments and, to
the extent consistent with applicable laws, rules and regulations, seek confidential treatment of
such terms.

     7.3 Permitted Disclosures. The confidentiality obligations under this ARTICLE 7 shall
not apply to the extent that a party is required to disclose information by applicable law,
regulation or order of a governmental agency or a court of competent jurisdiction, provided that
such party shall provide written notice thereof to the other party and sufficient opportunity to
object to any such disclosure or to request confidential treatment thereof.

ARTICLE 8

INVENTIONS AND INTELLECTUAL PROPERTY RIGHTS

     8.1 Ownership of Inventions.

          8.1.1 Except as otherwise set forth in Sections 8.1.2 through 8.1.7 below, the entire right
and title in all discoveries, inventions or other technology, data or information (whether
patentable or not), together with all patent and other intellectual property rights therein, made
or conceived during and as a result of a Development Program or the performance of other
obligations under this Agreement, (e.g., manufacturing) (collectively, the “Inventions”) (a) by
employees of Gen-Probe or others acting solely on behalf of Gen-Probe (the “Gen-Probe Inventions”)
shall be owned solely by Gen-Probe, (b) by employees of Novartis or others acting solely on behalf
of Novartis (the “Novartis Inventions”) shall be owned solely by Novartis, and (c) jointly by
employees of Gen-Probe or others acting on behalf of Gen-Probe and employees of Novartis or others
acting on behalf of Novartis (the “Joint Inventions”) shall be owned jointly by Gen-Probe and
Novartis.

49

 

               (a) Novartis Inventions shall be included within the Novartis IP Rights, Gen-Probe Inventions
shall be included within the Gen-Probe IP Rights, and Joint Inventions shall be within both the
Novartis IP Rights and Gen-Probe IP Rights, so that they are available for use within the scope of
this Agreement.

               (b) Each party shall have the right, subject to the provisions of this Agreement, to freely
exploit, transfer, license or encumber its rights in both its own inventions hereunder (except that
each party expressly agrees that this sentence does not create in any way an implied license to the
intellectual property of the other party and that there are no such implied licenses in this
Agreement) and in any Joint Invention hereunder (or the patent and other intellectual property
rights therein) without the consent of, or compensation or accounting to, the other party, except
as to a Joint Invention to the extent that:

               (i) Such use or application of a Joint Invention would require a license from the other
party (under a Valid Claim other than those claiming the Joint Invention), each party
expressly agreeing that in this Agreement there are no implied licenses to the intellectual
property of the other party; and

               (ii) except that, absent mutual written agreement or as provided for otherwise herein,
no use of any such Joint Invention shall be made during any term of this Agreement in
connection with a Competitive Probe Assay (which shall mean for all purposes of this
Agreement as to both parties, a nucleic acid probe-based assay which is used for the same
clinical indication as any Blood Screening Assay developed under this Agreement); and

               (iii) Such use or application of a Joint Invention resulting from application of
Section 8.1.6(d) or 8.1.6(e) is made in connection with any product which competes directly
with a nucleic acid probe-based assay product of the other party which has been sold as of
the Effective Date of this Agreement.

               (c) Notwithstanding any other provision of this Agreement, the parties agree that a Derivative
Invention (as defined in Section 8.1.4 below) as to which any substantial use would infringe a
claim of [...***...]), shall be owned jointly by the parties and considered a Joint Invention.
Gen-Probe waives any and all rights in any such Derivative Invention to the extent (and only to the
extent) that such Derivative Invention is used in connection with immunoassays or protein binding
assays and such use would infringe the [...***...]. Gen-Probe agrees that Novartis shall have
exclusive rights with respect to such uses. Novartis waives any and all rights in any such
Derivative Invention to the extent (and only to the extent) that such Derivative Invention is used
in connection with nucleic acid hybridization assays and such use would infringe the [...***...].
Novartis agrees that Gen-Probe shall have exclusive rights with respect to such uses.

               (d) Notwithstanding any other provision of this Agreement, the parties agree that a Derivative
Invention (as defined in Section 8.1.4 below) as to which any substantial use would infringe a
Valid Claim of [...***...]), shall be owned jointly by the parties and considered a

***Confidential Treatment Requested

50

 

Joint Invention. Gen-Probe waives any and all rights in any such Derivative Invention to the
extent (and only to the extent) that such Derivative Invention made by Novartis is used in
connection with immunoassays or protein binding assays, provided however that nothing contained
herein shall constitute a license to Novartis of any rights under the [...***...]. Novartis waives
any and all rights in any such Derivative Invention to the extent (and only to the extent) that
such Derivative Invention is used in connection with nucleic acid hybridization assays. Novartis
agrees that Gen-Probe shall have exclusive rights with respect to such uses.

               (e) Notwithstanding any other provision of this Agreement, the parties agree that a Derivative
Invention (as defined in Section 8.1.4 below) made by Novartis as to which any substantial use
would infringe a Valid Claim which issues from [...***...]), shall be owned jointly by the parties
and considered a Joint Invention. Gen-Probe waives any and all rights in any such Derivative
Invention to the extent (and only to the extent) that any such Derivative Invention made by
Novartis is used in connection with immunoassays or protein binding assays, provided however that
nothing contained herein shall constitute a license to Novartis of any rights under [...***...].
Novartis waives any and all rights in any such Derivative Invention to the extent (and only to the
extent) that such Derivative Invention is used in connection with nucleic acid hybridization
assays. Novartis agrees that Gen-Probe shall have exclusive rights with respect to such uses.
This subsection 8.1.1(e) shall apply only to claims of the [...***...] when such claims have
issued.

               (f) Any party granting a license of a Joint Invention shall require as a term of the license
that the licensee agree to the restrictions set forth in Sections 8.1.1(b), 8.1.1(c), 8.1.1(d) and
8.1.1(e) and to include such restrictions in any further licenses or sublicenses.

          8.1.2 Neither Novartis nor Gen-Probe shall have any rights in or to the patent rights or other
intellectual property rights of the other party for any use or application other than those
expressly and specifically granted by this Agreement.

          8.1.3 The parties acknowledge and agree that, notwithstanding that only limited rights have
been granted hereunder, certain new technology may be discovered, invented or created solely by
Novartis through Novartis’s use of the Gen-Probe IP Rights within the uses and in the manner
contemplated by this Agreement. The Parties also acknowledge and agree that, notwithstanding that
only limited rights have been granted hereunder, certain new technology may be discovered, invented
or created solely by Gen-Probe through Gen-Probe’s use of the Novartis IP Rights within the uses
and in the manner contemplated by this Agreement. The rights and obligations of the Parties with
respect to all such new technology shall be governed by this ARTICLE 8.

          8.1.4 As used herein, a “Derivative Invention” shall mean any Invention made after the date of
this Agreement and claimed in a Valid Claim of the Inventing Party which:

               (a) is discovered, invented or created by a party (the “Inventing Party”) during any term of
this Agreement; and

***Confidential Treatment Requested

51

 

               (b) was made through or with, and would not have been made but for, the Inventing Party’s use
of Confidential Information of the other party (the “Disclosing Party”), if such information was
confidential when the invention was made.

          8.1.5 Neither party shall use any Derivative Invention in connection with a Competitive Probe
Assay during any term of this Agreement.

          8.1.6 A Disclosing Party shall have the exclusive option to acquire, on Commercially
Reasonable Terms, all right, title and interest in any Derivative Invention which represents an
improvement to, and as to which any substantial use would infringe a Valid Claim for, that Core
Technology of the Disclosing Party (as defined in Schedule 8.1.6(e) and Schedule 8.7, as
applicable) which was the subject of the Confidential Information through or with which the
Derivative Invention was made and without which it would not have been made. The option hereby
granted the Disclosing Party shall expire six (6) months after the Derivative Invention is first
disclosed to the Disclosing Party by the Inventing Party unless the Disclosing Party has elected
within such period to exercise such option. With respect to any such Derivative Invention,
following the Disclosing Party’s election to acquire ownership:

               (a) The Disclosing Party may use such Derivative Invention for all uses and purposes other
than those prohibited by Section 8.1.5 and other than those which would require a license from the
Inventing Party under a Valid Claim (other than a Valid Claim for the Derivative Invention). The
Disclosing Party shall have the right to license the Derivative Invention without the consent of
the Inventing Party, but any such license shall contain the same use restrictions set forth in the
first sentence of this subparagraph (a); and

               (b) the Inventing Party may use such Derivative Invention for (i) any of the purposes
expressly permitted by the terms of this Agreement with respect to the Confidential Information of
the Disclosing Party and (ii) any use or application which does not require a license of a Valid
Claim of the Disclosing Party, but only to the extent that such use is not made in connection with
any product which competes directly with a nucleic acid probe-based assay product of the Disclosing
Party which has been sold as of the Effective Date of this Agreement. The Inventing Party shall
not have the right to sublicense its rights hereunder except with the consent of the Disclosing
Party, which consent shall not be unreasonably withheld. In any event, any such sublicense
approved by the Disclosing Party shall contain the same use restrictions set forth in clauses (i)
and (ii) of this subparagraph (b).

               (c) The “Commercially Reasonable Terms” referred to above shall give full recognition, in
favor of the Disclosing Party, to both the value of the Confidential Information of such Disclosing
Party with which the Derivative Invention was made (and without which the Derivative Invention
would not have been made) and the value of the rights granted to the Inventing Party as to such
Derivative Invention. The “Commercially Reasonable Terms” referred to above shall also give full
recognition, in favor of the Inventing Party, to the value of the inventive application of such
Confidential Information.

52

 

               (d) Notwithstanding any other provision of this Section 8.1.6, the parties agree that if
substantial uses of a Derivative Invention would infringe a Valid Claim for Core Technology of
both parties (as defined in Schedule 8.1.6(e) and Schedule 8.7, as applicable), then such
Derivative Invention shall be considered as a Joint Invention under Section 8.1.1,
provided, however, that this subsection (d) shall not apply to:

               (i) A Derivative Invention as to which any substantial use would infringe any Valid
Claim to the same or substantially the same subject matter claimed in the patents and patent
applications identified on Schedule 8.7 as items A1 through A11, A16, B1 through B3, B5
through B6, C1 through C6, or D1; or

               (ii) A Derivative Invention as to which any substantial use would infringe any Valid
Claim which issues from the patent applications identified on Schedule 8.7 as items A13 or
A15, effective immediately upon issuance or approval of such claim as to Derivative
Inventions made after that date. (Any license of a Derivative Invention shall include such
limitation.)

               (e) The parties agree, solely for purposes of the use restriction of Sections 8.1.6(a) and
(b)(ii) and Sections 8.1.7(a)(i) and 8.1.7(b)(ii), that the term “Valid Claim” shall not include
unissued claims set forth in pending patent applications pertaining to the Core Technology of the
Disclosing Party identified on Schedule 8.1.6(e) and Schedule 8.7, respectively; provided,
however, that the term “Valid Claim” shall include a claim of such a patent application immediately
upon issuance or approval of the claim and that any license of a Derivative Invention shall include
such limitation. This subsection (e) shall not apply to exempt from the use restrictions
referenced above a Derivative Invention as to which any substantial use would infringe any Valid
Claim to the same or substantially the same subject matter claimed in the patent applications
identified on Schedule 8.7 as items A9 through A11, B6, C5 or C6.

          8.1.7 An Inventing Party shall own all right, title and interest in any Derivative Invention
which is not subject to Section 8.1.6 or which the Disclosing Party does not elect to acquire
within the six-month period permitted by Section 8.1.6. With respect to any such Derivative
Invention,

               (a) The Inventing Party may use such Derivative Invention for all uses and purposes other than
those prohibited by Section 8.1.5, but only to the extent that (i) such use does not require a
license under a Valid Claim of the Disclosing Party of further rights to Confidential Information
of the Disclosing Party which was previously disclosed hereunder or (ii) such use is not made in
connection with any product which competes directly with a nucleic acid probe-based assay product
of the Disclosing Party which is sold as of the Effective Date of this Agreement. The Inventing
Party shall have the right to license the Derivative Invention without the consent of the
Disclosing Party, but any such license shall contain the same use restrictions set forth in the
first sentence of this subparagraph (a); and

               (b) The Disclosing Party may use such Derivative Invention (i) for any of the purposes
expressly permitted by the terms of this Agreement and (ii) pursuant to the terms of a license
granted under Section 8.1.7(c), for all uses and applications other than those prohibited under
Section 8.1.5, which would not require a license from the Inventing Party under a Valid Claim
(other than a Valid Claim for the Derivative Invention). Upon exercise of the

53

 

option for a license, the Disclosing Party shall not have the right to sublicense its rights
thereunder except with the consent of the Inventing Party, which consent shall not be unreasonably
withheld. In any event, any such sublicense approved by the Inventing Party shall contain the same
use restrictions set forth in clauses (i) and (ii) of this subparagraph (b).

               (c) Upon request, the Inventing Party shall grant a nonexclusive license to the Disclosing
Party on Commercially Reasonable Terms to be negotiated to enable the Disclosing Party to use such
Derivative Invention for the purposes described in Section 8.1.7(b)(ii). The “Commercially
Reasonable Terms” referred to above shall give full recognition, in favor of the Disclosing Party,
to the value of the Confidential Information of such Disclosing Party with which the Derivative
Invention was made (and without which the Derivative Invention would not have been made). The
“Commercially Reasonable Terms” referred to above shall also give full recognition, in favor of the
Inventing Party, to the value of the inventive application of such Confidential Information.

          8.1.8 Without limiting the generality of Section 8.1.7, each Inventing Party under Section
8.1.7 agrees not to assert its rights in a Derivative Invention in such a manner as would block or
diminish the Disclosing Party’s rights to practice independently of the Derivative Invention
itself, the technology of the Disclosing Party directly related to the Confidential Information
with which the Derivative Invention was made and without which the Derivative Invention would not
have been made.

          8.1.9 Gen-Probe and Novartis shall promptly report to each other any and all Derivative
Inventions as each may discover, invent or create during the Blood Screening Term.

          8.1.10 Gen-Probe and Novartis shall execute and deliver to each other such assignments,
instruments or other documents as each may reasonably consider necessary to assure compliance with
the provisions of this Section 8.1. Novartis shall have the exclusive right to prosecute and
defend any and all patents and patent applications concerning any Derivative Invention owned by
Novartis and, as between Gen-Probe and Novartis, Novartis shall be solely responsible for the
expense of such patents and patent applications. Gen-Probe shall have the exclusive right to
prosecute and defend any and all proceedings concerning any Derivative Invention owned by Gen-Probe
and, as between Gen-Probe and Novartis, Gen-Probe shall be solely responsible for the expense of
such proceedings. As to any Derivative Invention assigned to the Disclosing Party upon exercise of
the option described in Section 8.1.6, the Disclosing Party shall take all such actions as may be
reasonably and specifically requested by the Inventing Party in connection with the prosecution of
a patent application to protect the Inventing Party’s rights in the Derivative Invention under
Section 8.1.6(b), provided that the Inventing Party shall be fully responsible for all incremental
costs and expenses incurred in connection with any such actions. If the Inventing Party requests
any such action, the parties shall thereafter reasonably cooperate in the prosecution of such
patent application.

          8.1.11 In the event the Parties cannot agree as to the classification of any technology for
any purpose under this ARTICLE 8 (including the mediation described in Section 11.1), the Parties
shall consider in good faith the possibility of submitting such disputes for accelerated decision
by an expert arbitration under such guidelines and expedited schedule as may be mutually agreed
(provided that no party shall be under an obligation to so agree). In the

54

 

absence of such mutual agreement, such disagreement or dispute as to classification shall be
resolved by arbitration as provided in this Agreement, except that the arbitrator may, at the
request of either party, appoint one or more experts, individually or jointly, to advise and report
on such classification, and the arbitrator shall place such reliance on such advice or report as he
or she deems appropriate.

          8.1.12 Nothing in this Agreement shall be interpreted as giving a party the right to analyze,
dissect, or disassemble any instrument, reagent, component, object, software or other property of
the other party provided under the terms of this Agreement, and which is not properly available
from other sources which have the right to transfer such property and authorize such activity, in
order to circumvent the need for a license of the technology reflected therein.

     8.2 Patent Rights. Except as provided in Section 8.1.10, each party shall be
responsible for and shall control, at its sole expense, the preparation, filing, prosecution,
maintenance and enforcement of all patent rights owned by or licensed to it (except for those
patent rights licensed to it from the other party) which are the subject of this Agreement. The
parties shall jointly have the right to prepare, file, prosecute, maintain, and enforce patent
rights covering Joint Inventions as described in Section 8.1.1 and the expenses thereof shall be
reasonably shared by parties as they may agree prior to the initiation of any such proceedings.
Each party shall cooperate with the other party, execute all lawful papers and instruments and make
all rightful oaths and declarations, as reasonably requested by the other party and at the other
party’s expense, as may be necessary in connection with the preparation, prosecution, maintenance
and enforcement of all patent rights which are the subject of this Agreement. Each party shall
place appropriate patent markings on all products which would infringe the patent rights of the
other party licensed under this Agreement, to the extent such patent marking is required by
applicable law, regulation or order to enable the other party to enforce such patent rights, all as
requested in writing by the other party.

     8.3 Copyrights.

          8.3.1 Gen-Probe Copyrights and Novartis Copyrights. Each party hereby acknowledges
that the other party has claimed, or may claim, copyright protection with respect to certain parts
of the Products and related materials. Each party further acknowledges the validity of the other
party’s right to claim copyright protection with respect to such items. Each party shall take no
action or make no omission which is in any way inconsistent with the other party’s claim of
copyright protection with respect to such items.

          8.3.2 Copyright Protection. In order to protect against infringement of the other
party’s copyrights, each party shall mark all of the other party’s copyrighted materials, as
requested by the other party in writing, used by such party in conducting its activities
contemplated by this Agreement with appropriate copyright markings. Each party shall cooperate
with the other party, take such actions and execute such documents, as reasonably requested by the
other party and at the other party’s expense, to assist the other party in the protection of the
other party’s copyrights. Any dispute as to which party owns a copyright will be resolved pursuant
to ARTICLE 11.

55

 

     8.4 Trademarks.

          8.4.1 Gen-Probe Marks and Novartis Marks. Gen-Probe shall own the Gen-Probe Marks and
shall pay all expenses of the registration thereof. Novartis shall own the Novartis Marks and
shall pay all expenses of the registration thereof. Except as otherwise expressly set forth in
this Agreement, each party shall not use, without the prior express written consent of the other
party, any of the other party’s marks (i.e., the Gen-Probe Marks or the Novartis Marks, as
applicable), or any word, title, expression, trademark, design or marking that is confusingly
similar thereto. Subject to Section 5.5, each party shall not alter, remove, cover or modify any
of the other party’s marks (i.e., the Gen-Probe Marks or the Novartis Marks, as applicable) from
the Products, their packaging or labeling without the other party’s prior express written consent.
Gen-Probe shall control, at its sole cost, the registration, prosecution, maintenance and
enforcement of the Gen-Probe Marks. Novartis shall control, at its sole cost, the registration,
prosecution, maintenance and enforcement of the Novartis Marks.

     8.5 Other Technology Rights. Except as otherwise expressly provided in this
Agreement, under no circumstances shall a party, as a result of this Agreement, obtain any
ownership interest or other right in any discovery, invention or other technology, data or
information (or any patent, copyright, trademark, or other intellectual property rights therein) of
the other party, including items transferred by the other party to such party at any time pursuant
to this Agreement. Except as expressly provided in this Agreement, neither party shall be under
any obligation to grant to the other party any rights in any patent, copyright, trademark, or other
intellectual property.

     8.6 Third Party Technology. The Supervisory Board will discuss Third Party patent
rights which may be necessary for (i) Blood Screening Assays or (ii) modifications to Blood
Screening Assays or Blood Screening Instruments. The Supervisory Board will consider the costs of
acquiring rights in such Third Party patent rights in connection with such Products, allocate the
costs between the parties, and agree upon methods for implementing such cost allocations. Pursuant
to the foregoing and subject to the conditions of Section 6.2, the parties agree to share the
payment obligation of Novartis and Gen-Probe for the license of HIV-1 intellectual property rights
owned by the National Institutes of Health and Institut Pasteur as follows: Novartis will pay
two-thirds of the obligation and Gen-Probe shall pay one-third of the obligation. Gen-Probe shall
make all payments due hereunder to Novartis.

     8.7 Stanford Agreement. The patent rights designated as “Selective Amplification”,
U.S. Patent No. 5,437,990 (Item A.2 on Schedule 8.7) Application No. 080,479 with a filing date of
July 31, 1987 are sublicensed to Novartis by Gen-Probe under the terms of a co-exclusive license
agreement (the “Stanford Agreement”) effective April 27, 1997 between Gen-Probe and The Board of
Trustees of the Leland Stanford Junior University, Palo Alto, California (“Stanford”). Under the
terms of the Stanford Agreement, certain provisions as set forth in Schedule 8.9 attached hereto
are incorporated into this Agreement by reference.

56

 

     8.8 Teknika Agreement. Gen-Probe is a party to a non-assertion agreement effective
February 7, 1997 (the “Teknika Agreement”) with Organon Teknika B.V., having a place of business at
Boseind 15, 5281 RM Boxtel, The Netherlands (“Teknika”), which agreement grants certain rights and
imposes certain conditions with respect to the transcription-based amplification patent rights set
forth in Schedule 8.7. Novartis agrees, at the request of Teknika, to permit and to cooperate
fully with an annual review of its manufacturing records (and such other records as may be
required) by an impartial, technically qualified third party to verify compliance with the
provisions of Section 3.3 of the Teknika Agreement. Selection of such third party shall be subject
to the approval of Novartis, such approval to be not unreasonably withheld. The results of such a
review as provided to Teknika will consist solely of a finding of compliance or non-compliance.
The cost of such review shall be born by Teknika and shall not be unreasonably burdensome for
Novartis.

     8.9 Continuation of Rights. In the event the Stanford Agreement or Teknika Agreement
is terminated for any reason, the rights under such agreements which are granted by Gen-Probe to
Novartis under this Agreement, as applicable, may be continued with Stanford and/or Teknika, as
applicable, provided that certain conditions precedent, as set forth in Schedule 8.9, shall have
been fulfilled.

ARTICLE 9

INDEMNIFICATION AND INSURANCE

     9.1 Indemnity.

          9.1.1 By Gen-Probe. Gen-Probe shall indemnify and hold Novartis harmless from and
against all losses, liabilities, damages and expenses (including reasonable attorneys’ fees and
costs) resulting from any claims, demands, actions or other proceedings by any Third Party arising
from (a) the breach of any representation, warranty or covenant by Gen-Probe under this Agreement,
(b) the failure of Gen-Probe or its subcontractor to manufacture the Products in conformity with
the specifications therefor, (c) the negligence or willful misconduct of Gen-Probe in performing
its obligations under this Agreement; or (d) the manufacture, sale, or use of any instrument or
assay sold by or on behalf of Gen-Probe, its Third Party licensees, or any of their Affiliates, or
distributors (other than by Gen-Probe to Novartis under the terms of this Agreement); in each case
except to the extent arising from the negligence or willful misconduct of Novartis.

          9.1.2 By Novartis. Novartis shall indemnify and hold Gen-Probe harmless from and
against all losses, liabilities, damages and expenses (including reasonable attorneys’ fees and
costs) resulting from any claims, demands, actions or other proceedings by any Third Party arising
from (a) the breach of any representation, warranty or covenant by Novartis under this Agreement,
(b) the failure of Novartis or its subcontractor to manufacture the Products in conformity with the
specifications therefor, in the event Novartis has assumed responsibility for the manufacture of
such Products, (c) the negligence or willful misconduct of Novartis in performing its obligations
under this Agreement; or (d) except to the extent Section 9.1.1 applies, the manufacture, sale, or
use of any instrument or assay sold by or on behalf of Novartis, or its

57

 

Affiliates, or distributors; except in each case to the extent arising from the negligence or
willful misconduct of Gen-Probe.

     9.2 Procedure. A party (the “Indemnitee”) that intends to claim indemnification under
this ARTICLE 9 shall promptly notify the other party (the “Indemnitor”) of any claim, demand,
action or other proceeding for which the Indemnitee intends to claim such indemnification. The
Indemnitor shall have the right to participate in, and, to the extent the Indemnitor so desires,
jointly with any other indemnitor similarly noticed, to assume the defense thereof with counsel
selected by the Indemnitor; provided, however, that the Indemnitee shall have the
right to retain its own counsel, with the reasonable fees and expenses to be paid by the
Indemnitee, if the Indemnitee reasonably determines that representation of the Indemnitee by
counsel retained by the Indemnitor would be inappropriate due to actual or potential differing
interests between the Indemnitee and any other party represented by such counsel in such
proceedings. The indemnity obligations under this ARTICLE 9 shall not apply to amounts paid in
settlement of any claim, demand, action or other proceeding if such settlement is effected without
the consent of the Indemnitor, which consent shall not be unreasonably withheld or delayed. The
failure to deliver notice to the Indemnitor within a reasonable time after the commencement of any
such action or other proceeding, if prejudicial to its ability to defend such action or other
proceeding, shall relieve such Indemnitor of any liability to the Indemnitee under this ARTICLE 9,
but the omission so to deliver notice to the Indemnitor will not relieve it of any liability that
it may have to any Indemnitee otherwise than under this ARTICLE 9. The Indemnitor may not settle,
or otherwise consent to an adverse judgment in, any such action or other proceeding that diminishes
the rights or interests of the Indemnitee without the express written consent of the Indemnitee.
The Indemnitee, its employees and agents, shall cooperate fully with the Indemnitor and its legal
representatives in the investigation of any claim, demand, action or other proceeding covered by
this indemnification.

     9.3 Insurance. Each party shall maintain liability insurance (including product
liability insurance) with respect to conduct of its obligations under this Agreement in such
amounts as it customarily maintains with respect to the conduct of its similar activities. Each
party shall maintain such insurance for so long as each continues to conduct such obligations, and
thereafter for so long as it maintains insurance for itself covering its similar activities.

ARTICLE 10

TERM AND TERMINATION

     10.1 Expiration. Unless terminated earlier pursuant to Section 10.2 below, this
Agreement shall expire on the expiration of the Blood Screening Term.

     10.2 Termination.

          10.2.1 Breach. Each party may terminate this Agreement upon or after the material
breach of any material provision of this Agreement, if the breaching party has not cured such
breach within ninety (90) days after notice thereof from the non-breaching party.

58

 

               (a) Any dispute with respect to the right of a party to terminate all or a portion of this
Agreement pursuant to this Section 10.2.1 shall be subject to resolution pursuant to ARTICLE 11.
During the pendency of any arbitration proceeding, at the request of the non-breaching party, the
arbitrator may take such interim steps and make such preliminary orders as the arbitrator deems
necessary to preserve the rights of the non-breaching party pending a final arbitration award,
including ordering the grant, on a temporary basis, of such licenses or rights as may be necessary
to enable the non-breaching party to preserve its economic interest in the Products for the Blood
Screening Field. At the conclusion of any such arbitration if the arbitrator determines that the
respondent materially breached this Agreement and that money damages will not adequately compensate
the claimant and that no other remedy is adequate in the circumstances considered as a whole, then
the arbitrator may order the breaching party to grant to the non-breaching party such rights
(including a nonexclusive, worldwide license, bearing a reasonable commercial royalty, under
intellectual property rights of the breaching party which are the subject of this Agreement) as may
be reasonably necessary to enable the claimant to complete development already in progress of,
make, use, offer for sale, sell and/or import Products for use in the Blood Screening Field for the
lesser of (a) five years or (b) the then-remaining period of this Agreement.

          10.2.2 Voluntary Bankruptcy. Each party may terminate this Agreement if the other
party shall (a) seek the liquidation, dissolution, or winding up of itself (other than dissolution
or winding up for the purposes of reconstruction or amalgamation) or the composition or
readjustment of all or substantially all of its debts, (b) apply for or consent to the appointment
of, or the taking of possession by, a receiver, custodian, trustee or liquidator of itself or of
all or substantially all of its assets, (c) make a general assignment for the benefit of its
creditors, (d) commence a voluntary case under the Bankruptcy Code, (e) file a petition seeking to
take advantage of any other law relating to bankruptcy, insolvency, reorganization, winding-up or
composition or readjustment of debts, or (f) adopt any resolution of its Board of Directors or
stockholders for the purpose of effecting any of the foregoing.

          10.2.3 Involuntary Bankruptcy. Each party may terminate this Agreement if a
proceeding or case shall be commenced without the application or consent of the other party and
such proceeding or case shall continue undismissed, or an order, judgment or decree approving or
ordering any of the following shall be entered and continue unstayed in effect, for a period of
ninety (90) days from and after the date service of process is effected upon the other party,
seeking (a) its liquidation, reorganization, dissolution or winding up, or the composition or
readjustment of all or substantially all of its debts, (b) the appointment of a trustee, receiver,
custodian, liquidator or the like of itself or of all or substantially all of its assets, or (c)
similar relief under any law relating to bankruptcy, insolvency, reorganization, winding up or
composition or readjustment of debts.

     10.3 Effect of Expiration and Termination. Except as provided in Section 10.2.1(a),
upon expiration or termination of this Agreement, all rights and licenses granted hereunder shall
terminate. Expiration or termination of this Agreement shall not relieve the parties of any
obligation accruing prior to such expiration or termination. The provisions of Section 2.2
(disclaimer of warranties),Section 5.7 (product warranties), Section 6.6 (audit of payments),
Article 7 (confidentiality), Section 8.1 (ownership of inventions), the third sentence of Section
8.2 (duty to cooperate with patent filings), Section 8.5 (other technology rights), Article 9

59

 

(insurance and indemnification), Section 10.3 (effect of expiration and termination), Article
11 (arbitration), and Article 12 (miscellaneous) shall survive the expiration or termination of
this Agreement.

ARTICLE 11

ARBITRATION

     11.1 Executive Mediation. Prior to submitting any dispute arising out of or related
to this Agreement to arbitration pursuant to Section 11.2, the matter shall be submitted to the
Chief Executive Officers of the parties for resolution. If such officers are unable to resolve the
matter directly, they may, by mutual agreement, utilize such dispute resolution methods, including
mediation, as are mutually agreed. If no resolution is reached within fifteen (15) days following
submission of such dispute to such officers, unless otherwise mutually agreed, the dispute shall be
submitted to arbitration pursuant to Section 11.2.

     11.2 Arbitration Procedure. Any controversy or claim relating to, arising out of, or
in any way connected to any provision of this Agreement shall be finally resolved by final and
binding arbitration in accordance with this Section by a single arbitrator who is a former state or
federal judge, to be conducted in California. Unless the parties agree otherwise, the arbitration
shall be conducted by JAMS, or by any similar arbitration provider who can provide a former judge
to conduct such arbitration if JAMS is no longer in existence. JAMS may order a change of venue
upon a showing of good cause by respondent. Subject to the JAMS Appeal Procedure described in
Section 11.3 below, the decision of the arbitrator shall be final, nonappealable and binding upon
the parties, and it may be entered in any court of competent jurisdiction. The arbitrator shall be
bound by all rules relating to the admissibility of evidence, including without limitation, all
relevant privileges and the attorney work product doctrine. Discovery shall be permitted in
accordance with the rules and procedures of the forum state unless otherwise agreed to by the
parties or ordered by the arbitrator on the basis of strict necessity adequately demonstrated by
the party requesting an extension of time. The arbitrator shall have the power to grant equitable
relief where applicable under the law. The arbitrator shall issue a written opinion setting forth
his or her decision and the reasons therefor within thirty (30) days after the arbitration
proceeding is concluded. The obligation of the parties to submit any dispute arising under or
related to this Agreement to arbitration as provided in this ARTICLE 11 shall survive the
expiration or earlier termination of this Agreement. Notwithstanding the foregoing, but subject to
Section 10.2.1(a), either party may seek and obtain an injunction or other appropriate relief from
a court to preserve or protect intellectual property rights or to preserve the status quo with
respect to any matter pending conclusion of the arbitration proceeding, but no such application to
a court shall in any way be permitted to stay or otherwise impede the process of the arbitration
proceeding.

     11.3 Review. The decision of the arbitrator shall be subject to review only in
accordance with the JAMS “Optional Appeal Procedure” in effect upon execution of this Agreement or
any other comparable arbitration appeal procedure. The parties agree to submit any request for
review in accordance with said procedure. The JAMS Appeal Panel appointed under said procedure
will apply the same standard of review as the first-level appellate court in the jurisdiction where
the arbitration was conducted would apply under similar circumstances.

60

 

The decision and award of the JAMS Appeal Panel (and the decision and award of the original
arbitrator if there is no appeal pursuant to this Section 11.3) will be final for all purposes and
binding upon the parties, and it may be entered in any court of competent jurisdiction.

ARTICLE 12

MISCELLANEOUS

     12.1 Notices. Any consent, notice or report required or permitted to be given or made
under this Agreement by one of the parties to the other shall be in writing, addressed to such
other party at its address indicated below, or to such other address as the addressee shall have
last furnished in writing to the addressor, and shall be effective upon receipt by the addressee.

	 	 	 

	If to Gen-Probe:

	 	Gen-Probe Incorporated
	 

	 	10210 Genetic Center Drive
	 

	 	San Diego, California 92121
	 

	 	Attention: President and
	 

	 	Chief Executive Officer
	 
	 	 
	If to Novartis:

	 	Novartis Vaccines and Diagnostics, Inc.
	 

	 	4560 Horton Street
	 

	 	Emeryville, California 94608
	 

	 	Attention: President, Diagnostics

     12.2 Force Majeure. In the event that a party is prevented or delayed from fulfilling
or performing any of its obligations under this Agreement (other than an obligation to pay money)
due to the occurrence of causes beyond the reasonable control of such party, including but not
limited to fires, floods, embargoes, wars, acts of war (whether war is declared or not),
insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, acts of God
or acts, omissions or delays in acting by any governmental authority or the other party, then such
party’s performance shall be excused, and the time for performance shall be extended, for the
period of inability or delay due to such occurrence; provided, however, that such party shall have
used its Commercially Reasonable Efforts to avoid such inability or delay, and such party shall
have given prompt written notice to the other party of such occurrence. Nothing contained in this
section shall limit Novartis’s right to manufacture or have manufactured any Product pursuant to
the terms of this Agreement, provided always that in the event of a force majeure, Novartis and
Gen-Probe shall apply all legally-available safety stocks to meet Novartis’s need before such right
to manufacture or have manufactured shall accrue and further provided that Novartis shall not
exercise such right in the event of a force majeure unless the Supervisory Board has met and
discussed all available options and reasonably not been able to agree that re-establishment of
production at a Gen-Probe facility is the most efficient alternative for maintaining continuity of
production.

61

 

     12.3 Assignment.

          12.3.1 This Agreement may not be directly or indirectly assigned or otherwise transferred,
nor, except as expressly provided hereunder, may any rights or obligations hereunder be assigned or
transferred by either party (whether voluntarily, by operation of law or otherwise) without the
consent of the other party which shall not be unreasonably withheld; provided,
however, that, except as otherwise provided in Section 12.3.2 below, either party may,
without such consent, assign or transfer this Agreement and its rights and obligations hereunder in
connection with the transfer or sale of all or substantially all of its assets (including without
limitation all of its assets relating to this Agreement), or in the event of its merger,
consolidation, other Change in Control or similar transaction. Any permitted assignee or
transferee shall assume all obligations of its assignor or transferor under this Agreement. On any
such assignment, the assignor shall be relieved of all obligations assigned hereunder, except those
accrued prior to the date of assignment and except as provided in Section 12.3.2 below. Any
purported assignment or transfer in violation of this Section 12.3 shall be void.

          12.3.2 Assignment by a party of its rights and obligations under this Agreement shall not
relieve that party of its obligations under ARTICLE 7, ARTICLE 8, or ARTICLE 11. Assignment by a
party of its rights and obligations under this Agreement shall not relieve it of its obligations
under Section 3.2.1 or any then-existing restrictions on licensing of intellectual property
pertaining to specific viruses or markers as to which such party became obligated, prior to such
assignment, pursuant to the last sentence of Section 3.2.2 and if following such assignment such
transferring party makes, uses or sells any nucleic acid probe-based assay for use in the Blood
Screening Field for the detection or quantitation of any virus or marker subject to Section 3.2.1
or such licensing restrictions of Section 3.2.2, such use shall be considered as a “license” for
purposes of Section 3.2.1 or such licensing restrictions of Section 3.2.2; however a license to the
assignee pursuant to Section 12.3.1 shall not be considered a license for purposes of Section 3.2.1
or such licensing restrictions of Section 3.2.2.

          12.3.3 Gen-Probe hereby acknowledges that it has given its consent to Novartis’s assignment of
its rights under this Agreement with respect to the Products for the Blood Screening Field to any
transferee, other than the parties identified in this Section, provided that such transferee is
reasonably capable of performing all of Novartis’s obligations in connection therewith and provided
that such transferee receives a license from Novartis of the Novartis IP Rights as reasonably
necessary to perform all obligations of Novartis in connection therewith. Novartis shall have no
right to directly or indirectly assign or otherwise transfer its rights and obligations with
respect to the Products (whether voluntarily, by operation of law or otherwise) to any of the
following (or their respective Affiliates): Abbott Laboratories, Inc.; Roche Diagnostic Systems,
Inc.; or Becton, Dickinson and Company. The rights granted in this Section 12.3.3 are personal to
Novartis and shall not be assignable.

     12.4 Severability. Each party hereby acknowledges that it does not intend to violate
any public policy, statutory or common laws, rules, regulations, treaty or decision of any
government agency or executive body thereof of any country or community or association of
countries. Should one or more provisions of this Agreement be or become invalid, the parties shall
substitute, by mutual consent, valid provisions for such invalid provisions, which valid provisions
in their economic effect are sufficiently similar to the invalid provisions that it can be

62

 

reasonably assumed that the parties would have entered into this Agreement with such
provisions. In case such provisions cannot be agreed upon, the invalidity of one or several
provisions of this Agreement shall not affect the validity of this Agreement as a whole, unless the
invalid provisions are of such essential importance to this Agreement that it is to be reasonably
assumed that the parties would not have entered into this Agreement without the invalid provisions.

     12.5 Applicable Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of California, without regard to the conflicts of law principles
thereof.

     12.6 Entire Agreement. Except as set forth herein, this Agreement contains the entire
understanding of the parties with respect to the subject matter hereof as of the Effective Date.
Nothing contained in this Section shall affect other agreements between the parties which are not
directly related to the subject matter of this agreement.

          12.6.1 Except as set forth herein, as of the Effective Date, Gen-Probe and Novartis agree to
prospectively terminate and hereby terminate (i) the 1998 Agreement, and (ii) all amendments,
supplemental agreements, side letter agreements, settlement agreements and addenda relating thereto
(together with the 1998 Agreement, the “Prior Agreements”), and further prospectively terminate and
hereby discharge any and all executory obligations thereunder, regardless of whether the Prior
Agreements provide that any such obligations shall survive termination. Gen-Probe and Novartis
further agree that any and all action(s), cause(s) of action, suits, debts, liability, claims,
demands, damages, losses, costs or expenses, of any nature whatsoever, known or unknown, fixed or
contingent (“Claims”) accruing after the Effective Date, arising out of, based upon, or relating to
this Agreement, and not expressly released by the Prior Agreements, shall be brought solely under
the terms and conditions of this Agreement.

          12.6.2 Notwithstanding Section 12.6.1, the following agreements are not terminated and survive
the execution of this Agreement and shall not be merged and integrated with this Agreement,
provided that all references in the following agreements to the 1998 Agreement (or any other Prior
Agreement) shall, mutatis mutandis, be deemed to be references to this Agreement:

(a) The Confidentiality and Joint Interest Agreement dated October 30, 2001;

(b) The Addendum for the Development of Special Software for the Tecan EVO
Instrument, effective January 1, 2008;

(c) The Future Blood Screening Assay — Ultrio 2 Addendum, dated October 1,
2008;

(d) The Confidentiality and Joint Interest Agreement dated February 4, 2009;

(e) The Quality Agreement for Alliance Partnership, dated May 28, 2009;

63

 

(f) The Regulatory Affairs Roles and Responsibilities Agreement, dated May
2008; and

(g) The specific provisions of Amendment No. 11 to the 1998 Agreement which
directly concern the Panther Instrument, which provisions shall survive
until such time as the new product development addendum for the Panther
Instrument is signed by the Parties.

          12.6.3 Gen-Probe and Novartis hereby agree that any and all Claims accruing prior to the
Effective Date and arising out of, based upon, or relating to the Prior Agreements (whether
discovered prior to or after the Effective Date of this Agreement), shall survive the execution of
this Agreement and shall be brought under the terms and conditions of the Prior Agreements.

          12.6.4 Notwithstanding Section 12.6.1, the execution of this Agreement shall in no way affect
any rights and obligations under the Prior Agreements with respect to the Clinical Diagnostic
Assays, Clinical Diagnostic Instruments, and the Clinical Diagnostic Field (as such terms are
defined in the 1998 Agreement), which rights and obligations shall be wholly unaffected by this
Agreement, as between Gen-Probe and Bayer Corporation (as the successor to such rights and
obligations).

     12.7 Amendment. This Agreement may be amended, or any term hereof modified, only by a
written instrument duly executed by both parties.

     12.8 Expenses and Attorney’s Fees. The prevailing party in any dispute between the
parties which is the subject of arbitration or litigation shall be entitled to recover the expenses
reasonably incurred in connection with such arbitration or litigation, including reasonable
attorney’s fees. The amount of such expenses and fees due the prevailing party shall be subject to
the arbitration provisions of ARTICLE 11.

     12.9 Independent Contractors. It is expressly agreed that Gen-Probe and Novartis
shall be independent contractors and that the relationship between the two parties shall not
constitute a partnership, joint venture or agency. Neither Gen-Probe nor Novartis shall have the
authority to make any statements, representations or commitments of any kind, or to take any
action, which shall be binding on the other, without the prior consent of the party to do so.

     12.10 Waiver. The waiver by either party of any right hereunder or the failure to
perform or of a breach by the other party shall not be deemed a waiver of any other right hereunder
or of any other breach or failure by said other party whether of a similar nature or otherwise.

     12.11 Drafting Party. The provisions of this Agreement, and the documents and
instruments referred to in the Agreement, have been prepared, examined, negotiated and revised by
each party and their respective lawyers, and no implication will be drawn and no provision will be
construed against any party by virtue of the purported identity of the drafter of this Agreement,
or any portion of this Agreement.

64

 

     12.12 Third Parties. None of the provisions of this Agreement shall be for the benefit of
or enforceable by any Third Party.

     12.13 Affiliates. The rights and obligations of Novartis under this Agreement shall
apply to Novartis’s Affiliates, and the rights and obligations of Gen-Probe under this Agreement
shall apply to Gen-Probe’s Affiliates, provided that Novartis and Gen-Probe shall be fully
responsible for the performance by their respective Affiliates of their respective obligations
under this Agreement.

     12.14 Counterparts. This Agreement may be executed in two or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute one and the same
instrument.

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth
above.

	 	 	 	 	 	 	 	 	 

	GEN-PROBE INCORPORATED	 	NOVARTIS VACCINES AND DIAGNOSTICS, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	By

	 	/s/ Carl W. Hull
 

Carl W. Hull
	 	By
	 	/s/ Peter Maag
 

Peter Maag
	 	 
	 

	 	President & CEO
	 	 	 	President, Diagnostics	 	 
	 

	 	July 24, 2009
	 	 	 	July 24, 2009	 	 

65

 

Schedule 1.51

Transcription-Based Amplification Versions

     “GEN-PROBE Version” shall mean transcription-based nucleic acid amplification using reverse
transcriptase, RNA polymerase and [...***...] wherein

     (a) the reverse transcriptase and RNase H activities are provided by a [...***...]

     (b) said protein has a minimal reverse transcriptase activity of [...***...] (where the unit
definition and assay conditions are equivalent to those set forth below); and

     (c) the amplification reaction is performed at [...***...]

     “TEKNIKA Version” shall mean transcription-based nucleic acid amplification using reverse
transcriptase, RNA polymerase and [...***...] wherein

     (a) [...***...]

     (b) [...***...] and

     (c) the amplification reaction is performed at [...***...]

ENZYME ASSAYS

[...***...]

[...***...]

***Confidential Treatment Requested

1

 

[...***...]

[...***...]

[...***...]

Equivalent unit definitions and assay conditions may be substituted as long as they produce results
that may be quantitatively converted by established valid procedures (e.g., multiplication by a
conversion factor or by reference to a standard curve) to the assay conditions and unit definitions
set forth above.

For example, [...***...]

Data supporting equivalence of any substitutions must be made available for inspection as set forth
in this Agreement.

***Confidential Treatment Requested

2

 

Schedule 3.1.6

Licensed Manufacturers

	 	 	 	 	 	 	 
	 	 	Legal	 	Location of	 	 
	Product	 	Manufacturer	 	Manufacture	 	Current Document
	PROCLEIX®

OptivaTM Reagent 

Addition Station (RAS)

	 	Chiron Corporation
	 	Stratec Biomedical

Systems

Germany
	 	CFG, FDA 510(k)
Clearance, EIR
(Chiron), ISO 13485
(Chiron), ISO
9001:2000 (Chiron),
Declaration of
Conformity
	 
	 	 	 	 	 	 
	PROCLEIX®

OptivaTM Front End 

Pipetter (FEP)

	 	Gen Probe Incorp

Incorporated
	 	Stratec Biomedical

Systems

Germany
	 	Certificate of
Exportability, EIR
(Gen-Probe), ISO
13485 (Gen- Probe),
ISO 9001:2000
(Chiron),Declaration
of Conformity
	 
	 	 	 	 	 	 
	PROCLEIX®

TIGRIS®

System

	 	Gen-Probe Incorporated
	 	KMC Systems
Incorporated U.S.A.
	 	Certificate of
Exportability, ER
(Gen-Probe), ISO
13485 (Gen- Probe),
ISO 9001:2000
(Chiron),
Declaration of
Conformity
	 
	 	 	 	 	 	 
	PROCLEIX®

Reagent Preparation 

Incubator

	 	Gen-Probe

Incorporated
	 	Barnstead/ Lab- Line
U.S.A.
	 	Certificate of
Exportability, EIR
(Gen-Probe), ISO
13485 (Gen- Probe),
ISO 9001:2000
(Chiron),
Declaration of
Conformity
	 
	 	 	 	 	 	 
	PROCLEIX® System

	 	Gen-Probe

Incorporated
	 	 	 	 
	 
	 	 	 	 	 	 
	Target Capture
System

	 	Gen Probe Incorporated	 	 	 	CFG, FDA
510(k) Clearance,
EIR (Gen-Probe),
ISO 13485 (Gen-
Probe), ISO
9001:2000 (Chiron),
Declaration of
Conformity
	 
	 	 	 	 	 	 
	HC+ Luminometer

	 	Gen-Probe

Incorporated
	 	MGM Instruments
Incorporated
U.S.A.	 	 
	 
	 	 	 	 	 	 
	TECAN GENESIS RSP 150/8

	 	Gen-Probe Incorporated
	 	TECAN AG Switzerland	 	 
	 
	 	 	 	 	 	 
	Panther

	 	Expected to be
Gen-Probe Incorporated
	 	Stratec
Biomedical Systems

Germany
	 	TBD

1

 

Schedule 5.3.1(a)

Labeling Requirements

	 	 	 	 	 
	Part Number	 	Description	 	Label Options
	301034

	 	PROFICIENCY PANELS
	 	IVD
	301030

	 	5000T KIT DOMESTIC
	 	IVD
	301031

	 	1000T KIT DOMESTIC
	 	IVD
	301027

	 	TMA FLUIDS DOMESTIC
	 	IVD
	301026

	 	DISCRIMINATORY KIT DOMESTIC
	 	IVD
	301036

	 	CALIBRATORS DOMESTIC
	 	IVD
	301038

	 	AUTO DETECT DOMESTIC
	 	IVD
	301035

	 	CONTROL SET DOMESTIC
	 	IVD
	301030E

	 	5000T KIT EXPORT
	 	IVD
	301031E

	 	1000T KIT EXPORT
	 	IVD
	301026E

	 	DISCRIMINATORY KIT EXPORT
	 	IVD
	301036E

	 	CALIBRATORS EXPORT
	 	IVD
	301035E

	 	CONTROL SET EXPORT
	 	IVD
	TU0018

	 	TTU (1000 Tests) SAS	 	 
	TU0022

	 	TTU (1000 Tests) eSAS	 	 
	104578

	 	TTC (1000 Tests)	 	 
	102085

	 	Sealing Cards	 	 

1

 

Schedule 5.3.3

Sample Purchase Order

[...***...]

***Confidential Treatment Requested

1

 

[...***...]

***Confidential Treatment Requested

2

 

[...***...]

***Confidential Treatment Requested

3

 

[...***...]

***Confidential Treatment Requested

4

 

Schedule 6.1.2(e)

Reimbursement of Development Costs for FEP and RAS Components of eSAS2 Instrument

     (a) [Definitions.

          (i) Revenues from the FEP Component and RAS Component. As used in this Schedule
6.1.2(e), “revenues from the PEP Component and RAS Component” for a fiscal quarter shall mean all
amounts received by a Party or a Party’s Affiliates for the sale, transfer, placement, lease or
other disposition of the FEP Component and RAS Component during such fiscal quarter; provided,
however, that:

     (A) Revenues for Collaboration Combination Products. If a PEP Component or RAS
Component is sold in combination with one or more non-FEP Component or non-RAS Component
instruments or instrument components (a “Collaboration Combination Product”) for a single price or
on a single invoice to the customer, the “revenues from the FEP Component and RAS Component” with
respect to such Collaboration Combination Product shall be calculated by multiplying the total
amount received by a Party or its Affiliates for such Collaboration Combination Product by the
fraction A/B, where A is the gross selling price of the FEP Component or RAS Component sold
separately and B is the gross single price or aggregate prices on a single invoice to the customer
for such Collaboration Combination Product. Such calculation of the Collaboration Combination
Product revenues shall be negotiated in good faith between the Parties and resolved pursuant to
ARTICLE 11 if they are unable to agree.

     (B) Revenues for Lease, Rental or Placement Programs. If the Ea Component or RAS
Component is not sold separately but rather is leased, placed or rented pursuant to a
reagent/rental program or comparable sale or lease program (including instrument
upgrade/maintenance programs) (each a “Program”) where the instrument revenue is included in such
Program revenue, then the “revenues from the FEP Component and RAS Component” with respect to such
Program shall: (i) be one hundred fifteen percent (115%) of the Fully Burdened Manufacturing Costs
(as defined below) until Novartis has been reimbursed for all FEP Component and RAS Component
Development Costs, and one hundred percent (100%) thereafter; based upon an imputed instrument
depreciation factor consistent with Novartis’s then- current accounting policy that provides for a
depreciation of at least three (3) years for each FEP Component and RAS Component.

     (C) Nothing herein shall amend the manner in which the Agreement determines the revenues for
Combination Products where the FEP Component or RAS Component is sold in combination with one or
more Third Party products.

          (ii) As used in this Schedule 6.1.2(e):

     (A) “FEP Component” shall mean the front end pipettor component developed pursuant to the
Modified Blood Screening Instrument — eSAS 2 Addendum, dated January 1, 2002, under the 1998
Agreement.

     (B) “Fully Burdened Manufacturing Costs” of the FEP Component and RAS Component shall mean
one hundred and twenty five percent (125%) of the reasonable Third

3

 

Party OEM invoice cost of the FkP Component or RAS Component (including freight, taxes,
etc.). The foregoing amount shall be used in lieu of the actual internal costs incurred or
allocated to the purchase for QA, purchasing, receiving and warehousing, etc.

     (C) the “Gen-Probe Blood Screening Split” used under Section (b) below with respect to sales
of the FEP Component or RAS Component in the Blood Screening Field shall be calculated, for a given
fiscal quarter, by taking the dollar weighted average of the Applicable Purchase Price earned by
Gen-Probe for all Blood Screening Assays sold as calculated under 1.2.1 and 1.2.2 of the Agreement
during such fiscal quarter.

     (D) the “Gen-Probe Clinical Diagnostic Split” used under Section (c) below with respect to
sales of the FEP Component or RAS Component in the Clinical Diagnostic Field shall be equal to the
Novartis Blood Screening Split.

     (E) the “Novartis Blood Screening Split” used under Section (b) below with respect to sales of
the FEP Component and RAS Component in the Blood Screening Field shall be the remainder of (I) one
hundred percent (100%) less (II) the Gen-Probe Blood Screening Split

     (F) the “Novartis Clinical Diagnostic Split” used under Section (c) below with respect to
sales of the FEP Component or RAS Component in the Clinical Diagnostic Field shall be equal to the
Gen-Probe Blood Screening Split.

     (G) “RAS Component” shall mean the reagent addition station component developed pursuant to
the Modified Blood Screening Instrument — eSAS 2 Addendum, dated January 1, 2002, under the 1998
Agreement.

     (b) Instrument Sales; Novartis Sales oft-EP Components and RAS Components.

          (i) Until Novartis has been reimbursed for all I-EP Component and RAS Component Development
Costs, within forty-five (45) days following the end of each fiscal quarter Novartis shall (A)
first, calculate (and provide written notice to Gen-Probe of such calculation) the revenues from
FEP Components and RAS Components sold and received by Novartis or its Affiliates during such
fiscal quarter; (B) second, calculate (and provide written notice to Gen-Probe of such calculation)
one hundred and fifty percent (150%) of the Fully Burdened Manufacturing Costs for the FEP
Components and RAS Components sold in such fiscal quarter by Novartis and its Affiliates; (C)
third, calculate (and provide written notice to Gen-Probe of such calculation) and retain the
lesser of (I) revenues from the FEP Components and RAS Components sold and received by Novartis and
its Affiliates in such fiscal quarter or (II) one hundred and fifty percent (150%) of the Fully
Burdened. Manufacturing Costs for the FEP Components and RAS Components sold in such fiscal quarter
by Novartis and its Affiliates; (D) fourth, apply and credit (and provide written notice to
Gen-Probe of such calculation) the difference between such retained amount and one hundred percent
(100%) of the Fully Burdened Manufacturing Costs for the FEP Components and RAS Components sold in
such fiscal quarter by Novartis and its Affiliates as reimbursement to Novartis of the PEP
Component and RAS Component Development Costs; (E) fifth, calculate (and provide written notice to
Gen-Probe of such calculation) and retain the Novartis Blood Screening Split, if any; and (F)
sixth, pay to Gen- Probe an amount equal to the Gen-Probe Blood Screening Split, if any.

4

 

          (ii) After Novartis has been reimbursed for all FEP Component and RAS Component Development Costs
under subparagraph (b)(i) above, within forty-five (45) days following the end of each fiscal
quarter Novartis shall thereafter (A) first, calculate (and provide written notice to Gen-Probe of
such calculation) revenues from the PEP Components and RAS Components sold and received by Novartis
and its Affiliates in such fiscal quarter; (B) second, calculate (and provide written notice to
Gen-Probe of such calculation) and retain one hundred and fifteen percent (115%) of the Fully
Burdened Manufacturing Costs for the FEP Components and RAS Components sold in such fiscal quarter
by Novartis and its Affiliates; (C) third, calculate (and provide written notice to Gen-Probe of
such calculation) and retain the Novartis Blood Screening Split, if any; and (D) fourth, pay to
Gen-Probe an amount equal to the Gen- Probe Blood Screening Split, if any.

          (iii) If the FEP Component or RAS Component is not sold separately by Novartis but rather is
leased, placed or rented by Novartis pursuant to a Program (as defined in subsection (a)(i)(B)
above), within forty-five (45) days following the end of each fiscal quarter Novartis shall
calculate (and (provide written notice to Gen-Probe of such calculation) and shall be entitled to
retain any and all revenues from the FEP Components and RAS Components sold, leased, placed or
rented pursuant to a Program and received by Novartis and its Affiliates in such fiscal quarter.

     (c) Instrument Sales; Gen-Probe Sales of FEP Components and RAS Components.

          (i) Within forty-five (45) days following the end of each fiscal quarter Gen-Probe sells PEP
Components and RAS Components, Gen-Probe shall (A) first, calculate (and provide written notice to
Novartis of such calculation) the revenues for the FEP Components and RAS Components received by
Gen-Probe and its Affiliates during such fiscal quarter from the sale, transfer, placement, lease
or other disposition of the FEP Components and RAS Components in the Clinical Diagnostic Field; (B)
second, calculate (and provide written notice to Novartis of such calculation) and retain one
hundred and fifteen percent (115%) of the Fully Burdened Manufacturing Costs for such FEP
Components and RAS Components; (C) third, calculate (and provide written notice to Novartis of such
calculation) and retain an amount equal to the Gen-Probe Clinical Diagnostic Split, if any; and (D)
fourth, pay to Novartis an amount equal to the Novartis Clinical Diagnostic Split, if any.

     (d) Service Revenues. Each Party is entitled to retain the aggregate commercially
reasonable revenues received by such Party and its Affiliates in consideration for required
maintenance and servicing of the FEP Components and RAS Components consistent with standard
industry practices; provided, however that the revenues retained may not exceed fifteen percent
(15%) of the Fully Burdened Manufacturing Costs of the FEP Components and RAS Components per year;
provided however that in the event that the revenues exceed fifteen percent (15%) of the Fully
Burdened Manufacturing Costs of the FEP Components and RAS Components in any given year, such
excess shall be shared by Gen-Probe and Novartis such that, for maintenance and service revenues of
FEP Components and RAS Components used in the Blood Screening Field, the parties shall receive such
amount equal to their respective Blood Screening Splits, and for maintenance and service revenues
of FEP Components and RAS Components used in the Clinical Diagnostic Field, the parties shall
receive such amount equal to their respective Clinical Diagnostic Splits.]

5

 

Schedule 8.1.6(e)

Novartis Corporation Core Technologies

     Novartis Core Technology means (1) technology claimed in Valid Claims of the following patents
and (2) technology claimed in Valid Claims of patent applications pending before the United States
Patent & Trademark Office to the extent that such applications are substantially equivalent to the
claims in the patent applications listed below, both (1) and (2) together with any unlisted patents
and U.S. patent applications from which any of the listed patents claim priority and any and all
patents which have issued or in the future issue from the listed patents and applications and all
divisionals, continuations, continuations-in-part, reissues, renewals, re-examinations, extensions,
or additions thereof (all only to the extent that the claims thereof are to the same or
substantially the same subject matter claimed in the listed patents or patent applications).

HUMAN IMMUNODEFICIENCY VIRUS (HIV)

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Title of Invention	 	Patent/Pub. No.	 	 	Issue/Pub. Date	 	 	Priority Date	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 

HEPATITIS C VIRUS (HCV)

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Title of Invention	 	Patent/Pub. No.	 	 	Issue/Pub. Date	 	 	Priority Date	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 

[...***...]

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Title of Invention	 	Patent/Pub. No.	 	 	Issue/Pub. Date	 	 	Priority Date	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 

***Confidential Treatment Requested

1

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Title of Invention	 	Patent/Pub. No.	 	 	Issue/Pub. Date	 	 	Priority Date	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 

[...***...]

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Title of Invention	 	Patent/Pub. No.	 	 	Issue/Pub. Date	 	 	Priority Date	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 

***Confidential Treatment Requested

2

 

Schedule 8.7

Gen-Probe Incorporated Core Technologies

     Gen-Probe Core Technologies means (1) technology claimed in Valid Claims of the following
patents and (2) technology claimed in Valid Claims of patent-applications pending before the United
States Patent & Trademark Office to the extent that such applications are substantially equivalent
to the claims in the patent applications listed below, both (1) and (2) together with any unlisted
patents and U.S. patent applications from which any of the listed patents claim priority and any
and all patents which have issued or in the future issue from the listed patents and applications
and all divisionals, continuations, continuations-in-part, reissues, renewals, re-examinations,
extensions, or additions thereof (all only to the extent that the claims thereof are to the same or
substantially the same subject matter claimed in the listed patents or patent applications).

A. [...***...]

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	Title of Invention	 	Issue/Pub No	 	 	Issue/Pub Date	 	 	Priority Date	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 

***Confidential Treatment Requested

1

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	Title of Invention	 	Issue/Pub No	 	 	Issue/Pub Date	 	 	Priority Date	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 

B. [...***...]

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 

C. [...***...]

     [...***...]

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 

***Confidential Treatment Requested

2

 

D. [...***...]

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 

E. [...***...]

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 
	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 

F. [...***...]

     [...***...]

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	[...***...]	 	 	[...***...]
	 	 	[...***...]	 	 	 	[...***...]	 	 	 	[...***...]	 

***Confidential Treatment Requested

3

 

Schedule 8.9

     Additional Clauses Relating to the Stanford Agreement and the Teknika Agreement

(Note: The text set forth below is quoted from the Stanford Agreement and the
Teknika Agreement, and all section references within the quoted text to paragraphs,
sections, and articles refer to the paragraphs, sections, and articles of the
applicable Stanford Agreement and the Teknika Agreement, and not to those of this
Agreement between Novartis and Gen-Probe.)

Stanford License

     The Stanford Agreement sets forth the following terms and conditions relating to required
provisions in any sublicense and to the continuation of sublicenses following termination of the
Stanford Agreement.

     4.3.2 Any such sublicense shall also expressly include the provisions of ARTICLEs 7, 8, and 9
for the benefit of STANFORD.

     4.3.3 Upon termination of this Agreement for any cause, any sublicense granted hereunder shall
continue with STANFORD provided the sublicensee agrees to thereafter assume the obligations of
GEN-PROBE insofar as they correspond to the scope of the sublicense.

7. REPORTS, PAYMENTS, AND ACCOUNTING

     7.1 Quarterly Royalty Payment and Report. GEN-PROBE shall make written reports and royalty
payments to STANFORD within ninety (90) days after the end of each calendar quarter. This report
shall state the number, description, and aggregate Net Sales of Licensed Product(s) during such
completed calendar quarter, and resulting calculation pursuant to Paragraph 6.2 of earned royalty
payment due STANFORD for such completed calendar quarter. Concurrent with the making of each such
report, GEN-PROBE shall include payment due STANFORD of royalties for the calendar quarter covered
by such report.

     7.2 Accounting, GEN-PROBE agrees to keep records for a period of three (3) years showing the
manufacturing, sales, use, and other disposition of products sold or otherwise disposed of under
the license herein granted in sufficient detail to enable the royalties payable hereunder by
GEN-PROBE to be determined, and further agrees to permit its books and records to be examined to
the extent necessary to verify reports provided for in Paragraph 7.1 by an independent certified
public accountant, provided that such audits occur no more than one (1) time per calendar year and
provided further that accountant shall report to STANFORD only errors regarding calculation of
royalties. Such examination is to be made by STANFORD, at the expense of STANFORD, except in the
event that the results of the audit reveal a discrepancy in GEN-PROBE’S favor of ten percent (10%)
or more, then the audit fees shall be paid by GENPROBE.

1

 

8. WARRANTY AND NEGATION OF WARRANTIES

     8.1 Nothing in this Agreement is or shall be construed as:

     (a) A warranty or representation by STANFORD as to the validity or scope of any Licensed
Patent(s);

     (b) A warranty or representation that anything made, used, sold, or otherwise disposed of
under any license granted in this Agreement is or will be free from of patents, copyrights, and
other rights of third parties;

     (c) An obligation to bring or prosecute actions or suits against third parties for
infringement, except to the extent and in the circumstances described in ARTICLE 12; or

     (d) Granting by implication, estoppel, or otherwise any licenses under patents of STANFORD or
other persons other than Licensed Patent(s), regardless of whether such patents are dominant or
subordinate to any Licensed Patent(s)

     8.2 EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, STANFORD MAKES NO REPRESENTATIONS AND
EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE LICENSED
PRODUCT(S) WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS OF THIRD PARTIES.

9. INDEMNITY

     9.1 GEN-PROBE agrees to indemnify, hold harmless, and defend STANFORD and its trustees,
officers, employees, students, and agents against any and all claims for death, illness, personal
injury, property damage, and improper business practices arising out of the manufacture, use, sale,
or other disposition of Invention, Licensed Patent(s), or Licensed Product(s) by GEN-PROBE, its
sublicenses or their customers.

     9.2 GEN-PROBE shall at all times comply, through insurance or self-insurance, with all
statutory workers’ compensation and employers’ liability requirements covering any and all
employees with respect to activities performed under this Agreement.

     9.3 GEN-PROBE shall maintain, beginning, on the first day GEN-PROBE or any GEN-PROBE
sublicensee ships a therapeutics product manufactured by the licensed process, commercial general
liability insurance, including products liability insurance, with minimum limits of liability of $5
million with reputable and financially secure insurance carrier(s) to cover the activities of
GEN-PROBE and its sublicensee(s). Any and all such policies of insurance described in the previous
sentence shall include as additional named insureds STANFORD, Stanford Health Services, their
trustees, directors, officers, employees, students and agents, and shall provide that such policies
may not, without 30 days prior written notice to STANFORD, be canceled or changed to materially
adversely affect any such additional named insured’s coverage. Such insurance shall be written to
cover liability of such additional named insureds

2

 

incurred beginning on the first day GEN-PROBE or any GEN-PROBE sublicensee ships a
therapeutics product.

Teknika Agreement

     The Teknika Agreement sets forth the following sets forth the following terms and conditions
relating to rights of Gen-Probe’s Licensees should a breach by Gen-Probe terminate its rights under
the Teknika Agreement:

     10.3 Upon termination of this Agreement, as permitted by Section 10.2, the non- breaching
party shall grant direct immunity from legal action to Licensees of the breaching party, under the
terms and conditions set forth in this Agreement, provided that:

     (a) the non-breaching party shall have received express written notice of the license granted
to such Licensee prior to the effective termination date of this Agreement;

(b) the Licensee expressly agreed in writing on or before the ninetieth (90th) day prior to the
effective termination date of this Agreement to be bound by the terms and conditions of this
Agreement.

3exv4w1

Exhibit 4.1

 

 

MGM MIRAGE

9% Senior Secured Notes due 2020

INDENTURE

Dated as of March 16, 2010

U.S. BANK NATIONAL ASSOCIATION

Trustee

 

 

-1-

 

TABLE OF CONTENTS

	 	 	 	 	 	 	 
	 	 	 	 	Page	 
	 	 	 
	 	 	 	 
	ARTICLE I
	DEFINITIONS AND INCORPORATION BY REFERENCE
	SECTION 1.01
	 	Definitions

	 	 	1	 
	SECTION 1.02
	 	Rules of Construction

	 	 	36	 
	 	 	 
	 	 	 	 
	ARTICLE II
	THE NOTES
	SECTION 2.01
	 	Form and Dating

	 	 	37	 
	SECTION 2.02
	 	Execution and Authentication

	 	 	37	 
	SECTION 2.03
	 	Registrar, Paying Agent and Depositary

	 	 	38	 
	SECTION 2.04
	 	Paying Agent To Hold Money In Trust

	 	 	38	 
	SECTION 2.05
	 	Holder Lists

	 	 	39	 
	SECTION 2.06
	 	Transfer and Exchange

	 	 	39	 
	SECTION 2.07
	 	Replacement Notes

	 	 	51	 
	SECTION 2.08
	 	Outstanding Notes

	 	 	51	 
	SECTION 2.09
	 	Intentionally Omitted

	 	 	52	 
	SECTION 2.10
	 	Temporary Notes

	 	 	52	 
	SECTION 2.11
	 	Cancellation

	 	 	52	 
	SECTION 2.12
	 	Defaulted Interest

	 	 	53	 
	SECTION 2.13
	 	CUSIP, ISIN or Common Code Numbers

	 	 	53	 
	 	 	 
	 	 	 	 
	ARTICLE III
	REDEMPTION
	SECTION 3.01
	 	Optional Redemption

	 	 	54	 
	SECTION 3.02
	 	Election To Redeem; Notice To Trustee

	 	 	54	 
	SECTION 3.03
	 	Selection By Trustee of Notes To Be Redeemed or Purchased

	 	 	54	 
	SECTION 3.04
	 	Notice of Redemption

	 	 	55	 
	SECTION 3.05
	 	Deposit of Redemption Price

	 	 	56	 
	SECTION 3.06
	 	Notes Payable on Redemption Date

	 	 	56	 
	SECTION 3.07
	 	Notes Redeemed in Part

	 	 	56	 
	SECTION 3.08
	 	Mandatory Disposition of Notes Pursuant to Gaming Laws

	 	 	56	 
	 	 	 
	 	 	 	 
	ARTICLE IV
	COVENANTS
	SECTION 4.01
	 	Payment of Principal, Premium and Interest

	 	 	58	 
	SECTION 4.02
	 	Reports

	 	 	58	 
	SECTION 4.03
	 	Officer’s Certificate as to Compliance

	 	 	59	 
	SECTION 4.04
	 	Maintenance of Office or Agency

	 	 	59	 
	SECTION 4.05
	 	Money For Notes; Payments To Be Held In Trust

	 	 	59	 
	SECTION 4.06
	 	Corporate Existence

	 	 	61	 
	SECTION 4.07
	 	Subsidiary Guarantee

	 	 	61	 
	SECTION 4.08
	 	Further Assurances and Gaming Approval

	 	 	61	 
	SECTION 4.09
	 	Change of Control

	 	 	62	 

-i-

 

	 	 	 	 	 	 	 
	 	 	 	 	Page	 
	 	 	 
	 	 	 	 
	SECTION 4.10
	 	Non-Collateral Asset Sales

	 	 	64	 
	SECTION 4.11
	 	Collateral Asset Sales

	 	 	67	 
	SECTION 4.12
	 	Event of Loss

	 	 	69	 
	SECTION 4.13
	 	Limitation on Incurrence of Indebtedness and Issuance of Disqualified
Stock and Preferred Stock

	 	 	72	 
	SECTION 4.14
	 	Limitation on Liens

	 	 	77	 
	SECTION 4.15
	 	Limitation on Sale and Leaseback Transactions

	 	 	78	 
	SECTION 4.16
	 	Limitation on Restricted Payments

	 	 	78	 
	SECTION 4.17
	 	Limitation on Layered Indebtedness

	 	 	82	 
	SECTION 4.18
	 	Transactions With Affiliates

	 	 	82	 
	SECTION 4.19
	 	Dividend and Other Payment Restrictions Affecting Restricted Subsidiaries

	 	 	83	 
	SECTION 4.20
	 	Designation of Restricted and Unrestricted Subsidiaries

	 	 	85	 
	SECTION 4.21
	 	Insurance

	 	 	85	 
	SECTION 4.22
	 	Payments For Consent

	 	 	85	 
	SECTION 4.23
	 	Suspension of Covenants

	 	 	86	 
	 	 	 
	 	 	 	 
	ARTICLE V
	CONSOLIDATION, MERGER, CONVEYANCE, TRANSFER OR LEASE
	SECTION 5.01
	 	Merger, Consolidation or Sale of All or Substantially All Assets

	 	 	87	 
	SECTION 5.02
	 	Merger, Consolidation or Sale of All or Substantially All Assets of
Subsidiary Guarantors

	 	 	88	 
	 	 	 
	 	 	 	 
	ARTICLE VI
	DEFAULTS AND REMEDIES
	SECTION 6.01
	 	Events of Default

	 	 	89	 
	SECTION 6.02
	 	Acceleration of Maturity; Rescission and Annulment

	 	 	91	 
	SECTION 6.03
	 	Collection of Indebtedness and Suits For Enforcement By Trustee

	 	 	92	 
	SECTION 6.04
	 	Trustee May File Proofs of Claim

	 	 	92	 
	SECTION 6.05
	 	Trustee May Enforce Claims Without Possession of Debt Securities

	 	 	93	 
	SECTION 6.06
	 	Application of Money Collected

	 	 	93	 
	SECTION 6.07
	 	Limitation on Suits

	 	 	94	 
	SECTION 6.08
	 	Unconditional Right of Holders To Receive Principal, Premium and Interest

	 	 	94	 
	SECTION 6.09
	 	Restoration of Rights and Remedies

	 	 	95	 
	SECTION 6.10
	 	Rights and Remedies Cumulative

	 	 	95	 
	SECTION 6.11
	 	Delay or Omission Not Waiver

	 	 	95	 
	SECTION 6.12
	 	Control By Holders

	 	 	95	 
	SECTION 6.13
	 	Waiver of Existing Defaults

	 	 	96	 
	SECTION 6.14
	 	Undertaking For Costs

	 	 	96	 
	SECTION 6.15
	 	Waiver of Stay or Extension Laws

	 	 	96	 
	SECTION 6.16
	 	Disqualified Holders

	 	 	97	 
	 	 	 
	 	 	 	 
	ARTICLE VII
	TRUSTEE
	SECTION 7.01
	 	Certain Duties and Responsibilities

	 	 	97	 
	SECTION 7.02
	 	Notice of Defaults

	 	 	98	 
	SECTION 7.03
	 	Certain Rights of Trustee

	 	 	98	 

-ii-

 

	 	 	 	 	 	 	 
	 	 	 	 	Page	 
	 	 	 
	 	 	 	 
	SECTION 7.04
	 	Not Responsible For Recitals or Issuance of Notes

	 	 	100	 
	SECTION 7.05
	 	May Hold Notes

	 	 	100	 
	SECTION 7.06
	 	Money Held In Trust

	 	 	101	 
	SECTION 7.07
	 	Compensation and Reimbursement

	 	 	101	 
	SECTION 7.08
	 	Disqualification; Conflicting Interests

	 	 	102	 
	SECTION 7.09
	 	Corporate Trustee Required; Eligibility

	 	 	102	 
	SECTION 7.10
	 	Resignation and Removal; Appointment of Successor

	 	 	102	 
	SECTION 7.11
	 	Acceptance of Appointment By Successor

	 	 	103	 
	SECTION 7.12
	 	Merger, Conversion, Consolidation or Succession to Business

	 	 	104	 
	SECTION 7.13
	 	Preferential Collection of Claims Against Company

	 	 	104	 
	SECTION 7.14
	 	Appointment of Authenticating Agent

	 	 	104	 
	SECTION 7.15
	 	Paying Agent; Registrar

	 	 	106	 
	SECTION 7.16
	 	Reports By Trustee

	 	 	106	 
	 	 	 
	 	 	 	 
	ARTICLE VIII
	DISCHARGE OF INDENTURE; DEFEASANCE
	SECTION 8.01
	 	Satisfaction and Discharge of Indenture

	 	 	108	 
	SECTION 8.02
	 	Application of Trust Money

	 	 	109	 
	SECTION 8.03
	 	Applicability of Article

	 	 	109	 
	SECTION 8.04
	 	Legal Defeasance and Covenant Defeasance

	 	 	109	 
	SECTION 8.05
	 	Conditions to Legal or Covenant Defeasance

	 	 	110	 
	SECTION 8.06
	 	Deposited Moneys and Government Securities To Be Held In Trust

	 	 	111	 
	SECTION 8.07
	 	Repayment to Company

	 	 	111	 
	 	 	 
	 	 	 	 
	ARTICLE IX
	SUPPLEMENTAL INDENTURES
	SECTION 9.01
	 	Amendment, Supplement and Waiver

	 	 	112	 
	SECTION 9.02
	 	Execution of Supplemental Indentures

	 	 	114	 
	SECTION 9.03
	 	Effect of Supplemental Indentures

	 	 	114	 
	SECTION 9.04
	 	Reference in Notes to Supplemental Indentures

	 	 	115	 
	SECTION 9.05
	 	Revocation and Effect of Consents and Waivers

	 	 	115	 
	 	 	 
	 	 	 	 
	ARTICLE X
	SUBSIDIARY GUARANTEES
	SECTION 10.01
	 	Subsidiary Guarantee

	 	 	115	 
	SECTION 10.02
	 	Execution and Delivery of Subsidiary Guarantee

	 	 	116	 
	SECTION 10.03
	 	Limitation of Subsidiary Guarantor’s Liability

	 	 	117	 
	SECTION 10.04
	 	Contribution

	 	 	117	 
	SECTION 10.05
	 	Rights Under The Subsidiary Guarantee

	 	 	117	 
	SECTION 10.06
	 	Primary Obligations

	 	 	118	 
	SECTION 10.07
	 	Waivers

	 	 	118	 
	SECTION 10.08
	 	Releases

	 	 	119	 
	SECTION 10.09
	 	No Election

	 	 	119	 
	SECTION 10.10
	 	Financial Condition of The Company

	 	 	119	 

-iii-

 

	 	 	 	 	 	 	 
	 	 	 	 	Page	 
	 	 	 
	 	 	 	 
	ARTICLE XI
	COLLATERAL AND SECURITY
	SECTION 11.01
	 	Collateral and Collateral Documents; Additional Collateral

	 	 	119	 
	SECTION 11.02
	 	Collateral Opinions

	 	 	120	 
	SECTION 11.03
	 	Possession and Use of Collateral; Disposition of Collateral Without
Release and Not Constituting Collateral Asset Sale

	 	 	121	 
	SECTION 11.04
	 	Specified Releases of Collateral

	 	 	122	 
	SECTION 11.05
	 	Release and Reconveyance of Collateral

	 	 	123	 
	SECTION 11.06
	 	Purchaser Protected

	 	 	123	 
	SECTION 11.07
	 	Authorization of Actions To Be Taken By The Trustee and The Collateral
Agent Under The Collateral Documents

	 	 	123	 
	SECTION 11.08
	 	Certain TIA Requirements

	 	 	124	 
	SECTION 11.09
	 	Equal and Ratable Lien Sharing by Holders of Notes and Holders of Pari
Passu Secured Indebtedness

	 	 	124	 
	SECTION 11.10
	 	Reserved

	 	 	124	 
	SECTION 11.11
	 	Enforcement of Security Interests

	 	 	124	 
	 	 	 
	 	 	 	 
	ARTICLE XII
	MISCELLANEOUS
	SECTION 12.01
	 	Notices

	 	 	125	 
	SECTION 12.02
	 	Communication By Holders With Other Holders

	 	 	125	 
	SECTION 12.03
	 	Certificate and Opinion as to Conditions Precedent

	 	 	126	 
	SECTION 12.04
	 	Statements Required in Certificate or Opinion

	 	 	126	 
	SECTION 12.05
	 	Rules By Trustee, Paying Agent and Registrar

	 	 	126	 
	SECTION 12.06
	 	Business Days

	 	 	126	 
	SECTION 12.07
	 	Governing Law

	 	 	127	 
	SECTION 12.08
	 	No Recourse Against Others

	 	 	127	 
	SECTION 12.09
	 	Successors

	 	 	127	 
	SECTION 12.10
	 	Multiple Originals

	 	 	127	 
	SECTION 12.11
	 	Table of Contents; Headings

	 	 	128	 
	SECTION 12.12
	 	Severability

	 	 	128	 
	SECTION 12.13
	 	No Adverse Interpretation of Other Agreements

	 	 	128	 
	SECTION 12.14
	 	No Parent Liability

	 	 	128	 
	SECTION 12.15
	 	Additional Waiver

	 	 	128	 

-iv-

 

EXHIBITS

EXHIBIT A —FORM OF NOTE

EXHIBIT B — FORM OF CERTIFICATE OF TRANSFER

EXHIBIT C — FORM OF CERTIFICATE OF EXCHANGE

EXHIBIT D — FORM OF JOINDER

EXHIBIT E — FORM OF DEED OF TRUST

EXHIBIT F — FORM OF SECURITY AGREEMENT

EXHIBIT G — FORM OF PLEDGE AGREEMENT

EXHIBIT H — FORM OF TRANSFERABILITY CERTIFICATE

EXHIBIT I — FORM OF TRANSFERABILITY CERTIFICATE

-v-

 

     INDENTURE dated as of March 16, 2010, among MGM MIRAGE, a Delaware corporation (the
“Company”), the Subsidiary Guarantors party hereto, and U.S. BANK NATIONAL ASSOCIATION (the
“Trustee”), having its Corporate Trust Office at 60 Livingston Avenue, St. Paul, MN 55107-1419.

     Each party agrees as follows for the benefit of the other parties and for the equal and
ratable benefit of the Holders of (i) the Company’s 9% Senior Secured Notes due 2020 issued on the
Closing Date (as defined herein) (the “Initial Notes”) and (ii) if and when issued pursuant to this
Indenture and the Registration Rights Agreement (as defined herein), any Exchange Notes (as defined
herein) (all such notes in clauses (i) and (ii) being referred to collectively as the “Notes”, and
for purposes of this Indenture, all references to Notes to be issued or authenticated upon
transfer, replacement or exchange shall be deemed to refer to Notes of the applicable series):

ARTICLE I

DEFINITIONS AND INCORPORATION BY REFERENCE

     SECTION 1.01 DEFINITIONS.

     “Acceptable Event of Loss Commitment” has the meaning given in Section 4.12(a)(ii).

     “Acceptable Non-Collateral Commitment” has the meaning given in Section 4.10(b).

     “Acquired Indebtedness” means, with respect to any specified Person,

     (a) Indebtedness of any other Person existing at the time such other Person is merged
with or into or becomes a Restricted Subsidiary of such specified Person, including
Indebtedness Incurred in connection with, or in contemplation of, such other Person merging
with or into or becoming a Restricted Subsidiary of such specified Person, and

     (b) Indebtedness secured by a Lien encumbering any asset acquired by such specified
Person.

     “Additional Assets” means (i) any property or assets that replace the property or assets that
are the subject of an Asset Sale; (ii) any property or assets (other than Indebtedness and Capital
Stock) used or to be used by the Company or a Restricted Subsidiary or otherwise useful in a
Similar Business (including any capital expenditures on any property or assets already so used);
(iii) the Capital Stock of a Person that is engaged in a Similar Business and becomes a Restricted
Subsidiary as a result of the acquisition of such Capital Stock by the Company or another
Restricted Subsidiary; or (iv) Capital Stock of any Person that at such time is a Restricted
Subsidiary acquired from a third party.

     “Additional Interest” means all additional interest then owing pursuant to the Registration
Rights Agreement.

     “Additional Lien” has the meaning given in Section 4.14(a).

     “Affiliate” of any specified Person means any other Person directly or indirectly controlling
or controlled by or under direct or indirect common control with such specified Person. For
purposes of this definition, “control” (including, with correlative meanings, the terms
“controlling,” “controlled by” and “under common control with”), as used with respect to any
Person, shall mean the possession,

 

 

directly or indirectly, of the power to direct or cause the direction of the management or
policies of such Person, whether through the ownership of voting securities, by agreement or
otherwise. For the purpose of this definition, no Non-Control Entity shall be deemed an Affiliate
of the Company or any Restricted Subsidiary.

     “Affiliate Transaction” has the meaning given in Section 4.18(a).

     “After-Acquired Collateral Documents” has the meaning given in Section 11.01(b).

     “After-Acquired Property” has the meaning given in Section 11.01(b).

     “Agent” means any Registrar or Paying Agent.

     “Ancillary Mortgage Documents” means with respect to Collateral consisting of real property
and the Mortgage relating to such Collateral, (i) an opinion of counsel (which counsel shall be
satisfactory to the Collateral Agent) with respect to the enforceability of the Mortgage, and such
other related matters as the Collateral Agent may reasonably request, in each case in form and
substance satisfactory to the Collateral Agent, (ii) ALTA lenders policy(ies) of title insurance
with respect to such Collateral issued by a title company reasonably satisfactory to the Collateral
Agent insuring fee simple title with respect to such Collateral and insuring that the Mortgage
creates a valid and enforceable first priority lien on the Collateral encumbered thereby, together
with all endorsements and co-insurance reasonably requested by the Collateral Agent, (iii) an
ALTA/ACSM survey with respect to such Collateral dated a date, and prepared by a Person and in form
and substance, reasonably satisfactory to the Collateral Agent, (iv) one or more environmental
assessment reports which, in their totality, provide a detailed environmental assessment of such
Collateral, in form and substance and from an independent environmental assessment firm
satisfactory to the Collateral Agent and (v) any consents or estoppels reasonably deemed necessary
or advisable by the Collateral Agent in connection with the Mortgage, in form and substance
reasonably satisfactory to the Collateral Agent, in each case in substantially the form entered
into with respect to the Collateral in existence on the Closing Date.

     “Applicable Premium” means with respect to any Note on any Redemption Date, as determined by
the Company, the excess of:

     (a) the sum of the present values at such Redemption Date of the remaining scheduled
payments of principal and interest on the Note (excluding accrued but unpaid interest to the
Redemption Date), discounted to the Redemption Date on a semiannual basis using a discount
rate equal to the Treasury Rate as of such Redemption Date plus 50 basis points; over

     (b) the principal amount of the Note.

     “Applicable Procedures” means, with respect to any transfer or exchange of or for beneficial
interests in any Global Note, the rules and procedures of the Depositary, Euroclear and Clearstream
that apply to such transfer or exchange at the relevant time.

     “Attributable Debt” in respect of a Sale and Leaseback Transaction means, at any date of
determination, (a) if such Sale and Leaseback Transaction is a Capitalized Lease Obligation, the
amount of Indebtedness represented thereby according to the definition of “Capitalized Lease
Obligation” and (b) in all other instances, the present value of the total Obligations of the
lessee for rental payments

-2-

 

during the remaining term of the lease included in such Sale and Leaseback Transaction
calculated using a discount rate equal to the rate of interest applicable to the Notes.

     “Authenticating Agent” has the meaning specified in Section 7.14.

     “Authentication Order” has the meaning given in Section 2.02.

     “Bankruptcy Law” means Title 11, U.S. Code, or any similar federal, state or foreign law for
the relief of debtors.

     “Bellagio/TMCH Collateral” means the assets securing each of the 10.375% Secured Notes, the
11.125% Secured Notes and the Bellagio/TMCH Guarantees thereof including (i) the Bellagio Hotel and
Casino (“Bellagio”), located in Las Vegas, Nevada, The Mirage Casino Hotel (“TMCH”), located in Las
Vegas, Nevada, the real property on which each of Bellagio and TMCH is located and all existing and
future personal property of Bellagio, LLC and The Mirage Casino-Hotel (other than cash, deposit
accounts, gaming and liquor licenses, other assets and properties in which the grant of security is
restricted by law or contract and certain excluded assets), (ii) upon receipt of the necessary
gaming approvals, 100% of the equity interests in of Bellagio, LLC and The Mirage Casino-Hotel, and
(iii) any replacement or substitute collateral permitted to be provided pursuant to the 10.375%
Secured Notes/11.125% Secured Notes Indenture.

     “Bellagio/TMCH Guarantee” means any guarantee of the 10.375% Secured Notes and the 11.125%
Secured Notes by a Bellagio/TMCH Guarantor.

     “Bellagio/TMCH Guarantor” means any Subsidiary Guarantor that is required by the terms of the
10.375% Secured Notes/11.125% Secured Notes Indenture to guarantee the 10.375% Secured Notes and
the 11.125% Secured Notes and to grant Liens securing its guarantee on assets included in the
Bellagio/TMCH Collateral.

     “Bellagio, LLC” means Bellagio, LLC, a Nevada limited liability company.

     “Beneficial Owner” has the meaning assigned to such term in Rule 13d-3 and Rule 13d-5 under
the Exchange Act, except that in calculating the beneficial ownership of any particular “person”
(as that term is used in Section 13(d)(3) of the Exchange Act), such “person” will be deemed to
have beneficial ownership of all securities that such “person” has the right to acquire by
conversion or exercise of other securities, whether such right is currently exercisable or is
exercisable only after the passage of time.

     “Beneficiaries” means the Holders and the Trustee.

     “Board of Directors” means, with respect to any Person, the Board of Directors (or any similar
governing body) of such Person, or unless the context otherwise requires, any authorized committee
of the Board of Directors (or such body) of such Person. Unless otherwise specified, “Board of
Directors” means the Board of Directors of the Company.

     “Board Resolution” means a duly adopted resolution of the Board of Directors. Unless
otherwise specified, “Board Resolution” means a duly adopted resolution of the Board of Directors
of the Company.

-3-

 

     “Broker-Dealer” means any broker-dealer that receives Exchange Notes for its own account in
any Exchange Offer in exchange for Notes that were acquired by such broker-dealer as a result of
market-making or other trading activities.

     “Business Day” means each day which is not a Legal Holiday.

     “Capital Stock” means:

     (a) in the case of a corporation, corporate stock;

     (b) in the case of an association or business entity, any and all shares, interests,
participations, rights or other equivalents (however designated) of corporate stock;

     (c) in the case of a partnership or limited liability company, partnership or
membership interests (whether general or limited); and

     (d) any other interest or participation that confers on a Person the right to receive a
share of the profits and losses of, or distributions of assets or properties of, the issuing
Person.

     “Capitalized Lease Obligation” means, at the time any determination thereof is to be made, the
amount of the liability in respect of a capital lease that would at such time be required to be
capitalized and reflected as a liability on a balance sheet (excluding the footnotes thereto) in
accordance with GAAP.

     “Cash Equivalents” means:

     (a) Government Securities due within one year after the date of the making of the
Investment;

     (b) readily marketable direct obligations of any State of the United States of America
or any political subdivision of any such State or any public agency or instrumentality
thereof given on the date of such Investment a credit rating of at least Aa by Moody’s or AA
by S&P in each case due within one year from the making of the Investment;

     (c) certificates of deposit issued by, bank deposits in, eurodollar deposits through,
bankers’ acceptances of, and repurchase agreements covering Government Securities executed
by any bank or by any bank incorporated under the laws of the United States of America, any
State thereof or the District of Columbia and having on the date of such Investment combined
capital, surplus and undivided profits of at least $250,000,000, or total assets of at least
$5,000,000,000, in each case due within one year after the date of the making of the
Investment;

     (d) certificates of deposit issued by, bank deposits in, eurodollar deposits through,
bankers’ acceptances of, and repurchase agreements covering Government Securities executed
by any branch or office located in the United States of America of a bank incorporated under
the laws of any jurisdiction outside the United States of America having on the date of such
Investment combined capital, surplus and undivided profits of at least $500,000,000, or
total

-4-

 

assets of at least $15,000,000,000, in each case due within one year after the date of
the making of the Investment;

     (e) repurchase agreements covering Government Securities executed by a broker or dealer
registered under Section 15(b) of the Exchange Act having on the date of the Investment
capital of at least $50,000,000, due within 90 calendar days after the date of the making of
the Investment; provided that the maker of the Investment receives written confirmation of
the transfer to it of record ownership of the Government Securities on the books of a
“primary dealer” in such Government Securities or on the books of such registered broker or
dealer, as soon as practicable after the making of the Investment;

     (f) readily marketable commercial paper or other debt securities issued by corporations
doing business in and incorporated under the laws of the United States of America or any
State thereof or of any corporation that is the holding company for a bank described in
clause (c) or (d) above given on the date of such Investment a credit rating of at least P-1
by Moody’s or A-1 by S&P, in each case due within one year after the date of the making of
the Investment;

     (g) a readily redeemable “money market mutual fund” sponsored by a bank described in
clause (c) or (d) hereof, or a registered broker or dealer described in clause (e) hereof,
that has and maintains an investment policy limiting its investments primarily to
instruments of the types described in clauses (a) through (f) hereof and given on the date
of such Investment a credit rating of at least Aa by Moody’s and AA by S&P;

     (h) corporate notes or bonds having an original term to maturity of not more than one
year issued by a corporation incorporated under the laws of the United States of America or
any State thereof, or a participation interest therein; provided that any commercial paper
issued by such corporation is given on the date of such Investment a credit rating of at
least Aa by Moody’s and AA by S&P; and

     (i) Investments similar to any of the foregoing denominated in foreign currencies in
which the Company or any Subsidiary or Non-Control Entity transacts business.

     “Casualty” means any casualty, loss, damage, destruction or other similar loss with respect to
real or personal property or improvements.

     “Change of Control” means the occurrence of any of the following:

     (a) the direct or indirect sale, transfer, conveyance or other disposition (other than
by way of merger or consolidation), in one or a series of related transactions, of all or
substantially all of the assets or properties of the Company and its Restricted
Subsidiaries, taken as a whole, to any “person” (as that term is used in Section 13(d)(3) of
the Exchange Act) other than to Tracinda and its Affiliates;

     (b) the adoption of a plan relating to the liquidation or dissolution of either the
Company or any successor thereto;

     (c) the consummation of any transaction (including, without limitation, any merger or
consolidation) the result of which is that any “person” (as defined in clause (a) above),

-5-

 

other than Tracinda and any of its Affiliates, becomes the Beneficial Owner directly or
indirectly, of more than 50% of the outstanding Voting Stock of the Company, measured by
voting power rather than number of Equity Interests, and does not by contract or otherwise
possess the power to vote or direct the voting of the amount of Voting Stock necessary to
elect a majority of the Board of Directors;

     (d) the first day on which a majority of the members of the Board of Directors are not
Continuing Directors; or

     (e) the Company consolidates with, or merges with or into, any Person or sells,
assigns, conveys, transfers, leases or otherwise disposes of all or substantially all of its
assets and properties to any Person, or any Person consolidates with, or merges with or
into, the Company, in any such event pursuant to a transaction in which any of the
outstanding Voting Stock of the Company is converted into or exchanged for cash, securities
or other property, other than any such transaction where the Voting Stock of the Company
outstanding immediately prior to such transaction is converted into or exchanged for Voting
Stock (other than Disqualified Stock) of the surviving or transferee Person constituting a
majority of the outstanding shares of such Voting Stock of such surviving or transferee
Person (immediately after giving effect to such issuance).

     “Change of Control Offer” has the meaning given in Section 4.09(a).

     “Change of Control Payment” has the meaning given in Section 4.09(a).

     “Change of Control Payment Date” has the meaning given in Section 4.09(b)(ii).

     “CityCenter” means the development of that name owned by a joint venture of Subsidiaries of
the Company and Dubai World on an approximately 67 acre site on the Las Vegas Strip and further
described in the Company’s public filings with the Commission.

     “Clearstream” means Clearstream Banking, societe anonyme, Luxembourg.

     “Closing Date” means March 16, 2010.

     “Collateral” means all of the assets and properties subject to the Liens created by the
Collateral Documents, including any Replacement Collateral but, in any event, excluding Excluded
Assets.

     “Collateral Agent” means the Trustee, in its capacity as “Collateral Agent” under this
Indenture and under the Collateral Documents, and any successor thereto in such capacity.

     “Collateral Asset Sale” means the sale, conveyance, transfer or other disposition, whether in
a single transaction or a series of related transactions, of Collateral. Notwithstanding the
foregoing, the following shall in each case not be considered a Collateral Asset Sale: (i) a
transfer of assets or properties by the Company to a Collateral Grantor or by a Collateral Grantor
to another Collateral Grantor, (ii) an issuance of Equity Interests by a Collateral Grantor to the
Company or to another Collateral Grantor, (iii) a disposition of either obsolete equipment or
equipment that is damaged, worn out or otherwise no longer useful in the business and (iv) any
surrender or waiver of contract rights or a settlement, release or surrender of contract, tort or
other claims of any kind or a grant of any Lien not prohibited by the Indenture.

-6-

 

     “Collateral Asset Sale Offer” has the meaning given in Section 4.11(d).

     “Collateral Asset Sale Payment” has the meaning given in Section 4.11(d).

     “Collateral Asset Sale Payment Date” has the meaning given in Section 4.11(d)(ii).

     “Collateral Documents” means, collectively, the Deed of Trust, the Security Agreement and the
Pledge Agreement, and any other security agreements, pledge agreements, mortgages, collateral
assignments, deeds of trust and all other pledges, agreements or other documents that create or
purport to create or perfect a Lien in the assets of the Collateral Grantor in favor of the
Collateral Agent (for the benefit of the Holders), in each case as they may be amended from time to
time, and any instruments of assignment or other instruments or agreements executed pursuant to the
foregoing.

     “Collateral Grantor” means MGM Grand Hotel or any other Restricted Subsidiary that pledges
Collateral to the Collateral Agent as security for the Notes.

     “Commission” means the U.S. Securities and Exchange Commission.

     “Company” means the Person named as the “Company” in the first paragraph of this instrument
until a successor Person shall have become such pursuant to the applicable provisions of this
Indenture, and thereafter “Company” shall mean such successor Person.

     “Company Request” and “Company Order” mean, respectively, a written request or order signed in
the name of the Company by the Chairman of the Board of Directors, the President or an Executive or
Senior Vice President and by the Treasurer, an Assistant Treasurer, the Controller, an Assistant
Controller, the Secretary or an Assistant Secretary of the Company, and delivered to the Trustee.

     “Condemnation” means any taking by a Governmental Authority of assets or property, or any part
thereof or interest therein, for public or quasi-public use under the power of eminent domain, by
reason of any public improvement or condemnation or in any other manner.

     “Condemnation Award” means all proceeds of any Condemnation or transfer in lieu thereof.

     “Consolidated Depreciation and Amortization Expense” means with respect to any Person for any
period, the total amount of depreciation and amortization expense, including the amortization of
deferred financing fees of such Person and its Restricted Subsidiaries for such period on a
consolidated basis and otherwise determined in accordance with GAAP.

     “Consolidated EBITDA” means, with respect to any Person for any period, the Consolidated Net
Income of such Person for such period

     (a) increased (without duplication) by:

     (i) provision for taxes based on income or profits or capital gains, including,
without limitation, state, franchise and similar taxes and foreign withholding taxes
of such Person paid or accrued during such period to the extent the same was
deducted (and not added back) in computing Consolidated Net Income; plus

-7-

 

     (ii) Consolidated Fixed Charges of such Person for such period (including (x)
net losses on Hedging Obligations or other derivative instruments entered into for
the purpose of hedging interest rate risk and (y) costs of surety bonds in
connection with financing activities, in each case, to the extent included in
Consolidated Fixed Charges) to the extent the same was deducted (and not added back)
in calculating such Consolidated Net Income; plus

     (iii) Consolidated Depreciation and Amortization Expense of such Person for
such period to the extent the same were deducted (and not added back) in computing
Consolidated Net Income; plus

     (iv) preopening and start-up expenses that are required by GAAP to be charged
as an expense prior to or upon opening, to the extent that such preopening and
start-up expenses were deducted in computing Consolidated Net Income; plus

     (v) any other non-cash charges, including any write-offs or write-downs,
reducing Consolidated Net Income for such period (provided that if any such non-cash
charges represent an accrual or reserve for potential cash items in any future
period, the cash payment in respect thereof in such future period shall be
subtracted from Consolidated EBITDA to such extent, and excluding amortization of a
prepaid cash item that was paid in a prior period); plus

     (vi) the amount of loss on sale of receivables and related assets to a Special
Purpose RE Subsidiary in connection with a RE Receivables Sale;

     (b) decreased by (without duplication) non-cash gains increasing Consolidated Net
Income of such Person for such period, excluding any non-cash gains to the extent they
represent the reversal of an accrual or reserve for a potential cash item that reduced
Consolidated EBITDA in any prior period; and

     (c) increased or decreased by (without duplication):

     (i) any net gain or loss resulting in such period from Hedging Obligations and
the application of the provisions of Statement of Financial Accounting Standards
Board’s “Accounting Standards Codification” relating to accounting for derivatives
and hedging; plus or minus, as applicable,

     (ii) any net gain or loss resulting in such period from currency translation
gains or losses related to currency remeasurements of Indebtedness (including any
net loss or gain resulting from hedge agreements for currency exchange risk), in
each case to the extent the same was deducted or added back in computing
Consolidated Net Income, as applicable; provided, for any period ending during the
one year period after the opening of CityCenter, that portion of Consolidated EBITDA
for such period attributable to (1) cash dividends or distributions received by a
Restricted Subsidiary from CityCenter except dividends or distributions of income
from the sales of condominium units and (2) cash management fees received by the
Company or a Restricted Subsidiary in respect of the management of CityCenter shall
in each of clauses (1) and (2) be annualized at each date of determination by taking
the product of (x) such Consolidated EBITDA and (y) the fraction equal to four
divided by the number of full fis-

-8-

 

cal quarters that have elapsed since the opening of CityCenter.

     “Consolidated Fixed Charge Coverage Ratio” means, with respect to any Person for any period,
the ratio of Consolidated EBITDA of such Person for such period to the Consolidated Fixed Charges
of such Person for such period. In the event that the Company or any Restricted Subsidiary Incurs,
assumes, guarantees, redeems, retires or extinguishes any Indebtedness (other than Indebtedness
Incurred under any revolving credit facility unless such Indebtedness has been permanently repaid
and has not been replaced) or issues or redeems Disqualified Stock or Preferred Stock subsequent to
the commencement of the period for which the Consolidated Fixed Charge Coverage Ratio is being
calculated but prior to or simultaneously with the event for which the calculation of the
Consolidated Fixed Charge Coverage Ratio is made (the “Consolidated Fixed Charge Coverage Ratio
Calculation Date”), then the Consolidated Fixed Charge Coverage Ratio shall be calculated giving
pro forma effect to such Incurrence, assumption, guarantee, redemption, retirement or
extinguishment of Indebtedness, or such issuance or redemption of Disqualified Stock or Preferred
Stock, as if the same had occurred at the beginning of the applicable four-quarter period.

     For purposes of making the computation referred to above, Investments, acquisitions,
dispositions, mergers, consolidations and disposed operations (as determined in accordance with
GAAP) that have been made by the Company or any of its Restricted Subsidiaries during the
four-quarter reference period or subsequent to such reference period and on or prior to or
simultaneously with the Consolidated Fixed Charge Coverage Ratio Calculation Date shall be
calculated on a pro forma basis, assuming that all such Investments, acquisitions, dispositions,
mergers, consolidations and disposed operations (and the change in any associated fixed charge
obligations and the change in Consolidated EBITDA resulting therefrom) had occurred on the first
day of the four-quarter reference period. If since the beginning of such period any Person that
subsequently became a Restricted Subsidiary or was merged with or into the Company or any of its
Restricted Subsidiaries since the beginning of such period shall have made any Investment,
acquisition, disposition, merger, consolidation or disposed operation that would have required
adjustment pursuant to this definition, then the Consolidated Fixed Charge Coverage Ratio shall be
calculated giving pro forma effect thereto for such period as if such Investment, acquisition,
disposition, merger, consolidation or disposed operation had occurred at the beginning of the
applicable four-quarter period.

     For purposes of this definition, whenever pro forma effect is to be given to an Investment,
acquisition, disposition, merger or consolidation or any other transaction, the pro forma
calculations shall be made in good faith by a responsible financial or accounting officer of the
Company in accordance with Regulation S-X of the Securities Act, as promulgated by the Commission
(and may include, for the avoidance of doubt, cost savings adjustments in compliance with such
Regulation). If any Indebtedness bears a floating rate of interest and is being given pro forma
effect, the interest on such Indebtedness shall be calculated as if the rate in effect on the
Consolidated Fixed Charge Coverage Ratio Calculation Date had been the applicable rate for the
entire period (taking into account any Hedging Obligations applicable to such Indebtedness).
Interest on a Capitalized Lease Obligation shall be deemed to accrue at an interest rate reasonably
determined by a responsible financial or accounting officer of the Company to be the rate of
interest implicit in such Capitalized Lease Obligation in accordance with GAAP. For purposes of
making the computation referred to above, interest on any Indebtedness under a revolving credit
facility computed on a pro forma basis shall be computed based upon the average daily balance of
such Indebtedness during the applicable period except as set forth in the first paragraph of this
definition. Interest on Indebtedness that may optionally be determined at an interest rate based
upon a factor of a prime or similar rate, a Eurocurrency interbank offered rate, or

-9-

 

other rate, shall be deemed to have been based upon the rate actually chosen, or, if none,
then based upon such optional rate chosen as the Company may designate.

     “Consolidated Fixed Charges” means, with respect to any Person for any period, the sum of:

     (a) Consolidated Interest Expense of such Person for such period;

     (b) the product of (i) all cash dividends or other distributions paid (excluding items
eliminated in consolidation) on any series of Preferred Stock of any Restricted Subsidiary
during such period, times (ii) a fraction, the numerator of which is one and the denominator
of which is one minus the then current combined federal, state and local statutory tax rate
of such Person, expressed as a decimal, determined on a consolidated basis in accordance
with GAAP; and

     (c) the product of (i) all dividends or other distributions accrued (excluding items
eliminated in consolidation) on any series of Disqualified Stock during such period, times
(ii) a fraction, the numerator of which is one and the denominator of which is one minus the
then current combined federal, state and local statutory tax rate of such Person, expressed
as a decimal, determined on a consolidated basis in accordance with GAAP.

     “Consolidated Interest Expense” means, with respect to any Person for any period, without
duplication, the sum of:

     (a) the consolidated interest expense of such Person and its Restricted Subsidiaries
for such period, whether paid or accrued (including, without limitation or duplication,
amortization of original issue discount, amortization or write-off of deferred financing
costs, non-cash interest payments, the interest component of any deferred payment
obligations, the interest component of all payments associated with Capitalized Lease
Obligations, imputed interest with respect to Attributable Debt, commissions, discounts and
other fees and charges incurred in respect of letter of credit or bankers’ acceptance
financings, and net payments (if any) pursuant to Hedging Obligations), plus

     (b) any interest accruing on Indebtedness of another Person that is guaranteed by such
Person or one of its Restricted Subsidiaries, which shall include, without limitation, any
interest accruing on Indebtedness of MGM Grand Detroit under the Credit Facility, plus

     (c) consolidated capitalized interest of such Person and its Restricted Subsidiaries
for such period, whether paid or accrued. For purposes of this definition, interest on a
Capitalized Lease Obligation shall be deemed to accrue at an interest rate reasonably
determined by such Person to be the rate of interest implicit in such Capitalized Lease
Obligation in accordance with GAAP.

     “Consolidated Net Income” means, with respect to any Person for any period, the aggregate of
the Net Income of such Person and its Restricted Subsidiaries for such period, on a consolidated
basis, and otherwise determined in accordance with GAAP; provided, however, that, without
duplication,

     (a) any after-tax effect, whether gains or losses, of items classified as extraordinary
or any non-cash item classified as nonrecurring shall be excluded,

-10-

 

     (b) the cumulative effect of a change in accounting principles during such period shall
be excluded,

     (c) any after-tax effect of income (loss) from disposed, abandoned, transferred, closed
or discontinued operations and any net after-tax gains or losses on disposal of disposed,
abandoned, transferred, closed or discontinued operations shall be excluded,

     (d) any after-tax effect of gains or losses (less related fees, expenses and charges)
attributable to asset dispositions other than in the ordinary course of business, as
determined in good faith by the Company, shall be excluded,

     (e) any after-tax effect, whether gains or losses (less related fees, expenses and
charges) attributable to the early extinguishment of Indebtedness, Hedging Obligations or
other derivative instruments shall be excluded,

     (f) the Net Income for such period of any Person that is not a Subsidiary or is an
Unrestricted Subsidiary or that is accounted for by the equity method of accounting, shall
be excluded; provided that Consolidated Net Income of the Company shall be increased by the
aggregate amount of Net Income of any such Person in respect of such period distributed to
the Company or any Restricted Subsidiary in the form of cash dividends or distributions,

     (g) any non-cash expense realized or resulting from stock option plans, employee
benefit plans or post-employment benefit plans of the Company or grants or sales of stock,
stock appreciation or similar rights, stock options, restricted stock, preferred stock or
other rights shall be excluded,

     (h) effects of purchase accounting adjustments (including the effects of such
adjustments pushed down to such Person and such Restricted Subsidiaries) in amounts required
or permitted by GAAP, resulting from the application of purchase accounting in relation to
any consummated acquisition or the amortization or write-off of any amounts thereof, net of
taxes, shall be excluded,

     (i) any impairment charges or asset write-offs, in each case pursuant to GAAP, and the
amortization of intangibles arising pursuant to GAAP shall be excluded, and

     (j) the Net Income for such period of any Restricted Subsidiary shall be excluded to
the extent that the declaration or payment of dividends or similar distributions by that
Restricted Subsidiary of its Net Income is not at the date of determination permitted
without any prior governmental approval (which has not been obtained) or, directly or
indirectly, by the operation of the terms of its charter or any agreement, instrument,
judgment, decree, order, statute, rule, or governmental regulation applicable to that
Restricted Subsidiary or its stockholders, unless such restriction with respect to the
payment of dividends or similar distributions has been legally waived, provided that
Consolidated Net Income of the Company will be increased by the amount of dividends or other
distributions or other payments actually paid in cash (or to the extent converted into cash)
or Cash Equivalents to the Company or a Restricted Subsidiary thereof in respect of such
period, to the extent not already included therein.

     Notwithstanding the foregoing, for the purpose of Section 4.16 only (other than clause (3)(IV)
of Section 4.16(a)), there shall be excluded from Consolidated Net Income any income arising from

-11-

 

the sale or other disposition, repurchase, redemption, repayment or return of capital, as
applicable, of Investments made by the Company or its Restricted Subsidiaries in Existing
Investment Entities, any distribution or dividend received from an Existing Investment Entity, the
sale or other disposition, repurchase, redemption, repayment or return of capital, as applicable,
of Restricted Investments made after the Closing Date by the Company or its Restricted Subsidiaries
in Persons that are not Existing Investment Entities and any distribution or dividend received from
any such Person.

     “Consolidated Net Tangible Assets” means, as of each date of determination, the total amount
of assets of the Company and its Subsidiaries, after deducting therefrom (a) all current
liabilities of the Company and its Subsidiaries (excluding (i) the current portion of long-term
Indebtedness, (ii) inter-company liabilities, and (iii) any liabilities which are by their terms
renewable or extendable at the option of the obligor thereon to a time more than twelve months from
the time as of which the amount thereof is being computed), and (b) all goodwill, trade names,
trademarks, patents, unamortized debt discount and expense and other like intangibles of the
Company and its Subsidiaries, all as set forth on the latest internally available consolidated
balance sheet of the Company prepared in accordance with GAAP.

     “Contingent Obligations” means, with respect to any Person, any obligation of such Person
guaranteeing any leases, dividends or other obligations that do not constitute Indebtedness
(“primary obligations”) of any other Person (the “primary obligor”) in any manner, whether directly
or indirectly, including, without limitation, any obligation of such Person, whether or not
contingent,

     (a) to purchase any such primary obligation or any property or asset constituting
direct or indirect security therefor,

     (b) to advance or supply funds

     (i) for the purchase or payment of any such primary obligation, or

     (ii) to maintain working capital or equity capital of the primary obligor or
otherwise to maintain the net worth or solvency of the primary obligor, or

     (c) to purchase property, assets, securities or services primarily for the purpose of
assuring the owner of any such primary obligation of the ability of the primary obligor to
make payment of such primary obligation against loss in respect thereof.

     “Continuing Directors” means, as of any date of determination, with respect to any Person, any
member of the Board of Directors of such Person who:

     (a) was a member of such Board of Directors on the Closing Date; or

     (b) was nominated for election or elected to such Board of Directors with the approval
of a majority of the Continuing Directors who were members of such Board of Directors at the
time of such nomination or election.

     “Convertible Debt-Linked Derivative Transaction” means (i) the Investment in and exercise by
Borrower of rights under derivative securities linked to Equity Interests underlying Indebtedness
convertible into, or exchangeable for, Equity Interests, or similar financial instruments acquired
by the Company in connection with the issuance by the Company of such Indebtedness and (ii) the
payment

-12-

 

of any termination fees or similar payments in connection with the termination of Equity
Interests issued substantially contemporaneously with an Incurrence of Indebtedness by the Company
convertible into, or exchangeable for, Equity Interests.

     “Corporate Trust Office” means the office of the Trustee specified in Section 12.01 or any
other office specified by the Trustee from time to time pursuant to such Section.

     “corporation” means a corporation, association, company or business trust.

     “Covenant Defeasance” has the meaning given in Section 8.04(c).

     “Covenant Suspension Event” has the meaning given in Section 4.23(a).

     “Credit Facility” means (i) the Fifth Amended and Restated Loan Agreement, dated as of October
3, 2006, among the Company, as Borrower and MGM Grand Detroit, LLC, as Co-Borrower, the Banks
therein named, and Bank of America, N.A., as Administrative Agent (and their successors and assigns
from time to time party thereto), including any related notes, guarantees, collateral documents,
instruments and agreements executed in connection therewith, as amended, modified, renewed,
extended, refunded, replaced or refinanced, in whole or in part, from time to time, including any
agreement or indenture extending the maturity thereof, refinancing, replacing or otherwise
restructuring all or any portion of the Indebtedness under such agreement or agreements or
indenture or indentures or any successor or replacement agreement or agreements or indenture or
indentures or increasing the amount loaned or issued thereunder or altering the maturity thereof
and (ii) whether or not the credit agreement referred to in clause (i) remains outstanding, if
designated by the Company to be included in the definition of “Credit Facility,” one or more (A)
debt facilities or commercial paper facilities, providing for revolving credit loans, term loans,
receivables financing (including through the sale of receivables to lenders or to special purpose
entities formed to borrow from lenders against such receivables) or letters of credit, (B)
unsecured debt securities, indentures or other forms of debt financing (including convertible or
exchangeable debt instruments or bank guarantees or bankers’ acceptances) or (C) instruments or
agreements evidencing any other Indebtedness, in each case, with the same or different borrowers or
issuers and, in each case, as amended, supplemented, modified, extended, restructured, renewed,
refinanced, restated, replaced or refunded in whole or in part from time to time.

     “Credit Facility Refinancing Indebtedness” has the meaning given in Section 4.13(c).

     “Deed of Trust” means the Deed of Trust, Assignment of Rents and Leases, Security Agreement
and Fixture Filing, dated as of the Closing Date, granted by MGM Grand Hotel to Nevada Title
Company, as trustee, for the benefit of the Trustee.

     “Default” means any event that is, or with the passage of time or the giving of notice or both
would be, an Event of Default.

     “Defaulted Interest” has the meaning specified in Section 2.12(a).

     “Definitive Note” means one or more certificated Notes registered in the name of the Holder
thereof, issued in accordance with Section 2.06, and substantially in the form of Exhibit A hereto.

     “Depositary” means, with respect to the Notes issued in whole or in part in global form, the
person specified in or pursuant to Section 2.03 as the Depositary with respect to the Notes, until
a suc-

-13-

 

cessor shall have been appointed and become such pursuant to the applicable provisions of this
Indenture, and thereafter, “Depositary” means or includes such successor.

     “Designated Non-cash Consideration” means the fair market value (as determined in good faith
by the board of directors of the Company and evidenced by a certified Board Resolution delivered to
the Trustee) of non-cash consideration received by the Company or one of its Restricted
Subsidiaries in connection with a Non-Collateral Asset Sale or Collateral Asset Sale that is so
designated as Designated Non-cash Consideration pursuant to an Officer’s Certificate, setting forth
the basis of such valuation, less the amount of Cash Equivalents received in connection with a
subsequent sale of such Designated Non-cash Consideration.

     “Disqualified Holder” has the meaning given in Section 3.08.

     “Disqualified Stock” means, with respect to any Person, any Capital Stock of such Person
which, by its terms, or by the terms of any security into which it is convertible or for which it
is putable or exchangeable, or upon the happening of any event, matures or is mandatorily
redeemable (other than solely as a result of a change of control or asset sale) pursuant to a
sinking fund obligation or otherwise, or is redeemable at the option of the holder thereof (other
than solely as a result of a change of control or asset sale), in whole or in part, in each case
prior to the date 91 calendar days after the Maturity Date of the Notes; provided, however, that if
such Capital Stock is issued to any plan for the benefit of employees of the Company or its
Subsidiaries or by any such plan to such employees, such Capital Stock shall not constitute
Disqualified Stock solely because it may be required to be repurchased by the Company or its
Subsidiaries in order to satisfy applicable statutory or regulatory obligations. The amount of any
Disqualified Stock shall be the greater of the face amount and the maximum redemption or repurchase
price thereof.

     “Distribution Compliance Period” means the 40-day Distribution Compliance Period provided for
in Regulation S.

     “Dollar” or “$” means a dollar or other equivalent unit in such coin or currency of the United
States that, at the time of payment, is legal tender for the payment of public and private debts.

     “DTC” has the meaning given in Section 2.03.

     “Dubai World” means Dubai World, a Dubai, United Arab Emirates government decree entity.

     “Equity Interests” means Capital Stock and all warrants, options or other rights to acquire
Capital Stock, but excluding any debt security that is convertible into, or exchangeable for,
Capital Stock.

     “Euroclear” means Euroclear Bank, S.A./N.V., or its successor, as operator of the Euroclear
system.

     “Event of Default” has the meaning specified in Section 6.01.

     “Event of Loss” means, with respect to any Collateral, any (a) Casualty of such Collateral,
(b) Condemnation or seizure (other than pursuant to foreclosure or confiscation or requisition of
the use of

-14-

 

such Collateral) or (c) settlement in lieu of clause (b) above, in each case having a fair
market value in excess of $50.0 million.

     “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and
regulations of the Commission promulgated thereunder.

     “Exchange Notes” means the Unrestricted Definitive Notes issued in exchange for the Initial
Notes pursuant to the Exchange Offer in Section 2.06(f).

     “Exchange Offer” has the meaning set forth in the Registration Rights Agreement.

     “Excluded Assets” means the cash, deposit accounts, other assets and properties to the extent
the grant of security therein is restricted by law or contract (and which is not subject to the
Uniform Commercial Code or a similar statutory override), trade name “MGM Grand” and related
trademarks, service marks and copyrights (provided that upon the transfer of the MGM Grand
trademark from the Company or the Collateral Grantor to another Restricted Subsidiary that is not a
Collateral Grantor such Restricted Subsidiary will grant to MGM Grand Hotel a perpetual
non-exclusive license (subject to customary termination provisions) to such trademark providing for
an annual royalty not to exceed 1% total revenues of MGM Grand Hotel, which license and rights
thereunder will be part of the Collateral).

     “Existing Investment Entity” means any Non-Control Entity, any Unrestricted Subsidiary or any
other Person in which the Company or any of its Restricted Subsidiaries has made an Investment
existing as of the Closing Date that is designated as an Existing Investment Entity in writing by
the Company to the Trustee.

     “Existing Notes” means that Existing Senior Notes and the Existing Subordinated Notes.

     “Existing Senior Notes” means (a) the Company’s 8.50% senior notes due 2010 in the aggregate
principal amount of $782.0 million, (b) the Company’s 6.75% senior notes due 2012 in the aggregate
principal amount of $544.7 million, (c) the Company’s 5.875% senior notes due 2014 in the aggregate
principal amount of $508.9 million, (d) the Company’s 6.625% senior notes due 2015 in the aggregate
principal amount of $875 million, (e) the Company’s 6.75% senior notes due 2013 in the aggregate
principal amount of $484.2 million, (f) the Company’s 6.875% senior notes due 2016 in the aggregate
principal amount of $242.9 million, (g) the Company’s 7.50% senior notes due 2016 in the aggregate
principal amount of $732.7 million, (h) the Company’s 7.625% senior notes due 2017 in the aggregate
principal amount of $743.0 million, (i) the 13% Secured Notes, (j) the Mandalay Senior Notes, (k)
the Mirage Notes, (l) the 10.375% Secured Notes, (m) the 11.125% Secured Notes and (n) the
Company’s 11.375% senior notes due 2018 in the aggregate principal amount of $475 million.

     “Existing Subordinated Notes” means the Subordinated MGM Notes and the Subordinated Mandalay
Notes.

     “Fair Market Value” means, with respect to the consideration received or paid in any
transaction or series of transactions, the fair market value thereof as determined in good faith by
the Board of Directors.

     “Funding Guarantor” has the meaning given in Section 10.04.

-15-

 

     “GAAP” means generally accepted accounting principles in the United States of America as in
effect on the Closing Date (for purposes of the definitions of the terms “Consolidated Depreciation
and Amortization Expense,” “Consolidated EBITDA,” “Consolidated Fixed Charge Coverage Ratio,”
“Consolidated Fixed Charges,” “Consolidated Interest Expense,” “Consolidated Net Income,” and
“Consolidated Net Tangible Assets,” all defined terms in the Indenture to the extent used in or
relating to any of the foregoing definitions, and all ratios and computations based on any of the
foregoing definitions) and as set forth in the Financial Accounting Standards Board’s “Accounting
Standards Codification” as may be amended from time to time (for all other purposes of such
Indenture). All ratios and computations based on GAAP contained in the applicable Indenture shall
be computed in conformity with GAAP.

     “Gaming Authority” means the Nevada Gaming Commission, the Nevada State Gaming Control Board,
the New Jersey Casino Control Commission, the New Jersey Division of Gaming Enforcement, the
Michigan Gaming Control Board, the Detroit City Council, the Mississippi Gaming Commission, the
Illinois Gaming Board or any similar commission or agency which has, or may at any time after the
date of this Indenture have, jurisdiction over the gaming activities of the Company or a Restricted
Subsidiary of the Company or any successor thereto.

     “Gaming Facility” means any gaming or pari-mutuel wagering establishment and any related
building, restaurant, hotel, theater, parking facilities, retail shops, land, golf courses and
other recreation and entertainment facilities, and vessel, barge, ship and equipment.

     “Gaming Laws” means the gaming laws of a jurisdiction or jurisdictions to which the Company or
a Subsidiary of the Company is, or may at any time after the date of this Indenture be, subject.

     “Gaming Licenses” means any license, permit, franchise or other authorization from any
governmental authority required on the date of this Indenture or at any time thereafter to own,
lease, operate or otherwise conduct the gaming business of the Company and its Restricted
Subsidiaries.

     “Global Note Legend” means the legend set forth in Section 2.06(g)(ii), which is required to
be placed on all Global Notes issued under this Indenture.

     “Global Notes” means one or more Notes substantially in the form attached hereto as Exhibit A
issued under this Indenture that is deposited with or on behalf of and registered in the name of
the Depositary or its nominee.

     “Government Securities” means readily marketable (a) direct full faith and credit obligations
of the United States of America or obligations guaranteed by the full faith and credit of the
United States of America and (b) obligations of an agency or instrumentality of, or corporation
owned, controlled or sponsored by, the United States of America that are generally considered in
the securities industry to be implicit obligations of the United States of America.

     “Governmental Authority” means the government of the United States or any other nation, or of
any political subdivision thereof, whether state or local, and any agency, authority,
instrumentality, regulatory body, court, central bank or other entity exercising executive,
legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to
government (including any supra-national bodies such as the European Union or the European Central
bank).

-16-

 

     “Guarantee” means a guarantee (other than by endorsement of negotiable instruments for
collection in the ordinary course of business), direct or indirect, in any manner (including
letters of credit and reimbursement agreements in respect thereof), of all or any part of any
Indebtedness or other obligations.

     “Guaranteed Obligations” has the meaning specified in Section 10.01(a).

     “Hedging Obligations” means, with respect to any Person, the obligations of such Person under
any interest rate swap agreement, interest rate cap agreement, interest rate collar agreement,
commodity swap agreement, commodity cap agreement, commodity collar agreement, foreign exchange
contract, currency swap agreement or similar agreement providing for the transfer, modification or
mitigation of interest rate, commodity or currency risks either generally or under specific
contingencies.

     “Holder” means the Person in whose name a Note is registered on the Registrar’s books.

     “Incur” means issue, assume, enter into any guarantee of, incur or otherwise become liable
for; and the terms “Incurs,” “Incurred” and “Incurrence” shall have a correlative meaning; provided
that any Indebtedness or Equity Interests of a Person existing at the time such Person becomes a
Subsidiary (whether by merger, consolidation, acquisition or otherwise) shall be deemed to be
Incurred by such Subsidiary at the time it becomes a Subsidiary. Accrual of interest, the
accretion of accreted value and the payment of interest in the form of additional Indebtedness will
not be deemed to be an Incurrence of Indebtedness. Any Indebtedness issued at a discount
(including Indebtedness on which interest is payable through the issuance of additional
Indebtedness) shall be deemed Incurred at the time of original issuance of the Indebtedness at the
initial accreted amount thereof.

     “Indebtedness” means, with respect to any Person, without duplication:

     (a) any indebtedness of such Person, whether or not contingent:

     (i) in respect of borrowed money;

     (ii) evidenced by bonds, notes, debentures or similar instruments or letters of
credit or bankers’ acceptances (or, without duplication, reimbursement agreements in
respect thereof);

     (iii) representing the balance deferred and unpaid of the purchase price of any
property (including Capitalized Lease Obligations), except (A) any such balance that
constitutes a trade payable or similar obligation to a trade creditor, in each case
accrued in the ordinary course of business and (B) any earn-out obligations until
such obligation becomes a liability on the balance sheet of such Person in
accordance with GAAP; or

     (iv) representing net obligations under any Hedging Obligations;
if and to the extent that any of the foregoing Indebtedness (other than letters
of credit and Hedging Obligations) would appear as a liability upon a
balance sheet (excluding the footnotes thereto) of such Person prepared in
accordance with GAAP;

-17-

 

     (b) to the extent not otherwise included, any obligation by such Person to be liable
for, or to pay, as obligor, guarantor or otherwise on, the obligations of the type referred
to in clause (a) of a third Person (whether or not such items would appear upon the balance
sheet of the such obligor or guarantor), other than by endorsement of negotiable instruments
for collection in the ordinary course of business; and

     (c) to the extent not otherwise included, the obligations of the type referred to in
clause (a) of a third Person secured by a Lien on any asset owned by such first Person,
whether or not such Indebtedness is assumed by such first Person; provided, however, that
notwithstanding the foregoing, Indebtedness shall be deemed not to include (i) Contingent
Obligations Incurred in the ordinary course of business and not in connection with
Indebtedness under clause (a) or (ii) any obligation or commitment, contingent or otherwise,
to make an Investment (other than any guarantee of or other obligation or commitment to pay
any Indebtedness for borrowed money of another Person).

     “Indenture” means this Indenture as amended or supplemented from time to time.

     “Independent Financial Advisor” means an accounting, appraisal, investment banking firm or
consultant to Persons engaged in Similar Businesses of nationally recognized standing that is, in
the good faith judgment of the Company, qualified to perform the task for which it has been
engaged.

     “Indirect Participant” means an entity that, with respect to any Depositary, clears through or
maintains a direct or indirect, custodial relationship with a Participant.

     “Initial Notes” has the meaning specified in the preamble hereto.

     “Initial Purchasers” means Banc of America Securities LLC, RBS Securities Inc., Barclays
Capital Inc., J.P. Morgan Securities Inc., BNP Paribas Securities Corp., Daiwa Securities America
Inc., Citigroup Global Markets Inc., Deutsche Bank Securities Inc., UBS Securities LLC, Commerzbank
Capital Markets Corp., Morgan Stanley & Co. Incorporated, Wells Fargo Securities, LLC, Comerica
Securities, Inc., Scotia Capital (USA) Inc. and U.S. Bancorp Investments, Inc.

     “Interest Payment Date” with respect to any Note means March 15 and September 15 of each year,
commencing September 15, 2010, provided that if such Interest Payment Date is not a Business Day,
interest due on such Interest Payment Date shall be payable on the next succeeding Business Day.

     “Investment Grade Rating” means a rating equal to or higher than Baa3 (or the equivalent) by
Moody’s or BBB- (or the equivalent) by S&P.

     “Investments” means, with respect to any Person, all investments by such Person in other
Persons (including Affiliates) in the form of loans (including guarantees), advances or capital
contributions (excluding accounts receivable or credit extended, trade credit, advances to
customers, commission, travel and similar advances or credit extended to officers and employees, in
each case made in the ordinary course of business), purchases or other acquisitions for
consideration of Indebtedness, Equity Interests or other securities issued by any other Person,
completion guarantees issued in favor of any person other than a Restricted Subsidiary of the
Company (but only to the extent that any obligations of the Company or any of its Restricted
Subsidiaries with respect to such completion guarantee is required by GAAP to be classified on the
balance sheet of the Company as a liability) and invest-

-18-

 

ments that are required by GAAP to be classified on the balance sheet (excluding the footnotes) of
the Company in the same manner as the other investments included in this definition to the extent
such transactions involve the transfer of cash or other property. For purposes of the definition
of “Unrestricted Subsidiary” and Section 4.16:

     (a) “Investments” shall include the portion (proportionate to the Company’s equity
interest in such Subsidiary) of the fair market value of the net assets of a Subsidiary of
the Company at the time that such Subsidiary is designated an Unrestricted Subsidiary;
provided, however, that upon a redesignation of such Subsidiary as a Restricted Subsidiary,
the Company shall be deemed to continue to have a permanent “Investment” in an Unrestricted
Subsidiary in an amount (if positive) equal to:

     (i) the Company’s “Investment” in such Subsidiary at the time of such
redesignation; less

     (ii) the portion (proportionate to the Company’s equity interest in such
Subsidiary) of the fair market value of the net assets of such Subsidiary at the
time of such redesignation; and

     (b) any property transferred to or from an Unrestricted Subsidiary shall be valued at
its fair market value at the time of such transfer, in each case as determined in good faith
by the Company.

     “Legal Defeasance” has the meaning given in Section 8.04(b).

     “Legal Holiday” means a Saturday, a Sunday or a day on which commercial banking institutions
are not required to be open in the State of New York.

     “Letter of Transmittal” means the letter of transmittal to be prepared by the Company and sent
to all Holders of the Notes for use by such Holders in connection with an Exchange Offer.

     “Lien” means, with respect to any asset, any mortgage, lien (statutory or otherwise), pledge,
hypothecation, charge, security interest, preference, priority or encumbrance of any kind in
respect of such asset, whether or not filed, recorded or otherwise perfected under applicable law,
including any conditional sale or other title retention agreement, or any lease in the nature
thereof; provided that in no event shall an operating lease be deemed to constitute a Lien.

     “Loss Proceeds Offer” has the meaning given in Section 4.12(b).

     “Loss Proceeds Offer Payment” has the meaning given in Section 4.12(b).

     “Loss Proceeds Offer Payment Date” has the meaning given in Section 4.12(b)(ii).

     “Mandalay” means Mandalay Resort Group, a Nevada corporation.

     “Mandalay Senior Notes” means (a) Mandalay’s 6.375% Senior Notes due 2011 in the aggregate
principal amount of $128.7 million; (b) Mandalay’s Floating Rate Convertible Senior Debentures due
2033 in the aggregate principal amount of $5.9 million; (c) Mandalay’s 7% Debentures due 2036

-19-

 

in the aggregate principal amount of $0.6 million; and (d) Mandalay’s 6.7% Debentures due 2096
in the aggregate principal amount of $4.3 million.

     “Maturity” when used with respect to any Note means the date on which the principal of such
Note or an installment of principal becomes due and payable as therein or herein provided, whether
at the Stated Maturity or by declaration of acceleration, call for redemption, repayment or
otherwise.

     “Maturity Date” means March 15 , 2020.

     “MGM Grand Detroit” means MGM Grand Detroit, LLC, a Delaware limited liability company.

     “MGM Grand Hotel” means MGM Grand Hotel, LLC, a Nevada limited liability company.

     “Mirage” means Mirage Resorts, Incorporated, a Nevada corporation.

     “Moody’s” means Moody’s Investors Service, Inc. and any successor to its rating agency
business.

     “Mortgage” means a deed of trust, assignment of leases and rents, security agreement and
fixture filing executed and delivered by any Collateral Grantor on or after the Closing Date
substantially in the form of the Deed of Trust or in such form as may be approved by the Collateral
Agent, with such changes thereto as may be recommended by the Collateral Agent’s local counsel
based on local laws or customary local mortgage or deed of trust practices, as such security
instrument may be modified from time to time.

     “Net Income” means, with respect to any Person, the net income (loss) of such Person,
determined in accordance with GAAP and before any reduction in respect of Preferred Stock
dividends.

     “Net Loss Proceeds” means, with respect to any Event of Loss, the proceeds in the form of cash
or Cash Equivalents from (a) insurance proceeds, (b) Condemnation Awards or (c) damages awarded by
any judgment received by the Company or any of its Restricted Subsidiaries from such Event of Loss,
net of reasonable costs relating to such Event of Loss, including legal, appraisal or insurance
adjuster fees, any relocation expenses incurred as a result thereof, taxes paid or payable as a
result thereof (after taking into account any available tax credits or deductions and any tax
sharing arrangements), amounts required to be applied to the repayment of Indebtedness secured by a
Lien on such assets or properties (other than Collateral or as required by Section 4.10(b)(i)) and
any deduction of appropriate amounts to be provided by the Company or any of its Restricted
Subsidiaries as a reserve in accordance with GAAP against any liabilities associated with such
Event of Loss, including pension and other post-employment benefit liabilities and liabilities
related to environmental matters or against any indemnification obligations.

     “Net Loss Proceeds Deposit Account” has the meaning given in Section 4.12(a).

     “Net Proceeds” means the aggregate cash proceeds and Cash Equivalents received by the Company
or any of its Restricted Subsidiaries in respect of any Non-Collateral Asset Sale or Collateral
Asset Sale (each, an “Asset Sale”), including any cash and Cash Equivalents received upon the sale
or other disposition of any non-cash consideration received in any Asset Sale (in each case,
including any cash payments received by way of deferred payment of principal pursuant to a note or
installment

-20-

 

receivable or otherwise, but only as and when received, but excluding any other consideration
received in the form of assumption by the acquiring Person of Indebtedness or other obligations
relating to the properties or assets that are the subject of such Asset Sale or received in any
other non-cash form), in each case, net of costs relating to such Asset Sale and the sale or
disposition of such non-cash consideration, including legal, accounting and investment banking
fees, brokerage and sales commissions, any relocation expenses incurred as a result thereof and
taxes paid or payable as a result thereof (after taking into account any available tax credits or
deductions and any tax sharing arrangements) and any deduction of appropriate amounts to be
provided by the Company or any of its Restricted Subsidiaries as a reserve in accordance with GAAP
against any liabilities associated with such asset sale, including pension and other
post-employment benefit liabilities and liabilities related to environmental matters or against any
indemnification obligations.

     “New York-New York” means the New York-New York Hotel and Casino located in Las Vegas, Nevada.

     “New York-New York Collateral” means the assets securing the 13% Secured Notes and the New
York-New York Guarantees thereof, including (i) New York-New York, the real property on which New
York-New York is located and all existing and future personal property of New York-New York Hotel &
Casino, LLC (other than certain excluded assets), (ii) upon receipt of the necessary gaming
approvals, 100% of the equity interests in New York-New York Hotel & Casino, LLC, and (iii) any
replacement or substitute collateral permitted to be provided pursuant to the 13% Secured Notes
Indenture.

     “New York-New York Collateral Documents” means the deeds of trust, security agreements, pledge
agreements and other collateral documents in respect of the New York-New York Collateral, in each
case as amended, modified, renewed, extended, refunded, replaced or refinanced, in whole or in
part, from time to time

     “New York-New York Guarantee” means any guarantee of the 13% Secured Notes by a New York-New
York Guarantor.

     “New York-New York Guarantor” means any Subsidiary Guarantor that is required by the terms of
the 13% Secured Notes Indenture to guarantee the 13% Secured Notes and to grant Liens securing its
guarantee on assets included in the New York-New York Collateral.

     “Non-Collateral Asset Sale” means (a) the sale, conveyance, transfer or other disposition of
any assets or properties other than Collateral and rights in respect thereof (including, without
limitation, by way of a sale and leaseback) other than in the ordinary course of business, and (b)
the issue or sale by the Company or any of its Restricted Subsidiaries of Equity Interests of any
of the Restricted Subsidiaries (other than Equity Interests that constitute Collateral or
directors’ qualifying shares or to the extent required by law), in the case of either clause (a) or
(b), whether in a single transaction or a series of related transactions that have a fair market
value (as determined in good faith by the Board of Directors and evidenced by a certified Board
Resolution delivered to the Trustee) in excess of $250.0 million or for net cash proceeds in excess
of $250.0 million. Notwithstanding the foregoing, the following shall in each case not be
considered a Non-Collateral Asset Sale: (a) a transfer of assets or properties by the Company to a
Restricted Subsidiary or by a Restricted Subsidiary to the Company or to another Restricted
Subsidiary; (b) an issuance of Equity Interests by a Restricted Subsidiary to the Company or to
another Restricted Subsidiary; (c) a Restricted Payment or a Permitted Investment that is permitted
by Section 4.16; (d) a disposition of cash or Cash Equivalents; (e) a disposition of either

-21-

 

obsolete equipment or equipment that is damaged, worn out or otherwise no longer useful in the
business; (f) any Sale and Leaseback Transaction involving an asset (other than a Gaming Facility)
in respect of which Sale and Leaseback Transaction less than $250.0 million of Attributable Debt is
Incurred; (g) any surrender or waiver of contract rights or a settlement, release or surrender of
contract, tort or other claims of any kind or a grant of any Lien not prohibited by the terms of
this Indenture; (h) any financing transaction with respect to property built or acquired by the
Company or any Restricted Subsidiary after the Closing Date, including without limitation any Sale
and Leaseback Transaction or asset securitization; (i) foreclosure or any similar action with
respect to any property or other asset of the Company or any of its Restricted Subsidiaries; (j)
any RE Receivables Sale; (k) any disposition of Capital Stock of a Restricted Subsidiary pursuant
to an agreement or other obligation with or to a Person (other than the Company or a Restricted
Subsidiary) from whom such Restricted Subsidiary was acquired or from whom such Restricted
Subsidiary acquired its business and assets (having been newly formed in connection with such
acquisition), made as part of such acquisition and in each case comprising all or a portion of the
consideration in respect of such sale or acquisition; (l) like kind exchanges of properties where
such properties have substantially equivalent fair market values (as determined in good faith by
the Company or, if such fair market values is $250.0 million or more, the Board of Directors of the
Company and in such case evidenced by the delivery to the Trustee of a certified copy of Board
Resolutions documenting such determination) and (m) the sale of equity interests in the Borgata
Hotel Casino and Spa and related real property in Atlantic City, New Jersey.

     “Non-Collateral Asset Sale Offer” has the meaning given in Section 4.10(b)(ii).

     “Non-Collateral Asset Sale Payment” has the meaning given in Section 4.10(b)(ii).

     “Non-Collateral Asset Sale Payment Date” has the meaning given in Section 4.10(c)(ii).

     “Non-Control Entity” means any partnership, joint venture, limited liability company or
similar entity of which 20% or more of the capital accounts, distribution rights, total equity and
voting interests or general or limited partnership interests, as applicable, are owned or
controlled, directly or indirectly, by a Person or one or more of the other Subsidiaries of that
Person, or a combination thereof, whether in the form of membership, general, special or limited
partnership interests or otherwise, but with respect to which such Person and its other
Subsidiaries do not have the collective right to elect a majority of the Board of Directors or
other equivalent governing body, and otherwise lack the power to direct the management, of such
partnership, joint venture, limited liability company or similar entity. Unless otherwise
specified, “Non-Control Entity” refers to a Non-Control Entity of the Company.

     “Non-Recourse Indebtedness” means Indebtedness, Disqualified Stock or Preferred Stock of an
Unrestricted Subsidiary

     (a) as to which none of the Company or any Restricted Subsidiary:

     (i) provides credit support of any kind (including
any undertaking, agreement or instrument that would constitute
Indebtedness),

     (ii) is directly or indirectly liable (as a guarantor or otherwise), or

     (iii) constitutes the lender or purchaser, and

-22-

 

     (b) no default with respect to which (including any rights that the holders thereof may
have to take enforcement action against an Unrestricted Subsidiary) would permit (upon
notice, lapse of time or both) any holder of any other Indebtedness (other than the Notes)
of any of the Company or any Restricted Subsidiary to declare a default on such other
Indebtedness or cause the payment thereof to be accelerated or payable prior to its stated
maturity.

     “Non-U.S. Person” means any Person other than a U.S. Person.

     “Note Register” means a register in which, subject to such reasonable regulations as it may
prescribe, the Company shall provide for the registration of the Notes and of transfers and
exchanges of such Notes which the Company shall cause to be kept at the Corporate Trust Office of
the Trustee (or at the appropriate office of any other Registrar appointed hereunder).

     “Notes” has the meaning stated in the recital of this Indenture and more particularly means
any Notes authenticated and delivered under this Indenture. For all purposes of this Indenture,
the term “Notes” shall include any Exchange Notes to be issued and exchanged for the Initial Notes
pursuant to the Registration Rights Agreement and this Indenture.

     “Notes Custodian” or “Custodian” means the custodian with respect to any Global Note (as
appointed by the Depositary), or any successor entity thereto covered in 2.03.

     “Notice of Default” has the meaning given in Section 6.01.

     “Obligations” means any principal, interest (including any interest accruing subsequent to the
filing of a petition in bankruptcy, reorganization or similar proceeding at the rate provided for
in the documentation with respect thereto, whether or not such interest is an allowed claim under
applicable state, federal or foreign law), penalties, fees, indemnifications, reimbursements
(including reimbursement obligations with respect to letters of credit and banker’s acceptances),
damages and other liabilities, and guarantees of payment of such principal, interest, penalties,
fees, indemnifications, reimbursements, damages and other liabilities, payable under the
documentation governing any Indebtedness.

     “Offering Memorandum” means the offering memorandum dated March 9, 2010 relating to the sale
of the Initial Notes.

     “Officer” means the Chairman of the Board, the Chief Executive Officer, Chief Financial
Officer, Chief Operating Officer, the President, any Executive Vice President, Senior Vice
President or Vice President, the Treasurer, the Secretary, any Assistant Treasurer or Assistant
Secretary of the Company or a Subsidiary Guarantor.

     “Officer’s Certificate” means a certificate signed on behalf of the Company by an Officer of
the Company or on behalf of a Restricted Subsidiary by an Officer of such Restricted Subsidiary,
who must be the principal executive officer, the principal financial officer, the treasurer or the
principal accounting officer of the Company or any officer of such Subsidiary Guarantor that meets
the requirements set forth herein.

     “Opinion of Counsel” means a written opinion from legal counsel who is acceptable to the
Trustee. The counsel may be an employee of or counsel to the Company, a Subsidiary of the Company
or the Trustee.

-23-

 

     “Outstanding Notes” has the meaning set forth in Section 2.08.

     “Pari Passu Indebtedness” has the meaning given in Section 4.10(b)(i).

     “Pari Passu Secured Indebtedness” has the meaning given in Section 4.11(d).

     “Participant” means, with respect to the Depositary, Euroclear or Clearstream, a Person who
has an account with the Depositary, Euroclear or Clearstream, respectively (and, with respect to
DTC, shall include Euroclear and Clearstream).

     “Paying Agent” has the meaning given in Section 2.03.

     “Permitted Investment” means:

     (a) any Investment in the Company or any of its Restricted Subsidiaries, provided that
any Investment that results in a transfer of Collateral to any Restricted Subsidiary shall
constitute a Permitted Investment only if such Restricted Subsidiary is a Subsidiary
Guarantor and the Collateral Agent shall have received such instruments and documents as may
be necessary to ensure that the Liens of the Collateral Documents continue to apply to such
Collateral and continue to be of first priority;

     (b) any Investment in cash and Cash Equivalents, provided that in the case of
Investments of Collateral, such Investments constitute Collateral under the Collateral
Documents;

     (c) any Investment by the Company or any of its Restricted Subsidiaries in a Person
that is engaged in a Similar Business if as a result of such Investment:

     (i) such Person becomes a Restricted Subsidiary; or

     (ii) such Person, in one transaction or a series of related transactions, is
merged or consolidated with or into, or transfers or conveys substantially all of
its assets and properties to, or is liquidated into, the Company or a Restricted
Subsidiary, and, in each case, any Investment held by such Person; provided that
such Investment was not acquired by such Person in contemplation of such
acquisition, merger, consolidation or transfer;

     (d) any Investment in securities or other assets or properties, including earnouts, not
constituting cash and Cash Equivalents and received in connection with (i) a Non-Collateral
Asset Sale made pursuant to the provisions of Section 4.10 or any other disposition of
assets or properties not constituting a Non-Collateral Asset Sale or (ii) a Collateral Asset
Sale made pursuant to and in accordance with Section 4.11;

     (e) any Investment existing on the Closing Date, including any Investments in Existing
Investment Entities;

     (f) any Investment acquired by the Company or any of its Restricted Subsidiaries:

-24-

 

     (i) in exchange for any other Investment or accounts receivable held by the
Company or any such Restricted Subsidiary in connection with or as a result of a
bankruptcy, workout, reorganization or recapitalization of the issuer of such other
Investment or accounts receivable; or

     (ii) as a result of a foreclosure by the Company or any of its Restricted
Subsidiaries with respect to any secured Investment or other transfer of title with
respect to any secured Investment in default;

     (g) Hedging Obligations permitted under Section 4.13(b)(ix);

     (h) any Investment in CityCenter, including without limitation CityCenter Holdings,
LLC, so long as no Default shall have occurred and be continuing or would occur as a
consequence thereof;

     (i) Investments the payment for which consists of Equity Interests (exclusive of
Disqualified Stock) of the Company; provided, however, that such Equity Interests will not
increase the amount available for Restricted Payments under clause (3) of Section 4.16(a);

     (j) guarantees of Indebtedness of the Company and any Restricted Subsidiary permitted
under Section 4.13;

     (k) loans and advances to officers, directors and employees, in each case incurred in
the ordinary course of business or consistent with past practices or to fund such Person’s
purchase of Equity Interests of the Company or any direct or indirect parent company
thereof;

     (l) so long as no Default shall have occurred and be continuing or would occur as a
consequence thereof, an Investment of up to 42 acres of undeveloped land in respect of the
joint venture with Kerzner International and Istithmar previously announced by the Company
in its filings with the Commission; and

     (m) (a) Investments in or by any Special Purpose RE Subsidiary, or in connection with a
RE Receivables Sale by or to or in favor of any Special Purpose RE Entity, including
Investments of funds held in accounts permitted or required by the arrangements governing
such RE Receivables Sale or any related Indebtedness, or (b) any promissory note issued by
the Company to a Special Purpose RE Entity.

	 	 	“Permitted Liens” means, with respect to any Person:

     (a) pledges or deposits by such Person under workmen’s compensation laws, unemployment
insurance laws or similar legislation or regulatory requirements, deposits made in the
ordinary course of business to secure liability to insurance carriers; good faith deposits
in connection with bids, tenders, contracts (other than for the payment of Indebtedness) or
leases to which such Person is a party; deposits to secure public or statutory obligations
of such Person or deposits of cash or U.S. government bonds to secure bid, surety, customs
or appeal bonds in proceedings to which such Person is a party; deposits as security for
contested taxes or import duties or for the payment of rent, in each case incurred in the
ordinary course of business; and deposits made by the Company or any of its Restricted
Subsidiaries in connection with any letter of intent or purchase agreement permitted
hereunder;

-25-

 

     (b) inchoate Liens and Liens incident to construction on or maintenance of property,
including carriers’, warehousemen’s and mechanics’ Liens, now or hereafter filed of record
for which adequate reserves have been set aside (or deposits made pursuant to applicable
law) and which are being contested in good faith by appropriate proceedings or other Liens
arising out of judgments or awards against such Person with respect to which such Person
shall then be proceeding with an appeal or other proceedings for review if adequate reserves
have been set aside by such Person in accordance with GAAP;

     (c) Liens for taxes, assessments or other governmental charges not yet past due; or
Liens for taxes, assessments or other governmental charges which are being contested in good
faith by appropriate proceedings, if adequate reserves with respect thereto have been set
aside in accordance with GAAP;

     (d) (i) survey exceptions, encumbrances, easements or reservations of, or rights of
others for, licenses, rights-of-way, sewers, electric lines, telegraph and telephone lines,
pipelines, conduits, cables, wire communication lines, power lines and substations, streets,
trails, walkways, drainage, irrigation, water, and sewerage purposes, dikes, canals,
ditches, the removal of oil, gas, coal, or other minerals, and other similar purposes, or
present or future zoning laws, ordinances or other restrictions as to the use, occupancy or
enjoyment of real properties or Liens incidental to the conduct of the business of such
Person or to the ownership of its properties which were not incurred in connection with
Indebtedness and which do not in the aggregate materially adversely affect the fair market
value or use of the real property for the purposes for which it is or may reasonably be
expected to be held, (ii) minor defects and irregularities in title to any real property
which in the aggregate does not materially impair the fair market value or use of the real
property for the purposes for which it is or may reasonably be expected to be held, (iii)
leases, subleases, licenses or sublicenses granted to others in the ordinary course of
business which do not materially interfere with the ordinary conduct of the business of the
Company or any of its Restricted Subsidiaries and do not secure Indebtedness and (iv) Liens
arising from Uniform Commercial Code financing statement filings regarding operating leases
entered into by the Company and its Restricted Subsidiaries in the ordinary course of
business;

     (e) Liens securing Indebtedness permitted to be Incurred pursuant to Section
4.13(b)(iv) and Liens securing Indebtedness or other obligations of a Restricted Subsidiary
owing to the Company or another Restricted Subsidiary permitted to be Incurred in accordance
with Section 4.13 or Liens in favor of the Company or any Subsidiary Guarantor;

     (f) Liens existing on the Closing Date (other than Liens securing Indebtedness);

     (g) Liens on assets or properties or shares of stock of a Person at the time such
Person becomes a Subsidiary or Liens on assets or properties at the time the Company or a
Restricted Subsidiary acquired the property, including any acquisition by means of a merger
or consolidation with or into the Company or any of its Restricted Subsidiaries; provided,
however, that in each case such Liens do not secure Indebtedness and are not created or
incurred in connection with, or in contemplation of, such other Person becoming such a
Subsidiary or such acquisition, as the case may be; and provided, further, that in each case
such Liens may not extend to any other property owned by the Company or any of its
Restricted Subsidiaries;

-26-

 

     (h) Liens to secure any refinancing, refunding, extension, renewal or replacement (or
successive refinancing, refunding, extensions, renewals or replacements) as a whole, or in
part, of any Indebtedness secured by any Lien referred to in the foregoing clauses (e), (f)
and (g); provided, however, that (i) such new Lien shall be limited to all or part of the
same property that secured the original Lien (plus improvements on such property), and (ii)
the Indebtedness secured by such Lien at such time is not increased to any amount greater
than the sum of (A) the outstanding principal amount or, if greater, committed amount of the
Indebtedness described under clauses (e), (f) and (g) at the time the original Lien became a
Permitted Lien, and (B) an amount necessary to pay any fees and expenses, including
premiums, related to such refinancing, refunding, extension, renewal or replacement;

     (i) Liens securing judgments for the payment of money not constituting an Event of
Default under Section 6.01(e) so long as such Liens are adequately bonded and any
appropriate legal proceedings that may have been duly initiated for the review of such
judgment have not been finally terminated or the period within which such proceedings may be
initiated has not expired;

     (j) (i) Liens in favor of customs and revenue authorities arising as a matter of law to
secure payment of customs duties in connection with the importation of goods in the ordinary
course of business; (ii) Liens arising out of conditional sale, title retention, consignment
or similar arrangements for the sale or purchase of goods entered into by the Company or any
of its Restricted Subsidiaries in the ordinary course of business; and (iii) Liens on
specific items of inventory of other goods and proceeds of any Person securing such Person’s
obligations in respect of bankers’ acceptances issued or created for the account of such
Person to facilitate the purchase, shipment or storage of such inventory or other goods;

     (k) Liens that are contractual rights of set-off (i) relating to the establishment of
depository relations with banks not given in connection with the issuance of Indebtedness or
(ii) relating to pooled deposit or sweep accounts of the Company or any of its Restricted
Subsidiaries to permit satisfaction of overdraft or similar obligations Incurred in the
ordinary course of business of the Company and its Restricted Subsidiaries;

     (l) any encumbrance or restriction (including put and call arrangements) with respect
to Capital Stock of any joint venture or similar arrangement pursuant to any joint venture
or similar agreement;

     (m) Liens securing Indebtedness in an aggregate principal amount as of the date of the
Incurrence of such Indebtedness, including, without limitation, Liens securing the Notes and
the related Subsidiary Guarantees of the Notes (and exchange notes in respect thereof), the
10.375% Secured Notes, the 11.125% Secured Notes, the 13% Secured Notes and all other
Secured Indebtedness then outstanding, not to exceed 16.5% of Consolidated Net Tangible
Assets at the time of such Incurrence;

     (n) rights reserved to or vested in any Governmental Authority to control or regulate,
or obligations or duties to any Governmental Authority with respect to the use of any
property or, any right, power, franchise, grant, license, or permit;

-27-

 

     (o) covenants, conditions, and restrictions affecting the use of property which in the
aggregate do not materially impair the fair market value or use of the property for the
purposes for which it is or may reasonably be expected to be held;

     (p) any other statutory Liens arising in the ordinary course of business with respect
to obligations which are not delinquent or are being contested in good faith, provided that,
if delinquent, adequate reserves have been set aside with respect thereto and, by reason of
nonpayment, no property is subject to a material risk of loss or forfeiture;

     (q) any Lien created by an agreement or instrument entered into by the Company or a
Restricted Subsidiary in the ordinary course of its business which consists of a restriction
on the assignability, transfer or hypothecation of such agreement or instrument;

     (r) Liens on cash collateral deposited by the Company to secure Indebtedness permitted
under Section 6.7(k) of the Credit Facility as in effect on the date of the Indenture in an
aggregate amount not to exceed 105% of the aggregate amount of Indebtedness outstanding
under such Section 6.7(k) at any time;

     (t) other non-consensual Liens incurred in the ordinary course of business but not in
connection with an issuance of Indebtedness, which do not in the aggregate, when taken
together with all other Liens, materially impair the value or use of the property of the
Company and the Restricted Subsidiaries, taken as a whole; and

     (u) Liens securing Indebtedness or other obligations of any Special Purpose RE Entity
or Liens in favor of any Special Purpose RE Entity in connection with a RE Receivables Sale.

     For purposes of this definition, the term “Indebtedness” shall be deemed to include interest
on such Indebtedness. The foregoing notwithstanding, (a) none of the Liens set forth above (other
than those set forth in clauses (a), (b), (c), (d)(i) and (ii), (j)(i), (k) and (n)) shall apply to
any assets or properties that constitute Collateral and (b) and none of the Liens set forth above
shall be a Permitted Lien to the extent it has priority over the Collateral Agent’s Liens and
security interests in any of the Collateral.

     “Person” means any individual, corporation, limited liability company, partnership, joint
venture, association, joint stock company, trust, unincorporated organization, government or any
agency or political subdivision thereof or any other entity.

     “Place of Payment” when used with respect to the Notes means the Corporate Trust Office of the
Trustee or such other location as may be established under Section 4.04.

     “Pledge Agreement” means the Pledge Agreement executed by Mirage in favor of the Collateral
Agent, substantially in the form attached hereto as Exhibit G.

     “Pledged Interests” means all of the ownership interests of MGM Grand Hotel owned by the
Company or any other Restricted Subsidiary pledged to the Collateral Agent as security for the
Notes.

     “Predecessor Note” of any particular Note means every previous Note evidencing all or a
portion of the same debt as that evidenced by such particular Note; and, for the purposes of this
definition,

-28-

 

any Note authenticated and delivered under Section 2.07 in lieu of a mutilated, lost,
destroyed or stolen Note shall be deemed to evidence the same debt as the mutilated, lost,
destroyed or stolen Note.

     “Preferred Stock” means any Equity Interest with preferential rights of payment of dividends
or upon liquidation, dissolution, or winding up.

     “Private Placement Legend” means the legend set forth in Section 2.06(g)(i) to be placed on
all Notes issued under this Indenture except where specifically stated otherwise by the provisions
of this Indenture.

     “Protected Purchaser” means a purchaser of a Note, or of an interest therein, who: (i) gives
value; (ii) does not have notice of any adverse claim to the Note; and (iii) obtains control of the
Note.

     “Purchase Date” means any of the Change of Control Payment Date, the Non-Collateral Asset Sale
Payment Date, the Collateral Asset Sale Payment Date and the Loss Proceeds Offer Payment Date, as
applicable.

     “QIB” means a “qualified institutional buyer” as defined in Rule 144A.

     “RE Receivables Sale” means any sale, transfer, assignment, participation, encumbrance,
hypothecation, pledge, conveyance or other disposition of, or creation or incurrence of any Lien
on, real estate or real estate-related assets relating to condominiums, apartments and air rights
and other similar rights related thereto by the Company or any Subsidiary thereof to or in favor of
any Special Purpose RE Entity, or by any Special Purpose RE Subsidiary, in each case in connection
with the Incurrence by a Special Purpose RE Entity of Indebtedness, or obligations to make payments
to the obligor on Indebtedness, which may be secured by a Lien in respect of such real estate or
real estate-related assets.

     “Redemption Date” means the date fixed for redemption of any Note pursuant to this Indenture.

     “Redemption Price” has the meaning given in Section 3.01.

     “Real Estate” means the hotels and casinos commonly known as the MGM Grand Las Vegas and the
real property upon which the hotels and casinos are located.

     “Real Estate Receivables” means any receivables, accounts, notes, loans or similar instruments
or agreements created in connection with extensions of credit to purchasers of real estate or real
estate-related assets or rights from the Company or a Subsidiary or Non-Control Entity of the
Company relating to condominiums, apartments, leases and air rights and other similar and/or
appurtenant rights related thereto.

     “Refinancing Indebtedness” has the meaning given in Section 4.13(b)(x).

     “Registrar” has the meaning given in Section 2.03.

     “Registration Rights Agreement” means the Registration Rights Agreement with respect to the
Notes dated as of the Closing Date, among the Company, the Subsidiary Guarantors and the Initial
Purchasers, as such agreement may be amended, modified or supplemented from time to time.

-29-

 

     “Regular Record Date” for the interest payable on the Notes on any Interest Payment Date
means the March 1 or September 1 (whether or not a Business Day), as the case may be, immediately
preceding such Interest Payment Date.

     “Regulation S” means Regulation S promulgated under the Securities Act.

     “Regulation S Global Note” means one or more Global Notes bearing the Private Placement Legend
issued in an aggregate principal amount equal to the aggregate principal amount of the Initial
Notes sold in reliance on Rule 903 of Regulation S on the Closing Date.

     “Released Property” has the meaning given in Section 11.04(b)(i).

     “Replacement Collateral” has the meaning given in Section 4.11(b).

     “Replacement Collateral Documents” has the meaning given in Section 4.11(b).

     “Replacement Gaming Collateral” has the meaning given in Section 4.11(b).

     “Replacement Pledged Equity” has the meaning given in Section 4.11(b).

     “Responsible Officer” means any officer within the corporate trust department of the Trustee
who customarily performs functions similar to those performed by the Persons who at the time shall
be such officers, respectively, or to whom any corporate trust matter is referred because of such
person’s knowledge of and familiarity with the particular subject and who shall have direct
responsibility for the administration of this Indenture.

     “Restricted Definitive Note” means one or more Definitive Notes issued under this Indenture
bearing the Private Placement Legend.

     “Restricted Global Note” means one or more Global Notes bearing the Private Placement Legend,
issued under this Indenture; provided that in no case shall an Exchange Note issued in accordance
with this Indenture and the terms of any Registration Rights Agreement be a Restricted Global Note.

     “Restricted Investment” means an Investment (including an Investment made in a Non-Control
Entity or an Unrestricted Subsidiary) other than a Permitted Investment.

     “Restricted Payment” has the meaning given in Section 4.16(a).

     “Restricted Subsidiary” means, at any time, any direct or indirect Subsidiary of the Company
(including any foreign subsidiary) that is not then an Unrestricted Subsidiary; provided, however,
that if any Unrestricted Subsidiary ceases to be an Unrestricted Subsidiary, such Subsidiary shall
be included in the definition of “Restricted Subsidiary”; provided, further, that for purposes of
the calculation of Consolidated Fixed Charges, Consolidated Interest Expense, Consolidated Net
Income and the calculation of the amount of Restricted Payments that may be made pursuant to clause
(3) of Section 4.16(a) only, MGM Grand Detroit shall be deemed to be a Restricted Subsidiary.

     “Reversion Date” has the meaning given in Section 4.23(b).

-30-

 

     “Rule 144” has the meaning promulgated under the Securities Act.

     “Rule 144A” means Rule 144A promulgated under the Securities Act.

     “Rule 144A Global Note” means one or more Global Notes bearing the Private Placement Legend
that will be issued in an aggregate principal amount equal to the aggregate principal amount of the
Initial Notes to be resold by the Initial Purchasers in reliance on Rule 144A on the Closing Date.

     “Rule 14e-1” has the meaning given in Section 4.09(c).

     “S&P” means Standard & Poor’s, a division of The McGraw-Hill Companies, Inc., and any
successor to its rating agency business.

     “Sale and Leaseback Transaction” means any arrangement providing for the leasing by the
Company or any of its Restricted Subsidiaries of any real or tangible personal property or assets,
which property has been or is to be sold or transferred by the Company or such Restricted
Subsidiary to a third Person in contemplation of such leasing.

     “Secured Indebtedness” means any Indebtedness of the Company or any of its Restricted
Subsidiaries secured by a Lien.

     “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations
of the Commission promulgated thereunder.

     “Security Agreement” means the Security Agreement executed by MGM Grand Hotel in favor of the
Collateral Agent, substantially in the form attached hereto as Exhibit F.

     “Shelf Registration Statement” means a shelf registration statement prepared pursuant to the
Registration Rights Agreement in respect of the Initial Notes.

     “Significant Subsidiary” means a Restricted Subsidiary of the Company that would be a
“significant subsidiary” as defined in Article I, Rule 1-02(w) of Regulation S-X, promulgated
pursuant to the Securities Act, as in effect on the Closing Date; provided that for purposes of
this Indenture, each reference therein to 10% shall be deemed to be 2.5%.

     “Similar Business” means any business conducted or proposed to be conducted by the Company and
its Restricted Subsidiaries on the Closing Date or any business that is similar, reasonably
related, complementary, incidental or ancillary thereto.

     “Special Record Date” for the payment of any Defaulted Interest means a date fixed by the
Trustee pursuant to Section 2.12.

     “Special Purpose RE Entity” means (x) any Special Purpose RE Subsidiary or (y) any other
Person that is engaged in the business of acquiring, selling, collecting, financing, securitizing,
syndicating or refinancing Real Estate Receivables and/or related assets.

     “Special Purpose RE Financing” means any financing or refinancing of assets consisting of Real
Estate Receivables of the Company or any Restricted Subsidiary that have been transferred to a
Special Purpose RE Entity or made subject to a Lien in a RE Receivables Sale.

-31-

 

     “Special Purpose RE Financing Fees” means any remuneration, compensation, distributions or
payments made directly or by means of discounts with respect to any participation interest issued
or sold in connection with, and other fees paid to a Person that is not a Restricted Subsidiary in
connection with, any Special Purpose RE Financing.

     “Special Purpose RE Financing Undertakings” means representations, warranties, covenants,
indemnities, guarantees of performance and (subject to clause (y) of the proviso below) other
agreements and undertakings entered into or provided by the Company or any of its Restricted
Subsidiaries that the Company determines in good faith (which determination shall be conclusive)
are customary or otherwise necessary or advisable in connection with a Special Purpose RE Financing
or a RE Receivables Sale; provided that (x) it is understood that Special Purpose RE Financing
Undertakings may consist of or include (i) reimbursement and other obligations in respect of notes,
letters of credit, surety bonds and similar instruments provided for credit enhancement purposes or
(ii) Hedging Obligations, or other similar obligations entered into by the Company or any
Restricted Subsidiary, in respect of any Special Purpose RE Financing or RE Receivables Sale, and
(y) subject to the preceding clause (x), any such other agreements and undertakings shall not
include any Guarantee of Indebtedness of a Special Purpose RE Subsidiary by the Company or a
Restricted Subsidiary that is not a Special Purpose RE Subsidiary.

     “Special Purpose RE Subsidiary” means a Subsidiary of the Company that (a) is engaged solely
in (x) the business of acquiring, selling, collecting, financing, securitizing, syndicating, or
refinancing Real Estate Receivables, all proceeds thereof and all rights (contractual and other),
collateral and other assets relating thereto, and (y) any business or activities incidental or
related to such business, and (b) is designated as a “Special Purpose RE Subsidiary” by the
Company.

     “Specified Refinanced Debt” has the meaning given in Section 4.13(c).

     “Stated Maturity” means, with respect to any security, the date specified in such security as
the fixed date on which the payment of principal of such security is due and payable, including
pursuant to any mandatory redemption provision (but excluding any provision providing for the
repurchase of such security at the option of the holder thereof upon the happening of any
contingency).

     “Subordinated Indebtedness” means, with respect to the Notes,

     (a) any Indebtedness of the Company which is by its terms subordinated in right of
payment to the Notes, and

     (b) any Indebtedness of any Subsidiary Guarantor which is by its terms subordinated in
right of payment to the Subsidiary Guarantee of such entity of the Notes.

     “Subordinated Indebtedness” in any event includes the Existing Subordinated Notes.

     “Subordinated Mandalay Notes” means the 7.625% Senior Subordinated Debentures due 2013 of
Mandalay.

     “Subordinated MGM Notes” means the 8.375% Senior Subordinated Notes due 2011 of the Company.

-32-

 

     “Subsidiary” of any specified Person means any corporation, partnership or limited liability
company of which at least a majority of the outstanding Capital Stock (or other Equity Interests)
having by the terms thereof ordinary voting power for the election of directors (or the equivalent)
(irrespective of whether or not at the time Capital Stock (or other Equity Interests) of any other
class or classes shall have or might have voting power by reason of the happening of any
contingency) is at the time directly or indirectly owned by such Person, or by one or more of its
other Subsidiaries, or by such Person and one or more of its other Subsidiaries.

     “Subsidiary Guarantee” means the guarantee by any Subsidiary Guarantor of the Company’s
Obligations under this Indenture and the Notes.

     “Subsidiary Guarantor” means each Restricted Subsidiary that Guarantees the Notes in
accordance with the terms of this Indenture and its successors and assigns, until released from its
obligations under its Subsidiary Guarantee in accordance with the terms of this Indenture.

     “Successor Company” has the meaning given in Section 5.01(a).

     “Successor Guarantor” has the meaning given in Section 5.02(a)(i).

     “supplemental indenture” has the meaning given in Section 9.01(a).

     “Suspended Covenants” has the meaning given in Section 4.23(a).

     “Suspension Period” has the meaning given in Section 4.23(a).

     “The Mirage Casino-Hotel” means The Mirage Casino-Hotel, a Nevada corporation.

     “TIA” means the Trust Indenture Act of 1939 (15 U.S.C. §§ 77aaa-77bbbb) as in effect on the
date of this Indenture, except as stated in Section 9.03.

     “Title Policy” has the meaning given in Section 4.24.

     “10.375% Secured Notes” means the 10.375% Senior Secured Notes due May 15, 2014 of the Company
in existence on the Closing Date (and any exchange notes in respect thereof issued pursuant to the
10.375%/11.125% Secured Notes Indenture or any agreement in existence on the Closing Date).

     “11.125% Secured Notes” means the 11.125% Senior Secured Notes due November 15, 2017 of the
Company in existence on the Closing Date (and any exchange notes in respect thereof issued pursuant
to the 10.375%/11.125% Secured Notes Indenture or any agreement in existence on the Closing Date).

     “10.375%/11.125% Secured Notes Indenture” means the Indenture governing the 10.375% Secured
Notes and the 11.125% Secured Notes as in effect on the Closing Date.

     “13% Secured Notes” means the 13% Senior Secured Notes due November 15, 2013 of the Company in
existence on the Closing Date (and any exchange notes in respect thereof issued pursuant to the 13%
Secured Notes Indenture or any agreement in existence on the Closing Date).

-33-

 

     “13% Secured Notes Indenture” means the Indenture governing the 13% Secured Notes as in effect
on the Closing Date.

     “13% Secured Notes Issue Date” has the meaning given in Section 4.16(a).

     “Tracinda” means Tracinda Corporation, a Nevada corporation.

     “Transaction Documents” has the meaning given in Section 12.14.

     “Transferability Certificate” means the Transferability Certificate set forth as Exhibit I
hereto, or another certificate acceptable to the Trustee.

     “Treasury Rate” means, as of any Redemption Date, the yield to maturity as of such Redemption
Date of United States Treasury securities with a constant maturity (as compiled and published in
the most recent Federal Reserve Statistical Release H.15 (519) that has become publicly available
at least two Business Days prior to the Redemption Date (or, if such Statistical Release is no
longer published, any publicly available source of similar market data)) most nearly equal to the
period from the Redemption Date to the maturity date for the Notes; provided, however, that if the
period from the Redemption Date to the maturity date for the Notes is less than one year, the
weekly average yield on actually traded United States Treasury securities adjusted to a constant
maturity of one year will be used.

     “Trustee” means the Person named as the “Trustee” in the first paragraph of this Indenture
until a successor Trustee shall have become such pursuant to the applicable provisions of this
Indenture, and thereafter “Trustee” shall mean or include each Person who is then a Trustee
hereunder. Unless the context otherwise requires, “Trustee” shall include the Trustee in its
capacity as Collateral Agent.

     “Trust Officer” means, when used with respect to the Trustee or Paying Agent, any officer
within the corporate trust department of the Trustee or Paying Agent, as applicable, including any
vice president, assistant vice president, assistant secretary, assistant treasurer, trust officer
or any other officer of the Trustee or Paying Agent who customarily performs functions similar to
those performed by the persons who at the time shall be such officers, respectively, or to whom any
corporate trust matter is referred because of such person’s knowledge of and familiarity with the
particular subject and who shall have direct responsibility for the administration of this
Indenture.

     “Uniform Commercial Code” means the Nevada Uniform Commercial Code.

     “United States” means the United States of America (including the States and the District of
Columbia), its territories and possessions and other areas subject to its jurisdiction.

     “Unrestricted Definitive Note” means one or more Definitive Notes issued under this Indenture
that do not bear and are not required to bear the Private Placement Legend.

     “Unrestricted Global Note” means one or more Global Notes issued under this Indenture that
does not bear and is not required to bear the Private Placement Legend.

-34-

 

     “Unrestricted Subsidiary” means

     (a) Subsidiaries of the Company formed under the laws of foreign nations whose only
tangible assets or properties are located in foreign nations, and Subsidiaries of the
Company that own as their sole asset the stock or other securities and obligations of such
foreign Subsidiaries;

     (b) MGM Grand Detroit and its Subsidiaries, MGMM Insurance Company and M3 Nevada
Insurance Company;

     (c) Nevada Landing Partnership, but only until receipt of approval from the Illinois
Gaming Board of its Subsidiary Guarantee, after which it shall become a Restricted
Subsidiary; and

     (d) any Subsidiary of the Company (including any newly-formed or newly-acquired
Subsidiary) that is designated as an Unrestricted Subsidiary in writing by the Company to
the Trustee, and any Subsidiary of such an Unrestricted Subsidiary, but only so long as the
conditions under Section 4.20 and in the definition of “Investment” are satisfied upon such
designation.

     Notwithstanding the foregoing, no Subsidiary shall be designated as, or otherwise
constitute, an Unrestricted Subsidiary if:

     (i) it has outstanding any Indebtedness other than Non-Recourse Indebtedness;

     (ii) it has guaranteed or granted any Liens securing any Indebtedness of the Company or
any Restricted Subsidiary; or

     (iii) it is subject to any of the covenants of the Credit Facility, our Existing Notes
or any other existing or future senior subordinated notes or senior notes of the Company or
any Restricted Subsidiary; provided that clauses (i), (ii) and (iii) shall not apply to (A)
MGM Grand Detroit’s Indebtedness and covenants under the Credit Facility as long as its
liability under the Credit Facility is limited to that portion of the loans under the Credit
Facility which are actually borrowed or the proceeds of which are actually received by MGM
Grand Detroit and (B) Nevada Landing Partnership with respect to its obligations under the
Credit Facility and the Existing Notes. In addition, no Collateral Grantor shall be
designated as an Unrestricted Subsidiary.

     “U.S. Person” means a U.S. person as defined in Rule 902(o) under the Securities Act.

     “Vice President” includes, with respect to the Company, any Executive or Senior Vice President
and includes, with respect to the Trustee, any Vice President, whether or not designated by a
number or word or words added before or after the title “Vice President.”

     “Voting Stock” of any Person as of any date means the Capital Stock of such Person that is at
the time entitled to vote in the election of the Board of Directors of such Person or all interests
in such Person with the ability to control management or actions of such Person.

-35-

 

     “Weighted Average Life to Maturity” means, when applied to any Indebtedness, Disqualified
Stock or Preferred Stock, as the case may be, at any date, the quotient obtained by dividing:

     (a) the sum of the products of the number of years from the date of determination to
the date of each successive scheduled principal payment of such Indebtedness or redemption
or similar payment with respect to such Disqualified Stock or Preferred Stock multiplied by
the amount of such payment; by

     (b) the sum of all such payments.

     “Wholly-Owned Subsidiary” of any Person means a Subsidiary of such Person, 100% of the
outstanding Equity Interests of which (other than directors’ qualifying shares) shall at the time
be owned by such Person or by one or more Wholly-Owned Subsidiaries of such Person.

     SECTION 1.02 RULES OF CONSTRUCTION.

     Unless the context otherwise requires:

     (a) a term has the meaning assigned to it;

     (b) an accounting term not otherwise defined has the meaning assigned to it
in accordance with GAAP and all financial calculations and determinations contemplated by
this Indenture shall be made in conformity with GAAP;

     (c) “or” is not exclusive;

     (d) “including” means “including without limitation”;

     (e) words in the singular include the plural and words in the plural include
the singular;

     (f) all references to “principal” of the Notes include redemption price and
purchase price and all references to “interest” on the Notes include Additional Interest, if
any, as well as interest accruing after the commencement of a proceeding under Title 11,
U.S. Code or any similar federal or state law for the relief of debtors (including
post-petition interest), whether or not allowed or allowable as a claim in any such
proceeding;

     (g) all exhibits are incorporated by reference herein and expressly made a
part of this Indenture;

     (h) all references to articles, sections and exhibits (and subparts thereof)
are to this Indenture;

     (i) all references to statutes or rules (or their subparts) include
amendments and replacement or successor provisions;

     (j) all references to Persons include their successors; and

-36-

 

     (k) unless otherwise specifically indicated, the term “consolidated” with
respect to any Person refers to such Person consolidated with its Restricted Subsidiaries,
and excludes from such consolidation any Unrestricted Subsidiary as if such Unrestricted
Subsidiary were not an Affiliate of such Person;

ARTICLE II

THE NOTES

     SECTION 2.01 FORM AND DATING.

     (a) General. The Notes and the Trustee’s certificate of authentication shall be
substantially in the form of Exhibit A. The Notes may have notations, legends or endorsements
required by law, stock exchange rule, usage or this Indenture. Each Note shall be dated the date
of its authentication. The Notes shall be in denominations of $2,000 and integral multiples of
$1,000.

     The terms and provisions contained in the Notes shall constitute, and are hereby expressly
made, a part of this Indenture and the Company, any Restricted Subsidiary and the Trustee, by their
execution and delivery of this Indenture, expressly agree to such terms and provisions and to be
bound thereby. However, to the extent any provision of any Note conflicts with the express
provisions of this Indenture, the provisions of this Indenture shall govern and be controlling.

     (b) Global Notes. Notes issued in global form shall be substantially in the form of
Exhibit A (including the Global Note Legend thereon and the “Schedule of Exchanges of Interests in
the Global Note” attached thereto). Notes issued in definitive form shall be substantially in the
form of Exhibit A (but without the Global Note Legend thereon and without the “Schedule of
Exchanges of Interests in the Global Note” attached thereto). Each Global Note shall represent
such of the outstanding Notes as shall
be specified therein and each shall provide that it shall represent the aggregate principal
amount of outstanding Notes from time to time endorsed thereon and that the aggregate principal
amount of outstanding Notes represented thereby may from time to time be reduced or increased, as
appropriate, to reflect exchanges, redemptions or transfers of beneficial interests from one Global
Note to another Global Note. Any endorsement of a Global Note to reflect the amount of any
increase or decrease in the aggregate principal amount of outstanding Notes represented thereby
shall be made by the Trustee or the Notes Custodian, at the direction of the Trustee, in accordance
with instructions given by the Holder or beneficial owner thereof as required by Section 2.06.

     (c) Form of Initial Notes, Etc. All Initial Notes issued on the Closing Date are
being or will be offered and sold by the Initial Purchasers only (i) to QIBs (in which case they
will be evidenced by Rule 144A Global Notes) or (ii) in reliance on Regulation S under the
Securities Act (in which case they will be evidenced by Regulation S Global Notes).

     SECTION 2.02 EXECUTION AND AUTHENTICATION.

     The Notes shall be executed on behalf of the Company by its Chairman of the Board of
Directors, its President, one of its Executive or Senior Vice Presidents or Chief Executive
Officers or its Treasurer, and attested by its Secretary or one of its Assistant Secretaries. The
signature of any of these officers may be manual or facsimile.

     If an Officer whose signature is on a Note no longer holds that office at the time a Note is
authenticated, the Note shall nevertheless be valid. A Note shall not be valid until authenticated
by the

-37-

 

manual signature of the Trustee. The signature shall be conclusive evidence that the Note
has been authenticated under this Indenture. The Trustee shall, upon a written order of the
Company signed by an Officer (an “Authentication Order”), authenticate and, if requested therein,
deliver (a) Initial Notes for original issuance up to the aggregate principal amount stated in such
Authentication Order in such form as may be provided therein or in this Indenture and (b) in
accordance with Section 2.06(f), Exchange Notes; provided that the aggregate principal amount of
the Notes at any time may not exceed $845,000,000, except as provided in Section 2.07. The Trustee
may appoint an authenticating agent acceptable to the Company to authenticate Notes. An
authenticating agent may authenticate Notes whenever the Trustee may do so. Each reference in this
Indenture to authentication by the Trustee includes authentication by such agent. An
authenticating agent has the same rights as an Agent to deal with Holders or an Affiliate of the
Company.

     SECTION 2.03 REGISTRAR, PAYING AGENT AND DEPOSITARY.

     The Company shall maintain an office or agency in the Borough of Manhattan, the City of New
York, where Notes may be presented for registration of transfer or for exchange (“Registrar”) and
an office or agency where Notes may be presented for payment (“Paying Agent”). Until otherwise
designated by the Company, the Company’s office or agency in New York shall be the office of the
Trustee maintained for such purpose. The Registrar shall keep a register of the Notes and of their
transfer and exchange. The Company may appoint one or more co-registrars and one or more
additional paying agents. The term “Registrar” includes any co-registrar and the term “Paying
Agent” includes any additional paying agent. The Company shall enter into an appropriate agency
agreement with any Registrar, Paying Agent or other Agent not a party to this Indenture, which
shall incorporate any applicable terms of the TIA. The Company may change any Paying Agent or
Registrar without notice to any Holder. The Registrar or Paying Agent may resign at any time upon
not less than 10 Business Days’ prior written notice to the Company; provided, however, that the
Trustee may resign as Paying Agent or Registrar only if the Trustee also resigns as Trustee in
accordance with Section 7.10.

     The Company shall notify the Trustee in writing of the name and address of any Agent not a
party to this Indenture. If the Company fails to appoint or maintain another entity as Registrar
or Paying Agent, the Trustee shall act as such. The Company or any of its Subsidiaries may act as
Paying Agent or Registrar.

     The Company initially appoints The Depository Trust Company (“DTC”) to act as Depositary with
respect to the Global Notes. The Company initially appoints the Trustee to act as the Registrar
and Paying Agent and to act as Notes Custodian with respect to the Global Notes.

     SECTION 2.04 PAYING AGENT TO HOLD MONEY IN TRUST.

     Principal of, premium, if any, and interest on the Notes will be payable at the office of the
Paying Agent or, at the option of the Company, payment of interest may be made by check mailed to
the Holders at their respective addresses set forth in the Note Register; provided, all payments or
principal, premium, if any, and interest with respect to the Notes represented by one or more
Global Notes registered in the name or held by the Depositary shall be made by wire transfer of
immediately available funds to accounts specified by the Holder prior to 10:00 a.m., New York time,
on each due date of the principal and interest on any Note. The Company shall require each Paying
Agent other than the Trustee to agree in writing that the Paying Agent shall hold in trust for the
benefit of Holders or the Trustee all money held by the Paying Agent for the payment of principal,
premium or interest on the

-38-

 

Notes, and shall notify the Trustee in writing of any default by the
Company in making any such payment. While any such default continues, the Trustee may require a
Paying Agent, and in such event any such Paying Agent shall have the obligation, to pay all money
held by it to the Trustee. The Company at any time may require a Paying Agent to pay all money
held by it to the Trustee. Upon payment over to the Trustee, the Paying Agent (if other than the
Company or a Subsidiary) shall have no further liability for such money. If the Company or a
Subsidiary acts as Paying Agent, it shall segregate and hold in a separate trust fund for the
benefit of the Holders all money held by it as Paying Agent. Upon any bankruptcy or reorganization
proceedings relating to the Company, the Trustee shall serve as Paying Agent for the Notes.

     Any money deposited with any Paying Agent, or then held by the Company or a domestic
Subsidiary in trust for the payment of principal or interest on any Note and remaining unclaimed
for two years after such principal and interest has become due and payable shall be paid to the
Company at its request, or, if then held by the Company or a domestic Subsidiary, shall be
discharged from such trust; and the Holders shall thereafter, as general unsecured creditors, look
only to the Company for payment thereof, and all liability of the Paying Agent with respect to such
money, and all liability of the Company or such permitted Subsidiary as trustee thereof, shall
thereupon cease.

     SECTION 2.05 HOLDER LISTS.

     The Trustee shall preserve in as current a form as is reasonably practicable the most recent
list available to it of the names and addresses of all Holders and shall otherwise comply with TIA
§ 312(a). If the Trustee is not the Registrar, the Company shall furnish, or shall cause the
Registrar (if other than the Company) to furnish, to the Trustee at least seven Business Days
before each Interest Payment Date and at such other times as the Trustee may request in writing, a
list in such form and as of such date as the Trustee may reasonably require of the names and
addresses of the Holders of Notes and, to the extent applicable, the Company shall otherwise comply
with TIA § 312(a).

     SECTION 2.06 TRANSFER AND EXCHANGE.

     (a) Transfer and Exchange of Global Notes. A Global Note may not be transferred as
a whole except by the Depositary to a nominee of the Depositary, by a nominee of the Depositary to
the
Depositary or to another nominee of the Depositary, or by the Depositary or any such nominee
to a successor Depositary or a nominee of such successor Depositary. Beneficial interests in
Global Notes will be exchanged by the Company for Definitive Notes, subject to any applicable laws,
if (i) the Company delivers to the Trustee notice from the Depositary that it is unwilling or
unable to continue to act as Depositary and a successor Depositary is not appointed by the Company
within 90 days after the date of such written notice from the Depositary, or (ii) upon request of
the Trustee or Holders of a majority of the aggregate principal amount of outstanding Notes if
there shall have occurred and be continuing a Default with respect to the Notes; provided that in
no event shall any temporary Note that is a Global Note issued pursuant to Regulation S be
exchanged by the Company for Definitive Notes prior to (A) the expiration of the Distribution
Compliance Period and (B) the receipt by the Registrar of any certificate identified by the Company
and its counsel to be required pursuant to Rule 903 or Rule 904 under the Securities Act. In any
such case, the Company will notify the Trustee in writing that, upon surrender by the Participants
and Indirect Participants of their interests in such Global Note, Definitive Notes will be issued
to each Person that such Participants, Indirect Participants and DTC jointly identify as being the
beneficial owner of the related Notes. Global Notes also may be exchanged or replaced, in whole or
in part, as provided in Sections 2.07 and 2.10 hereof. Every Note authenticated and delivered in
exchange for, or in lieu of, a Global Note or any portion thereof, pur-

-39-

 

suant to this Section 2.06 or
Section 2.07 or 2.10 hereof, shall be authenticated and delivered in the form of, and shall be, a
Global Note. A Global Note may not be exchanged for another Note other than as provided in this
Section 2.06. However, beneficial interests in a Global Note may be transferred and exchanged as
provided in Section 2.06(b), (c), (d) or (f).

     (b) Transfer and Exchange of Beneficial Interests in the Global Notes. The transfer
and exchange of beneficial interests in the Global Notes shall be effected through the Depositary,
in accordance with the provisions hereof and the Applicable Procedures. Beneficial interests in
the Restricted Global Notes shall be subject to restrictions on transfer comparable to those set
forth in this Indenture to the extent required by the Securities Act. Transfers of beneficial
interests in the Global Notes also shall require compliance with the applicable provisions below.

     (i) Transfer of Beneficial Interests in the Same Global Note; Transfers of Beneficial
Interests in Unrestricted Global Notes for Interests in Other Unrestricted Global Notes.
Beneficial interests in any Restricted Global Note may be transferred to Persons who take delivery
thereof in the form of a beneficial interest in the same Restricted Global Note in accordance with
the transfer restrictions set forth in the Private Placement Legend; provided, however, that prior
to the expiration of the Distribution Compliance Period, no transfer of beneficial interests in a
Regulation S Global Note may be made to a U.S. Person or for the account or benefit of a U.S.
Person (other than an Initial Purchaser) unless permitted by applicable law and made in compliance
with Sections 2.06(b)(ii) and (iii) below. Beneficial interests in any Unrestricted Global Note
may be transferred to Persons who take delivery thereof in the form of a beneficial interest in an
Unrestricted Global Note. No written orders or instructions shall be required to be delivered to
the Registrar to effect the transfers described in this Section 2.06(b)(i) unless specifically
stated above.

     (ii) All Other Transfers and Exchanges of Beneficial Interests in Global Notes. In connection
with all transfers and exchanges of beneficial interests that are not subject to Section
2.06(b)(i), the transferor of such beneficial interest must deliver to the Registrar either (A) (1)
a written order from a Participant or an Indirect Participant given to the Depositary in accordance
with the Applicable Procedures directing the Depositary to credit or cause to be credited a
beneficial interest in another Global Note in an amount equal to the beneficial interest to be
transferred or exchanged and (2) instructions given in accordance with the Applicable Procedures
containing information regarding the Participant account to be credited with such increase or, (B)
(1) if Definitive Notes are at such time permitted to be issued pursuant to this Indenture, a
written order from a Participant or an Indirect Participant given to the Depositary in accordance
with the Applicable Procedures directing the Depositary to cause to be issued a Definitive Note in
an amount equal to the beneficial interest to be transferred or exchanged and (2) instructions
given by the Depositary to the Registrar containing information regarding the Person in whose
name such Definitive Note shall be registered to effect the transfer or exchange referred to in (1)
above. Upon consummation of an Exchange Offer by the Company in accordance with Section 2.06(f),
the requirements of this Section 2.06(b)(ii) shall be deemed to have been satisfied upon receipt by
the Registrar of the instructions contained in the Letter of Transmittal delivered by the Holder of
such beneficial interests in the Restricted Global Notes. Upon satisfaction of all of the
requirements for transfer or exchange of beneficial interests in Global Notes contained in this
Indenture and the Notes or otherwise applicable under the Securities Act, the Trustee or Notes
Custodian shall adjust the principal amount of the relevant Global Note(s) pursuant to Section
2.06(h).

     (iii) Transfer of Beneficial Interests to Another Restricted Global Note. A beneficial
interest in any Restricted Global Note may be transferred to a Person who takes delivery thereof in
the

-40-

 

form of a beneficial interest in another Restricted Global Note if the transfer complies with
the requirements of Section 2.06(b)(ii) and the Registrar receives the following:

     (A) if the transferee will take delivery in the form of a beneficial interest in a Rule
144A Global Note, then the transferor must deliver a certificate in the form of Exhibit
B hereto, including the certifications in item (1) thereof; and

     (B) if the transferee will take delivery in the form of a beneficial interest in a
Regulation S Global Note, then the transferor must deliver a certificate in the form of
Exhibit B hereto, including the certifications in item (2) thereof.

     (iv) Transfer or Exchange of Beneficial Interests in a Restricted Global Note for Beneficial
Interests in an Unrestricted Global Note. A beneficial interest in any Restricted Global Note may
be exchanged for a beneficial interest in an Unrestricted Global Note or transferred to a Person
who takes delivery thereof in the form of a beneficial interest in an Unrestricted Global Note if
the exchange or transfer complies with the requirements of Section 2.06(b)(ii), and

     (A) such exchange or transfer is effected pursuant to the Exchange Offer in accordance
with the Registration Rights Agreement and the Holder of the beneficial interest to be
transferred, in the case of an exchange, or the transferee, in the case of a transfer,
certifies in the applicable Letter of Transmittal that it is not (1) a Broker-Dealer, (2) a
Person participating in the distribution of the Exchange Notes or (3) a Person who is an
“affiliate” (as defined in Rule 144) of the Company;

     (B) such transfer is effected pursuant to a Shelf Registration Statement in accordance
with the Registration Rights Agreement;

     (C) such transfer is effected by a Broker-Dealer pursuant to an Exchange Offer
Registration Statement in accordance with the Registration Rights Agreement; or

     (D) the Registrar receives the following:

     (y) if the Holder of such beneficial interest in a Restricted Global Note
proposes to exchange such beneficial interest for a beneficial interest in an
Unrestricted Global Note, a certificate from such Holder in the form of Exhibit
C hereto, including the certifications in item (1)(a) thereof, or

     (z) if the Holder of such beneficial interest in a Restricted Global Note
proposes to transfer such beneficial interest to a Person who shall take delivery
thereof in the
form of a beneficial interest in an Unrestricted Global Note, a certificate
from such Holder in the form of Exhibit B hereto, including the applicable
certifications in item (4) thereof;

and, in each such case set forth in Section 2.06(b)(iv)(D), if the Registrar so requests or
if the Applicable Procedures so require, an Opinion of Counsel in form reasonably acceptable
to the Registrar to the effect that such exchange or transfer is in compliance with the
Securities Act and that the restrictions on transfer contained herein and in the Private
Placement Legend are no longer required in order to maintain compliance with the Securities
Act.

-41-

 

     If any such transfer is effected pursuant to Section 2.06(b)(iv)(B) or (D) above at a time
when an Unrestricted Global Note has not yet been issued, the Company shall issue and, upon receipt
of an Authentication Order in accordance with Section 2.02 hereof, the Trustee shall authenticate
one or more Unrestricted Global Notes in an aggregate principal amount equal to the aggregate
principal amount of beneficial interests transferred pursuant to Section 2.06(b)(iv)(B) or (D)
above.

     Beneficial interests in an Unrestricted Global Note cannot be exchanged for, or transferred to
Persons who take delivery thereof in the form of, a beneficial interest in a Restricted Global
Note.

     (c) Transfer or Exchange of Beneficial Interests for Definitive Notes.

     (i) Transfer or Exchange of Beneficial Interests in Restricted Global Notes for Restricted
Definitive Notes. If any Holder of a beneficial interest in a Restricted Global Note proposes to
exchange such beneficial interest for a Restricted Definitive Note or to transfer such beneficial
interest to a Person who takes delivery thereof in the form of a Restricted Definitive Note, then,
upon receipt by the Registrar of the following documentation:

     (A) if the Holder of such beneficial interest in a Restricted Global Note proposes to
exchange such beneficial interest for a Restricted Definitive Note, a certificate from such
Holder in the form of Exhibit C hereto, including the certifications in item (2)(a)
thereof;

     (B) if such beneficial interest is being transferred to a QIB in accordance with Rule
144A under the Securities Act, a certificate from such Holder to the effect set forth in
Exhibit B hereto, including the certifications in item (1) thereof;

     (C) if such beneficial interest is being transferred to a Non-U.S. Person in an
offshore transaction in accordance with Rule 903 or Rule 904 under the Securities Act, a
certificate from such Holder to the effect set forth in Exhibit B hereto, including
the certifications in item (2) thereof;

     (D) if such beneficial interest is being transferred pursuant to an exemption from the
registration requirements of the Securities Act in accordance with Rule 144 under the
Securities Act, a certificate to the effect set forth in Exhibit B hereto, including
the certifications in item (3)(a) thereof;

     (E) if such beneficial interest is being transferred to the Company or any of its
Subsidiaries, a certificate to the effect set forth in Exhibit B hereto, including
the certifications in item (3)(b) thereof; or

     (F) if such beneficial interest is being transferred pursuant to an effective
registration statement under the Securities Act, a certificate to the effect set forth in
Exhibit B hereto, including the certifications in item (3)(c) thereof, the Trustee shall cause the aggregate
principal amount of the applicable Global Note to be reduced accordingly pursuant to Section
2.06(h), and the Company shall execute and, upon receipt of an Authentication Order pursuant
to Section 2.02, the Trustee shall authenticate and deliver to the Person designated in the
certificate a Restricted Definitive Note in the appropriate principal amount. Any
Restricted Definitive Note issued in exchange for a beneficial interest in a Restricted
Global Note pursuant to this Section 2.06(c) shall be registered in such name or names and
in such authorized denomination or denominations as the Holder of such beneficial interest
shall instruct the Regi-

-42-

 

strar through instructions from the Depositary and the Participant or
Indirect Participant. The Trustee shall deliver such Restricted Definitive Notes to the
Persons in whose names such Notes are so registered. Any Restricted Definitive Note issued
in exchange for a beneficial interest in a Restricted Global Note pursuant to this Section
2.06(c)(i) shall bear the Private Placement Legend and shall be subject to all restrictions
on transfer contained therein.

     (ii) Transfer or Exchange of Beneficial Interests in Restricted Global Notes for Unrestricted
Definitive Notes. A Holder of a beneficial interest in a Restricted Global Note may exchange such
beneficial interest for an Unrestricted Definitive Note or may transfer such beneficial interest to
a Person who takes delivery thereof in the form of an Unrestricted Definitive Note only if:

     (A) such exchange or transfer is effected pursuant to an Exchange Offer in accordance
with the Registration Rights Agreement and the Holder of such beneficial interest, in the
case of an exchange, or the transferee, in the case of a transfer, certifies in the
applicable Letter of Transmittal that it is not (1) a Broker-Dealer, (2) a Person
participating in the distribution of the Exchange Notes or (3) a Person who is an
“affiliate” (as defined in Rule 144) of the Company;

     (B) such transfer is effected pursuant to a Shelf Registration Statement in accordance
with the Registration Rights Agreement and the Registrar receives a certificate from such
Holder to such effect;

     (C) such transfer is effected by a Broker-Dealer pursuant to the Exchange Offer
Registration Statement in accordance with the Registration Rights Agreement; or

     (D) the Registrar receives the following:

     (y) if the Holder of such beneficial interest in a Restricted Global Note
proposes to exchange such beneficial interest for a Definitive Note that does not
bear the Private Placement Legend, a certificate from such Holder in the form of
Exhibit C hereto, including the certifications in item (1)(b) thereof; or

     (z) if the holder of such beneficial interest in a Restricted Global Note
proposes to transfer such beneficial interest to a Person who shall take delivery
thereof in the form of a Definitive Note that does not bear the Private Placement
Legend, a certificate from such holder in the form of Exhibit B hereto,
including the applicable certifications in item (4) thereof,

and, in each such case set forth in this Section 2.06(c)(ii)(D), if the Registrar so
requests or if the Applicable Procedures so require, an Opinion of Counsel in form
reasonably acceptable to the Registrar to the effect that such exchange or transfer is in
compliance with the Securities Act and that the restrictions on transfer contained herein
and in the Private Placement Legend are no longer required in order to maintain compliance
with the Securities Act.

     If any such transfer is effected pursuant to Section 2.06(c)(ii)(B) or (D) above at a time
when an Unrestricted Global Note has not yet been issued, the Company shall issue and, upon receipt
of an Authentication Order in accordance with Section 2.02 hereof, the Trustee shall authenticate
one or more Unrestricted Global Notes in an aggregate principal amount equal to the aggregate
principal amount of beneficial interests transferred pursuant to Section 2.06(c)(ii)(B) or (D)
above.

-43-

 

     (iii) Transfer or Exchange of Beneficial Interests in Unrestricted Global Notes for
Unrestricted Definitive Notes. If any Holder of a beneficial interest in an Unrestricted Global
Note proposes to exchange such beneficial interest for a Definitive Note or to transfer such
beneficial interest to a Person who takes delivery thereof in the form of a Definitive Note, then,
upon satisfaction of the conditions set forth in Section 2.06(b)(ii), the Trustee shall cause the
aggregate principal amount of the applicable Global Note to be reduced accordingly pursuant to
Section 2.06(h), and the Company shall execute and, upon receipt of an Authentication Order
pursuant to Section 2.02, the Trustee shall authenticate and deliver to the Person designated in
the certificate a Definitive Note in the appropriate principal amount. Any Definitive Note issued
in exchange for a beneficial interest pursuant to this Section 2.06(c)(iii) shall be registered in
such name or names and in such authorized denomination or denominations as the Holder of such
beneficial interest shall instruct the Registrar through instructions from the Depositary and the
Participant or Indirect Participant. The Trustee shall deliver such Definitive Notes to the
Persons in whose names such Notes are so registered. Any Definitive Note issued in exchange for a
beneficial interest pursuant to this Section 2.06(c)(iii) shall not bear the Private Placement
Legend.

     (d) Transfer or Exchange of Definitive Notes for Beneficial Interests.

     (i) Transfer or Exchange of Restricted Definitive Notes for Beneficial Interests in Restricted
Global Notes. If any Holder of a Restricted Definitive Note proposes to exchange such Note for a
beneficial interest in a Restricted Global Note or to transfer such Restricted Definitive Notes to
a Person who takes delivery thereof in the form of a beneficial interest in a Restricted Global
Note, then, upon receipt by the Registrar of the following documentation:

     (A) if the Holder of such Restricted Definitive Note proposes to exchange such Note for
a beneficial interest in a Restricted Global Note, a certificate from such Holder in the
form of Exhibit C hereto, including the certifications in item (2)(b) thereof;

     (B) if such Restricted Definitive Note is being transferred to a QIB in accordance with
Rule 144A under the Securities Act, a certificate to the effect set forth in Exhibit
B hereto, including the certifications in item (1) thereof; or

     (C) if such Restricted Definitive Note is being transferred to a Non-U.S. Person in an
offshore transaction in accordance with Rule 903 or Rule 904 under the Securities Act, a
certificate to the effect set forth in Exhibit B hereto, including the
certifications in item (2) thereof, the Trustee shall cancel the Restricted Definitive Note,
increase or cause to be increased the aggregate principal amount of, in the case of clause
(A) above, the appropriate Restricted Global Note, in the case of clause (B) above, the Rule
144A Global Note, and in the case of clause (C) above, the Regulation S Global Note.

     (ii) Transfer or Exchange of Restricted Definitive Notes for Beneficial Interests in
Unrestricted Global Notes. A Holder of a Restricted Definitive Note may exchange such Note for a
beneficial interest in an Unrestricted Global Note or transfer such Restricted Definitive Note to a
Person who takes delivery thereof in the form of a beneficial interest in an Unrestricted Global
Note only if:

     (A) such exchange or transfer is effected pursuant to the Exchange Offer in accordance
with the Registration Rights Agreement and the Holder, in the case of an exchange, or the
transferee, in the case of a transfer, certifies in the applicable Letter of Transmittal
that it is

-44-

 

not (1) a Broker-Dealer, (2) a Person participating in the distribution of the
Exchange Notes or (3) a Person who is an “affiliate” (as defined in Rule 144) of the
Company;

     (B) such transfer is effected pursuant to a Shelf Registration Statement in accordance
with the Registration Rights Agreement;

     (C) such transfer is effected by a Broker-Dealer pursuant to an Exchange Offer
Registration Statement in accordance with the Registration Rights Agreement; or

     (D) the Registrar receives the following:

     (y) if the Holder of such Definitive Notes proposes to exchange such Notes for
a beneficial interest in an Unrestricted Global Note, a certificate from such Holder
in the form of Exhibit C hereto, including the certifications in item (1)(c)
thereof; or

     (z) if the Holder of such Definitive Notes proposes to transfer such Notes to a
Person who shall take delivery thereof in the form of a beneficial interest in an
Unrestricted Global Note, a certificate from such Holder in the form of Exhibit
B hereto, including the applicable certifications in item (4) thereof;

and, in each such case set forth in this Section 2.06(d)(ii)(D), if the Registrar so
requests or if the Applicable Procedures so require, an Opinion of Counsel in form
reasonably acceptable to the Registrar to the effect that such exchange or transfer is in
compliance with the Securities Act and that the restrictions on transfer contained in this
Indenture and in the Private Placement Legend are no longer required in order to maintain
compliance with the Securities Act.

     Upon satisfaction of the conditions of any of the provisions in this Section 2.06(d)(ii), the
Trustee shall cancel the Definitive Notes so transferred or exchanged and increase or cause to be
increased the aggregate principal amount of the Unrestricted Global Note.

     (iii) Transferor Exchange of Unrestricted Definitive Notes for Beneficial Interests in
Unrestricted Global Notes. A Holder of an Unrestricted Definitive Note may exchange such Note for
a beneficial interest in an Unrestricted Global Note or transfer such Unrestricted Definitive Notes
to a Person who takes delivery thereof in the form of a beneficial interest in an Unrestricted
Global Note at any time. Upon receipt of a request for such an exchange or transfer, the Trustee
shall cancel the applicable Unrestricted Definitive Note and increase or cause to be increased the
aggregate principal amount of one of the Unrestricted Global Notes.

     If any such exchange or transfer from an Unrestricted Definitive Note or a Restricted
Definitive Note, as the case may be, to a beneficial interest is effected pursuant to Section
2.06(d)(ii)(B), (ii)(D) or (iii) above at a time when an Unrestricted Global Note has not yet been
issued, the Company shall issue and, upon receipt of an authentication order in accordance with
Section 2.02 hereof, the Trustee shall authenticate one or more Unrestricted Global Notes in an
aggregate principal amount equal to the principal amount of Unrestricted Definitive Notes or
Restricted Definitive Notes, as the case may be, so transferred.

     (e) Transfer or Exchange of Definitive Notes for Definitive Notes. Upon request by
a Holder of Definitive Notes and such Holder’s compliance with the provisions of this Section
2.06(e),

-45-

 

the Registrar shall register the transfer or exchange of Definitive Notes. Prior to such registration
of transfer or exchange, the requesting Holder shall present or surrender to the Registrar the
Definitive Notes duly endorsed or accompanied by a written instruction of transfer in form
satisfactory to the Registrar duly executed by such Holder or its attorney, duly authorized in
writing. In addition, the requesting Holder shall provide any additional certifications, documents
and information, as applicable, required pursuant to the following provisions of this Section
2.06(e).

     (i) Transfer of Restricted Definitive Notes to Restricted Definitive Notes. Any Restricted
Definitive Note may be transferred to and registered in the name of Persons who take delivery
thereof in the form of a Restricted Definitive Note if the Registrar receives the following:

     (A) if the transfer will be made pursuant to Rule 144A under the Securities Act, then
the transferor must deliver a certificate in the form of Exhibit B hereto, including
the certifications in item (1) thereof;

     (B) if the transfer will be made pursuant to Rule 903 or Rule 904, then the transferor
must deliver a certificate in the form of Exhibit B hereto, including the
certifications in item (2) thereof; and

     (C) if the transfer will be made pursuant to any other exemption from the registration
requirements of the Securities Act, then the transferor must deliver a certificate in the
form of Exhibit B hereto, including, if the Registrar so requests, a certification
or Opinion of Counsel in form reasonably acceptable to the Company to the effect that such
transfer is in compliance with the Securities Act.

     (ii) Transfer or Exchange of Restricted Definitive Notes for Unrestricted Definitive Notes.
Any Restricted Definitive Note may be exchanged by the Holder thereof for an Unrestricted
Definitive Note or transferred to a Person or Persons who take delivery thereof in the form of an
Unrestricted Definitive Note if

     (A) such exchange or transfer is effected pursuant to an Exchange Offer in accordance
with the Registration Rights Agreement and the Holder, in the case of an exchange, or the
transferee, in the case of a transfer, certifies in the applicable Letter of Transmittal
that it is not (1) a Broker-Dealer, (2) a Person participating in the distribution of the
Exchange Notes or (3) a Person who is an “affiliate” (as defined in Rule 144) of the
Company;

     (B) any such transfer is effected pursuant to a Shelf Registration Statement in
accordance with the Registration Rights Agreement;

     (C) any such transfer is effected by a Broker-Dealer pursuant to an Exchange Offer
Registration Statement in accordance with the Registration Rights Agreement; or

     (D) the Registrar receives the following:

     (y) if the Holder of such Restricted Definitive Notes proposes to exchange such
Notes for an Unrestricted Definitive Note, a certificate from such Holder in the
form of Exhibit C hereto, including the applicable certifications in item
(1)(d) thereof; or

-46-

 

     (z) if the Holder of such Restricted Definitive Notes proposes to transfer such
Notes to a Person who shall take delivery thereof in the form of an Unrestricted
Definitive Note, a certificate from such Holder in the form of Exhibit B
hereto, including the
applicable certifications in item (4) thereof; and, in each such case set forth
in this Section 2.06(e)(ii)(D), if the Registrar so requests, an Opinion of Counsel
in a form reasonably acceptable to the Company to the effect that such exchange or
transfer is in compliance with the Securities Act and that the restrictions on
transfer contained in this Indenture and in the Private Placement Legend are no
longer required in order to maintain compliance with the Securities Act.

     (iii) Transfer of Unrestricted Definitive Notes to Unrestricted Definitive Notes. A Holder of
Unrestricted Definitive Notes may transfer such Notes to a Person who takes delivery thereof in the
form of an Unrestricted Definitive Note. Upon receipt of a request to register such a transfer,
the Registrar shall register the Unrestricted Definitive Notes pursuant to the instructions from
the Holder thereof.

     (f) Exchange Offer. Upon the occurrence of an Exchange Offer in accordance with the
Registration Rights Agreement, the Company shall issue and, upon receipt of an authentication order
in accordance with Section 2.02 hereof, the Trustee shall authenticate (i) one or more Unrestricted
Global Notes in an aggregate principal amount equal to the principal amount of the beneficial
interests in the Restricted Global Notes tendered for acceptance by Persons that make the
certifications in the applicable Letters of Transmittal required by the Registration Rights
Agreement, and accepted for exchange in an Exchange Offer and (ii) Definitive Notes in an aggregate
principal amount equal to the principal amount of the Restricted Definitive Notes accepted for
exchange in an Exchange Offer. Concurrently with the issuance of such Notes, the Trustee shall
cause the aggregate principal amount of the applicable Restricted Global Notes to be reduced
accordingly, and the Company shall execute and the Trustee shall authenticate and deliver to the
Persons designated by the Holders of Restricted Definitive Notes so accepted Unrestricted
Definitive Notes in the appropriate principal amounts.

     (g) Legends. The following legends shall appear on the faces of all Global Notes
and Definitive Notes issued under this Indenture unless specifically stated otherwise in the
applicable provisions hereof.

     (i) Private Placement Legend.

     (A) Except as permitted by Section 2.06(g)(i)(B) below, each Global Note (other than an
Unrestricted Global Note) and each Definitive Note (and all Notes issued in exchange
therefor or substitution thereof) shall bear a legend in substantially the following form:

THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “SECURITIES ACT”), AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE
TRANSFERRED EXCEPT IN ACCORDANCE WITH THE FOLLOWING SENTENCE. BY ITS ACQUISITION
HEREOF OR OF A BENEFICIAL INTEREST HEREIN, THE ACQUIRER:

     (1) REPRESENTS THAT IT, AND ANY ACCOUNT FOR WHICH IT IS ACTING, IS A “QUALIFIED
INSTITUTIONAL BUYER” (WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT) AND
THAT IT EXERCISES SOLE INVESTMENT DISCRETION WITH RESPECT TO EACH

-47-

 

SUCH ACCOUNT, AND

     (2) AGREES FOR THE BENEFIT OF THE COMPANY THAT IT WILL NOT OFFER, SELL, PLEDGE
OR OTHERWISE TRANSFER THIS SECURITY OR ANY BENEFICIAL INTEREST HEREIN PRIOR TO THE
RESALE RESTRICTION TERMINATION DATE (AS DEFINED IN THE NEXT PARAGRAPH), EXCEPT:

     (A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF, OR

     (B) PURSUANT TO A REGISTRATION STATEMENT THAT HAS BECOME EFFECTIVE
UNDER THE SECURITIES ACT, OR

     (C) TO A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A
UNDER THE SECURITIES ACT, OR

     (D) PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144
UNDER THE SECURITIES ACT OR ANY OTHER AVAILABLE EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. THE RESALE RESTRICTION
TERMINATION DATE WILL BE THE DATE (1) THAT IS AT LEAST ONE YEAR AFTER THE
LAST ORIGINAL ISSUE DATE HEREOF AND (2) ON WHICH THE COMPANY INSTRUCTS THE
TRUSTEE THAT THIS LEGEND SHALL BE DEEMED REMOVED FROM THIS SECURITY, IN
ACCORDANCE WITH THE PROCEDURES DESCRIBED IN THE INDENTURE RELATING TO THIS
SECURITY. PRIOR TO THE REGISTRATION OF ANY TRANSFER IN ACCORDANCE WITH
(2)(D) ABOVE, THE COMPANY AND THE TRUSTEE RESERVE THE RIGHT TO REQUIRE THE
DELIVERY OF SUCH LEGAL OPINIONS, CERTIFICATIONS OR OTHER EVIDENCE AS MAY
REASONABLY BE REQUIRED IN ORDER TO DETERMINE THAT THE PROPOSED TRANSFER IS
BEING MADE IN COMPLIANCE WITH THE SECURITIES ACT AND APPLICABLE STATE
SECURITIES LAWS. NO REPRESENTATION IS MADE AS TO THE AVAILABILITY OF ANY
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT.

The Private Placement Legend shall be deemed removed from the face of any Note without further
action of the Company, the Trustee or the Holder of such Note at such time as the Company shall
have delivered a Transferability Certificate executed by an Officer to the Trustee certifying that
the Private Placement Legend can be removed because such Note may be resold to the public in
accordance with Rule 144 without regard to volume, manner of sale or any other restrictions
contained in Rule 144 (other than the holding period requirement in paragraph (d)(1)(ii) of Rule
144 so long as such holding period requirement is satisfied at such time of determination) by
Holders that are not Affiliates of the Company. Concurrently with such deemed removal of the
Private Placement Legend, the CUSIP Number for each Restricted Global Note shall be deemed to be
552953BE0.

-48-

 

     (B) Notwithstanding the foregoing, any Global Note or Definitive Note issued pursuant to
Section 2.06(b)(iv), (c)(ii), (c)(iii), (d)(ii), (d)(iii), (e)(ii), (e)(iii) or (f) of this Section
2.06 (and all Notes issued in exchange therefor or substitution thereof) shall not bear the Private
Placement Legend.

     (ii) Global Note Legend. Each Global Note shall bear a legend in substantially the following
form: UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST
COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER,
EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH
OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE
& CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY
TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL
INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. THIS NOTE IS A
GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR
A NOMINEE OF THE DEPOSITARY OR A SUCCESSOR DEPOSITARY. THIS NOTE IS NOT EXCHANGEABLE FOR
SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE EXCEPT IN
THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND NO TRANSFER OF THIS NOTE (OTHER THAN A
TRANSFER OF THIS NOTE AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE
OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR
ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY) MAY BE
REGISTERED EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE.

     (iii) Regulation S Temporary Global Note Legend. Each temporary Note that is a Global Note
issued pursuant to Regulation S shall bear a legend in substantially the following form: THE
RIGHTS ATTACHING TO THIS REGULATION S TEMPORARY GLOBAL NOTE, AND THE CONDITIONS AND PROCEDURES
GOVERNING ITS EXCHANGE FOR DEFINITIVE NOTES, ARE AS SPECIFIED IN THE INDENTURE. THE HOLDER OF THIS
NOTE BY ACCEPTANCE HEREOF ALSO AGREES, REPRESENTS AND WARRANTS THAT IF IT IS A PURCHASER IN A SALE
THAT OCCURS OUTSIDE THE UNITED STATES WITHIN THE MEANING OF REGULATION S OF THE SECURITIES ACT, IT
ACKNOWLEDGES THAT, UNTIL EXPIRATION OF THE “40-DAY DISTRIBUTION COMPLIANCE PERIOD” WITHIN THE
MEANING OF RULE 903 OF REGULATION S, ANY OFFER OR SALE OF THIS NOTE SHALL NOT BE MADE BY IT TO A
U.S. PERSON TO OR FOR THE ACCOUNT OR BENEFIT OF A U.S. PERSON WITHIN THE MEANING OF RULE 902(k)
UNDER THE SECURITIES ACT.

     (h) Cancellation and/or Adjustment of Global Notes. At such time as all beneficial
interests in a particular Global Note have been exchanged for Definitive Notes or a particular
Global Note has been redeemed, repurchased or cancelled in whole and not in part, each such Global
Note shall be returned to or retained and cancelled by the Trustee in accordance with Section 2.11
hereof. At any time prior to such cancellation, if any beneficial interest in a Global Note is
exchanged for or transferred to a Person who will take delivery thereof in the form of a beneficial
interest in another Global Note or for Definitive Notes, the principal amount of Notes represented
by such Global Note shall be reduced accordingly and an endorsement shall be made on such Global
Note by the Trustee or by the Depositary at the direction of the Trustee to reflect such reduction;
and if the beneficial interest is be-

-49-

 

ing exchanged for or transferred to a Person who will take
delivery thereof in the form of a beneficial interest in another Global Note, such other Global
Note shall be increased accordingly and an endorsement shall be made on such Global Note by the
Trustee or by the Depositary at the direction of the Trustee to reflect such increase.

     (i) General Provisions Relating to Transfers and Exchanges.

     (i) To permit registrations of transfers and exchanges, the Company shall execute and the
Trustee shall authenticate Global Notes and Definitive Notes upon the Company’s order or at the
Registrar’s request.

     (ii) No service charge shall be made to a Holder of a beneficial interest in a Global Note or
to a Holder of a Definitive Note for any registration of transfer or exchange, but the Company may
require payment of a sum sufficient to cover any transfer tax or similar governmental charge
payable in connection therewith (other than any such transfer taxes or similar governmental charge
payable upon exchange or transfer pursuant to Sections 2.02, 2.10, 3.07 and 9.04).

     (iii) The Registrar shall not be required to register the transfer of or exchange any Note
selected for redemption in whole or in part, except for the unredeemed portion of any Note being
redeemed in part.

     (iv) The Registrar shall retain copies of all certificates, Opinions of Counsel, notices and
other written communications received pursuant to Section 2.06. The Company shall have the right
to inspect and make copies of all such certificates, Opinions of Counsel, notices or other written
communications at any reasonable time upon the giving of reasonable notice to the Registrar. All
Global Notes and Definitive Notes issued upon any registration of transfer or exchange of Global
Notes or Definitive Notes shall be the valid obligations of the Company, evidencing the same
indebtedness, and entitled to the same benefits under this Indenture, as the Global Notes or
Definitive Notes surrendered upon such registration of transfer or exchange.

     (v) The Company, Trustee and Registrar shall not be required (A) to issue, to register the
transfer of or to exchange any Notes during a period beginning at the opening of business on a
Business Day 15 days before the day of any selection of Notes for redemption under Section 3.02
hereof and ending at the close of business on the day of selection or (B) to register the transfer
of or to exchange any Note so selected for redemption in whole or in part, except the unredeemed
portion of any Note being redeemed in part or (C) to register the transfer of or to exchange a Note
between a record date and the next succeeding interest payment date.

     (vi) Prior to due presentment for the registration of a transfer of any Note, the Trustee, any
Agent and the Company may deem and treat the Person in whose name any Note is registered as the
absolute owner of such Note for the purpose of receiving payment of principal of and interest on
such Notes and for all other purposes, and none of the Trustee, any Agent or the Company shall be
affected by notice to the contrary.

     (vii) The Trustee shall authenticate Global Notes and Definitive Notes in accordance with the
provisions of Section 2.02 hereof.

-50-

 

     (viii) All certifications, certificates and Opinions of Counsel required to be submitted to
the Registrar pursuant to this Section 2.06 to effect a registration of transfer or exchange may be
submitted by facsimile.

     (ix) Notwithstanding anything herein to the contrary, as to any certifications and
certificates delivered to the Registrar pursuant to this Section 2.06, the Registrar’s duties shall
be limited to confirming that any such certifications and certificates delivered to it are in the
form of Exhibits B, C and I attached hereto. The Registrar shall not be responsible for confirming
the truth or accuracy of representations made in any such certifications or certificates.

     SECTION 2.07 REPLACEMENT NOTES.

     If a mutilated Note is surrendered to the Registrar or if the Holder of a Note claims that the
Note has been lost, destroyed or wrongfully taken, the Company shall issue and the Trustee shall
authenticate a replacement Note if the Holder (i) satisfies the Company or the Trustee within a
reasonable time after he has notice of such loss, destruction or wrongful taking and the Registrar
does not register a transfer prior to receiving such notification, (ii) makes such request to the
Company or the Trustee prior to the Note being acquired by a Protected Purchaser and (iii)
satisfies any other reasonable requirements of the Trustee and the Company including evidence of
the destruction, loss or theft of the Note. Such Holder shall furnish an indemnity bond sufficient
in the judgment of the Trustee to protect the Company, any Restricted Subsidiary, the Trustee, the
Paying Agent, and the Registrar from any loss that any of them may
suffer if a Note is replaced, including, but not limited to any loss or liability which any of
them may suffer if a Note is replaced and subsequently presented or claimed for payment. The
Company and the Trustee may charge the Holder for their expenses in replacing a Note including the
payment of a sum sufficient to cover any tax or other governmental charge that may be required. In
the event any such mutilated, lost, destroyed or wrongfully taken Note has become or is about to
become due and payable, the Company in its discretion may pay such Note instead of issuing a new
Note in replacement thereof.

     Every replacement Note is an additional obligation of the Company and shall be entitled to all
of the benefits of this Indenture equally and proportionally with all other Notes duly issued
hereunder.

     The provisions of this Section 2.07 are exclusive and shall preclude (to the extent lawful)
all other rights and remedies with respect to the replacement or payment of mutilated, lost,
destroyed or wrongfully taken Notes.

     SECTION 2.08 OUTSTANDING NOTES.

     Outstanding Notes means, as of the date of determination, all Notes theretofore authenticated
and delivered under this Indenture, except:

     (a) Notes theretofore cancelled by the Trustee or delivered to the Trustee
for cancellation, including Notes tendered and exchanged for other securities of the
Company;

     (b) Notes for which payment or redemption money in the necessary amount has
been theretofore deposited with the Trustee or any Paying Agent (other than the Company) in
trust or set aside and segregated in trust by the Company (if the Company shall act as its
own Paying Agent) for the Holders of such Notes; provided, however, that if such Notes are
to be redeemed, then notice of such redemption has been duly given pursuant to this
Indenture or

-51-

 

provision therefor satisfactory to the Trustee has been made and the date for
such redemption has passed;

     (c) Notes, except to the extent provided in Section 8.04, with respect to
which the Company has effected defeasance as provided in Article VIII; and

     (d) Notes paid pursuant to Section 2.07 and Notes in exchange for or in lieu
of which other Notes have been authenticated and delivered pursuant to this Indenture, other
than any such Notes in respect of which there shall have been presented to the Trustee proof
satisfactory to it that such Notes are held by a bona fide purchaser in whose hands such
Notes are valid obligations of the Company; provided, however, that in determining whether
the Holders of the requisite principal amount of Outstanding Notes have performed any Act
hereunder, Notes owned by the Company or any other obligor upon such Notes or any Affiliate
of the Company or of such other obligor shall be disregarded and deemed not to be
Outstanding Notes (provided that in connection with any offer by the Company or any obligor
to purchase or exchange Notes, Notes tendered by Holder shall be Outstanding until the date
of purchase or exchange), except that, in determining whether the Trustee shall be protected
in relying upon any such Act, only such Notes which a Trust Officer of the Trustee actually
knows to be so owned shall be so disregarded. Notes so owned which have been pledged in
good faith may be regarded as Outstanding Notes if the pledgee establishes to the
satisfaction of the Trustee the pledgee’s right to act with respect to such Notes and that
the pledgee is not the Company or any other obligor upon such Notes or any Affiliate of the
Company or of such other obligor.

     SECTION 2.09 INTENTIONALLY OMITTED.

     SECTION 2.10 TEMPORARY NOTES.

     Until certificates representing Notes are ready for delivery, the Company may prepare and the
Trustee, upon receipt of an Authentication Order, shall authenticate temporary Notes. Temporary
Notes shall be substantially in the form of Definitive Notes but may have variations that the
Company considers appropriate for temporary Notes and as shall be reasonably acceptable to the
Trustee. Without unreasonable delay, the Company shall prepare and the Trustee shall authenticate
Definitive Notes in exchange for temporary Notes. Holders of temporary Notes shall be entitled to
all of the benefits of this Indenture.

     SECTION 2.11 CANCELLATION.

     All Notes surrendered for payment, redemption, transfer or exchange shall, if surrendered to
any Person other than the Trustee, be delivered to the Trustee at its Corporate Trust Office. All
Notes so delivered shall be promptly cancelled by the Trustee. The Company may at any time deliver
to the Trustee for cancellation any Notes previously authenticated and delivered hereunder which
the Company may have acquired in any manner whatsoever, and may deliver to the Trustee (or to any
other Person for delivery to the Trustee) for cancellation any Notes previously authenticated
hereunder which the Company has not issued, and all Notes so delivered shall be promptly cancelled
by the Trustee. No Notes shall be authenticated in lieu of or in exchange for any Notes cancelled
as provided in this Section 2.11, except as permitted by this Indenture. All cancelled Notes held
by the Trustee shall be delivered to the Company upon Company Request. The acquisition of any
Notes by the Company shall not operate as a redemption or satisfaction of the indebtedness
represented thereby unless and

-52-

 

until such Notes are surrendered to the Trustee for cancellation.
The Notes shall not be disposed of until exchanged in full for Definitive Notes or until payment
thereon is made in full.

     SECTION 2.12 DEFAULTED INTEREST.

     (a) Any interest on any Note which is payable but is not punctually paid or duly
provided for on any Interest Payment Date (herein called “Defaulted Interest”) shall forthwith
cease to be payable to the registered Holder on the relevant Regular Record Date by virtue of his
having been such registered Holder, and such Defaulted Interest may be paid by the Company, at its
election in each case, as provided in clause (i) or (ii) below:

     (i) The Company may elect to make payment of any Defaulted Interest to the Persons in
whose names such Notes (or their respective Predecessor Note) are registered at the close of
business on a special record date (the “Special Record Date”) for the payment of such
Defaulted Interest, which shall be fixed in the following manner. The Company shall notify
the Trustee in writing of the amount of Defaulted Interest proposed to be paid on each such
Note and the date of the proposed payment, and at the same time the Company shall deposit
with the Trustee prior to 10:00 a.m., New York City time, an amount of money equal to the
aggregate amount proposed to be paid in respect of such Defaulted Interest or shall make
arrangements satisfactory to the Trustee for such deposit prior to the date of the proposed
payment, such money when deposited to be held in trust for the benefit of the Persons
entitled to such Defaulted Interest as in this clause provided. Thereupon the Trustee shall
fix a Special Record Date for the payment of such Defaulted Interest. The Trustee shall
promptly notify the Company of such Special Record Date and, in the name and at the expense
of the Company, shall cause notice of the proposed payment of such Defaulted Interest and
the Special Record Date therefor to be mailed, first-class postage prepaid, to the Holders
of such Notes at their addresses as they appear in the Note Register, not less than 15
calendar days prior to such Special Record Date. Notice of the proposed
payment of such Defaulted Interest and the Special Record Date therefor having been
mailed as aforesaid, such Defaulted Interest shall be paid to the Persons in whose names
such Notes (or their respective Predecessor Note) are registered at the close of business on
such Special Record Date and shall no longer be payable pursuant to the following clause
(ii).

     (ii) The Company may make payment of any Defaulted Interest on the Notes in any other
lawful manner not inconsistent with the requirements of any securities exchange on which
such Notes may be listed, and upon such notice as may be required by such exchange, if,
after notice is given by the Company to the Trustee of the proposed payment pursuant to this
clause, such manner of payment shall be deemed practicable by the Trustee.

     (b) Subject to the foregoing provisions of this Section 2.12, each Note delivered
under this Indenture upon transfer of, in exchange for, or in lieu of, any other Note shall carry
the rights to interest accrued and unpaid, and to accrue, which were carried by such other Note.

     SECTION 2.13 CUSIP, ISIN OR COMMON CODE NUMBERS.

     The Company in issuing the Notes may use “CUSIP,” “ISIN” or “Common Code” numbers (if then
generally in use) and, if so, the Trustee shall use such numbers in notices of redemption or
repurchase as a convenience to Holders; provided, however, that any such notice may state that no
representation is made as to the correctness of such numbers either as printed on the Notes or as
contained in

-53-

 

any notice of a redemption or repurchase and that reliance may be placed only on the
other identification numbers printed on the Notes, and any such redemption or repurchase shall not
be affected by any defect in or omission of such numbers. The Company shall promptly notify the
Trustee of any change in “CUSIP,” “ISIN” or “Common Code” numbers.

ARTICLE III

REDEMPTION

     SECTION 3.01 OPTIONAL REDEMPTION.

     Prior to March 15, 2014, the Company may redeem all or a part of the Notes, in accordance with
the provisions of this Article III, at a redemption price equal to 100% of the principal amount of
Notes redeemed plus the Applicable Premium as of, and accrued and unpaid interest and Additional
Interest, if any, to the Redemption Date, subject to the rights of Holders on the relevant Regular
Record Date prior to the Redemption Date to receive interest due on the relevant Interest Payment
Date.

     On or after March 15, 2014, the Company may redeem all or a portion of the Notes, on not less
than 30 nor more than 60 calendar days’ prior notice, in amounts of $2,000 or an integral multiple
of $1,000 in excess thereof at the following redemption prices (expressed as percentages of the
principal amount, the “Redemption Price”), if redeemed during the 12-month period beginning on
March 15 of the years indicated below:

	 	 	 	 	 
	 	 	Redemption
	Year	 	Price
	2014
	 	 	104.500	%
	2015
	 	 	103.000	%
	2016
	 	 	101.500	%
	2017 and thereafter
	 	 	100.000	%

     The amount payable to the holder of a Note shall be equal to the applicable redemption price
of the Notes redeemed, plus accrued and unpaid interest, if any, to the Redemption Date (subject to
the rights of Holders on the relevant record date prior to the Redemption Date to receive interest
due on the relevant interest payment date).

     SECTION 3.02 ELECTION TO REDEEM; NOTICE TO TRUSTEE.

     The election of the Company to redeem the Notes shall be evidenced by a Board Resolution. The
Company shall, not less than 30 Business Days (unless a shorter notice period is acceptable to the
Trustee) nor more than 60 calendar days before the Redemption Date fixed by the Company, notify the
Trustee of such Redemption Date, the Redemption Price, the CUSIP numbers and the principal amount
of Notes to be redeemed.

     SECTION 3.03 SELECTION BY TRUSTEE OF NOTES TO BE REDEEMED OR PURCHASED.

     If the Company is purchasing or redeeming less than all of the Notes issued by it at any time,
the Trustee will select the Notes to be purchased or redeemed (a) if the Notes are listed on any
national securities exchange, in compliance with the requirements of the principal national
securities exchange

-54-

 

on which the Notes are listed or (b) on a pro rata basis to the extent
practicable or, to the extent that selection on a pro rata basis is not practicable, by lot or such
other similar method in accordance with the procedures of the Depositary. The portions of the
principal amount of Notes so selected for partial redemption shall be equal to the minimum
authorized denominations for Notes pursuant to Section 2.01(a) or any integral multiple thereof.
In any case when more than one Note is registered in the same name, the Trustee, in its discretion,
may treat the aggregate principal amount so registered as if it were represented by one Note.

     The Trustee shall promptly notify the Company and the Depositary (if other than itself) in
writing of the Notes selected for redemption and, in the case of any Notes selected for partial
redemption, the principal amount thereof to be redeemed.

     For all purposes of this Indenture, unless the context otherwise requires, all provisions
relating to the redemption of Notes shall relate, in the case of any Note redeemed or to be
redeemed only in part, to the portion of the principal amount of such Note which has been or is to
be redeemed.

     SECTION 3.04 NOTICE OF REDEMPTION.

     Notice of redemption shall be given by the Company, or at the Company’s written request, by
the Trustee in the name and at the expense of the Company, not less than 20 Business Days and not
more than 60 calendar days prior to the Redemption Date (which date may be extended in accordance
with applicable law) to each Holder at such Holder’s registered address or otherwise in accordance
with the procedures of the Depositary; provided that a notice of redemption may be mailed more than
60 calendar days prior to a Redemption Date if such notice is issued in connection with the
satisfaction and discharge of this Indenture pursuant to Section 8.01 or Covenant Defeasance or
Legal Defeasance pursuant to Section 8.04. Any notice so given shall be conclusively presumed to
have been duly given, whether or not any such Holder receives such notice. Failure to give such
notice, or any defect in such notice to the Holder of any Note, in whole or in part, shall not
affect the sufficiency of any notice of redemption with respect to the Holder of any other Note.

     All notices of redemption shall identify the Notes to be redeemed (including CUSIP number) and
shall state:

     (a) the Redemption Date,

     (b) the Redemption Price,

     (c) that the Notes are being redeemed by the Company pursuant to provisions
contained in this Indenture or the terms of such Notes, together with a brief statement of
the facts permitting such redemption,

     (d) that (i) all Outstanding Notes are to be redeemed, or (ii) if less than
all Outstanding Notes are to be redeemed, the identification (and, in the case of partial
redemption, the principal amount) of the particular Notes to be redeemed,

     (e) in the case of Notes that are to be redeemed in part only, that on or
after the Redemption Date, upon surrender of such Notes, the Holders of such Notes will
receive, without charge, new Notes in authorized denominations for the principal amount
thereof remaining unredeemed,

-55-

 

     (f) that on the Redemption Date the Redemption Price will become due and
payable upon each such Note to be redeemed, and that interest thereon, if any, shall cease
to accrue on and after said date, and

     (g) the Place or Places of Payment where such Notes are to be surrendered for
payment of the Redemption Price.

     SECTION 3.05 DEPOSIT OF REDEMPTION PRICE.

     On or prior to 10:00 a.m., New York City time, on the Redemption Date for the Notes to be
redeemed, the Company shall deposit with the Trustee or with a Paying Agent (or, if the Company is
acting as its own Paying Agent, segregate and hold in trust as provided in Section 4.05) an amount
of money sufficient to pay the Redemption Price of such Notes which are to be redeemed on that
date.

     SECTION 3.06 NOTES PAYABLE ON REDEMPTION DATE.

     Notice of redemption having been given as aforesaid, any Notes so to be redeemed shall, on the
Redemption Date, become due and payable at the Redemption Price and from and after such date
(unless the Company shall default in the payment of the Redemption Price) such Notes shall cease to
bear interest. Upon surrender of any such Note for redemption in accordance with said notice, such
Note shall be paid by the Company at the Redemption Price; provided, however, that installments of
interest on Notes which have a Stated Maturity on or prior to the Redemption Date for such Notes
shall be payable according to the terms of such Notes and the provisions of Section 2.04, Section
2.12 and Section 4.05.

     If any Note called for redemption shall not be so paid upon surrender thereof for redemption,
the principal (and premium, if any) shall, until paid, bear interest from the Redemption Date at
the rate prescribed therefor in such Note.

     SECTION 3.07 NOTES REDEEMED IN PART.

     Any Note which is to be redeemed only in part shall be surrendered at the Corporate Trust
Office with, if the Company, the Depositary for such Notes or the Trustee so requires, due
endorsement by, or a written instrument of transfer in form satisfactory to the Company, the
Depositary for such Notes and the Trustee duly executed by, the Holder thereof or such Holder’s
attorney duly authorized in writing, and the
Company shall execute, and the Trustee shall authenticate and deliver to the Holder of such
Note without service charge, a new Note or Notes, of like tenor and form, of any authorized
denomination as requested by such Holder in aggregate principal amount equal to and in exchange for
the unredeemed portion of the principal of the Note so surrendered. In the case of a Note
providing appropriate space for such notation, at the option of the Holder thereof, the Trustee, in
lieu of delivering a new Note or Notes as aforesaid, may make a notation on such Note of the
payment of the redeemed portion thereof.

     SECTION 3.08 MANDATORY DISPOSITION OF NOTES PURSUANT TO GAMING LAWS.

     Each Holder and beneficial owner, by accepting or otherwise acquiring an interest in the
Notes, shall be deemed to have agreed that if the Gaming Authority of any jurisdiction in which the
Company or any of its Subsidiaries conducts or proposes to conduct gaming activities requires that
a

-56-

 

Person who is a Holder or beneficial owner must be licensed, qualified or found suitable under
the applicable Gaming Laws, such Holder or beneficial owner, as the case may be, shall apply for a
license, qualification or a finding of suitability within the required time period in accordance
with such Gaming Laws. If such Person fails to apply or become licensed or qualified or is found
unsuitable (a “Disqualified Holder”), then the Company shall have the right, at its option,
notwithstanding any other provision of this Indenture:

     (a) to require such Person to dispose of its Notes or beneficial interest
therein within 30 calendar days of receipt of notice of the Company’s election or such
earlier date as may be requested or prescribed by such Gaming Authority; or

     (b) to redeem such Notes, which Redemption Date may be less than 30 calendar
days following the notice of redemption if so requested or prescribed by the Gaming
Authority, at a redemption price equal to:

     (i) the lesser of:

     (A) the Person’s cost, plus accrued and unpaid interest, if any, to the earlier
of the Redemption Date or the date of the finding of unsuitability or failure to
comply; and

     (B) 100% of the principal amount thereof, plus accrued and unpaid interest to
the earlier of the Redemption Date or the date of the finding of unsuitability or
failure to comply; or

     (ii) such other amount as may be required by applicable Gaming Laws or by order of the
applicable Gaming Authority.

     The Company shall notify the Trustee in writing of any such Disqualified Holder status or
redemption as soon as practicable. The Company shall not be responsible for any costs or expenses
any such Holder or beneficial owner may incur in connection with its application for a license,
qualification or a finding of suitability. Notwithstanding any other provision of this Indenture,
immediately upon the imposition of a requirement to dispose of Notes by a Gaming Authority, such
Person shall, to the extent required by applicable Gaming Laws, have no further right (i) to
exercise, directly or indirectly, through any trustee, nominee or any other person or entity, any
right conferred by such Notes or (ii) to receive any interest, dividends or any other distributions
or payments with respect to such Notes or any remuneration in any form with respect to such Notes
from the Company or the Trustee, except the redemption price. Additionally, to the extent required
by applicable Gaming Laws, Notes held by a Disqualified Holder shall, so long as held by such
Person, be disregarded for the purposes of providing notices, directions,
waivers, or other actions and determining the sufficiency of such notices, directions, waivers
or actions.

-57-

 

ARTICLE IV

COVENANTS

     SECTION 4.01 PAYMENT OF PRINCIPAL, PREMIUM AND INTEREST.

     The Company covenants and agrees for the benefit of the Notes, that it will duly and
punctually pay the principal of (and premium, if any) and interest on the Notes in accordance with
the terms of the Notes, this Indenture and the other Transaction Documents.

     SECTION 4.02 REPORTS.

     In the event the Company is not subject to the reporting requirements of Section 13 or 15(d)
of the Exchange Act or otherwise does not report on an annual and quarterly basis on forms provided
for such annual and quarterly reporting pursuant to rules and regulations promulgated by the
Commission, the Company shall make available to the Trustee, post to the Company’s publicly
accessible website, and otherwise make available to any Holder, without cost to any Holder, within
15 calendar days after the time the Company would be required to file such information with the
Commission, if it were subject to Section 13 or 15(d) of the Exchange Act, from and after the
Closing Date,

     (a) within 90 calendar days (or any other time period then in effect under
the rules and regulations of the Exchange Act with respect to the filing of a Form 10-K by a
non-accelerated filer) after the end of each fiscal year, annual reports on Form 10-K, or
any successor or comparable form, containing the information required to be contained
therein, or required in such successor or comparable form;

     (b) within 45 calendar days (or any other time period then in effect under
the rules and regulations of the Exchange Act with respect to the filing of a Form 10-K by a
non-accelerated filer) after the end of each of the first three fiscal quarters of each
fiscal year, reports on Form 10-Q containing all quarterly information that would be
required to be contained in Form 10-Q, or any successor or comparable form;

     (c) promptly from time to time after the occurrence of an event required to
be therein reported and within the time period then in effect under the rules and
regulations of the Exchange Act, such reports on Form 8-K, or any successor or comparable
form; and

     (d) any other information, documents and other reports which the Company
would be required to file with the Commission if it were subject to Section 13 or 15(d) of
the Exchange Act;

in each case, in a manner that complies in all material respects with the requirements specified in
such form; provided that none of the foregoing reports shall be required to contain the financial
statements of MGM Grand Hotel required by Rule 3-16 of Regulation S-X of the Commission. In
addition, to the extent not satisfied by the foregoing, the Company agrees that, for so long as any
Notes are outstanding, it will furnish to Holders and to securities analysts and prospective
investors, upon their request, the information required to be delivered pursuant to Rule 144A(d)(4)
under the Securities Act.

     Delivery of such reports, information and documents to the Trustee is for informational
purposes only and the Trustee’s receipt of such reports, information and documents shall not
constitute constructive notice of any information contained therein or determinable from
information contained

-58-

 

therein, including the Company’s compliance with any of its covenants
hereunder (as to which the
Trustee is entitled to rely conclusively on the Officer’s Certificate described in Section
4.03). The Trustee is under no duty to examine such reports, information or documents to ensure
compliance with the provisions of this Indenture or to ascertain the correctness or accuracy of the
information or the statements contained therein. The Trustee is entitled to assume such compliance
and correctness unless an Officer of the Trustee is informed in writing otherwise.

     SECTION 4.03 OFFICER’S CERTIFICATE AS TO COMPLIANCE.

     The Company will deliver to the Trustee, within 120 calendar days after the end of each fiscal
year, a certificate of the principal executive officer, principal financial officer or principal
accounting officer of the Company stating whether or not, to the knowledge of the signer thereof,
the Company and the Restricted Subsidiaries are in compliance with all covenants and conditions
under the Transaction Documents, and, in the event of any noncompliance, specifying such
noncompliance and the nature and status thereof of which such signer may have knowledge. For
purposes of this Section 4.03, such compliance shall be determined without regard to any period of
grace or requirement of notice provided under the Transaction Documents.

     The Company shall, within 30 calendar days, upon becoming aware of any Event of Default,
deliver to the Trustee a statement specifying such Default.

     Except with respect to a payment Default and any Default described in the certificates
delivered pursuant to this Section 4.03, the Trustee shall have no duty to review, ascertain or
confirm the Company’s compliance with, or the breach of any representation, warranty or covenant
set forth in this Indenture.

     SECTION 4.04 MAINTENANCE OF OFFICE OR AGENCY.

     The Company will maintain in each Place of Payment for the Notes an office or agency where
such Notes may be presented or surrendered for payment, where such Notes may be surrendered for
registration of transfer or exchange, and where notices and demands to or upon the Company in
respect of such Notes and this Indenture may be served. The Company shall give prompt written
notice to the Trustee of the location, and any change in the location, of such office or agency.
If at any time the Company shall fail to maintain any such required office or agency or shall fail
to furnish the Trustee with the address thereof, such presentations, surrenders, notices and
demands may be made or served at the Corporate Trust Office of the Trustee and the Company hereby
appoints the Trustee as its agent to receive all presentations, surrenders, notices and demands.

     The Company may also from time to time designate different or additional offices or agencies
to be maintained for such purposes (in or outside of such Place of Payment), and may from time to
time rescind any such designations; provided, however, that no such designation or rescission shall
in any manner relieve the Company of its obligations described in the preceding paragraph. The
Company shall give prompt written notice to the Trustee of any such additional designation or
rescission of designation and any change in the location of any such different or additional office
or agency.

     SECTION 4.05 MONEY FOR NOTES; PAYMENTS TO BE HELD IN TRUST.

     The Company shall maintain one or more Paying Agents for the Notes in the Borough of
Manhattan, City of New York. The initial Paying Agent for the Notes shall be the Trustee.

-59-

 

     Whenever the Company shall have one or more Paying Agents with respect to the Notes, it shall,
by or on each due date of the principal (and premium, if any) or interest on any such Notes,
deposit with any such Paying Agent a sum sufficient to pay the principal (and premium, if any) or
interest so becoming due (in same day funds and, if a Global Note is an Outstanding Note, by 10:00
a.m., New York City time, in order for the Trustee to make payment to the Depositary for the Notes
in accordance with rules of such Depositary), such sum to be held in trust for the benefit of the
Persons entitled thereto, and (unless any such Paying Agent is the Trustee) the Company shall
promptly notify the Trustee of its action or failure so to act.

     The Company shall cause each Paying Agent with respect to the Notes other than the Trustee to
execute and deliver to the Trustee an instrument in which such Paying Agent shall agree with the
Trustee, subject to the provisions of this Section 4.05, that such Paying Agent shall:

     (a) hold all sums held by it for the payment of the principal of (and
premium, if any) or interest on the Notes in trust for the benefit of the Persons entitled
thereto until such sums shall be paid to such Persons or otherwise disposed of as herein
provided;

     (b) give the Trustee notice of any default by the Company (or any other
obligor upon the Notes) in the making of any payment of principal (and premium, if any) or
interest on the Notes; and

     (c) at any time during the continuance of any such default, upon the written
request of the Trustee, forthwith pay to the Trustee all sums so held in trust by such
Paying Agent.

     The Company may at any time, for the purpose of obtaining the satisfaction and discharge of
this Indenture or for any other purpose, pay, or by Company Order direct any Paying Agent to pay,
to the Trustee all sums held in trust by the Company or such Paying Agent, such sums to be held by
the Trustee upon the same trusts as those upon which such sums were held by the Company or such
Paying Agent; and, upon such payment by any Paying Agent to the Trustee, such Paying Agent shall be
released from all further liability with respect to such money.

     Any money deposited with the Trustee or any Paying Agent, or then held by the Company, in
trust for the payment of the principal of (and premium, if any) or interest on any Note and
remaining unclaimed for two years after such principal (and premium, if any) or interest has become
due and payable shall be paid to the Company upon Company Request, or (if then held by the Company)
shall be discharged from such trust; and the Holder of such Note shall thereafter, as an unsecured
general creditor, look only to the Company for payment thereof, and all liability of the Trustee or
such Paying Agent with respect to such trust money, and all liability of the Company as trustee
thereof, shall thereupon cease; provided, however, that the Trustee or such Paying Agent, before
being required to make any such repayment, shall at the expense of the Company cause to be
transmitted in the manner and to the extent provided by Section 12.02, notice that such money
remains unclaimed and that, after a date specified therein, which shall not be less than 30
calendar days from the date of such notification, any unclaimed balance of such money then
remaining will be repaid to the Company upon Company Request.

-60-

 

     SECTION 4.06 CORPORATE EXISTENCE.

     Subject to Article V, the Company shall do or cause to be done all things necessary to
preserve and keep in full force and effect its and each Restricted Subsidiary’s corporate,
partnership,

limited liability company and other existence, rights (charter and statutory) and franchises;
provided, however, that the Company shall not be required to preserve any such right or franchise
if the Company shall determine that the preservation thereof is no longer desirable in the conduct
of the business of the Company and the Restricted Subsidiaries, taken as a whole.

     SECTION 4.07 SUBSIDIARY GUARANTEE.

     (a) Each Restricted Subsidiary shall (i) become a Subsidiary Guarantor by executing
this Indenture (directly, by supplemental indenture or a joinder agreement, a form of which is
attached hereto as Exhibit D) or by executing a Subsidiary Guarantee in substantially the form of
Article X hereto, (ii) execute any Collateral Documents as are necessary, subject to any required
approval of any Gaming Authority, to create and convey to the Collateral Agent for the benefit of
the Holders a perfected first-priority lien on all Collateral (subject to Permitted Liens) held by
such Restricted Subsidiary and (iii) deliver an Opinion of Counsel relating to the enforceability
and authorization of such Subsidiary Guarantee in accordance with the terms of this Indenture and,
if applicable, perfection of the Liens in favor of the Collateral Agent on the Collateral owned by
such Restricted Subsidiary; provided that any newly-formed, newly-acquired or newly designated
Restricted Subsidiary that does not own any assets or properties that would constitute Collateral
shall have 10 calendar days after its formation, acquisition or designation to become a Subsidiary
Guarantor.

     (b) In the event of a sale or other disposition of all of the assets and properties
of any Restricted Subsidiary, by way of merger, consolidation or otherwise, or a sale or other
disposition of all of the Capital Stock of any Restricted Subsidiary (other than to the Company or
a Restricted Subsidiary), then such Restricted Subsidiary (in the event of a sale or other
disposition, by way of such a merger, consolidation or otherwise, of all of the Capital Stock of
such Restricted Subsidiary) or the Person acquiring the property (in the event of a sale or other
disposition of all of the assets and properties of such Restricted Subsidiary) shall be released
and relieved of any Obligations under its Subsidiary Guarantee and the Collateral Documents;
provided that the Net Proceeds of such sale or other disposition are applied in accordance with the
provisions of Section 4.10 hereof and that such sale or transaction complies with the other
provisions hereof. In addition, any Subsidiary Guarantor will be automatically and unconditionally
released from all obligations under its Subsidiary Guarantee (i) in the event the Board of
Directors designates a Restricted Subsidiary to be an Unrestricted Subsidiary; provided that such
designation is conducted in accordance with the applicable provisions hereof and (ii) upon legal or
covenant defeasance of the Company’s obligations in accordance with Section 8.04, or satisfaction
and discharge of this Indenture in accordance with Section 8.01.

     SECTION 4.08 FURTHER ASSURANCES AND GAMING APPROVAL.

          (a) The Company and the Restricted Subsidiaries shall execute and file any and all
further documents, financing statements (including UCC-3 continuation statements), agreements and
instruments, and take all further action that may be required under applicable law, or that the
Collateral Agent may reasonably request, in order to grant, preserve, protect and perfect the
validity and priority of the security interests created or intended to be created by the Collateral
Documents in the Collateral. In addition, from time to time, the Company will reasonably promptly
secure the Obligations under this Indenture and the Collateral Documents by pledging or creating,
or causing to be

-61-

 

pledged or created, perfected security interests with respect to the Collateral.
Such security interests and Liens will be created under the Collateral Documents and other security
agreements, mortgages, deeds of trust and other instruments and documents in form and substance
reasonably satisfactory to the Collateral Agent.

          (b) The pledge of the Pledged Interests pursuant to the Collateral Documents and any
restriction on the ability of the Company or any of its Restricted Subsidiaries to encumber the
shares and ownership interests of any Restricted Subsidiary that is a Nevada registered Subsidiary
or which holds Nevada Gaming Licenses requires the prior approval of the Nevada State Gaming
Control Board and the Nevada Gaming Commission in order to be effective. The Company shall as soon
as practicable after the Closing Date apply for and use commercially reasonable efforts after the
Closing Date to obtain such approval from the Nevada State Gaming Control Board and the Nevada
Gaming Commission.

          (c) Additionally, the Company shall petition the Illinois Gaming Board to approve
the Subsidiary Guarantee by Nevada Landing Partnership of the Notes, and upon receipt of such
approval, Nevada Landing shall execute the Subsidiary Guarantee.

     SECTION 4.09 CHANGE OF CONTROL.

     (a) If a Change of Control occurs, unless the Company has previously or concurrently
mailed a redemption notice with respect to all Outstanding Notes pursuant to Section 3.01, the
Company will make an offer to purchase all of the Notes (the “Change of Control Offer”) at a price
in cash (the “Change of Control Payment”) equal to 101% of the aggregate principal amount thereof
plus accrued and unpaid interest and Additional Interest, if any, to the date of purchase, subject
to the right of Holders of record on the relevant Regular Record Date to receive interest due on
the relevant Interest Payment Date.

     (b) Within 30 calendar days following any Change of Control, the Company shall send
notice of the Change of Control Offer by first-class mail, with a copy to the Trustee, to each
Holder to the address of such Holder appearing in the Note Register or otherwise in accordance with
the procedures of the Depositary, with a copy to the Trustee, with the following information:

     (i) that a Change of Control Offer is being made pursuant to this Section 4.09 and that
all Notes properly tendered pursuant to such Change of Control Offer will be accepted for
payment by the Company;

     (ii) the amount of the Change of Control Payment and the purchase date with respect
thereto, which will be no earlier than 20 Business Days nor later than 60 calendar days from
the date such notice is mailed (the “Change of Control Payment Date”); provided that the
Change of Control Payment Date may be extended in accordance with applicable law;

     (iii) that any Note not properly tendered will remain outstanding and continue to
accrue interest;

     (iv) that unless the Company defaults in the payment of the Change of Control Payment,
all Notes accepted for payment pursuant to the Change of Control Offer will cease to accrue
interest on the Change of Control Payment Date;

-62-

 

     (v) that Holders electing to have any Notes purchased pursuant to a Change of Control
Offer will be required to surrender such Notes, with the form entitled “Option of Holder to
Elect Purchase” on the reverse of such Notes completed, to the Paying Agent at the address
specified in the notice prior to the close of business on the third Business Day preceding
the Change of Control Payment Date;

     (vi) that Holders will be entitled to withdraw their tendered Notes and their election
to require the Company to purchase such Notes; provided that the Paying Agent receives, not
later than the close of business on the expiration date of the Change of Control Offer, a
facsimile transmission or letter setting forth the name of the Holder of the Notes, the
principal amount of Notes tendered for purchase, and a statement that such Holder is
withdrawing its tendered Notes and its election to have such Notes purchased;

     (vii) the other instructions, as determined by the Company, consistent with the
provisions of this Section 4.09, that a Holder must follow; and

     (viii) if such notice is mailed prior to the occurrence of a Change of Control, stating
that the Change of Control Offer is conditional upon the occurrence of such Change of
Control.

     (c) The Company shall comply with the requirements of Rule 14e-1 under the Exchange
Act (“Rule 14e-1”) and any other securities laws and regulations thereunder to the extent such laws
or regulations are applicable in connection with the repurchase of Notes pursuant to a Change of
Control Offer. To the extent that the provisions of any securities laws or regulations conflict
with the provisions of this Indenture, the Company shall comply with the applicable securities laws
and regulations and shall not be deemed to have breached its obligations described in this
Indenture by virtue thereof.

     (d) On the Change of Control Payment Date, the Company shall, to the extent
permitted by law,

     (i) accept for payment all Notes issued by it or portions thereof properly tendered
pursuant to the Change of Control Offer;

     (ii) deposit with the Paying Agent an amount equal to the aggregate Change of Control
Payment in respect of all Notes or portions thereof so tendered; and

     (iii) deliver, or cause to be delivered, to the Trustee for cancellation the Notes so
accepted together with an Officer’s Certificate to the Trustee stating that such Notes or
portions thereof have been tendered to, and purchased by, the Company.

     (e) The Company shall not be required to make a Change of Control Offer following a
Change of Control if a third party makes the Change of Control Offer in the manner, at the times
and otherwise in compliance with the requirements set forth in this Indenture applicable to a
Change of Control Offer made by us and purchases all Notes validly tendered and not withdrawn under
such Change of Control Offer. Notwithstanding anything to the contrary herein, a Change of Control
Offer may be made in advance of a Change of Control, conditional upon such Change of Control, if a
definitive agreement is in place for the Change of Control at the time of making of the Change of
Control Offer.

-63-

 

     (f) The Company’s obligation to make an offer to repurchase the Notes as a result of
a Change of Control may be waived or modified with the written consent of the Holders of a majority
in principal amount of the Notes until a Change of Control has occurred.

     SECTION 4.10 NON-COLLATERAL ASSET SALES.

     (a) The Company shall not, and shall not permit any of its Restricted Subsidiaries
to, consummate a Non-Collateral Asset Sale, unless:

     (i) the Company or such Restricted Subsidiary, as the case may be, receives
consideration at the time of such Non-Collateral Asset Sale at least equal to the fair
market value (as determined in good faith by the Company or, if $250.0 million or more, the
Board of Directors and in such case evidenced by the delivery to the Trustee of a certified
copy of Board Resolutions documenting such determination) of the assets or properties sold
or otherwise disposed of; and

     (ii) at least 75% of the consideration therefor received by the Company or such
Restricted Subsidiary, as the case may be, is in the form of cash or Cash Equivalents;
provided that the following shall be deemed to be cash for purposes of this Section 4.10 and
for no other purpose:

     (A) any liabilities (as reflected in the Company’s or such Restricted
Subsidiary’s most recent balance sheet or in the footnotes thereto) of the Company
or such Restricted Subsidiary (other than liabilities that are by their terms
subordinated to the Notes or liabilities to the extent owed to the Company or any
Affiliate of the Company) that are assumed by the transferee of any such assets or
properties and for which the Company and all of its Restricted Subsidiaries have
been validly released by all applicable creditors in writing;

     (B) any Indebtedness (as reflected in the Company’s or such Restricted
Subsidiary’s most recent balance sheet or in the footnotes thereto) of the Company
or such Restricted Subsidiary (other than Indebtedness that is by its terms
subordinated to the Notes or Indebtedness to the extent owed to the Company or any
Affiliate of the Company) validity released in writing in exchange for assets of the
Company or its Restricted Subsidiaries;

     (C) any securities, notes or other similar obligations received by the Company
or such Restricted Subsidiary from such transferee that are converted by the Company
or such Restricted Subsidiary into cash (to the extent of the cash received) within
180 calendar days following the closing of such Non-Collateral Asset Sale;

     (D) any Additional Assets; and

     (E) any Designated Non-cash Consideration received by the Company or such
Restricted Subsidiaries in such Non-Collateral Asset Sale having an aggregate fair
market value (as determined in good faith by the board of directors of the Company
and evidenced by the delivery to the Trustee of a certified copy of Board
Resolutions documenting such determination), taken together with other Non-cash
Consideration received pursuant to this clause (e) that is at that time outstanding,
together with

-64-

 

any Designated Non-cash Consideration received pursuant to all
Collateral Asset Sales, not to exceed 1.5% of Consolidated Net Tangible Assets at
the time of the receipt of such Designated Non-cash Consideration (with the fair
market value of each item of Designated Non-cash Consideration being measured at the
time received and without giving effect to subsequent changes in value).

     (b) Within 360 calendar days after the receipt of any Net Proceeds of any
Non-Collateral Asset Sale, the Company or such Restricted Subsidiary shall apply the Net Proceeds
from such Non-Collateral Asset Sale,

     (i) to prepay, purchase, redeem or pay at maturity any Indebtedness that ranks equally
with the Notes or any Subsidiary Guarantee in right of payment (“Pari Passu Indebtedness”)
including Indebtedness outstanding pursuant to any agreement providing for revolving
Indebtedness so long as the commitment thereunder is permanently reduced by a corresponding
amount, at a price in cash in an amount not to exceed 100% of the principal amount thereof
(or such offer price required pursuant to the agreements governing such Indebtedness) plus
accrued and unpaid interest to the date of purchase; or

     (ii) to make an offer to all Holders (the “Non-Collateral Asset Sale Offer”) to prepay,
purchase or redeem the Notes, at an offer price in cash (the “Non-Collateral Asset Sale
Payment”) equal to 100% of their principal amount plus accrued and unpaid interest to the
date of purchase subject to the right of Holders of record on a Regular Record Date to
receive interest on the relevant Interest Payment Date in accordance with the procedures set
forth this Indenture and the Notes; or

     (iii) to make (A) an Investment in any one or more businesses; provided that such
Investment in any business is in the form of the acquisition of Capital Stock and results in
the Company or another of its Restricted Subsidiaries, as the case may be, owning an amount
of the Capital Stock of such business such that it constitutes a Restricted Subsidiary, (B)
capital expenditures or (C) acquisitions of Additional Assets in each of (A), (B) and (C),
used or useful in a Similar Business;

provided that, in the case of clause (iii) above, a binding commitment entered into not later than
such 360th day shall be treated as a permitted application of the Net Proceeds from the date of
such commitment so long as the Company, or such other Restricted Subsidiary enters into such
commitment with the good faith expectation that such Net Proceeds will be applied to satisfy such
commitment within 180 calendar days of such commitment (an “Acceptable Non-Collateral Commitment”)
and, in the event any Acceptable Non-Collateral Commitment is later cancelled or terminated for any
reason before the Net Proceeds are applied in connection therewith, such Net Proceeds are not
actually so invested or paid in accordance with clause (iii) above by the end of such 180-day
period or there remain Net Proceeds after any Investment, expenditure or acquisition made in
accordance with clause (iii) above, then such remaining Net Proceeds (if such remaining Net
Proceeds exceed $1.0 million) shall be applied in accordance with clause (i) or (ii) above;
provided further that in the case of clause (i) above, a written undertaking delivered to the
Trustee not later than such 360th day shall be treated as a permitted application of the
Net Proceeds so long as the repurchase, redemption, prepayment or repayment occurs within 180
calendar days after the end of the 360th day.

     (c) If the Company elects to make a Non-Collateral Asset Sale Offer pursuant to
clause (b)(ii) above, within 15 Business Days thereafter (or, if applicable, within 15 Business
Days after the

-65-

 

cancellation or termination of any Acceptable Non-Collateral Commitment before the
Net Proceeds are applied in connection therewith), the Company shall send a notice describing such
Non-Collateral Asset Sale and the Non-Collateral Asset Sale Offer by first-class mail, with a copy
to the Trustee, to each Holder to the address of such Holder appearing in the Note Register or
otherwise in accordance with the procedures of the Depositary with a copy to the Trustee, with the
following information:

     (i) that a Non-Collateral Asset Sale Offer is being made pursuant to this Section 4.10
and the maximum principal amount of the Notes that may be purchased by the Company pursuant
to the Non-Collateral Asset Sale Offer;

     (ii) the amount of the Non-Collateral Asset Sale Payment and the purchase date with
respect thereto, which will be no earlier than 20 Business Days nor later than 60 calendar
days from the date such notice is mailed (the “Non-Collateral Asset Sale Payment Date”);
provided that the Non-Collateral Asset Sale Payment Date may be extended in accordance with
applicable law;

     (iii) that any Note not tendered or accepted for payment will remain outstanding and
continue to accrue interest;

     (iv) that unless the Company defaults in the payment of the Non-Collateral Asset Sale
Payment, all Notes accepted for payment pursuant to the Non-Collateral Asset Sale Offer will
cease to accrue interest on the Non-Collateral Asset Sale Payment Date;

     (v) that Holders electing to have any Notes purchased pursuant to the Non-Collateral
Asset Sale Offer will be required to surrender such Notes, with the form entitled “Option of
Holder to Elect Purchase” on the reverse of such Notes completed, to the Paying Agent at the
address specified in the notice prior to the close of business on the third Business Day
preceding the Non-Collateral Asset Sale Payment Date;

     (vi) that Holders will be entitled to withdraw their tendered Notes and their election
to require the Company to purchase such Notes; provided that the Paying Agent receives, not
later than the close of business on the expiration date of the Non-Collateral Asset Sale
Offer, a facsimile transmission or letter setting forth the name of the Holder, the
principal amount of Notes tendered for purchase, and a statement that such Holder is
withdrawing its tendered Notes and its election to have such Notes purchased; and

     (vii) the other instructions, as determined by the Company, consistent with the
provisions of this Section 4.10, that a Holder must follow.

     (d) The Company shall comply with the requirements of Rule 14e-1 and any other
securities laws and regulations thereunder to the extent such laws or regulations are applicable in
connection with the repurchase of Notes pursuant to a Non-Collateral Asset Sale Offer. To the
extent that the provisions of any securities laws or regulations conflict with the provisions of
this Indenture, the Company will comply with the applicable securities laws and regulations and
shall not be deemed to have breached its obligations described in this Indenture by virtue thereof.

-66-

 

     (e) On the Non-Collateral Asset Sale Payment Date, the Company shall

     (i) accept for payment such principal amount of Notes required to be purchased under
the Non-Collateral Asset Sale Offer or portions thereof properly tendered pursuant to the
Non-Collateral Asset Sale Offer,

     (ii) deposit with the Paying Agent an amount equal to the aggregate Non-Collateral
Asset Sale Payment in respect of all Notes accepted for payment in the Non-Collateral Asset
Sale Offer, and

     (iii) deliver, or cause to be delivered, to the Trustee for cancellation the Notes so
accepted together with an Officer’s Certificate to the Trustee stating that such Notes or
portions thereof have been tendered to, and purchased by, the Company.

     (f) Any Net Proceeds remaining after application as set forth in Section 4.10(b)(i)
through (iii) may be used by the Company or any of its Restricted Subsidiaries for general
corporate purposes subject to the terms of this Indenture.

     (g) If the aggregate principal amount of Notes surrendered by the Holders in respect
of a Non-Collateral Asset Sale Offer exceeds the amount of Net Proceeds or the pro rata portion
thereof available for the Non-Collateral Asset Sale Offer, as the case may be, the Trustee shall
select the Notes to be purchased on a pro rata basis for all tendered Notes.

     (h) Pending the final application of any Net Proceeds pursuant to this Section 4.10,
the Company or any of its Restricted Subsidiaries may apply such Net Proceeds temporarily to reduce
Indebtedness outstanding under a revolving credit facility or otherwise invest such Net Proceeds in
Cash Equivalents not prohibited by this Indenture.

     SECTION 4.11 COLLATERAL ASSET SALES.

     (a) The Company shall not, and shall not permit any of its Restricted Subsidiaries
to, consummate a Collateral Asset Sale, unless:

     (i) the Company or such Restricted Subsidiary, as the case may be, receives
consideration at the time of such Collateral Asset Sale at least equal to the fair market
value (as determined in good faith by the Board of Directors and evidenced by the delivery
to the Trustee of a certified copy of Board Resolutions documenting such determination) of
the Collateral sold or otherwise disposed of; and

     (ii) at least 75% of the consideration therefor received by the Company or such
Restricted Subsidiary, as the case may be, is in the form of cash or Cash Equivalents and
100% of the Net Proceeds therefrom is deposited directly into a deposit account pledged to
the Collateral Agent to secure the Notes; provided that the remaining consideration for such
Collateral Asset Sale is pledged to the Collateral Agent to secure the Notes.

     (b) Within 180 calendar days after the receipt of any Net Proceeds of any Collateral
Asset Sale, the Company or such Restricted Subsidiary, may either use such Net Proceeds to purchase
additional domestic Gaming Facilities that are pledged to the Collateral Agent as replacement
collateral or may pledge to the Collateral Agent domestic Gaming Facilities already owned thereby
as replacement 

-67-

 

collateral (in each case, the “Replacement Gaming Collateral”) so long as (i) the
Replacement Gaming Collateral, together with any Collateral that is not included in such Collateral
Asset Sale, has a fair market value (as determined by the report or analysis of an independent
appraiser selected by or reasonably satisfactory to the Trustee delivered to the Trustee within
such 180-day period) at least equal to the value of the Collateral as of the date of disposition of
such Collateral, (ii) the Replacement Gaming Collateral is owned by a Subsidiary Guarantor that is
a Wholly-Owned Subsidiary of the Company, all the equity interests in which (the “Replacement
Pledged Equity”), along with the Replacement Gaming Collateral, are pledged to the Collateral Agent
for the benefit of the Holders, (iii) the Collateral Agent has a first priority Lien in the
Replacement Gaming Collateral and the Replacement Pledged Equity (collectively, the “Replacement
Collateral”) and receives all filings or documents, including any Mortgages, that create or purport
to create or perfect such first
priority Lien in the Replacement Collateral in favor of the Collateral Agent, for the benefit
of the Holders (the “Replacement Collateral Documents”), and Ancillary Mortgage Documents, legal
opinions and other documents and instruments as the Collateral Agent may request and (iv) the
granting of a Lien on such Replacement Collateral is permitted by the terms of all other
Indebtedness of the Company and its Restricted Subsidiaries and the Trustee receives a legal
opinion to that effect.

     (c) In the event that the Company or any of its Restricted Subsidiaries does not
comply with Section 4.11(b) with respect to granting a Lien on Replacement Collateral within 180
calendar days after the receipt of any Net Proceeds of any Collateral Asset Sale, the Company or
any of its Restricted Subsidiaries shall within the time frame set forth in Section 4.11(d) use
such Net Proceeds, together with any additional cash that may be required, to either (i) defease or
discharge the Notes and any other Indebtedness secured by a lien on such Collateral permitted
hereby and ranking equal to the Lien securing the Notes or Guarantees (“Pari Passu Secured
Indebtedness”) required to be paid pursuant to Section 8.01 or Section 8.04 or (ii) make the
Collateral Asset Sale Offer described in Section 4.11(d).

     (d) If the Company makes an offer to purchase the Notes after the consummation of a
Collateral Asset Sale (the “Collateral Asset Sale Offer”), it will offer to purchase all the Notes
and any Pari Passu Secured Indebtedness at a price in cash (the “Collateral Asset Sale Payment”),
in each case pro rata in proportion to the respective principal amounts of the Notes and such other
Pari Passu Secured Indebtedness required to be repaid, equal to 100% of the aggregate principal
amount thereof plus accrued and unpaid interest and Additional Interest, if any, to the date of
purchase, subject to the right of Holders of record on the relevant Regular Record Date to receive
interest due on the relevant Interest Payment Date. Within 15 Business Days after the expiration
of the 180-day period described in Section 4.11(c), the Company shall send notice of the Collateral
Asset Sale and the Collateral Asset Sale Offer by first-class mail, with a copy to the Trustee, to
each Holder to the address of such Holder appearing in the Note Register or otherwise in accordance
with the procedures of the Depositary, with a copy to the Trustee, with the following information:

     (i) that a Collateral Asset Sale Offer is being made pursuant to this Section 4.11 and
that all Notes properly tendered pursuant to such Collateral Asset Sale Offer will be
accepted for payment by the Company;

     (ii) the amount of the Collateral Asset Sale Payment and the purchase date with respect
thereto, which will be no earlier than 20 Business Days nor later than 60 calendar days from
the date such notice is mailed (the “Collateral Asset Sale Payment Date”); provided that the
Collateral Asset Sale Payment Date may be extended in accordance with applicable law;

-68-

 

     (iii) that any Note not properly tendered will remain outstanding and continue to
accrue interest;

     (iv) that unless the Company defaults in the payment of the Collateral Asset Sale
Payment, all Notes accepted for payment pursuant to the Collateral Asset Sale Offer will
cease to accrue interest on the Collateral Asset Sale Payment Date;

     (v) that Holders electing to have any Notes purchased pursuant to a Collateral Asset
Sale Offer will be required to surrender such Notes, with the form entitled “Option of
Holder to Elect Purchase” on the reverse of such Notes completed, to the Paying Agent at the
address specified in the notice prior to the close of business on the third Business Day
preceding the Collateral Asset Sale Payment Date;

     (vi) that Holders will be entitled to withdraw their tendered Notes and their election
to require the Company to purchase such Notes; provided that the Paying Agent receives, not
later than the close of business on the expiration date of the Collateral Asset Sale Offer,
a facsimile transmission or letter setting forth the name of the Holder, the principal
amount of Notes tendered for purchase, and a statement that such Holder is withdrawing its
tendered Notes and its election to have such Notes purchased; and

     (vii) the other instructions, as determined by the Company, consistent with the
provisions of this Section 4.11, that a Holder must follow.

     (e) The Company will comply with the requirements of Rule 14e-1 and any other
securities laws and regulations thereunder to the extent such laws or regulations are applicable in
connection with the repurchase of Notes pursuant to a Collateral Asset Sale Offer. To the extent
that the provisions of any securities laws or regulations conflict with the provisions of this
Indenture, the Company will comply with the applicable securities laws and regulations and shall
not be deemed to have breached its Obligations hereunder.

     (f) On the Collateral Asset Sale Payment Date, the Company shall

     (i) accept for payment all Notes and Pari Passu Secured Indebtedness issued by it or
portions thereof properly tendered pursuant to the Collateral Asset Sale Offer;

     (ii) deposit with the Paying Agent an amount equal to the aggregate Collateral Asset
Sale Payment in respect of all Notes and Pari Passu Secured Indebtedness or portions thereof
so tendered; and

     (iii) deliver, or cause to be delivered, to the Trustee for cancellation the Notes so
accepted together with an Officer’s Certificate to the Trustee stating that such Notes or
portions thereof have been tendered to, and purchased by, the Company.

     SECTION 4.12 EVENT OF LOSS.

     (a) In the case of an Event of Loss with respect to any Collateral, the Company or
the affected Restricted Subsidiary, as the case may be, shall deposit any Net Loss Proceeds
received from such Event of Loss directly into a deposit account pledged to the Collateral Agent to
secure the Notes

-69-

 

 and Pari Passu Secured Indebtedness (a “Net Loss Proceeds Deposit Account”) and
within 360 calendar days after such receipt will either:

     (i) grant a Lien in favor of the Collateral Agent on Replacement Gaming Collateral so
long as (A) the Replacement Gaming Collateral, together the remaining value of the
Collateral, collectively has a fair market value (as determined by the report or analysis of
an independent appraiser selected by or reasonably satisfactory to the Trustee delivered to
the Trustee within such 360-day period) at least equal to the lesser of (1) the value of the
Collateral immediately prior to the date of the Event of Loss or (2) the value of the
Collateral as of the Closing Date, (B) the Replacement Gaming Collateral is owned by a
Subsidiary Guarantor that is a Wholly-Owned Subsidiary of the Company, all the Replacement
Pledged Equity in which, along with the Replacement Gaming Collateral, are pledged to the
Collateral Agent for the benefit of the Holders and (C) the Collateral Agent has a first
priority Lien in the Replacement Collateral and receives such Replacement Collateral
Documents, Ancillary
Mortgage Documents, legal opinions and other documents and instruments as the
Collateral Agent may request; or

     (ii) rebuild, repair, replace or construct improvements to the affected property or
facility (or enter into a binding agreement to do so within 180 calendar days after the
execution of such agreement (an “Acceptable Event of Loss Commitment”) so that the fair
market value (as determined by the report or analysis of an independent appraiser selected
by or reasonably satisfactory to the Trustee delivered to the Trustee within such 360-day
period) of the Collateral after application of the Net Loss Proceeds shall be at least equal
to the lesser of (A) the value of the Collateral immediately prior to the date of the Event
of Loss or (B) the value of the Collateral as of the Closing Date; provided that in either
of clauses (i) and (ii) above, any such action shall be permitted by the terms of all other
Indebtedness of the Company and its Restricted Subsidiaries and the Trustee receives a legal
opinion to that effect; provided, further, that in the event any Acceptable Event of Loss
Commitment is later cancelled or terminated for any reason before the Net Loss Proceeds are
applied in connection therewith, or such Net Loss Proceeds are not actually so invested or
paid in accordance with clause (ii) above by the end of such 180-day period, then such Net
Loss Proceeds shall be applied in accordance with Section 4.12(b) below; provided, further,
that any Net Loss Proceeds deposited into the Net Loss Proceeds Deposit Account will be
available pursuant to the terms of the relevant deposit account control agreement to
reimburse the Company or any of its Restricted Subsidiaries for any amounts expended by such
Persons in connection with the rebuilding, repair, replacement or construction of the
affected property or facility pursuant to clause (ii) above, and Net Loss Proceeds in an
amount equal to any such reimbursed amount shall be deemed to be applied pursuant to clause
(ii) above upon such reimbursement.

     (b) In the event that the Company or any of its Restricted Subsidiaries is not able
to, or for any reason does not, comply with Section 4.12(a), the Company will make an offer (a
“Loss Proceeds Offer”) to Holders and to holders of Pari Passu Secured Indebtedness to purchase the
maximum principal amount of Notes and Pari Passu Secured Indebtedness, in each case pro rata in
proportion to the respective principal amount thereof outstanding, that may be purchased from the
unapplied Net Loss Proceeds at a price in cash (the “Loss Proceeds Offer Payment”) equal to 100% of
the aggregate principal amount of such Notes plus accrued and unpaid interest and Additional
Interest, if any, to the date of purchase. If the Company makes a Loss Proceeds Offer, within 15
Business Days after the earlier of (i) the election to make the Loss Proceeds Offer and (ii) the
expiration of the 360-day period described in Section 4.12(a) (or, if applicable, within 15
Business Days after the cancella-

-70-

 

tion or termination of any Acceptable Event of Loss Commitment
before the Net Proceeds are applied in connection therewith), the Company shall send notice of the
Loss Proceeds Offer by first-class mail, with a copy to the Trustee, to each Holder to the address
of such Holder appearing in the Note Register or otherwise in accordance with the procedures of the
Depositary with a copy to the Trustee, with the following information:

     (i) that a Loss Proceeds Offer is being made pursuant to this Section 4.12 and the
maximum principal amount of the Notes that may be purchased by the Company pursuant to the
Loss Proceeds Offer;

     (ii) the amount of the Loss Proceeds Offer Payment and the purchase date with respect
thereto, which will be no earlier than 20 Business Days nor later than 60 calendar days from
the date such notice is mailed (the “Loss Proceeds Offer Payment Date”); provided that the
Loss Proceeds Offer Payment Date may be extended in accordance with applicable law;

     (iii) that any Note not tendered or accepted for payment will remain outstanding and
continue to accrue interest;

     (iv) that unless the Company defaults in the payment of the Loss Proceeds Offer
Payment, all Notes accepted for payment pursuant to the Loss Proceeds Offer will cease to
accrue interest on the Loss Proceeds Offer Payment Date;

     (v) that Holders electing to have any Notes purchased pursuant to the Loss Proceeds
Offer will be required to surrender such Notes, with the form entitled “Option of Holder to
Elect Purchase” on the reverse of such Notes completed, to the Paying Agent at the address
specified in the notice prior to the close of business on the third Business Day preceding
the Loss Proceeds Offer Payment Date;

     (vi) that Holders will be entitled to withdraw their tendered Notes and their election
to require the Company to purchase such Notes; provided that the Paying Agent receives, not
later than the close of business on the expiration date of the Loss Proceeds Offer, a
facsimile transmission or letter setting forth the name of the Holder, the principal amount
of Notes tendered for purchase, and a statement that such Holder is withdrawing its tendered
Notes and its election to have such Notes purchased; and

     (vii) the other instructions, as determined by the Company, consistent with the
provisions of this Section 4.12, that a Holder must follow.

     (c) The Company will comply with the requirements of Rule 14e-1 and any other
securities laws and regulations thereunder to the extent such laws or regulations are applicable in
connection with the repurchase of Notes pursuant to a Loss Proceeds Offer. To the extent that the
provisions of any securities laws or regulations conflict with the provisions of this Indenture,
the Company will comply with the applicable securities laws and regulations and shall not be deemed
to have breached its obligations described in this Indenture by virtue thereof.

     (d) On the Loss Proceeds Offer Payment Date, the Company will

-71-

 

     (i) accept for payment such principal amount of Notes and Pari Passu Secured
Indebtedness or portions thereof required to be purchased by it under to the Loss Proceeds
Offer or portions thereof properly tendered pursuant to the Loss Proceeds Offer;

     (ii) deposit with the Paying Agent an amount equal to the aggregate Loss Proceeds Offer
Payment in respect of all Notes and Pari Passu Secured Indebtedness accepted for payment
into the Loss Proceeds Offer; and

     (iii) deliver, or cause to be delivered, to the Trustee for cancellation the Notes so
accepted together with an Officer’s Certificate to the Trustee stating that such Notes or
portions thereof have been tendered to, and purchased by, the Company.

     SECTION 4.13 LIMITATION ON INCURRENCE OF INDEBTEDNESS AND ISSUANCE OF DISQUALIFIED STOCK AND
PREFERRED STOCK.

     (a) The Company shall not, and shall not permit any of its Restricted Subsidiaries
to, directly or indirectly, Incur any Indebtedness (including Acquired Indebtedness) and the
Company
will not issue any shares of Disqualified Stock and will not permit any Restricted Subsidiary
to issue any shares of Disqualified Stock or Preferred Stock; provided, however, that the Company
may Incur Indebtedness (including Acquired Indebtedness) or issue shares of Disqualified Stock, and
its Restricted Subsidiaries may Incur Indebtedness (including Acquired Indebtedness) or issue
shares of Disqualified Stock or Preferred Stock, if the Consolidated Fixed Charge Coverage Ratio on
a consolidated basis for the Company and its Restricted Subsidiaries’ most recently ended four
fiscal quarters for which internal financial statements are available immediately preceding the
date on which such additional Indebtedness is Incurred or such Disqualified Stock or Preferred
Stock is issued would have been at least 2.00 to 1.00, determined on a pro forma basis (including a
pro forma application of the net proceeds therefrom), as if the additional Indebtedness had been
Incurred, or the Disqualified Stock or Preferred Stock had been issued, as the case may be, and the
application of proceeds therefrom had occurred at the beginning of such four-quarter period.

     (b) The foregoing limitations of clause (a) shall not apply to:

     (i) the Incurrence of Indebtedness and related obligations under the Credit Facility by
the Company, any of its Restricted Subsidiaries or MGM Grand Detroit and the issuance and
creation of letters of credit thereunder (with letters of credit being deemed to have a
principal amount equal to the face amount thereof), up to an aggregate principal amount at
any one time outstanding not to exceed (A) (1) $7.0 billion, plus (2) the amount, not to
exceed $1.0 billion in the aggregate, by which commitments to borrow under the Credit
Facility are increased pursuant to the terms thereof and/or the amount which the Company and
any of the Restricted Subsidiaries or MGM Grand Detroit may borrow pursuant to one or more
additional credit agreements having terms similar to the Credit Facility, less (B) any
scheduled amortization payments, prepayments of term loans (other than any such prepayment
effectuated in connection with refinancing or replacing any such term loan) or prepayments
of revolving loans accompanied by a corresponding permanent reduction of commitments
thereunder (other than any such reduction of commitments effectuated in connection with
refinancing or replacing any such revolving loans), in each case, since the 13% Secured
Notes Issue Date; provided that the amount of Indebtedness that the Company, any of its
Restricted Subsidiaries or MGM Grand Detroit may Incur pursuant to this clause (i) shall
never be reduced by this sub-

-72-

 

clause (B) to an amount that is less than 3.0 times Consolidated
EBITDA of the Company and its Restricted Subsidiaries for the most recently ended four
fiscal quarters for which internal financial statements are available immediately preceding
the date on which such Indebtedness is Incurred; provided further, that the liability of MGM
Grand Detroit under the Credit Facility and any other credit agreement entered into by MGM
Grand Detroit having terms similar to the Credit Facility is limited to that portion of the
loans under such credit facilities which are actually borrowed or the proceeds of which are
actually received by MGM Grand Detroit;

     (ii) the Incurrence by the Company and any Subsidiary Guarantor of Indebtedness
represented by the Notes (including any Subsidiary Guarantee) and any notes (including
Subsidiary Guarantees thereof) issued in exchange for the Notes pursuant to the Registration
Rights Agreement, if any, up to an aggregate principal amount at any one time outstanding
not to exceed $845.0 million;

     (iii) Indebtedness of the Company and its Restricted Subsidiaries in existence on the
Closing Date (other than Indebtedness described in clauses (b)(i) and (ii));

     (iv) Indebtedness (including Capitalized Lease Obligations), Disqualified Stock and
Preferred Stock Incurred or issued by the Company or any of its Restricted Subsidiaries, to
finance the purchase, lease or improvement of property (real or personal) or equipment
(other than software) that is used or useful in the business of the Company and its
Restricted Subsidiaries in an aggregate principal amount at the date of such Incurrence,
together with all other Indebtedness previously Incurred under this clause (iv) (and
including all Refinancing Indebtedness Incurred to refinance any Indebtedness Incurred
pursuant to this clause (iv)), not to exceed 1.5% of Consolidated Net Tangible Assets;
provided, however, that such Indebtedness exists at the date of such purchase or transaction
or is created within 180 calendar days thereafter;

     (v) Indebtedness of the Company or any Restricted Subsidiary arising in respect of (A)
letters of credit, bankers’ acceptances, worker’s compensation claims, payment obligations
in connection with self-insurance or similar obligations and bid, appeal and surety bonds,
in each case in the ordinary course of business and in amounts and for the purposes
customary in such Person’s industry and (B) completion guarantees (to the extent that the
Incurrence thereof does not result in the Incurrence of any direct or indirect obligation
for the payment of borrowed money of others);

     (vi) Indebtedness arising from agreements of the Company or its Restricted Subsidiaries
providing for indemnification, adjustment of purchase price or similar obligations, in each
case, Incurred or assumed in connection with the disposition of any business, assets or
properties or a Subsidiary, other than guarantees of Indebtedness Incurred by any Person
acquiring all or any portion of such business, assets or properties or a Subsidiary for the
purpose of financing such acquisition; provided, however, that

     (A) such Indebtedness is not reflected on the balance sheet of the Company, or
any of its Restricted Subsidiaries (contingent obligations referred to in a footnote
to financial statements and not otherwise reflected on the balance sheet will not be
deemed to be reflected on such balance sheet for purposes of this subclause (A));
and

-73-

 

     (B) the maximum assumable liability in respect of all such Indebtedness shall
at no time exceed the gross proceeds including non-cash proceeds (the fair market
value of such non-cash proceeds being measured at the time received and without
giving effect to any subsequent changes in value) actually received by the Company
and its Restricted Subsidiaries in connection with such disposition;

     (vii) Indebtedness between or among the Company and its Restricted Subsidiaries;
provided that any subsequent issuance or transfer of any Capital Stock or any other event
which results in the Restricted Subsidiary holding such Indebtedness ceasing to be a
Restricted Subsidiary or any subsequent transfer of any such Indebtedness (except to the
Company or another Restricted Subsidiary) shall be deemed, in each case, to be an Incurrence
of such Indebtedness not permitted by this clause (b)(vii); provided, further, that any
Indebtedness Incurred by any Collateral Grantor from the Company or any Restricted
Subsidiary shall be unsecured Indebtedness;

     (viii) shares of Preferred Stock of a Restricted Subsidiary issued to the Company or
another Restricted Subsidiary, provided that any subsequent issuance or transfer of any
Capital Stock or any other event which results in any such Restricted Subsidiary
ceasing to be a Restricted Subsidiary or any subsequent transfer of any such shares of
Preferred Stock (except to the Company or another Restricted Subsidiary) shall be deemed in
each case to be an issuance of such shares of Preferred Stock not permitted by this clause;

     (ix) Hedging Obligations (excluding Hedging Obligations entered into for speculative
purposes);

     (x) the Incurrence or issuance by the Company or any Restricted Subsidiary of
Indebtedness or Disqualified Stock, and the issuance by any Restricted Subsidiary of
Preferred Stock, in each case which serves to refund, refinance, replace, renew, extend,
prepay or defease any Indebtedness, Disqualified Stock or Preferred Stock of the Company or
any Restricted Subsidiary Incurred as permitted under clause (a) above, clauses (b)(ii),
(b)(iii) and (b)(iv) above, or this clause (b)(x), or any Indebtedness, Disqualified Stock
or Preferred Stock issued to so refund, refinance, replace, renew, extend, prepay or defease
such Indebtedness, Disqualified Stock or Preferred Stock, including additional Indebtedness,
Disqualified Stock or Preferred Stock Incurred to pay premiums (including tender premiums),
defeasance or similar costs and fees in connection therewith (the “Refinancing
Indebtedness”) prior to its respective maturity; provided, however, that:

     (A) such Refinancing Indebtedness has a Weighted Average Life to Maturity at
the time such Refinancing Indebtedness is Incurred which is not less than the
remaining Weighted Average Life to Maturity of the Indebtedness, Disqualified Stock
or Preferred Stock being refunded, refinanced, replaced, renewed, extended or
defeased,

     (B) the principal or other amount (or accreted value) of such Refinancing
Indebtedness does not exceed the principal or other amount (or accreted value, if
applicable) of the Indebtedness, Disqualified Stock or Preferred Stock extended,
refinanced, renewed, replaced, defeased, prepaid or refunded (plus all accrued
interest and dividends on the Indebtedness, Disqualified Stock or Preferred Stock
and the amount of all underwriting discounts, fees, expenses and premiums Incurred
in con-

-74-

 

nection therewith); provided that with respect to Refinancing Indebtedness
Incurred in respect of Indebtedness Incurred under clause (b)(iv) above, the
principal amount or accreted value, will not exceed the then current fair market
value of the asset encumbered in connection therewith,

     (C) to the extent such Refinancing Indebtedness refinances (1) Subordinated
Indebtedness, such Refinancing Indebtedness (i) is subordinated to or pari passu
with the Notes or the Subsidiary Guarantee, as applicable, at least to the same
extent as the Indebtedness being refinanced or refunded and (ii) has a final Stated
Maturity at the time such Refinancing Indebtedness is Incurred which is not less
than the final Stated Maturity of the Subordinated Indebtedness being refunded,
refinanced, replaced, renewed, extended or defeased or (2) Disqualified Stock or
Preferred Stock, such Refinancing Indebtedness must be Disqualified Stock or
Preferred Stock, respectively, and

     (D) such Indebtedness, Disqualified Stock or Preferred Stock is Incurred by a
Person that is an obligor (including as a guarantor) on or issuer of the
Indebtedness, Disqualified Stock or Preferred Stock being extended, refinanced,
renewed, replaced, defeased or refunded;

     (xi) Indebtedness arising from the honoring by a bank or other financial institution of
a check, draft or similar instrument drawn against insufficient funds in the ordinary course
of business, provided that such Indebtedness is extinguished within two Business Days of its
Incurrence;

     (xii) any guarantee by the Company or a Restricted Subsidiary of Indebtedness or other
obligations of any Restricted Subsidiary so long as the incurrence of such Indebtedness
incurred by such Restricted Subsidiary is permitted under the terms of this Indenture;

     (xiii) Indebtedness (A) of a Special Purpose RE Subsidiary secured by a Lien on all or
part of the assets disposed of in, or otherwise Incurred in connection with, an RE
Receivables Sale or (B) otherwise Incurred in connection with a Special Purpose RE
Financing; provided that (1) such Indebtedness is not recourse to the Company or any
Restricted Subsidiary that is not a Special Purpose RE Subsidiary (other than with respect
to Special Purpose RE Financing Undertakings), (2) in the event such Indebtedness shall
become recourse to the Company or any Restricted Subsidiary that is not a Special Purpose RE
Subsidiary (other than with respect to Special Purpose RE Financing Undertakings), such
Indebtedness will be deemed to be, and must be classified by the Company as, Incurred at
such time (or at the time initially Incurred) under one or more of the other provisions of
this covenant for so long as such Indebtedness shall be so recourse; and (3) in the event
that at any time thereafter such Indebtedness shall comply with the provisions of the
preceding subclause (1), the Company may classify such Indebtedness in whole or in part as
Incurred under this clause (xiii);

     (xiv) Indebtedness of any Person that is assumed by the Company or any Restricted
Subsidiary in connection with its acquisition of assets from such Person or any Affiliate
thereof or is issued and outstanding on or prior to the date on which such Person was
acquired by the Company or any Restricted Subsidiary or merged or consolidated with or into
any Restricted Subsidiary (other than Indebtedness Incurred to finance, or otherwise
Incurred in con-

-75-

 

nection with, such acquisition), provided that on the date of such
acquisition, merger or consolidation, after giving effect thereto, either (A) the Company
could Incur at least $1.00 of additional Indebtedness under the Consolidated Fixed Charge
Coverage Ratio test set forth in the clause (a) above or (B) the Consolidated Fixed Charge
Coverage Ratio of the Company would equal or exceed the Consolidated Fixed Charge Coverage
Ratio of the Company immediately prior to giving effect thereto; and

     (xv) the Incurrence or issuance by the Company or any of its Restricted Subsidiaries of
additional Indebtedness, Disqualified Stock or Preferred Stock in an aggregate principal or
other amount (or accreted value, as applicable) at the date of such Incurrence or issuance,
together with all other amounts previously Incurred or issued pursuant to this clause
(b)(xv), not to exceed 1.5% of Consolidated Net Tangible Assets.

     (c) For purposes of determining compliance with this Section 4.13, in the event that
an item of Indebtedness, Disqualified Stock or Preferred Stock (or any portion thereof) meets the
criteria of more than one of the categories of permitted Indebtedness, Disqualified Stock or
Preferred Stock described in clauses (b)(i) through (b)(xv) above or is entitled to be Incurred
pursuant to Section 4.13(a), the Company, in its sole discretion, will classify or reclassify such
item of Indebtedness, Disqualified Stock or Preferred Stock (or any portion thereof) and will only
be required to include the amount and type of such Indebtedness, Disqualified Stock or Preferred
Stock in one of the above clauses; provided that all Indebtedness from time to time outstanding
under the Credit Facility shall at
all times be treated as Incurred pursuant to clause (b)(i) above to the full extent of
Indebtedness permitted to be Incurred under such clause. Notwithstanding the foregoing, and
subject to the last sentence of this paragraph, any Indebtedness under the Credit Facility from
time to time Incurred under clause (b)(i) above the net proceeds of which Indebtedness were applied
to repay revolving Indebtedness outstanding under such clause (b)(i) (“Credit Facility Refinancing
Indebtedness”), may be reclassified as outstanding under clause (b)(x) above; provided that (i)
following the Incurrence of such Credit Facility Refinancing Indebtedness, Indebtedness under the
Credit Facility in a principal amount equal to the net proceeds of the Credit Facility Refinancing
Indebtedness is Incurred under clause (b)(i) above to repay or prepay Indebtedness Incurred under
clause (a) above or clauses (b)(ii), (b)(iii) or (b)(x) of the preceding paragraph (the “Specified
Refinanced Debt”) and (ii) the Credit Facility Refinancing Indebtedness, if it had been Incurred
and its net proceeds had been directly and contemporaneously applied to the repayment or prepayment
of the Specified Refinanced Debt at the time the Specified Refinanced Debt was repaid or prepaid,
would have satisfied the definition of Refinancing Indebtedness set forth in clause (b)(x) in
respect of such Specified Refinanced Debt. In addition, subject to the last sentence of this
paragraph, in the event that Indebtedness under the Credit Facility is first Incurred under clause
(b)(i) to repay or prepay Specified Refinanced Debt and thereafter the Company or any of its
Restricted Subsidiaries Incurs one or more issuances of Credit Facility Refinancing Indebtedness,
each of such issuances of Credit Facility Refinancing Indebtedness, in an amount equal to the
lesser of the amount of Specified Refinanced Debt repaid or prepaid and the amount of such Credit
Facility Refinancing Indebtedness, may be reclassified as outstanding under clause (b)(x) above;
provided that the Credit Facility Refinancing Indebtedness, if it had been Incurred and its net
proceeds had been directly and contemporaneously applied to the repayment or prepayment of the
Specified Refinanced Debt at the time the Specified Refinanced Debt was repaid or prepaid, would
have satisfied the definition of Refinancing Indebtedness set forth in clause (b)(x) in respect of
such Specified Refinanced Debt. In the event that the principal amount of the Credit Facility
Refinancing Indebtedness exceeds the amounts Incurred under the Credit Facility under clause (b)(i)
to repay or prepay Specified Refinanced Debt, such excess principal amount may be reclassified as
outstanding under Section 4.13(a) so long as any such reclassification would not cause a Default.

-76-

 

     Accrual of interest or dividends, the accretion of accreted value, the accretion or
amortization of original issue discount, the payment of interest in the form of additional
Indebtedness and the payment of dividends in the form of additional Disqualified Stock or Preferred
Stock, as applicable, will in each case not be deemed to be an Incurrence of Indebtedness,
Disqualified Stock or Preferred Stock for purposes of this Section 4.13.

     For purposes of determining compliance with any U.S. dollar-denominated restriction on the
Incurrence of Indebtedness, the U.S. dollar-equivalent principal amount of Indebtedness denominated
in a foreign currency shall be calculated based on the relevant currency exchange rate in effect on
the date such Indebtedness was Incurred, in the case of term debt, or first committed, in the case
of revolving credit debt; provided that if such Indebtedness is Incurred to refinance other
Indebtedness denominated in a foreign currency, and such refinancing would cause the applicable
U.S. dollar denominated restriction to be exceeded if calculated at the relevant currency exchange
rate in effect on the date of such refinancing, such U.S. dollar-denominated restriction shall be
deemed not to have been exceeded so long as the principal amount of such refinancing Indebtedness
does not exceed the principal amount of such Indebtedness being refinanced, plus the amount of any
reasonable premium (including reasonable tender premiums), defeasance costs and any reasonable fees
and expenses Incurred in connection with the issuance of such new Indebtedness.

     The principal amount of any Indebtedness Incurred to refinance other Indebtedness, if Incurred
in a different currency from the Indebtedness being refinanced, shall be calculated based on
the currency exchange rate applicable to the currencies in which such respective Indebtedness
is denominated that is in effect on the date of such refinancing.

     SECTION 4.14 LIMITATION ON LIENS.

     (a) The Company shall not, and shall not permit any Subsidiary Guarantor to,
directly or indirectly, create, incur, assume or otherwise cause to exist any Lien (except a
Permitted Lien) that secures obligations under any Indebtedness of the Company or any Subsidiary
Guarantor (any such Lien, the “Additional Lien”), on any asset or properties of the Company or any
Subsidiary Guarantor, or any income or profits therefrom, or assign or convey any right to receive
income therefrom except, in the case of any asset or property that does not constitute Collateral,
any Additional Lien if the Notes are, or in the case of Indebtedness of any Subsidiary Guarantor,
the Subsidiary Guarantee of such Subsidiary Guarantor is, equally and ratably secured with (or on a
senior basis to, in the case such Additional Lien secures any Subordinated Indebtedness) the
obligations secured by such Additional Lien.

     (b) Any Lien created for the benefit of the Holders pursuant to clause (a) above shall provide
by its terms that such Lien shall be automatically and unconditionally released and discharged upon
the release and discharge of the Additional Lien.

     (c) The foregoing notwithstanding, any restriction on the ability of the Company or any of its
Restricted Subsidiaries to encumber the shares and ownership interests of any Restricted Subsidiary
that is a Nevada registered Subsidiary or which holds Nevada Gaming Licenses pursuant to this
Section 4.14 shall not be effective unless and until it is approved by the Chairman of the Nevada
State Gaming Control Board, or the Nevada Gaming Commission upon the recommendation of the Nevada
State Gaming Control Board.

-77-

 

     SECTION 4.15 LIMITATION ON SALE AND LEASEBACK TRANSACTIONS.

     The Company shall not, and shall not permit any of its Restricted Subsidiaries to, enter into
any Sale and Leaseback Transaction; provided that the Company or any Restricted Subsidiary may
enter into a Sale and Leaseback Transaction with respect to any assets or properties other than
Collateral if:

     (a) the Company or such Restricted Subsidiary, as applicable, is able to (i)
Incur Indebtedness in an amount equal to the Attributable Debt relating to such Sale and
Leaseback Transaction under Section 4.13(a) and (ii) incur a Lien to secure such
Indebtedness in an amount equal to the Attributable Debt pursuant to Section 4.14;

     (b) the gross cash proceeds of such Sale and Leaseback Transaction are at
least equal to the fair market value, as determined in good faith by the Board of Directors
or that Restricted Subsidiary, as the case may be, and set forth in an Officer’s Certificate
delivered to the Trustee, of the property or assets that are the subject of such Sale and
Leaseback Transaction; and

     (c) the transfer of assets or properties in such Sale and Leaseback
Transaction is permitted by, and the Company or such Restricted Subsidiary applies the
proceeds of such transaction in compliance with, Section 4.10.

     SECTION 4.16 LIMITATION ON RESTRICTED PAYMENTS.

     (a) The Company shall not, and shall not permit any of its Restricted Subsidiaries
to, directly or indirectly:

     (i) declare or pay any dividend or make any payment or distribution on account of the
Company’s, or any of its Restricted Subsidiaries’ Equity Interests (other than pursuant to a
Convertible Debt-Linked Derivative Transaction), including, without limitation, payable in
connection with any merger or consolidation other than:

     (A) dividends or distributions by the Company payable solely in Equity
Interests (other than Disqualified Stock) of the Company; or

     (B) dividends, payments or distributions by a Restricted Subsidiary so long as,
in the case of any dividend, payment or distribution payable on or in respect of any
class or series of securities issued by a Restricted Subsidiary other than a
Wholly-Owned Subsidiary, (i) the Company or a Restricted Subsidiary receives at
least its pro rata share of such dividend or distribution in accordance with its
Equity Interests in such class or series of securities and (ii) the other
shareholders of the Restricted Subsidiary making such dividends, payments or
distributions are not Affiliates of such Restricted Subsidiary;

     (ii) purchase, redeem, defease or otherwise acquire or retire for value any Equity
Interests of the Company (other than pursuant to a Convertible Debt-Linked Derivative
Transaction), including, without limitation, in connection with any merger or consolidation;

-78-

 

     (iii) make any principal payment on, or redeem, repurchase, defease or otherwise
acquire or retire for value in each case, prior to any scheduled repayment, sinking fund
payment or maturity, any Subordinated Indebtedness (excluding Subordinated Indebtedness
between or among the Company and its Subsidiary Guarantors), other than the purchase,
repurchase or other acquisition of Subordinated Indebtedness purchased in anticipation of
satisfying a sinking fund obligation, principal installment or final maturity, in each case
due within one year of the date of purchase, repurchase or acquisition; or

     (iv) make any Restricted Investment

(all such payments and other actions set forth in clauses (i) through (iv) above (other than
any exceptions thereof) being collectively referred to as “Restricted Payments”), unless, at
the time of such Restricted Payment:

     (1) no Default shall have occurred and be continuing or would occur as a
consequence thereof;

     (2) immediately after giving effect to such transaction on a pro forma basis,
the Company could Incur $1.00 of additional Indebtedness under the Consolidated
Fixed Charge Coverage Ratio test set forth in Section 4.13(a); and

     (3) the aggregate amount of Restricted Payments does not exceed the sum,
without duplication, of:

     (I) 50% of the cumulative Consolidated Net Income (or if cumulative
Consolidated Net Income shall be a loss, minus 100% of such loss) of the
Company and the Restricted Subsidiaries during the period (treating such
period as a single accounting period) beginning on January 1, 2009 and
ending on the last day of the most recent fiscal quarter of the Company
ending immediately prior to the date of the making of such Restricted
Payment for which internal financial statements are available, plus

     (II) 100% of the aggregate net cash proceeds received by the Company
from any Person (other than from a Subsidiary of the Company) from the
issuance and sale of Equity Interests (other than Disqualified Stock) of the
Company or the amount by which Indebtedness of the Company or any Restricted
Subsidiary is reduced by the conversion or exchange of debt securities or
Disqualified Stock into or for Equity Interests (other than Disqualified
Stock) (to the extent that proceeds of the issuance of such Equity Interests
would have been able to be included in this clause if such Equity Interests
had been initially issued for cash) subsequent to November 14, 2008 (the
“13% Secured Notes Issue Date”) and on or prior to the date of the making of
such Restricted Payment, plus

     (III) 100% of the aggregate cash received by the Company subsequent to
the 13% Secured Notes Issue Date and on or prior to the date of the making
of such Restricted Payment upon the exercise of options or warrants (whether
issued prior to or after the 13% Secured Notes Issue Date) to purchase
Equity Interests (other than Disqualified Stock) of the Company, plus

-79-

 

     (IV) 100% of the aggregate cash and the fair market value of any
property or assets (excluding any Equity Interest, Indebtedness or other
securities (other than Cash Equivalents)) (such fair market value as
determined in the good faith reasonable judgment of the Company) received by
the Company or any Restricted Subsidiary (other than from the Company or any
Restricted Subsidiary) subsequent to the 13% Secured Notes Issue Date by
means of:

     (x) the sale or other disposition, repurchase, redemption,
repayment or return of capital, as applicable, of Investments made
by the Company or its Restricted Subsidiaries in Existing Investment
Entities and any distribution or dividend received from an Existing
Investment Entity; or

     (y) the sale or other disposition, repurchase, redemption,
repayment or return of capital, as applicable, of Restricted
Investments made after the 13% Secured Notes Issue Date by the
Company or its Restricted Subsidiaries in Persons that are not
Existing Investment Entities and any distribution or dividend
received from such Person, plus

     (V) to the extent that any Person becomes a Restricted Subsidiary or an
Unrestricted Subsidiary is redesignated as a Restricted Subsidiary after
the 13% Secured Notes Issue Date, the fair market value of the
Restricted Investment of the Company and its Restricted Subsidiaries in such
Person as of the date it becomes a Restricted Subsidiary or in such
Unrestricted Subsidiary on the date of redesignation as a Restricted
Subsidiary, plus

     (VI) to the extent that any completion guarantee executed by the
Company or any Restricted Subsidiary after the 13% Secured Notes Issue Date
constitutes a Restricted Investment, 100% of the amount by which (i) the
amount of the liability associated with such completion guarantee reflected
on the most recent internally available balance sheet of the Company
prepared in accordance with GAAP is less than (ii) the amount of the
liability associated with such completion guarantee on the immediately
preceding internally available balance sheet of the Company prepared in
accordance with GAAP.

     (b) Notwithstanding the foregoing, unless a Default has occurred and is continuing
or would result therefrom (other than in respect of clauses (i), (ii), (iii), (iv), (viii) and (x)
below), the provisions set forth in Section 4.16(a) will not prohibit, without duplication:

     (i) the payment of any dividend or the making of any distribution within 60 calendar
days after the date of declaration of such dividend or distribution if the making thereof
would have been permitted on the date of declaration; provided such dividend will be deemed
to have been made as of its date of declaration for purposes of this clause (i);

     (ii) the redemption, repurchase, retirement or other acquisition of Equity Interests of
the Company either (A) solely in exchange for Equity Interests (other than Disqualified
Stock) of the Company, or (B) through the application of net proceeds of a substantially
con-

-80-

 

current sale for cash (other than to a Subsidiary of the Company) of Equity Interests
(other than Disqualified Stock)of the Company;

     (iii) the payment, redemption, repurchase, retirement, defeasance or other acquisition
of Subordinated Indebtedness of the Company or any Restricted Subsidiary (A) solely in
exchange for (1) Equity Interests (other than Disqualified Stock) of the Company or (2)
Refinancing Indebtedness, or (B) through the application of the net proceeds of a sale for
cash (other than to the Company or any Restricted Subsidiary) within 45 calendar days of
such sale of (1) Equity Interests (other than Disqualified Stock) of the Company or (2)
Refinancing Indebtedness;

     (iv) redemptions, repurchases, defeasances, repayments or other acquisitions or
retirements for value of Equity Interests or Subordinated Indebtedness to the extent
required by any gaming authority having jurisdiction over the Company or any Restricted
Subsidiary or deemed necessary by the board of directors of the Company in order to avoid
the suspension, revocation or denial of a gaming license by any gaming authority or other
right to conduct lawful gaming operations;

     (v) Restricted Payments made on or after the Closing Date not to exceed, together with
all Restricted Payments made pursuant to this clause (v), 1.5% of Consolidated Net Tangible
Assets in the aggregate;

     (vi) repurchases by the Company of its common stock, options, warrants or other
securities exercisable or convertible into such common stock from employees, officers,
consultants or directors of the Company or any of its respective Subsidiaries upon
death, disability or termination of employment, relationship or directorship of such
employees, officers, consultants or directors in an aggregate amount not to exceed $20.0
million per fiscal year;

     (vii) any Investment in any Unrestricted Subsidiary or Non-Control Entity other than
CityCenter Holdings, LLC, a Delaware limited liability company, so long as immediately after
giving effect to any such Investment, on a pro forma basis the Consolidated Fixed Charge
Coverage Ratio for the Company and its Restricted Subsidiaries for the most recently ended
four fiscal quarters for which internal financial statements are available would have been
at least 2.25 to 1.00;

     (viii) the repurchase of Equity Interests deemed to occur upon the exercise of stock
options to the extent such Equity Interests represent a portion of the exercise price of
those stock options;

     (ix) the declaration and payment of regularly scheduled or accrued dividends or
distributions to holders of any class or series of Disqualified Stock of the Company or any
Restricted Subsidiary of the Company issued on or after the Closing Date in accordance with
the Consolidated Fixed Charge Coverage Ratio test set forth in Section 4.13(a);

     (x) payments in lieu of fractional shares of the Company’s Capital Stock; and

     (xi) that portion of Restricted Investments the payment for which consists exclusively
of the Company’s Equity Interests (other than Disqualified Stock).

-81-

 

     In determining the aggregate amount of Restricted Payments made subsequent to the Closing
Date, Restricted Payments made pursuant to clauses (ii)(A), (iii)(A)(2), (iii)(B)(2), (v), (vi),
(viii), (x) or (xi) of the immediately preceding paragraph shall, in each case, be excluded from
such calculation; provided that any amounts expended or liabilities incurred in respect of premiums
or similar payments in connection therewith shall be included in such calculation. The amount of
any Restricted Payment, if other than in cash, shall be equal to the fair market value of the
property involved, as determined in the good faith reasonable judgment of the Company.

     SECTION 4.17 LIMITATION ON LAYERED INDEBTEDNESS.

     The Company shall not, and shall not permit any Subsidiary Guarantor to, directly or
indirectly, Incur any Indebtedness (including Acquired Indebtedness) that is subordinated or junior
in right of payment to any Indebtedness of the Company or such Subsidiary Guarantor, as the case
may be, unless such Indebtedness is expressly subordinated in right of payment to the Notes or such
Subsidiary Guarantor’s Subsidiary Guarantee to the extent and in the same manner as such
Indebtedness is subordinated to other Indebtedness of the Company or such Subsidiary Guarantor, as
the case may be.

     Unsecured Indebtedness shall not be treated as subordinated or junior to Secured Indebtedness
merely because it is unsecured.

     SECTION 4.18 TRANSACTIONS WITH AFFILIATES.

     (a) The Company will not, and will not permit any of its Restricted Subsidiaries to,
make any payment to, or sell, lease, transfer or otherwise dispose of any of its assets or
properties to, or purchase any assets or properties from, or enter into or make or amend, any
transaction, contract, agreement, understanding, loan, advance or guarantee with, or for the
benefit of any Affiliate of the Company (each of the foregoing, an “Affiliate Transaction”),
unless:

     (i) such Affiliate Transaction is on terms that are not materially less favorable to
the Company or its relevant Restricted Subsidiary than those that would have been obtained
in a comparable transaction by the Company or such Restricted Subsidiary with an unrelated
Person on an arm’s-length basis;

     (ii) the Company delivers to the Trustee, with respect to any Affiliate Transaction or
series of related Affiliate Transactions involving aggregate payments or consideration in
excess of $25.0 million, a resolution adopted by the majority of the Board of Directors
approving such Affiliate Transaction and stating that such Affiliate Transaction complies
with clause (i) above; and

     (iii) the Company delivers to the Trustee, with respect to any Affiliate Transaction or
series of related Affiliate Transactions involving aggregate payments or consideration in
excess of $75.0 million, a written opinion from an Independent Financial Advisor that such
Affiliate Transaction is on terms that are fair to the Company and its Restricted
Subsidiaries from a financial point of view.

     (b) The foregoing provisions of clause (a) shall not apply to the following:

     (i) transactions between or among the Company or any of its Restricted Subsidiaries or
one or more Special Purpose RE Entities;

-82-

 

     (ii) Restricted Payments permitted by Section 4.16 and clauses (h) and (l) of the
definition of “Permitted Investment”;

     (iii) (1) the entering into, maintaining or performance of any employment contract,
collective bargaining agreement, benefit plan, program or arrangement, related trust
agreement or any other similar arrangement for or with any former, current or future
employee, officer or director heretofore or hereafter entered into in the ordinary course of
business, including vacation, health, insurance, deferred compensation, severance,
retirement, savings or other similar plans, programs or arrangements, (2) the payment of
compensation, performance of indemnification or contribution obligations, or any issuance,
grant or award of stock, options, other equity-related interests or other securities, to
former, current or future employees, officers, directors or consultants in the ordinary
course of business, (3) the payment of reasonable fees to directors of the Company or any of
its Subsidiaries (as determined in good faith by the Company or such Subsidiary), (4) any
transaction with an officer or director in the ordinary course of business not involving
more than $100,000 in any one case or series of related cases, or (5) management advances to
employees, officers, directors or consultants with respect to travel, entertainment or
moving related expenses incurred in the ordinary course of business or in connection with
closing or consolidating facilities and payments in respect thereof;

     (iv) any agreement as in effect as of the Closing Date, or any amendment thereto (so
long as any such amendment is not disadvantageous to the
Holders in any material respect when taken as a whole as compared to the applicable
agreement as in effect on the Closing Date);

     (v) transactions with customers, clients, suppliers, or purchasers or sellers of goods
or services, in each case in the ordinary course of business and otherwise in compliance
with the terms of this Indenture, which are fair to the Company and its Restricted
Subsidiaries, in the reasonable determination of the Board of Directors or the senior
management thereof, or are on terms at least as favorable as might reasonably have been
obtained at such time from an unaffiliated party; and

     (vi) any issuance or sale of Equity Interests (other than Disqualified Stock) of the
Company or capital contribution to the Company.

     SECTION 4.19 DIVIDEND AND OTHER PAYMENT RESTRICTIONS AFFECTING RESTRICTED SUBSIDIARIES.

     (a) The Company will not, and will not permit any of its Restricted Subsidiaries to,
directly or indirectly, create or otherwise cause or suffer to exist or become effective any
consensual encumbrance or consensual restriction on the ability of any Restricted Subsidiary to:

     (i) (A) pay dividends or make any other distributions to the Company or any of its
Restricted Subsidiaries on its Capital Stock or with respect to any other interest or
participation in, or measured by, its profits, or

     (B) pay any Indebtedness owed to the Company or any of its Restricted
Subsidiaries;

-83-

 

     (ii) make loans or advances to the Company or any of its Restricted Subsidiaries; or

     (iii) sell, lease or transfer any of its assets or properties to the Company or any of
its Restricted Subsidiaries.

     (b) The foregoing limitations of clause (a) shall not apply to such encumbrances or
restrictions existing under or by reason of:

     (i) contractual encumbrances or restrictions in effect on the Closing Date;

     (ii) the Credit Facility, this Indenture, the Notes, the Collateral Documents and the
other Transaction Documents;

     (iii) Indebtedness Incurred under the Consolidated Fixed Charge Coverage Ratio test set
forth in Section 4.13(a) so long as the restrictions are no more onerous in any material
respect than the restrictions of the same type contained in this Indenture;

     (iv) applicable law or any applicable rule, regulation or order;

     (v) any agreement or other instrument of a Person acquired by the Company or any
Restricted Subsidiaries in existence at the time of such acquisition (but not created in
contemplation thereof), which encumbrance or restriction is not applicable to any Person, or
assets or properties of any Person, other than the Person and its Subsidiaries, or the
assets or properties of the Person and its Subsidiaries, so acquired;

     (vi) contracts for the sale of assets or properties, including customary restrictions
with respect to a Subsidiary of the Company pursuant to an agreement that has been entered
into for the sale or disposition of all or substantially all of the Capital Stock or assets
and properties of such Subsidiary;

     (vii) (a) Secured Indebtedness or Capitalized Lease Obligations otherwise permitted to
be Incurred pursuant to Section 4.13 and Section 4.14 that limit the right of the debtor to
dispose of the assets or properties securing such Indebtedness or (b) Indebtedness in
connection with an RE Receivables Sale to or in favor of any Special Purpose RE Entity;

     (viii) restrictions on cash or other deposits or net worth imposed by customers under
contracts entered into in the ordinary course of business;

     (ix) customary provisions in joint venture agreements and other similar agreements
relating solely to such joint venture;

     (x) customary provisions contained in leases or licenses of intellectual property and
other agreements, in each case, entered into in the ordinary course of business; and

     (xi) any encumbrances or restrictions of the type referred to in clauses (a)(i),
(a)(ii) and (a)(iii) above imposed by any amendments, modifications, restatements, renewals,
increases, supplements, refundings, replacements or refinancings of the contracts,
instruments or obligations referred to in clauses (a)(i) through (a)(x) above; provided that such amend-

-84-

 

ments, modifications, restatements, renewals, increases, supplements, refundings,
replacements or refinancings are, in the good faith judgment of the Company, no more
restrictive with respect to such encumbrance and other restrictions taken as a whole than
those prior to such amendment, modification, restatement, renewal, increase, supplement,
refunding, replacement or refinancing.

     SECTION 4.20 DESIGNATION OF RESTRICTED AND UNRESTRICTED SUBSIDIARIES.

     The Board of Directors may designate any Restricted Subsidiary (including any newly-formed or
newly-acquired Subsidiary), other than a Restricted Subsidiary that owns any Collateral, to be an
Unrestricted Subsidiary if that designation would not cause a Default. If a Restricted Subsidiary
is designated as an Unrestricted Subsidiary, the aggregate fair market value (as determined in the
good faith reasonable judgment of the Company) of all outstanding Investments owned by the Company
or any of its Restricted Subsidiaries in the Subsidiary properly designated will be deemed an
Investment made in an Unrestricted Subsidiary as of the time of the designation and will reduce the
amount available for Restricted Payments under Section 4.16 or under the definition of “Permitted
Investments,” as determined by the Company. That designation will only be permitted at that time
if such Investment is then permissible under Section 4.16 and the Restricted Subsidiary otherwise
meets the definition of an “Unrestricted Subsidiary.” The Board of Directors may redesignate any
Unrestricted Subsidiary to be a Restricted Subsidiary if such redesignation would not cause a
Default.

     Any designation of a Subsidiary as an Unrestricted Subsidiary will be evidenced to the Trustee
by filing with the Trustee a certified copy of a resolution of the Board of Directors after giving
effect to such designation and an Officer’s Certificate certifying that such designation complied
with the preceding conditions and was permitted by Section 4.16.

     SECTION 4.21 INSURANCE.

     Until the Notes have been paid in full, the Company shall, and shall cause its Restricted
Subsidiaries to, maintain insurance with respect to the Collateral with carriers against such
risks, in such amounts and with such deductibles as the Company determines to be reasonably prudent
(as determined by the Board of Directors in good faith) and consistent with the past practices of
the Company, and name the Collateral Agent as additional insured or, with respect to casualty
insurance, loss payee, as the case may be, with losses in excess of $1.0 million payable jointly to
the Company and the Collateral Agent (unless a Default has occurred and is then continuing, in
which case all losses are payable solely to the Collateral Agent), with no recourse against the
Trustee or the Collateral Agent for the payment of premiums, deductibles, commissions or club
calls.

     SECTION 4.22 PAYMENTS FOR CONSENT.

     The Company shall not, and shall not permit any of its Restricted Subsidiaries to, directly or
indirectly, pay or cause to be paid any consideration to or for the benefit of any Holder for or as
an inducement to any consent, waiver or amendment of any of the terms or provisions of this
Indenture or the Notes unless such consideration is offered to be paid and is paid to all Holders
of the Notes that consent, waive or agree to amend in the time frame set forth in the solicitation
documents relating to such consent, waiver or agreement.

-85-

 

     SECTION 4.23 SUSPENSION OF COVENANTS.

     (a) During any period of time after the Closing Date that (i) the corporate family
rating of the Company is an Investment Grade Rating of either Moody’s or S&P and (ii) no Default
has occurred and is continuing (the occurrence of the events described in the foregoing clauses (i)
and (ii) being collectively referred to as a “Covenant Suspension Event”), the Company and its
Restricted Subsidiaries shall not be subject to the following covenants (the “Suspended
Covenants”): Sections 4.08 (except for Section 4.08(c)), 4.10, 4.11, 4.12, 4.13, 4.15, 4.16, 4.17,
4.18, 4.19 and 4.21.

     Additionally, at such time as the above referenced covenants are suspended (a “Suspension
Period”), we will no longer be required to pledge the Collateral with respect to the Notes and the
Trustee shall promptly terminate such Lien.

     (b) In the event that the Company and its Restricted Subsidiaries are not subject to
the Suspended Covenants for any period of time as a result of the foregoing, and on any subsequent
date (the “Reversion Date”) the corporate family rating of the Company is below an Investment Grade
Rating by both S&P or Moody’s, then the Company and its Restricted Subsidiaries will thereafter
again be subject to the Suspended Covenants with respect to future events and will be required to
reinstate the first priority Lien with respect to the Collateral or Replacement Collateral, in each
case to the extent permissible by the terms of all other Indebtedness of the Company and its
Restricted Subsidiaries. In connection therewith, the Collateral Agent shall be entitled to
receive (i) such Collateral Documents, title insurance, surveys, environmental reports, legal
opinions and other documents and instruments as the Collateral Agent may request and (ii) a legal
opinion to the effect that the granting of a Lien on the Collateral or replacement Collateral is
permitted by the terms of all
other Indebtedness of the Company and its Restricted Subsidiaries, in each case pursuant to
procedures set forth in this Indenture (and each such item described in (i) and (ii) in this
Section 4.23(b) shall be at the Company’s expense).

     (c)
On each Reversion Date, all Indebtedness Incurred during the Suspension Period prior to such
Reversion Date will be deemed to be Indebtedness in existence on the Closing Date, except that
Indebtedness under the Credit Facility shall be deemed Incurred under Section 4.13(b)(i) to the extent
permitted thereby, subject to the ability of the Company to reclassify amounts Incurred under such
Section 4.13(b)(i) to Section 4.13(b)(x) as permitted by the terms thereof. For purposes of calculating the
amount available to be made as Restricted Payments under clause (3) of Section 4.16(a), calculations under such
Section 4.16 shall be made as though Section 4.16 had been in effect during the entire period of time after the
Closing Date (including the Suspension Period). Restricted Payments made during the Suspension Period not otherwise
permitted pursuant to any of clauses (ii) through (xi) of Section 4.16(b) will reduce the amount available to be made
as Restricted Payments under clause (3) of Section 4.16(a); provided that the amount available to be made as Restricted
Payments on the Reversion Date shall not be reduced to below zero solely as a result of such Restricted Payments.
In addition, events during the Suspension Period that, if not for the Covenant Suspension Event, would have increased the
amount available to be made as Restricted Payments will increase the amount available to be made as Restricted
Payments under clause (3) of Section 4.16(a).

-86-

 

ARTICLE V

CONSOLIDATION, MERGER, CONVEYANCE, TRANSFER OR LEASE

     SECTION 5.01 MERGER, CONSOLIDATION OR SALE OF ALL OR SUBSTANTIALLY ALL ASSETS.

     The Company shall not, directly or indirectly, consolidate or merge with or into or wind up
into, or sell, assign, transfer, lease, convey or otherwise dispose of all or substantially all of
the Company’s assets and properties (determined on a consolidated basis), in one or more related
transactions, to any Person unless:

     (a) the Company is the surviving corporation or the Person formed by or
surviving any such consolidation or merger (if other than the Company) or to which such
sale, assignment, transfer, lease, conveyance or other disposition will have been made is a
corporation, partnership (including a limited partnership), trust or limited liability
company organized or existing under the laws of the jurisdiction of organization of the
Company or the laws of the United States, any state thereof, the District of Columbia or any
territory thereof (such Person, as the case may be, being herein called the “Successor
Company”); provided that in the case where the Successor Company is not a corporation, a
co-obligor of the Notes is a corporation;

     (b) the Successor Company, if other than the Company, expressly assumes all
the obligations of the Company under the Notes, this Indenture, the Collateral Documents and
the Registration Rights Agreement, pursuant to supplemental indentures or other documents or
instruments in form reasonably satisfactory to the Trustee;

     (c) immediately after such transaction after giving pro forma effect thereto,
no Default exists;

     (d) immediately after giving pro forma effect to such transaction and any
related financing transactions, as if such transactions had occurred at the beginning of the
applicable four-quarter period, the Company or the Successor Company, as applicable, would
be permitted to Incur at least $1.00 of additional Indebtedness pursuant to (i) the
Consolidated Fixed Charge Coverage Ratio test set forth in Section 4.13(a) or (ii) the
Consolidated Fixed Charge Coverage Ratio of the Company or the Successor Company, as
applicable, would not be less than the Consolidated Fixed Charge Coverage Ratio of the
Company immediately prior to giving effect to such transaction;

     (e) each Subsidiary Guarantor, unless it is the other party to the
transactions described above, in which case subclause (a)(ii) of Section 5.02 shall apply,
shall have by supplemental indenture or other documents or instruments in form reasonably
satisfactory to the Trustee confirmed that its Subsidiary Guarantee shall apply to such
Person’s obligations under this Indenture, the Notes, the Collateral Documents and the
Registration Rights Agreement; or

     (f) the Company (or, if applicable, the Successor Company) shall have
delivered to the Trustee an Officer’s Certificate and an Opinion of Counsel, each stating
that such consolidation, merger or transfer and such supplemental indentures or other
documents or instruments, if any, comply with this Indenture.

-87-

 

     SECTION 5.02 MERGER, CONSOLIDATION OR SALE OF ALL OR SUBSTANTIALLY ALL ASSETS OF SUBSIDIARY
GUARANTORS.

     Subject to certain limitations described in this Indenture governing release of a Subsidiary
Guarantee upon the sale, disposition or transfer of a Subsidiary Guarantor, no Subsidiary Guarantor
shall, and the Company shall not permit any Subsidiary Guarantor to, consolidate or merge with or
into or wind up into, or sell, assign, transfer, lease, convey or otherwise dispose of all or
substantially all of its assets and properties (determined on a consolidated basis), in one or more
related transactions, to any Person unless:

     (a) (i) such Subsidiary Guarantor is the surviving corporation or the Person
formed by or surviving any such consolidation or merger (if other than such Subsidiary
Guarantor) or to which such sale, assignment, transfer, lease, conveyance or other
disposition will have been made is a corporation, partnership, trust or limited liability
company organized or existing under the laws of the jurisdiction of organization of such
Subsidiary Guarantor, as the case may be, or the laws of the United States, any state
thereof, the District of Columbia or any territory thereof (such Subsidiary Guarantor or
such Person, as the case may be, being herein called the “Successor Guarantor”);

     (ii) the Successor Guarantor, if other than such Subsidiary Guarantor,
expressly assumes all the obligations of such Subsidiary Guarantor under this
Indenture, such Subsidiary Guarantor’s related Subsidiary Guarantee, if applicable,
the Collateral Documents and the Registration Rights Agreement pursuant to
supplemental indentures or other documents or instruments in form reasonably
satisfactory to the Trustee;

     (iii) immediately after such transaction after giving pro forma effect thereto,
no Default exists;

     (iv) the Company shall have delivered to the Trustee an Officer’s Certificate
and an Opinion of Counsel, each stating that such consolidation, merger or transfer
and such supplemental indentures and other documents or instruments, if any, comply
with this Indenture; and

     (v) if applicable, the Collateral transferred to the Successor Guarantor will
(i) continue to constitute Collateral under this Indenture and the Collateral
Documents, (ii) be subject to a first priority Lien in favor of the Collateral Agent
for the benefit of the Holders, and (iii) not be subject to any Lien, other than
Liens permitted by the terms of this Indenture; and

     (vi) to the extent that the assets and properties of the Person which is merged
or consolidated with or into the Successor Guarantor are assets and properties of
the type which would constitute Collateral under the Collateral Documents, the
Successor Guarantor will take such action as may be reasonably necessary to cause
such assets and properties to be made subject to a first priority Lien under the
Collateral Documents in the manner and to the extent required in this Indenture; or

     (b) the transaction is made in compliance with Section 4.10 or in the case of a
transaction involving a Collateral Grantor, Section 4.11.

-88-

 

     Subject to certain limitations described in this Indenture, the Successor Guarantor will
succeed to, and be substituted for, such Subsidiary Guarantor under this Indenture and such
Subsidiary Guarantor’s Subsidiary Guarantee. Notwithstanding the foregoing, any Subsidiary
Guarantor, other than a Collateral Grantor, may (i) merge into or transfer all or part of its
assets and properties to another Subsidiary Guarantor or the Company, (ii) merge with an Affiliate
of the Company solely for the purpose of reincorporating the Subsidiary Guarantor in the United
States, any state thereof, the District of Columbia or any territory thereof or (iii) convert into
a corporation, partnership, limited partnership, limited liability company or trust organized under
the laws of the jurisdiction of organization of such Subsidiary Guarantor, in each case without
regard to the requirements set forth in the preceding paragraph. The Collateral Grantor may
transfer the Excluded Assets to a Restricted Subsidiary.

ARTICLE VI

DEFAULTS AND REMEDIES

     SECTION 6.01 EVENTS OF DEFAULT.

     “Event of Default” wherever used herein with respect to the Notes means any one of the
following events (whatever the reason for such Event of Default and whether it shall be voluntary
or involuntary or be effected by operation of law, pursuant to any judgment, decree or order of any
court or any order, rule or regulation of any administrative or governmental body):

     (a) default in the payment of any interest upon the Notes when it becomes due
and payable, and continuance of such default for a period of 30 calendar days;

     (b) default in the payment of principal of or premium, if any, on the Notes
when due (including upon redemption or repurchase); or

     (c) failure by the Company or any Subsidiary Guarantor for 60 calendar days
after receipt of written notice given as provided below by the Trustee or the Holders of not
less than 25% in principal amount of the Outstanding Notes to comply with any of its
obligations, covenants or agreements (other than a default referred to in clauses (a) and
(b) above) contained in this Indenture, the Notes or the Collateral Documents; or

     (d) the acceleration of the maturity of, or the failure to pay at the
maturity of, any Indebtedness of the Company or any Restricted Subsidiary, at any one time,
in an amount in excess of the greater of (i) $25.0 million and (ii) 2.5% of Consolidated Net
Tangible Assets, if, as applicable, such acceleration is not annulled within 30 calendar
days after written notice given as provided below by the Trustee or the Holders of not less
than 25% in principal amount of the Outstanding Notes; or

     (e) entry of final judgments against the Company or any Restricted Subsidiary
which remain undischarged for a period of 60 calendar days, provided that the aggregate of
all such judgments exceeds $100 million and judgments exceeding $100 million remain
undischarged for 60 calendar days after written notice given as provided below by the
Trustee or the Holders of not less than 25% in principal amount of the Outstanding Notes; or

     (f) the entry of a decree or order for relief in respect of the Company or
any Significant Subsidiary by a court having jurisdiction in the premises in an involuntary
case under the federal Bankruptcy Laws, as now or hereafter constituted, or any other
applicable federal

-89-

 

or state bankruptcy, insolvency or other similar law, or a decree or
order adjudging the Company or any Significant Subsidiary a bankrupt or insolvent, or approving as properly
filed a petition seeking reorganization, arrangement, adjustment or composition of or in
respect of the Company or any Significant Subsidiary under any applicable federal or state
law, or appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or
other similar official) of the Company or any Significant Subsidiary or of any substantial
part of its property, or ordering the winding up or liquidation of its affairs, and the
continuance of any such decree or order unstayed and in effect for a period of 90
consecutive calendar days; or

     (g) the commencement by the Company or any Significant Subsidiary of a
voluntary case under the federal Bankruptcy Laws, as now or hereafter constituted, or any
other applicable federal or state bankruptcy, insolvency or other similar law, or the
consent by it to the entry of an order for relief in an involuntary case under any such law
or to the appointment of a receiver, liquidator, assignee, custodian, trustee, sequestrator
(or other similar official) of the Company or any Significant Subsidiary or of any
substantial part of its property, or the making by it of an assignment for the benefit of
its creditors, or the admission by it in writing of its inability to pay its debts generally
as they become due, or the taking of corporate action by the Company or any Significant
Subsidiary in furtherance of any such action; or

     (h) the Subsidiary Guarantee of any Significant Subsidiary shall for any
reason cease to be in full force and effect or be declared null and void, in each case for a
period of 15 calendar days after such Significant Subsidiary or the Company receives notice
of such cessation or declaration or any Officer of any Subsidiary Guarantor that is a
Significant Subsidiary, as the case may be, denies that it has any further liability under
its Subsidiary Guarantee or gives notice to such effect, other than by reason of the
termination of this Indenture or the release of any such Subsidiary Guarantee in accordance
with the terms hereof; or

     (i) any of the Collateral Documents ceases to be in full force and effect, or
any of the Collateral Documents ceases to give the Holders the first priority Liens
purported to be created thereby, or any of Collateral Documents is declared null and void,
in each case for a period of 15 calendar days after any Restricted Subsidiary or the Company
first receives notice of such cessation or the Company or any Restricted Subsidiary denies
in writing that it has any further liability under any Collateral Document or gives written
notice to such effect (in each case, other than in accordance with the terms of the terms
hereof or the terms of the Collateral Documents); or

     (j) any revocation, suspension or loss of any Gaming License which results in
the cessation of business for a period of more than 120 consecutive calendar days of the
business of any Gaming Facility or Gaming Facilities owned directly or indirectly in its
entirety by the Company and/or any of its Restricted Subsidiaries which, taken together,
collectively account for 10% or more of the Company’s Consolidated Net Tangible Assets or
10% or more of the Company’s and its Restricted Subsidiaries’ consolidated gross revenues
(other than any voluntary relinquishment of a Gaming License if such relinquishment is, in
the reasonable, good faith judgment of the Board of Directors, evidenced by a certified copy
of a Board Resolution delivered to the Trustee, both desirable in the conduct of the
business of the Company and its Restricted Subsidiaries, taken as a whole, and not
disadvantageous in any material respect to the Holders).

-90-

 

     A Default under clause (c), (d) or (e) of this Section 6.01 is not an Event of Default until
the Trustee or the Holders of at least 25% in aggregate principal amount of the Outstanding Notes
notify the Company in writing by registered or certified mail, return receipt requested, of the
Default and the
Company does not cure such Default within the time specified in clauses (c), (d) or (e) of
this Section 6.01, as applicable, after receipt of such notice. Such notice must specify the
Default, demand that it be remedied and state that such notice is a “Notice of Default”.

     SECTION 6.02 ACCELERATION OF MATURITY; RESCISSION AND ANNULMENT.

     If an Event of Default (other than an Event of Default described in clause (f) or (g) of
Section 6.01) occurs and is continuing, then in every such case the Trustee or the Holders of not
less than 25% in principal amount of the Outstanding Notes may declare the principal, premium, if
any, interest and other monetary obligations on the amount of all the Outstanding Notes to be due
and payable immediately, by a notice in writing to the Company (and to the Trustee if given by such
Holders), and upon any such declaration such principal amount of the Notes (or specified amount)
plus accrued and unpaid interest thereon (and premium, if payable) shall become immediately due and
payable; provided that the Trustee shall have no obligation to accelerate the Notes if in its best
judgment acceleration is not in the best interest of the Holders.

     At any time after such a declaration of acceleration with respect to the Notes has been made
and before a judgment or decree for payment of the money due has been obtained by the Trustee as
hereinafter in this Article provided, the Holders of at least a majority in principal amount of the
Outstanding Notes, by written notice to the Company and the Trustee, may rescind and annul such
declaration and its consequences if:

     (a) the Company has paid or deposited with the Trustee a sum sufficient to
pay:

     (i) all overdue installments of interest on the Notes;

     (ii) the principal of (and premium, if any, on) the Notes which has become due
otherwise than by such declaration of acceleration and interest thereon at the rate or rates
prescribed therefor in the Notes;

     (iii) to the extent that payment of such interest is lawful, interest upon overdue
installments of interest on the Notes at the rate or rates prescribed by the terms thereof;

     (iv) all sums paid or advanced by the Trustee hereunder and the reasonable
compensation, expenses, disbursements and advances of the Trustee, its agents and counsel;
and

     (b) all Events of Default with respect to the Notes, other than the
nonpayment of the principal of the Notes which has become due solely by such declaration of
acceleration, have been cured or waived as provided in Section 6.13. No such rescission and
waiver shall affect any subsequent default or impair any right consequent thereon.

     If an Event of Default described in clause (f) or (g) of Section 6.01 occurs with respect to
the Company or any Significant Subsidiary, the principal of, premium, if any, and accrued interest
on all the Notes shall be due and payable immediately without any further action or notice. In
addition to acceleration of maturity of the Notes, if an Event of Default occurs and is continuing,
the Collateral

-91-

 

Agent shall have the right to exercise remedies with respect to the Collateral, such
as foreclosure, as are available under this Indenture, the Collateral Documents and at law.

     SECTION 6.03 COLLECTION OF INDEBTEDNESS AND SUITS FOR ENFORCEMENT BY TRUSTEE.

     The Company covenants that, if:

     (a) default is made in the payment of any installment of interest on the
Notes when such interest or payment becomes due and payable and such default continues for a
period of 30 calendar days, or

     (b) default is made in the payment of principal of (or premium, if any, on)
the Notes at the Maturity thereof, then the Company will, upon demand of the Trustee, pay to
it, for the benefit of the Holders, the amount then due and payable on the Notes for the
principal (and premium, if any) and interest, if any, and, in addition thereto, such further
amount as shall be sufficient to cover the costs and expenses of collection, including the
reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and
counsel.

     If the Company fails to pay such amount forthwith upon such demand, the Trustee, in its own
name and as trustee of an express trust, may institute a judicial proceeding for the collection of
the sums so due and unpaid, and may prosecute such proceeding to judgment or final decree, and may
enforce the same against the Company or any other obligor upon the Notes and collect the moneys
adjudged or decreed to be payable in the manner provided by law out of the property of the Company
or any other obligor upon the Notes wherever situated.

     If an Event of Default with respect to the Notes occurs and is continuing, then the Trustee
may, in its discretion, proceed to protect and enforce its rights and the rights of the Holders by
such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and
enforce any such rights, whether for the specific enforcement of any covenant or agreement in this
Indenture or in aid of the exercise of any power granted herein, or to enforce any other proper
remedy.

     The Trustee shall be under no duty to the Company or any Subsidiary Guarantor to make or give
any presentment, demand for performance, notice of nonperformance, protest, notice of protest,
notice of dishonor, or other notice or demand, or to take any steps necessary to preserve any
rights against prior parties except as expressly provided in this Indenture.

     SECTION 6.04 TRUSTEE MAY FILE PROOFS OF CLAIM.

     In case of the pendency of any receivership, insolvency, liquidation, bankruptcy,
reorganization, arrangement, adjustment, composition or other judicial proceedings, or any
voluntary or involuntary case under the federal Bankruptcy Laws, as now or hereafter constituted,
relative to the Company or any Subsidiary Guarantor, or the property of the Company or of any
Subsidiary Guarantor or their creditors, the Trustee (irrespective of whether the principal of the
Notes shall then be due and payable as therein expressed or by declaration of acceleration or
otherwise and irrespective of whether the Trustee shall have made any demand on the Company or any
Subsidiary Guarantor for the payment of overdue principal or interest) shall be entitled and
empowered, by intervention in such proceeding or otherwise,

-92-

 

     (a) to file and prove a claim for the whole amount of principal (and premium,
if any) and interest owing and unpaid in respect of the Notes and to file such other papers
or documents as may be necessary or advisable in order to have the claims of the Trustee
(including any claim for the reasonable compensation, expenses, disbursements and advances of
the Trustee, its agents and counsel) and of the Holders allowed in such judicial proceeding,
and

     (b) to collect and receive any moneys or other property payable or
deliverable on any such claims and to distribute the same; and any receiver, assignee,
trustee, custodian, liquidator, sequestrator (or other similar official) in any such
proceeding is hereby authorized by each such Holder to make such payments to the Trustee,
and in the event that the Trustee shall consent to the making of such payments directly to
such Holders, to pay to the Trustee any amount due it for the reasonable compensation,
expenses, disbursements and advances of the Trustee, its agents and counsel, and any other
amounts due the Trustee under Section 7.07.

     Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to
or accept or adopt on behalf of any Holder any plan of reorganization, arrangement, adjustment or
composition affecting the Notes or the rights of any Holder thereof, or to authorize the Trustee to
vote in respect of the claim of any Holder in any such proceeding.

     SECTION 6.05 TRUSTEE MAY ENFORCE CLAIMS WITHOUT POSSESSION OF DEBT SECURITIES.

     All rights of action and claims under this Indenture, the Notes, the Subsidiary Guarantees or
the other Transaction Documents may be prosecuted and enforced by the Trustee without the
possession of any of the Notes or the Subsidiary Guarantees or the production thereof in any
proceeding relating thereto, and any such proceeding instituted by the Trustee shall be brought in
its own name, as trustee of an express trust, and any recovery of judgment shall, after provision
for the payment of the reasonable compensation, expenses, disbursements and advances of the
Trustee, its agents and counsel, be for the ratable benefit of the Holders in respect of which such
judgment has been recovered.

     SECTION 6.06 APPLICATION OF MONEY COLLECTED.

     Subject to the terms of the Collateral Documents, any money collected by the Trustee in
respect of the Notes pursuant to this Article or the other Transaction Documents shall be applied
in the following order, at the date or dates fixed by the Trustee and, in case of the distribution
of such money on account of principal (and premium, if any) or interest, upon presentation of the
Notes and the notation thereon of the payment if only partially paid and upon surrender thereof if
fully paid:

     FIRST: To the payment of all amounts due the Trustee under Section 7.07;

     SECOND: To the payment of the amounts then due and unpaid for principal of (and
premium, if any) and interest on the Notes ratably, without preference or priority of any
kind, according to the amounts due and payable on the Notes for principal (and premium, if
any) and interest, respectively;

     THIRD: Without duplication, to the Holders for any other obligations owing to such
Holders under the Notes, this Indenture or the other Transaction Documents; and

     FOURTH: The balance, if any, to the Person or Persons entitled thereto.

-93-

 

     SECTION 6.07 LIMITATION ON SUITS.

     Other than as set forth in this Section 6.07, except to enforce the right to receive payment
of principal, premium (if any) or interest when due, no Holder may pursue any remedy with respect
to this Indenture, the Notes or the other Transaction Documents unless:

     (a) such Holder has previously given the Trustee notice that an Event of
Default is continuing;

     (b) Holders of at least 25% in aggregate principal amount of the Outstanding
Notes have requested the Trustee to pursue the remedy;

     (c) Holders have offered the Trustee reasonable security or indemnity against
any loss, liability or expense satisfactory to the Trustee;

     (d) the Trustee has not complied with such request within 60 calendar days
after the receipt thereof and the offer of security or indemnity; and

     (e) Holders of a majority in aggregate principal amount of the Outstanding
Notes have not given the Trustee a direction inconsistent with such request within such
60-day period; it being understood and intended that no one or more of such Holders shall
have any right in any manner whatever by virtue of, or by availing of, any provision of this
Indenture, the Subsidiary Guarantees or the other Transaction Documents to affect, disturb
or prejudice the rights of any other such Holders, or to obtain or to seek to obtain
priority or preference over any other of such Holders or to enforce any right under this
Indenture, the Subsidiary Guarantees or the other Transaction Documents, except in the
manner herein provided and for the equal and ratable benefit of all of such Holders. For
the protection and enforcement of the provisions of this Section 6.07, each and every Holder
and the Trustee shall be entitled to such relief as can be given at law or in equity.

     The foregoing notwithstanding, in no event shall an individual Holder have the right to pursue
any remedy with respect to the Subsidiary Guarantee of MGM Grand Hotel or the Obligations or
Guaranteed Obligations of any Collateral Grantor pledging Collateral consisting of any Gaming
Facility or Gaming Facilities, without the agreement of Holders of at least 25% in aggregate
principal amount of Outstanding Notes.

     SECTION 6.08 UNCONDITIONAL RIGHT OF HOLDERS TO RECEIVE PRINCIPAL, PREMIUM AND INTEREST.

     Notwithstanding any other provision in this Indenture, except for restrictions imposed by
Gaming Laws or Gaming Authorities on payments by entities holding Gaming Licenses, the Holder of
any Note shall have the right, which is absolute and unconditional, to receive payment of the
principal of (and premium, if any) and interest on such Note on the respective Stated Maturity or
Stated Maturities expressed in such Note (or, in the case of redemption or purchase, on the
Redemption Date or Purchase Date, respectively) and to institute suit for the enforcement of any
such payment and interest thereon, and such right shall not be impaired without the consent of such
Holder except that no Holder shall have the right to institute any such suit, if and to the extent
that the institution or prosecution thereof or the entry of judgment therein would under applicable
law result in the surrender, impairment,

-94-

 

waiver, or loss of Liens upon any property subject to such
Lien in favor of the Beneficiaries of the Notes.

     SECTION 6.09 RESTORATION OF RIGHTS AND REMEDIES.

     If the Trustee or any Holder has instituted any proceeding to enforce any right or remedy
under any Transaction Document and such proceeding has been discontinued or abandoned for any
reason, or has been determined adversely to the Trustee or to such Holder, then and in every such
case the Company, the Trustee and the Holders shall, subject to any determination in such
proceeding, be restored severally and respectively to their former positions hereunder, and
thereafter all rights and remedies of the Trustee and the Holders shall continue as though no such
proceeding had been instituted.

     SECTION 6.10 RIGHTS AND REMEDIES CUMULATIVE.

     Except as otherwise expressly provided elsewhere in the Transaction Documents, no right or
remedy herein conferred upon or reserved to the Trustee or to the Holders is intended to be
exclusive of any other right or remedy, and every right and remedy shall, to the extent permitted
by law (including Gaming Laws), be cumulative and in addition to every other right and remedy given
hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or
employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent
assertion or employment of any other appropriate right or remedy.

     SECTION 6.11 DELAY OR OMISSION NOT WAIVER.

     No delay or omission of the Trustee or of any Holder to exercise any right or remedy accruing
upon any Event of Default shall impair any such right or remedy or constitute a waiver of any such
Event of Default or any acquiescence therein. Every right and remedy given by the Transaction
Documents or by law to the Trustee or to the Holders may be exercised from time to time, and as
often as may be deemed expedient, by the Trustee or by the Holders, as the case may be.

     SECTION 6.12 CONTROL BY HOLDERS.

     The Holders of at least a majority in principal amount of the Outstanding Notes shall have the
right to direct the time, method and place of conducting any proceeding for any remedy available to
the Trustee or the Collateral Agent or exercising any trust or power conferred on the Trustee with
respect to the Transaction Documents, provided that:

     (a) such direction shall not be in conflict with any rule of law (including
Gaming Laws) or with any of the Transaction Documents;

     (b) subject to the provisions of Section 7.01, the Trustee shall have the
right to decline to follow any such direction if the Trustee in good faith shall, by a Trust
Officer or Trust Officers of the Trustee, determine that such direction conflicts with law
or the Transaction Documents or that the Trustee determines is unduly prejudicial to the
rights of any other Holder of a Note or that would involve the Trustee in personal
liability; and

     (c) the Trustee may take any other action deemed proper by the Trustee which
is not inconsistent with such direction.

-95-

 

     SECTION 6.13 WAIVER OF EXISTING DEFAULTS.

     The Holders of not less than a majority in aggregate principal amount of the Outstanding
Notes, by notice to the Trustee, may, on behalf of the Holders of all the Notes, waive any existing
Default and its consequences hereunder or under the Collateral Documents and rescind any
acceleration with respect to the Notes (provided such rescission would not conflict with any
judgment of a court of competent jurisdiction), except a continuing Default in the payment of the
principal of (or premium, if any) or interest on any Note held by a non-consenting Holder.

     Upon any such waiver, such Default shall cease to exist, and any Event of Default arising
therefrom shall be deemed to have been cured for every purpose of the Notes under this Indenture,
but no such waiver shall extend to any subsequent or other default or impair any right consequent
thereon.

     In the event of any Event of Default specified in Section 6.01(d) above, such Event of Default
and all consequences thereof (excluding any resulting payment default, other than as a result of
acceleration of the Notes) shall be annulled, waived and rescinded, automatically and without any
action by the Trustee or the Holders, if within 20 calendar days after such Event of Default arose:

     (a) the Indebtedness or guarantee that is the basis for such Event of Default
has been discharged;

     (b) holders thereof have rescinded or waived the acceleration, notice or
action (as the case may be) giving rise to such Event of Default; or

     (c) the Default that is the basis for such Event of Default has been cured.

     SECTION 6.14 UNDERTAKING FOR COSTS.

     All parties to this Indenture agree, and each Holder of any Note by his acceptance thereof
shall be deemed to have agreed, that any court may in its discretion require, in any suit for the
enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any
action taken, suffered or omitted by it as Trustee, the filing by any party litigant in such suit
other than the Trustee of an undertaking to pay the costs of such suit, and that such court may in
its discretion assess reasonable costs, including reasonable attorneys’ fees and expenses, against
any party litigant in such suit, having due regard to the merits and good faith of the claims or
defenses made by such party litigant, but the provisions of this Section 6.14 shall not apply to
any suit instituted by the Trustee, to any suit instituted by any Holder or group of Holders
holding in the aggregate more than 10% in principal amount of the Outstanding Notes, or to any suit
instituted by any Holder of a Note for the enforcement of the payment of the principal of (or
premium, if any) or interest on such Note on or after the respective Stated Maturity or Stated
Maturities expressed in such Note (or, in the case of redemption or purchase, on or after the
Redemption Date or the Purchase Date, respectively).

     SECTION 6.15 WAIVER OF STAY OR EXTENSION LAWS.

     The Company and each Subsidiary Guarantor covenants (to the extent that it may lawfully do so)
that it will not at any time insist upon, or plead, or in any manner whatsoever claim or take the
benefit or advantage of, any stay or extension law wherever enacted, now or at any time hereafter
in force, which may affect the covenants or the performance of the Transaction Documents; and the
Company and each Subsidiary Guarantor (to the extent that it may lawfully do so) hereby expressly

-96-

 

waives all benefit or advantage of any such law, and covenants that it will not hinder, delay or
impede
the execution of any power herein granted to the Trustee, but will suffer and permit the
execution of every such power as though no such law had been enacted.

     SECTION 6.16 DISQUALIFIED HOLDERS.

     To the extent required by applicable Gaming Laws, Notes held by a Disqualified Holder shall,
so long as held by such Person, be disregarded for purposes of providing notices, directions,
waivers or other actions and determining the sufficiency of such notices, directions, waivers or
actions under this Article VI.

ARTICLE VII

TRUSTEE

     SECTION 7.01 CERTAIN DUTIES AND RESPONSIBILITIES.

     (a) Except during the continuance of an Event of Default,

     (1) the Trustee undertakes to perform such duties and only such duties as are
specifically set forth in this Indenture and the other Transaction Documents, and no implied
covenants or obligations shall be read into this Indenture or the other Transaction
Documents against the Trustee; and

     (2) the Trustee may conclusively rely, as to the truth of the statements and the
correctness of the opinions expressed therein, upon certificates or opinions furnished to
the Trustee and conforming to the requirements of this Indenture and the other Transaction
Documents; but in the case of any such certificates or opinions which by any provisions
hereof are specifically required to be furnished to the Trustee, the Trustee shall be under
a duty to examine the same to determine whether or not they conform to the requirements of
this Indenture.

     (b) In case an Event of Default has occurred and is continuing, the Trustee shall,
with respect to the Notes, exercise such of the rights and powers vested in it by this Indenture
and the other Transaction Documents, and use the same degree of care and skill in their exercise,
as a prudent person would exercise or use under the circumstances in the conduct of such person’s
own affairs.

     (c) No provision of this Indenture shall be construed to relieve the Trustee from
liability for its own negligent action, its own negligent failure to act, or its own willful
misconduct, except that

     (1) this subsection shall not be construed to limit the effect of subsection (a) of
this Section 7.01;

     (2) the Trustee shall not be liable for any error of judgment made in good faith by a
Trust Officer, unless it shall be proved that the Trustee was negligent in ascertaining the
pertinent facts;

     (3) the Trustee shall not be liable with respect to any action taken, suffered or
omitted to be taken by it in good faith with respect to Notes in accordance with the
direction of the Holders of at least a majority in principal amount of the Outstanding Notes
relating to

-97-

 

the time, method and place of conducting any proceeding for any remedy available
to the Trustee, or exercising any trust or power conferred upon the Trustee, under this
Indenture or the other Transaction Documents;

     (4) the Trustee shall not be required to expend or risk its own funds or otherwise
incur any financial liability in the performance of any of its duties hereunder, or in the
exercise of any of its rights or powers, if it shall have reasonable grounds for believing
that repayment of such funds or adequate indemnity against such risk or liability is not
reasonably assured to it; and

     (5) the Trustee shall cooperate and comply with any order or directive of a Gaming
Authority in connection with this Indenture or the other Transaction Documents, including
that the Trustee submit an application for any license, finding of suitability or other
approval pursuant to any Gaming Laws (unless the Trustee shall have submitted its
resignation) and will cooperate fully and completely in any proceeding related to such
application; provided the Company agrees to prepare (or cause the Subsidiary Guarantors to
prepare) all documentation in connection with any such order, directive, application and
proceeding and to reimburse the Trustee for all costs and expenses incurred by it in
connection therewith.

     (d) Whether or not therein expressly so provided, every provision of this Indenture
relating to the conduct or affecting the liability of or affording protection to the Trustee shall
be subject to the provisions of this Section 7.01.

     SECTION 7.02 NOTICE OF DEFAULTS.

     Within 90 calendar days after the occurrence of any Default hereunder, the Trustee shall give
notice to all Holders of such Default hereunder known to the Trustee, unless such Default shall
have been cured or waived. The Trustee may withhold from the Holders notice of any continuing
Default, except a Default relating to the payment of principal, premium, if any, or interest, if it
determines that withholding notice is in their interest.

     Notice given pursuant to this Section 7.02 shall be transmitted by mail:

     (a) to all registered Holders, as the names and addresses of the registered
Holders appear in the Note Register; and

     (b) to each Holder whose name and address appear in the information preserved
at the time by the Trustee in accordance with Section 7.02(a) of this Indenture.

     SECTION 7.03 CERTAIN RIGHTS OF TRUSTEE.

     Except as otherwise provided in Section 7.01:

     (a) the Trustee may conclusively rely, and shall be protected in acting or
refraining from acting, upon any resolution, certificate, statement, instrument, opinion,
report, notice, request, direction, consent, order, bond, debenture, note, other evidence of
indebtedness or other paper or document believed by it to be genuine and to have been signed
or presented by the proper party or parties;

-98-

 

     (b) any request or direction of the Company mentioned herein shall be
sufficiently evidenced by a Company Request or Company Order and any resolution of the Board
of Directors shall be sufficiently evidenced by a Board Resolution;

     (c) whenever in the administration of this Indenture the Trustee shall deem
it desirable that a matter be proved or established prior to taking, suffering or omitting
any action hereunder, the Trustee (unless other evidence be herein specifically prescribed)
may, in the absence of bad faith on its part, rely upon an Officer’s Certificate;

     (d) the Trustee may consult with counsel of its selection and the advice of
such counsel or any Opinion of Counsel shall be full and complete authorization and
protection in respect of any action taken, suffered or omitted by it hereunder in good faith
and in reliance thereon;

     (e) the Trustee shall be under no obligation to exercise any of the rights or
powers vested in it by this Indenture or the other Transaction Documents at the request or
direction of any of the Holders pursuant to this Indenture, unless such Holders shall have
offered to the Trustee security or indemnity satisfactory to it against the costs, expenses
and liabilities which might be incurred by it in compliance with such request or direction;

     (f) the Trustee shall not be bound to make any investigation into the facts
or matters stated in any resolution, certificate, statement, instrument, opinion, report,
notice, request, direction, consent, order, bond, debenture, note, other evidence of
indebtedness or other paper or document (including, without limitation, any investigation or
inquiry with respect to the accuracy of any calculations contained therein), but the
Trustee, in its discretion, may make such further inquiry or investigation into such facts
or matters as it may see fit, and, if the Trustee shall determine to make such further
inquiry or investigation, it shall be entitled to examine the books, records and premises of
the Company, personally or by agent or attorney;

     (g) the Trustee may execute any of the trusts or powers hereunder or perform
any duties hereunder either directly or by or through agents or attorneys and the Trustee
shall not be responsible for any misconduct or negligence on the part of any agent or
attorney appointed with due care by it hereunder;

     (h) except with respect to Section 4.01, the Trustee shall have no duty to
inquire as to the performance of the Company’s covenants in Article IV hereof. In addition,
the Trustee shall not be deemed to have knowledge of any Default in respect of the Notes
except (i) any Default occurring pursuant to Section 6.01(a), (b) or (c) or (ii) any Default
of which a Responsible Officer of the Trustee shall have received written notification or
obtained actual knowledge;

     (i) the Trustee shall not be liable for any action taken, suffered or omitted
to be taken by it in good faith and reasonably believed by it to be authorized or within the
discretion or rights or powers conferred upon it by this Indenture and the other Transaction
Documents;

     (j) the Trustee may request that the Company deliver an Officer’s Certificate
setting forth the names of individuals and/or titles of officers authorized at such time to
take specified actions pursuant to this Indenture, which Officer’s Certificate may be signed
by any

-99-

 

person authorized to sign an Officer’s Certificate, including any person specified as
so authorized in any such certificate previously delivered and not superseded;

     (k) whether or not therein expressly so provided, every provision of this
Indenture relating to the conduct or affecting the liability of or affording protection to
the Trustee for the Notes shall be subject to the provisions of Section 7.01(a);

     (l) the Trustee shall not be liable for interest on any money received by it
except as the Trustee may agree in writing with the Company;

     (m) the Trustee may deem any request or direction received from any Gaming
Authority to be a request or direction of the Company that satisfies the conditions set
forth in Section 7.03(b) above;

     (n) the Trustee shall not be responsible or liable for special, indirect, or
consequential loss or damage of any kind whatsoever (including, but not limited to, loss or
profit) irrespective of whether the Trustee has been advised of the likelihood of such loss
or damage and regardless of the form of action;

     (o) the Trustee shall not be required to give any note, bond or surety in
respect of the execution of the trusts and powers under this Indenture; and

     (p) the Trustee shall not be responsible or liable for any failure or delay
in the performance of its obligations under this Indenture arising out of or caused,
directly or indirectly, by circumstances beyond its reasonable control, including without
limitation, acts of God; earthquakes; fire; flood; terrorism; wars and other military
disturbances; sabotage; epidemics; riots; interruptions; loss or malfunction of utilities,
computer (hardware or software) or communication services; accidents; labor disputes; acts
of civil or military authorities and governmental action.

     The rights, privileges, protections, immunities and benefits given to the Trustee by the terms
of this Indenture, including, without limitation, its rights to be reimbursed or indemnified, are
extended to, and shall be enforceable by, the Trustee in its capacity as Trustee and Collateral
Agent under each of the Indenture and Collateral Documents, and each agent, custodian and other
Person employed to act hereunder.

     SECTION 7.04 NOT RESPONSIBLE FOR RECITALS OR ISSUANCE OF NOTES.

     The recitals contained herein and in the Notes, except the Trustee’s certificates of
authentication, shall be taken as the statements of the Company, and the Trustee assumes no
responsibility for their correctness. The Trustee makes no representations as to the validity or
sufficiency of this Indenture, the Subsidiary Guarantees or the Notes. The Trustee shall not be
accountable for the use or application by the Company of any Notes or the proceeds thereof.

     SECTION 7.05 MAY HOLD NOTES.

     The Trustee, any Paying Agent, the Registrar or any other agent of the Company, in its
individual or any other capacity, may become the owner or pledgee of Notes and, subject to Sections
7.08

-100-

 

and 7.13, may otherwise deal with the Company with the same rights it would have if it were
not Trustee, Paying Agent, Registrar or such other agent.

     SECTION 7.06 MONEY HELD IN TRUST.

     Money in any currency held by the Trustee or any Paying Agent in trust hereunder need not be
segregated from other funds except to the extent required by law. Neither the Trustee nor any
Paying Agent shall be under any liability for interest on any money received by it hereunder except
as otherwise agreed in writing with the Company.

     SECTION 7.07 COMPENSATION AND REIMBURSEMENT.

     The Company agrees:

     (a) to pay to the Trustee from time to time such compensation as shall be
agreed in writing between the Company and the Trustee in Dollars for all services rendered
by it hereunder (which compensation shall not be limited by any provision of law in regard
to the compensation of a trustee of an express trust);

     (b) except as otherwise expressly provided herein, to reimburse the Trustee
in Dollars upon its request for all reasonable expenses, disbursements and advances incurred
or made by the Trustee in accordance with any provision of this Indenture or the other
Transaction Documents (including costs incurred in connection with applications to any
Gaming Authority and including the reasonable compensation and the reasonable expenses and
disbursements of its agents and counsel), except any such expense, disbursement or advance
as may be attributable to its negligence or willful misconduct; and

     (c) to indemnify in Dollars the Trustee for, and to hold it harmless against,
any loss, liability or expense incurred without negligence or willful misconduct on its
part, arising out of or in connection with the acceptance or administration of this trust or
performance of its duties hereunder, including the costs and expenses of defending itself
against any claim (whether asserted by the Company, a Holder or any other Person) or
liability in connection with the exercise or performance of any of its powers or duties
hereunder. The indemnity described in this Section 7.07(c) shall survive the termination of
this Indenture and the resignation or removal of the Trustee (in any of its capacities
herein) with respect to such loss, liability or expense incurred in connection with the
Trustee’s acts or omissions prior to such termination of this Indenture or the resignation
or removal of the Trustee.

     In this Section 7.07, all references to the Trustee shall be deemed to include the Trustee and
its officers, directors, employees and agents.

     The obligations of the Company under this Section 7.07 to compensate and indemnify the Trustee
for reasonable expenses, disbursements and advances shall constitute additional Indebtedness under
this Indenture and shall survive the satisfaction and discharge of this Indenture and any rejection
or termination of this Indenture under any Bankruptcy Law. When the Trustee incurs expenses or
renders services after an Event of Default specified in Section 6.01(f) or (g) occurs, the expenses
and the compensation for the services of the Trustee are intended to constitute expenses of
administration under any Bankruptcy Law.

-101-

 

     SECTION 7.08 DISQUALIFICATION; CONFLICTING INTERESTS.

     The Trustee shall comply with the relevant provisions of the TIA with respect to conflicts of
interest and disqualification. If such provisions require the Trustee to resign with respect to
the Notes, the Company shall take prompt steps to have a successor appointed, in the manner and
with the effect hereinafter specified in this Article.

     SECTION 7.09 CORPORATE TRUSTEE REQUIRED; ELIGIBILITY.

     There shall at all times be a Trustee hereunder which shall be a corporation organized and
doing business under the laws of the United States of America, any State thereof or the District of
Columbia, authorized under such laws to exercise corporate trust powers, having a combined capital
and surplus of at least $100,000,000, subject to supervision or examination by Federal, State or
District of Columbia authority. If such corporation publishes reports of condition at least
annually, pursuant to law or to the requirements of the aforesaid supervising or examining
authority, then for the purposes of this Section 7.09, the combined capital and surplus of such
corporation shall be deemed to be its combined capital and surplus as set forth in its most recent
report of condition so published. Neither the Company nor any Affiliate of the Company shall serve
as Trustee upon any Notes.

     SECTION 7.10 RESIGNATION AND REMOVAL; APPOINTMENT OF SUCCESSOR.

     Subject to compliance with applicable Gaming Laws of which the Trustee has received prior
written notice:

     (a) No resignation or removal of the Trustee and no appointment of a
successor Trustee pursuant to this Article shall become effective until the acceptance of
appointment by the successor Trustee under Section 7.11.

     (b) The Trustee may resign at any time with respect to the Notes by giving
written notice thereof to the Company. If an instrument of acceptance by a successor
Trustee shall not have been delivered to the Trustee within 30 calendar days after the
giving of such notice of resignation, the resigning Trustee may petition any court of
competent jurisdiction for the appointment of a successor Trustee with respect to the Notes.

     (c) The Trustee may be removed at any time with respect to the Notes and a
successor Trustee appointed by Act of the Holders of at least a majority in principal amount
of the Outstanding Notes, delivered to the Trustee and to the Company. If an instrument of
acceptance by a successor Trustee shall not have been delivered to the Trustee within 30
calendar days after the giving of such notice of removal, the Trustee being removed may
petition any court of competent jurisdiction for the appointment of a successor Trustee with
respect to the Notes.

     (d) If at any time:

     (i) the Trustee shall fail to comply with Section 7.08 with respect to the
Notes after written request therefor by the Company or by any Holder who has been a
bona fide Holder for at least six months; or

-102-

 

     (ii) the Trustee shall cease to be eligible under Section 7.09 with respect to
the Notes and shall fail to resign after written request therefor by the Company or
by any such Holder; or

     (iii) the Trustee shall become incapable of acting or shall be adjudged a
bankrupt or insolvent or a receiver of the Trustee or of its property shall be
appointed or any public officer shall take charge or control of the Trustee or of
its property or affairs for the purpose of rehabilitation, conservation or
liquidation,

then, in any such case, (A) the Company, by a Board Resolution, may remove the Trustee with
respect to the Notes, or (B) subject to Section 6.14, any Holder who has been a bona fide
Holder of such a Note for at least six months may, on behalf of himself and all others
similarly situated, petition any court of competent jurisdiction for the removal of the
Trustee and the appointment of a successor Trustee for the Notes.

     (e) If the Trustee shall resign, be removed or become incapable of acting, or
if a vacancy shall occur in the office of Trustee for any cause, with respect to the Notes,
the Company, by a Board Resolution, shall promptly appoint a successor Trustee or Trustees
with respect to the Notes and shall comply with the applicable requirements of Section 7.11.
If, within one year after such resignation, removal or incapability, or the occurrence of
such vacancy, a successor Trustee with respect to the Notes shall be appointed by Act of the
Holders of at least a majority in principal amount of the Outstanding Notes delivered to the
Company and the retiring Trustee, the successor Trustee so appointed shall, forthwith upon
its acceptance of such appointment, become the successor Trustee with respect to the Notes
and, to that extent, supersede the successor Trustee appointed by the Company. If no
successor Trustee with respect to the Notes shall have been so appointed by the Company or
the Holders of the Notes and accepted appointment in the manner hereinafter provided, any
Holder who has been a bona fide Holder of such a Note for at least six months may, subject
to Section 6.07, on behalf of himself and all others similarly situated, petition any court
of competent jurisdiction for the appointment of a successor Trustee with respect to the
Notes.

     (f) The Company shall give notice of each resignation and each removal of the
Trustee with respect to the Notes and each appointment of a successor Trustee with respect
to the Notes in the manner and to the extent provided in Section 12.02 to the Holders. Each
notice shall include the name of the successor Trustee with respect to the Notes and the
address of its Corporate Trust Office.

     SECTION 7.11 ACCEPTANCE OF APPOINTMENT BY SUCCESSOR.

     Subject to compliance with applicable Gaming Laws:

     (a) In the case of an appointment hereunder of a successor Trustee with
respect to the Notes, each such successor Trustee so appointed shall execute, acknowledge
and deliver to the Company and to the retiring Trustee an instrument accepting such
appointment, and thereupon the resignation or removal of the retiring Trustee shall become
effective and such successor Trustee, without any further act, deed or conveyance, shall
become vested with all the rights, powers, trusts and duties of the retiring Trustee, but,
on request of the Company or the successor Trustee, such retiring Trustee shall, upon
payment of its charges, execute and deliver an instrument transferring to such successor
Trustee all the rights, powers and trusts of the

-103-

 

retiring Trustee, and shall duly assign,
transfer and deliver to such successor Trustee all
property and money held by such retiring Trustee hereunder, subject nevertheless to its
lien and claim, if any, provided for in Section 7.07.

     (b) Upon request of any such successor Trustee, the Company shall execute any
and all instruments for more fully and certainly vesting in and confirming to such successor
Trustee all such rights, powers and trusts referred to in paragraph (a) of this Section
7.11, as the case may be.

     (c) No successor Trustee shall accept its appointment unless at the time of
such acceptance such successor Trustee shall be qualified and eligible under this Article.

     SECTION 7.12 MERGER, CONVERSION, CONSOLIDATION OR SUCCESSION TO BUSINESS.

     Any corporation into which the Trustee may be merged or converted or with which it may be
consolidated, or any corporation resulting from any merger, conversion or consolidation to which
the Trustee shall be a party, or any corporation succeeding to all or substantially all of the
corporate trust business of the Trustee, shall be the successor of the Trustee hereunder, provided
that such corporation shall be otherwise qualified and eligible under this Article, without the
execution or filing of any paper or any further act on the part of any of the parties hereto. In
case any Notes shall have been authenticated, but not delivered, by the Trustee then in office, any
successor by merger, conversion or consolidation to such authenticating Trustee may adopt such
authentication and deliver the Notes so authenticated with the same effect as if such successor
Trustee had itself authenticated such Notes. In case any Notes shall not have been authenticated
by such predecessor Trustee, any such successor Trustee may authenticate and deliver such Notes, in
either its own name or that of its predecessor Trustee, with the full force and effect which this
Indenture provides for the certificate of authentication of the Trustee.

     SECTION 7.13 PREFERENTIAL COLLECTION OF CLAIMS AGAINST COMPANY.

     If and when the Trustee shall be or become a creditor of the Company (or other obligor under
the Notes), the Trustee shall be subject to the provisions of TIA § 311(a) regarding the collection
of claims against the Company or any Subsidiary Guarantor (or any such other obligor), excluding
any creditor relationship listed in TIA § 311(b). A Trustee who has resigned or been removed shall
be subject to TIA § 311(a) to the extent indicated therein.

     SECTION 7.14 APPOINTMENT OF AUTHENTICATING AGENT.

     As long as any Notes remain Outstanding Notes, upon a Company Request, there shall be an
authenticating agent (the “Authenticating Agent”) appointed, for such period as the Company shall
elect, by the Trustee to act as its agent on its behalf and subject to its direction in connection
with the authentication and delivery of the Notes. Notes authenticated by such Authenticating
Agent shall be entitled to the benefits of this Indenture and shall be valid and obligatory for all
purposes as if authenticated by such Trustee. Wherever reference is made in this Indenture to the
authentication and delivery of Notes by the Trustee or to the Trustee’s certificate of
authentication, such reference shall be deemed to include authentication and delivery on behalf of
the Trustee by an Authenticating Agent and a certificate of authentication executed on behalf of
such Trustee by such Authenticating Agent, except that only the Trustee may authenticate Notes upon
original issuance and pursuant to Section

-104-

 

2.07 hereof. Such Authenticating Agent shall at all
times be a corporation organized and doing business under the laws of the United States of America
or of any state, authorized under such laws to
exercise corporate trust powers, having a combined capital and surplus of at least $100,000,000
and subject to supervision or examination by federal or state authority. If such Authenticating
Agent publishes reports of condition at least annually, pursuant to law or to the requirements of
said supervising or examining authority, then for purposes of this Section 7.14, the combined
capital and surplus of such Authenticating Agent shall be deemed to be its combined capital and
surplus as set forth in its most recent report of condition so published. If at any time an
Authenticating Agent shall cease to be eligible in accordance with the provisions of this Section
7.14, such Authenticating Agent shall resign immediately in the manner and with the effect
specified in this Section 7.14.

     Any corporation into which any Authenticating Agent may be merged or converted, or with which
it may be consolidated, or any corporation resulting from any merger, conversion or consolidation
to which any Authenticating Agent shall be a party, or any corporation succeeding to all or
substantially all of the corporate agency or corporate trust business of any Authenticating Agent,
shall continue to be the Authenticating Agent with respect to the Notes for which it served as
Authenticating Agent without the execution or filing of any paper or any further act on the part of
the Trustee or such Authenticating Agent. Any Authenticating Agent may at any time, and if it
shall cease to be eligible shall, resign by giving written notice of resignation to the applicable
Trustee and to the Company.

     Upon receiving such a notice of resignation or upon such a termination, or in case at any time
any Authenticating Agent shall cease to be eligible in accordance with the provisions of this
Section 7.14 with respect to the Notes, the Trustee shall, upon Company Request, appoint a
successor Authenticating Agent, and the Company shall provide notice of such appointment to all
Holders of Notes in the manner and to the extent provided in Section 12.02. Any successor
Authenticating Agent, upon acceptance of its appointment hereunder, shall become vested with all
rights, powers, duties and responsibilities of its predecessor hereunder, with like effect as if
originally named as Authenticating Agent herein. The Company agrees to pay to the Authenticating
Agent from time to time reasonable compensation for its services. The Authenticating Agent for the
Notes shall have no responsibility or liability for any action taken by it as such at the direction
of the Trustee, except arising out of its negligence or willful misconduct.

     If an appointment is made pursuant to this Section 7.14, the Notes may have endorsed thereon,
in addition to the Trustee’s certificate of authentication, an alternative certificate of
authentication in the following form:

     This is one of the Notes designated therein referred to in the within mentioned Indenture.

	 	 	 	 	 
	 	U.S. Bank National Association, As Trustee

 	 
	 	By:  	 	 
	 	 	As Authenticating Agent 	 
	 	 	 
	 	By:  	
 	 
	 	 	Authorized Signatory 	 
	 	 	 	 

-105-

 

	 	 	 	 	 

     SECTION 7.15 PAYING AGENT; REGISTRAR.

     (a) Each Paying Agent or Registrar (other than the Company) shall be a corporation
organized and doing business under the laws of the United States of America or of any State and
having a combined capital and surplus of at least $100,000,000.

     (b) Each Paying Agent or Registrar may resign at any time by giving written notice
thereof to the Company. The Company, by a Board Resolution and upon giving written notice thereof
to the Paying Agent or Registrar, may remove such Paying Agent or Registrar at any time.

     (c) If any Paying Agent or Registrar shall resign, be removed or become incapable of
acting, or if a vacancy shall occur in the office of any Paying Agent or Registrar for any cause,
the Company, by a Board Resolution, shall promptly appoint a successor Paying Agent or Registrar.

     (d) The Company shall give notice of each resignation and each removal of any Paying
Agent or Registrar and each appointment of a successor Paying Agent or Registrar by mailing written
notice of such event by first-class mail, postage prepaid, to the Trustee. Each notice shall
include the name and address of the successor Paying Agent or Registrar.

     (e) The Trustee is hereby initially appointed Paying Agent and Registrar.

     (f) The Company shall enter into an appropriate written agency agreement with any
Paying Agent or Registrar not a party to this Indenture, which agreement shall implement the
provisions of this Indenture that relate to such Paying Agent or Registrar, including the
provisions of Section 7.01(c)(5). The Company shall notify the Trustee in writing of the name and
address of any such Paying Agent or Registrar.

     SECTION 7.16 REPORTS BY TRUSTEE.

     (a) Within 60 calendar days after May 15 of each year commencing with the first May
15 after the original issuance of the Notes, the Trustee shall transmit by mail to all Holders, in
the manner and to the extent provided in TIA § 313(c), a brief report dated as of such May 15 in
accordance with and with respect to the matters required by TIA § 313(a). The Trustee shall also
transmit by mail to all Holders of Notes, in the manner and to the extent provided in TIA § 313(c),
a brief report in accordance with and with respect to the matters required by TIA § 313(b)(2).

     (b) A copy of each report transmitted to Holders pursuant to this Section 7.16
shall, at the time of such transmission, be mailed to the Company and filed with each stock
exchange, if any, upon which the Notes are listed and also with the Commission. The Company will
notify the Trustee promptly if the Notes are listed on any stock exchange or of any delisting
thereof.

     (c) The Trustee will provide any applicable Gaming Authority upon its or the
Company’s request with (in the case of any Gaming Authority, to the address set forth in such
request or as otherwise directed in such request, and in the case of the Company, as provided in
Section 12.01 of this Indenture):

     (1) copies of all notices, reports and other written communications which the Trustee
gives to Holders;

-106-

 

     (2) a list of Holders promptly after the original issuance of the Notes, eight months
and two months prior to the expiration date of each then-current Gaming License held by the
Company or its Subsidiaries, and upon demand;

     (3) notice of any Event of Default under this Indenture or of any Default, any
acceleration of the indebtedness evidenced or secured hereby, the institution of any legal
actions or proceedings before any court or governmental authority in respect of this
Indenture and any rescission, annulment or waiver in respect of an Event of Default;

     (4) (4) notice of the removal or resignation of the Trustee within five Business Days
thereof;

     (5) notice of any transfer or assignment of rights under this Indenture (but no
transfers or assignments of the Notes) within five Business Days
thereof; and

     (6) a copy of any amendment to the Notes or this Indenture within five Business Days of
the effectiveness thereof. The notice specified in clause (3) above shall be in writing
and, except as set forth below, shall be given within five Business Days after the Trustee
has transmitted the notice required by Section 7.02. In the case of any notice in respect
of any Event of Default, such Notice shall be accompanied by a copy of any notice from the
Holders, or a representative thereof or the Trustee, to the Company and, if accompanied by
any such notice to the Company, shall be given simultaneously with the giving of any such
notice to the Company. In the case of any legal actions or proceedings, such notice shall
be accompanied by a copy of the complaint or other initial pleading or document.

     The Trustee shall in accordance with the limitations set forth herein cooperate with any
applicable Gaming Authority in order to provide such Gaming Authority with information and
documentation relevant to compliance with clause (3) above and as otherwise required by any
applicable Gaming Laws of which the Trustee has written notice.

     The Company will advise the Trustee in writing of the expiration date of any then-current
Gaming License held by the Company or its Subsidiaries at least nine months prior to the expiration
thereof and the Trustee until so advised may assume that such Gaming License has not expired.

     (d) Reports pursuant to this Section 7.16 shall be transmitted by mail:

     (1) to all Holders, as the names and addresses of such Holders appear in the Note
Register; and

     (2) except in the cases of reports pursuant to subsection (b) of this Section 7.16, to
each Holder of a Note whose name and address appear in the information preserved at the time
by the Trustee in accordance with Section 2.05.

     A copy of each such report shall, at the time of such transmission to Holders, be filed by the
Trustee with each stock exchange upon which the Notes are listed, with the Commission and also with
the Company. The Company will notify the Trustee promptly when any of the Notes are listed on any
stock exchange or of any delisting thereof.

-107-

 

ARTICLE VIII

DISCHARGE OF INDENTURE; DEFEASANCE

     SECTION 8.01 SATISFACTION AND DISCHARGE OF INDENTURE.

     This Indenture shall, upon Company Request, cease to be of further effect (except as to any
surviving rights of registration of transfer or exchange of the Notes herein expressly provided for
and rights to receive payments of principal (and premium, if any) and interest on the Notes) and
the Trustee, at the expense of the Company, shall execute proper instruments acknowledging
satisfaction and discharge of this Indenture, when:

     (a) either:

     (1) all Notes theretofore authenticated and delivered, except lost, stolen or
destroyed Notes which have been replaced or paid and Notes for whose payment money
has theretofore been deposited in trust, have been delivered to the Trustee for
cancellation; or

     (2) all Notes not theretofore delivered to the Trustee for cancellation have
become due and payable by reason of the making of a notice of redemption or
otherwise, will become due and payable within one year or are to be called for
redemption within one year under arrangements satisfactory to the Trustee for the
giving of notice of redemption by the Trustee in the name, and at the expense, of
the Company and the Company or any Subsidiary Guarantor has irrevocably deposited or
caused to be deposited with the Trustee as trust funds in trust solely for the
benefit of the Holders, cash in Dollars, Government Securities, or a combination
thereof, in such amounts as will be sufficient without consideration of any
reinvestment of interest to pay and discharge the entire Indebtedness on the Notes
not theretofore delivered to the Trustee for cancellation for principal, premium, if
any, and accrued interest to the date of maturity or redemption;

     (b) no Default (other than that resulting from borrowing funds to be applied
to make such deposit or any similar or simultaneous deposit relating to other Indebtedness)
with respect to this Indenture or the Notes shall have occurred and be continuing on the
date of such deposit or shall occur as a result of such deposit and such deposit will not
result in a breach or violation of, or constitute a default under any material agreement or
instrument (other than this Indenture) to which the Company or any Subsidiary Guarantor is a
party or by which the Company or any Subsidiary Guarantor is bound (other than resulting
from any borrowing of funds to be applied to make such deposit and any similar deposit
relating to other Indebtedness and the granting of liens in connection therewith);

     (c) the Company has paid or caused to be paid all sums payable by it under
this Indenture;

     (d) the Company has delivered irrevocable instructions to the Trustee to
apply the deposited money toward the payment of the Notes at maturity or the Redemption
Date, as the case may be; and

-108-

 

     (e) the Company has delivered an Officer’s Certificate and an Opinion of
Counsel to the Trustee stating that all conditions precedent to satisfaction and discharge
have been satisfied.

     SECTION 8.02 APPLICATION OF TRUST MONEY.

     Subject to the provisions of the last paragraph of Section 4.05, all money deposited with the
Trustee pursuant to Section 8.01 shall be held in trust and applied by it, in accordance with the
provisions of the Notes, and this Indenture, to the payment, either directly or through any Paying
Agent (including the Company acting as its own Paying Agent) as the Trustee may determine, to the
Persons entitled thereto, of the principal (and premium, if any) and interest for whose payment
such money has been deposited with the Trustee.

     SECTION 8.03 APPLICABILITY OF ARTICLE.

     Except as otherwise provided in Section 8.04, the Company may terminate its obligations under
the Notes and this Indenture as set forth in Section 8.04.

     SECTION 8.04 LEGAL DEFEASANCE AND COVENANT DEFEASANCE.

     (a) The Company may, at the option of its Board of Directors evidenced by a
resolution set forth in an Officer’s Certificate, at any time, elect to have either Section 8.04(b)
or 8.04(c) be applied to all Outstanding Notes upon compliance with the conditions set forth below
in this Article VIII.

     (b) Upon the Company’s exercise under Section 8.04(a) of the option applicable to
this Section 8.04(b), the Company and each Subsidiary Guarantor shall, subject to the satisfaction
of the conditions set forth in Section 8.05, be deemed to have been discharged from their
obligations with respect to the Notes, the Collateral Documents and any Subsidiary Guarantee on the
date the conditions set forth below are satisfied (hereinafter, “Legal Defeasance”). For this
purpose, Legal Defeasance means that the Company and each Subsidiary Guarantor shall be deemed to
have paid and discharged the entire Indebtedness represented by the Outstanding Notes and any
Subsidiary Guarantee, which Notes and Guarantee shall thereafter be deemed to be Outstanding Notes
only for the purposes of Section 8.04 and the other Sections of this Indenture referred to in (i)
and (ii) below, and to have satisfied all their other obligations under the Notes and this
Indenture (and the Trustee, on demand of and at the expense of the Company, shall execute proper
instruments acknowledging the same), except for the following provisions which shall survive until
otherwise terminated or discharged hereunder: (i) the rights of Holders to receive payments in
respect of the principal of, premium, if any, and interest on the Notes when such payments are due
solely out of the trust described in this Article VIII, (ii) the Company’s obligations with respect
to the Notes concerning issuing temporary Notes, registration of such Notes, mutilated, destroyed,
lost or stolen Notes and the maintenance of an office or agency for payment and money for security
payments held in trust, (iii) the rights, powers, trusts, duties and immunities of the Trustee, and
the Company’s obligations in connection therewith and (iv) Section 8.04 and Section 8.05. Subject
to compliance with this Article VIII, the Company may exercise its Legal Defeasance option
notwithstanding the prior exercise of its Covenant Defeasance option.

     (c) Upon the Company’s exercise under Section 8.04(a) of the option applicable to
this Section 8.04(c) subject to the satisfaction of the conditions set forth in Section 8.05, the
Company and each Subsidiary Guarantor shall be released from their Obligations under Sections 4.02,
4.03, 4.07,

-109-

 

and 4.08 through 4.23 and Article V with respect to the Outstanding Notes and the
Subsidiary Guarantees on and after the date the conditions set forth below are satisfied (hereinafter,
“Covenant Defeasance”), and the Notes shall thereafter be deemed not Outstanding Notes for the
purposes of any direction, waiver, consent or declaration or act of Holders (and the consequences
of any thereof) in connection with such Sections, but shall continue to be deemed Outstanding Notes
for all the other purposes hereunder. For this purpose, Covenant Defeasance means that, with
respect of any term, condition or limitation set forth in any such Section, whether directly or
indirectly, by reason of any reference elsewhere herein to any such Section or by reason of any
reference in any such Section to any other provision herein or in any other document and such
omission to comply shall not constitute a Default, but, except as specified above, the remainder of
this Indenture and the Notes shall be unaffected thereby. In addition, upon the Company’s exercise
of its Covenant Defeasance option, subject to the satisfaction of the conditions set forth in
Section 8.05, clauses (c) (with respect to Sections 4.02, 4.03, 4.07, and 4.08 through 4.23 and
Article V), (d), (e), (h), (i) and (j) of Section 6.01 shall not constitute Events of Default with
respect to the Notes and the Subsidiary Guarantees.

     SECTION 8.05 CONDITIONS TO LEGAL OR COVENANT DEFEASANCE.

     In order to exercise either Legal Defeasance or Covenant Defeasance:

     (a) the Company must irrevocably deposit with the Trustee, in trust, for the
benefit of the Holders, cash in Dollars, Government Securities, or a combination thereof, in
such amounts as will be sufficient, in the opinion of a nationally recognized firm of
independent public accountants, to pay the principal of, premium, if any, and interest due
on the Notes at the Stated Maturity or on the Redemption Date, as the case may be, of such
principal, premium, if any, or interest on the Notes and the Company must specify whether
the Notes are being defeased to Stated Maturity or to a particular Redemption Date;

     (b) in the case of Legal Defeasance, the Company shall have delivered to the
Trustee an Opinion of Counsel reasonably acceptable to the Trustee confirming that, subject
to customary assumptions and exclusions, (i) the Company has received from, or there has
been published by, the United States Internal Revenue Service a ruling, or (ii) since the
issuance of the Notes, there has been a change in the applicable U.S. federal income tax
law, in either case to the effect that, and based thereon such Opinion of Counsel shall
confirm that, subject to customary assumptions and exclusions, the Holders will not
recognize income, gain or loss for U.S. federal income tax purposes, as applicable, as a
result of such Legal Defeasance and will be subject to U.S. federal income tax on the same
amounts, in the same manner and at the same times as would have been the case if such Legal
Defeasance had not occurred;

     (c) in the case of Covenant Defeasance, the Company shall have delivered to
the Trustee an Opinion of Counsel in the United States, reasonably acceptable to the Trustee
confirming, subject to customary assumptions and exclusions, that the Holders of the
Outstanding Notes will not recognize income, gain or loss for U.S. federal income tax
purposes as a result of such Covenant Defeasance and will be subject to U.S. federal income
tax on the same amounts, in the same manner and at the same times as would have been the
case if such Covenant Defeasance had not occurred;

     (d) no Default (other than that resulting from borrowing funds to be applied
to make the deposit required to effect such Legal Defeasance or Covenant Defeasance and any
similar and simultaneous deposit relating to other Indebtedness and, in each case, the
granting

-110-

 

of Liens in connection therewith) shall have occurred and be continuing on the date
of such deposit;

     (e) such Legal Defeasance or Covenant Defeasance shall not result in a breach
or violation of, or constitute a default under any material agreement or instrument (other
than this Indenture and the other Transaction Documents) to which the Company or any
Subsidiary Guarantor is a party or by which the Company or any Subsidiary Guarantor is bound
(other than that resulting with respect to any Indebtedness being defeased from any
borrowing of funds to be applied to make the deposit required to effect such Legal
Defeasance or Covenant Defeasance and any similar and simultaneous deposit relating to such
Indebtedness, and the granting of Liens in connection therewith);

     (f) the Company shall have delivered to the Trustee an Opinion of Counsel to
the effect that, as of the date of such opinion and subject to customary assumptions and
exclusions following the deposit, the trust funds will not be subject to the effect of
Section 547 of Title 11 of the United States Code;

     (g) the Company shall have delivered to the Trustee an Officer’s Certificate
stating that the deposit was not made by the Company with the intent of defeating,
hindering, delaying or defrauding any creditors of the Company or any Subsidiary Guarantor
or others; and

     (h) the Company shall have delivered to the Trustee an Officer’s Certificate
and an Opinion of Counsel (which Opinion of Counsel may be subject to customary assumptions
and exclusions) each stating that all conditions precedent provided for or relating to the
Legal Defeasance or the Covenant Defeasance, as the case may be, have been complied with.

     SECTION 8.06 DEPOSITED MONEYS AND GOVERNMENT SECURITIES TO BE HELD IN TRUST.

     All moneys and Government Securities deposited with the Trustee pursuant to Section 8.05 in
respect of the Notes shall be held in trust and applied by it, in accordance with the provisions of
the Notes and this Indenture, to the payment, either directly or through any Paying Agent
(including the Company acting as its own Paying Agent) as the Trustee may determine, to the Holders
of such Notes, of all sums due and to become due thereon for principal (and premium, if any) and
interest, if any, but such money need not be segregated from other funds except to the extent
required by law.

     The Company shall indemnify the Trustee against any tax, fee or other charge imposed on or
assessed against the Government Securities deposited pursuant to Section 8.05 or the principal and
interest received in respect thereof other than any such tax, fee or other charge which by law is
for the account of the Holders of the Outstanding Notes.

     SECTION 8.07 REPAYMENT TO COMPANY.

     The Trustee and any Paying Agent shall promptly pay or return to the Company upon Company
Request any moneys or Government Securities held by them at any time that are not required for the
payment of the principal of (and premium, if any) and interest on the Notes for which money or
Government Securities have been deposited pursuant to Section 8.05.

-111-

 

     The provisions of the last paragraph of Section 4.05 shall apply to any money held by the
Trustee or any Paying Agent under this Article that remains unclaimed for two years after the
Maturity of the Notes for which money or Government Securities have been deposited pursuant to
Section 8.05.

ARTICLE IX

SUPPLEMENTAL INDENTURES

     SECTION 9.01 AMENDMENT, SUPPLEMENT AND WAIVER.

     (a) Except as provided in Sections 9.01(b) and (c), this Indenture, any Subsidiary
Guarantee, the Notes, the Collateral Documents and the Registration Rights Agreement may be amended
or supplemented by the execution of a supplemental indenture or in the case of any amendment or
supplement of the Collateral Documents or the Registration Rights Agreement, by execution of an
appropriate amendment or supplement (each a “supplemental indenture”) with the consent of the
Holders of at least a majority in principal amount of the Outstanding Notes, including consents
obtained in connection with a purchase of, or tender offer or exchange offer for, the Notes, and
any existing Default or compliance with any provision of this Indenture, the Notes, any Collateral
Document or the Registration Rights Agreement may be waived with the consent of the Holders of a
majority in principal amount of the then Outstanding Notes (including consents obtained in
connection with a purchase of or tender offer or exchange offer for the Notes).

     (b) Without the consent of each affected Holder, an amendment or waiver may not,
with respect to any Notes held by a non-consenting Holder:

     (i) reduce the principal amount of such Notes whose Holders must consent to an
amendment, supplement or waiver;

     (ii) reduce the principal of or change the fixed final maturity of any such Note or
alter or waive the provisions with respect to the redemption of such Notes (other than
provisions relating to Sections 4.09, 4.10, 4.11 and 4.12, but not including any provision
described in clause (xiii) below);

     (iii) reduce the rate of or change the time for payment of interest on any Note;

     (iv) waive a Default in the payment of principal of or premium, if any, or interest on
the Notes, except a rescission and annulment of a declaration of acceleration and the waiver
of the effects of such acceleration pursuant to Section 6.02, or in respect of a covenant or
provision contained in this Indenture or any Subsidiary Guarantee which cannot be amended or
modified without the consent of all Holders;

     (v) make any Note payable in money other than Dollars;

     (vi) make any change to Section 6.08 or 6.13;

     (vii) make any change to this Section 9.01;

     (viii) impair the right of any Holder to receive payment of principal of, premium, if
any, or interest on such Holder’s Notes on or after the due dates therefor or to institute suit for

-112-

 

the enforcement of any payment on or with respect to such Holder’s Notes or the
Subsidiary Guarantees;

     (ix) make any change to or modify the ranking of the Notes that would adversely affect
the Holders;

     (x) except as expressly permitted by this Indenture, modify the Subsidiary Guarantee of
any Significant Subsidiary in any manner adverse to the Holders;

     (xi) release the Liens created by the Collateral Documents on all or substantially all
the Collateral (other than in accordance with the terms hereof and the terms of the
Collateral Documents);

     (xii) make any change in the provisions hereof or in any Collateral Document dealing
with the application of proceeds of the Collateral that would adversely affect the Holders;
or

     (xiii) after the time a Change of Control Offer, Non-Collateral Asset Sale Offer,
Collateral Asset Sale Offer or Loss Proceeds Offer is required to have been made, reduce the
purchase amount or price or extend the latest expiration date or Purchase Date thereunder.

     (c) Notwithstanding clauses (a) and (b) above, the Company, any Subsidiary Guarantor
(with respect to a Subsidiary Guarantee or this Indenture to which it is a party, as applicable)
and the Trustee may amend or supplement this Indenture, the Collateral Documents, the Registration
Rights Agreement and any Subsidiary Guarantee or Notes without the consent of any Holder:

     (i) to cure any ambiguity, omission, mistake, defect or inconsistency;

     (ii) to provide for uncertificated Notes in addition to or in place of certificated
Notes;

     (iii) to comply with Article V;

     (iv) to provide for the assumption of the Company’s or any Subsidiary Guarantor’s
obligations to the Holders;

     (v) to make any change that would provide any additional rights or benefits to the
Holders or that does not adversely affect the legal rights under this Indenture or the other
Transaction Documents of any such Holder;

     (vi) to add covenants for the benefit of the Holders or to surrender any right or power
conferred upon the Company or any Subsidiary Guarantor;

     (vii) to evidence and provide for the acceptance and appointment under this Indenture
or the Collateral Documents of a successor Trustee or successor Collateral Agent thereunder
pursuant to the requirements thereof;

     (viii) to add a Subsidiary Guarantor hereunder or to release a Subsidiary Guarantor in
accordance with the terms hereof;

-113-

 

     (ix) to conform the text of this Indenture, Collateral Documents, Subsidiary Guarantees
or the Notes to the “Description of Notes” set forth in the Offering Memorandum of the
Company with respect to the offering of the Notes dated March 9, 2010 to the extent
that such provision in the Description of Notes was intended to be a verbatim, or
substantially verbatim, recitation of a provision of this Indenture, Collateral Documents,
Subsidiary Guarantee or Notes;

     (x) to make any amendment to Section 2.06, including without limitation to facilitate
the issuance and administration of the Notes; provided, however, that (i) compliance with
this Indenture as so amended would not result in the Notes being transferred in violation of
the Securities Act or any applicable securities law and (ii) such amendment does not
materially and adversely affect the rights of Holders to transfer Notes; or

     (xi) to provide for the release or addition of Collateral or Subsidiary Guarantees in
accordance with the terms hereof and of the other Transaction Documents.

     (d) The consent of the Holders is not necessary hereunder to approve the particular
form of any proposed amendment. It is sufficient if such consent approves the substance of the
proposed amendment.

     (e) After a supplemental indenture becomes effective, the Company shall mail to
Holders a notice briefly describing such supplemental indenture. The failure to give such notice
to all Holders, or any defect therein, shall not impair or affect the validity of an amendment
under this Section 9.01.

     (f) The terms of any document entered into pursuant to this Section 9.01 shall be
subject to the prior approval, if required, of any applicable Gaming Authority.

     (g) To the extent required by applicable Gaming Laws, Notes held by a Disqualified
Holder shall, so long as held by such Person, be disregarded for the purposes of providing notices,
directions, waivers, or other actions and determining the sufficiency of such notices, directions,
waivers or actions.

     SECTION 9.02 EXECUTION OF SUPPLEMENTAL INDENTURES.

     In executing, or accepting the additional trusts created by, any supplemental indenture
permitted by this Article or the modifications thereby of the trusts created by this Indenture, the
Trustee shall be entitled to receive, and (subject to Section 7.1) shall be fully protected in
relying upon, an Opinion of Counsel stating that the execution of such supplemental indenture is
authorized or permitted by this Indenture. The Trustee may, but shall not be obligated to, enter
into any such supplemental indenture which adversely affects the Trustee’s own rights, duties or
immunities under this Indenture or otherwise in a material way.

     SECTION 9.03 EFFECT OF SUPPLEMENTAL INDENTURES.

     Upon the execution of any supplemental indenture under this Article, this Indenture shall be
modified in accordance therewith, and such supplemental indenture shall form a part of this
Indenture for all purposes; and every Holder of Notes affected thereby theretofore or thereafter
authenticated and delivered hereunder shall be bound thereby.

-114-

 

     SECTION 9.04 REFERENCE IN NOTES TO SUPPLEMENTAL INDENTURES.

     Notes authenticated and delivered after the execution of any supplemental indenture pursuant
to this Article and affected thereby may, and shall, if required by the Trustee, bear a notation in
form approved by the Trustee as to any matter provided for in such supplemental indenture. If the
Company shall so determine, new Notes so modified as to conform, in the opinion of the Trustee and
the Board of Directors, to any such supplemental indenture may be prepared and executed by the
Company and authenticated and delivered by the Trustee in exchange for Outstanding Notes.

     SECTION 9.05 REVOCATION AND EFFECT OF CONSENTS AND WAIVERS.

     A consent to a supplemental indenture or waiver by a Holder shall bind such Holder and every
subsequent Holder of the applicable Note or portion thereof that evidences the same Indebtedness as
the consenting Holder’s Note, even if notation of the consent or waiver is not made on the Note.
However, any such Holder or subsequent Holder may revoke the consent or waiver as to such Holder’s
Note or portion thereof if the Trustee receives written notice of revocation before the date the
requisite number of consents are received by the Company or the Trustee. After a supplemental
indenture or waiver becomes effective, it shall bind every Holder. A supplemental indenture or
waiver becomes effective once the requisite number of consents are received by the Company or the
Trustee and any other conditions to effectiveness of such consent specified in the amendment or
waiver are satisfied.

     The Company may, but shall not be obligated to, fix a record date for the purpose of
determining the Holders entitled to give their consent or take any other action described above or
required or permitted to be taken pursuant to this Indenture. If a record date is fixed, then
notwithstanding the immediately preceding paragraph, those Persons who were Holders at such record
date (or their duly designated proxies), and only those Persons, shall be entitled to give such
consent or to revoke any consent previously given or to take any such action, whether or not such
Persons continue to be Holders after such record date.

ARTICLE X

SUBSIDIARY GUARANTEES

     SECTION 10.01 SUBSIDIARY GUARANTEE.

     (a) In consideration of good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, each of the Subsidiary Guarantors, jointly and severally, hereby
unconditionally guarantees to each Holder and to the Trustee, irrespective of the validity and
enforceability of this Indenture, the Notes owned by such Holder or the Obligations of the Company
under this Indenture, the Notes or the other Transaction Documents, that: (i) the principal of and
interest on such Notes will be paid in full when due, whether at the Stated Maturity or the
Interest Payment Date, by acceleration, call for redemption, upon a purchase offer or otherwise,
and interest on the overdue principal and interest, if any, of such Notes, if lawful, and all other
obligations of the Company to the Holders or the Trustee under this Indenture, such Notes and the
other Transaction Documents will be promptly paid in full or performed, all in accordance with the
terms of this Indenture, such Notes and the other Transaction Documents; and (ii) in case of any
extension of time of payment or renewal of any securities or any of such other Obligations, they
will be paid in full when due or performed in accordance with the terms of the extension or
renewal, whether at maturity, by acceleration, call for redemption, upon a purchase offer or
otherwise (collectively, the “Guaranteed Obligations”). This

-115-

 

Subsidiary Guarantee is a guarantee
of payment and not of collection. Without limitation of the foregoing, the Subsidiary Guarantee of MGM Grand Hotel requires, and each Collateral Grantor that pledges
Collateral consisting of real property
acknowledges and agrees, that any
Event of Default caused by any Person
shall be deemed to be for all purposes an Event
of Default under the Subsidiary Guarantee of MGM Grand
 Hotel, and on the part of each Collateral Grantor that
pledges Collateral consisting of real property, entitling the
Trustee or Holders, as applicable, to exercise any and all
remedies against any and all Collateral available to them
under the Collateral Documents.

     Failing payment when due of any amount so guaranteed for whatever reason, the Subsidiary
Guarantors shall be unconditionally and jointly and severally obligated to pay the same.

     (b) Each Subsidiary Guarantor agrees that (i) its obligations with regard to this
Subsidiary Guarantee shall be unconditional, irrespective of the validity, regularity or
enforceability of the Notes, this Indenture or the other Transaction Documents, any amendments to
this Indenture, such Notes or the other Transaction Documents, the absence of any action to enforce
the same or to exercise remedies against the Collateral, the recovery of any judgment against the
Company, any action to enforce the same or to exercise remedies against the Collateral or any other
circumstances that might otherwise constitute a legal or equitable discharge or defense of a
guarantor and (ii) this Subsidiary Guarantee will not be discharged except by complete performance
of the Obligations contained in the Notes, this Indenture and the other Transaction Documents.
Each of the Subsidiary Guarantors hereby waives diligence, presentment, demand of payment, filing
of claims with a court in the event of insolvency or bankruptcy of the Company, any right to
require a proceeding first against the Company or right to require the prior disposition of the
assets of the Company to meet its obligations, protest, notice and all demands whatsoever. Without
limiting the generality of the foregoing, each of the Subsidiary Guarantors hereby waives, to the
extent permitted under Nev. Rev. Stat. 40.495, any rights arising out of Nev. Rev. Stat. 40.430.

     (c) If any Holder or the Trustee is required by any court or otherwise to return to
either the Company or any Subsidiary Guarantor, or any Custodian, Trustee, or similar official
acting in relation to either the Company or any Subsidiary Guarantor, any amount paid by either the
Company or any of the Subsidiary Guarantors to the Trustee or such Holder, this Subsidiary
Guarantee, to the extent theretofore discharged, shall be reinstated in full force and effect with
respect to the applicable Notes. Each of the Subsidiary Guarantors agrees that it will not be
entitled to any right of subrogation in relation to the Holders in respect of any obligations
guaranteed hereby except as set forth in Section 10.05 hereof.

     (d) Each of the Subsidiary Guarantors agrees that (i) the maturity of the
Obligations guaranteed hereby shall be accelerated as provided in Section 6.02 hereof for the
purposes of this Subsidiary Guarantee, notwithstanding any stay, injunction or other prohibition
preventing such acceleration as to the Company of the Obligations guaranteed hereby, and (ii) in
the event of any declaration of acceleration of those obligations as provided in Section 6.02,
those obligations (whether or not due and payable) will forthwith become due and payable by each of
the Subsidiary Guarantors for the purpose of this Guarantee.

     SECTION 10.02 EXECUTION AND DELIVERY OF SUBSIDIARY GUARANTEE.

     To evidence its Subsidiary Guarantee set forth in Section 10.01, each of the Subsidiary
Guarantors agrees that this Indenture shall be executed on behalf of such Subsidiary Guarantor by a
duly authorized officer.

     Each of the Subsidiary Guarantors agrees that its Subsidiary Guarantee set forth in Section
10.01 shall remain in full force and effect and apply to all the Notes.

-116-

 

     If an Officer whose facsimile signature is on a Note no longer holds that office at the time
the Trustee authenticates the Note on which a Subsidiary Guarantee is endorsed, the Subsidiary
Guarantee shall be valid nevertheless.

     The delivery of any Note by the Trustee, after the authentication thereof hereunder, shall
constitute due delivery of the Subsidiary Guarantee set forth in this Indenture on behalf of the
Subsidiary Guarantors.

     SECTION 10.03 LIMITATION OF SUBSIDIARY GUARANTOR’S LIABILITY.

     Each Subsidiary Guarantor and by its acceptance hereof each Holder hereby confirms that it is
the intention of all such parties that the Subsidiary Guarantee by such Subsidiary Guarantor
pursuant to its Subsidiary Guarantee not constitute a fraudulent transfer or conveyance for
purposes of any federal or state law. To effectuate the foregoing intention, the Holders and each
Subsidiary Guarantor hereby irrevocably agree that the Obligations of each such Subsidiary
Guarantor under its Subsidiary Guarantee shall be limited to the maximum amount as will, after
giving effect to all other contingent and fixed liabilities of such Subsidiary Guarantor and after
giving effect to any collections from or payments made by or on behalf of any other Subsidiary
Guarantor in respect of the Obligations of such other Subsidiary Guarantor under its Subsidiary
Guarantee or pursuant to Section 10.04, result in the Obligations of such Subsidiary Guarantor
under such Subsidiary Guarantee not constituting a fraudulent conveyance or fraudulent transfer
under federal or state law.

     SECTION 10.04 CONTRIBUTION.

     In order to provide for just and equitable contribution among the Subsidiary Guarantors, the
Subsidiary Guarantors agree, inter se, that in the event any payment or distribution is made by any
Subsidiary Guarantor in respect of the Notes (a “Funding Guarantor”) under its Subsidiary
Guarantee, such Funding Guarantor shall be entitled to a contribution from each other Subsidiary
Guarantor in a pro rata amount based on the net worth of each Subsidiary Guarantor (including the
Funding Guarantor) for all payments, damages and expenses incurred by that Funding Guarantor in
discharging the Company’s obligations with respect to the Notes or any other Subsidiary Guarantor’s
obligations with respect to the Subsidiary Guarantee.

     SECTION 10.05 RIGHTS UNDER THE SUBSIDIARY GUARANTEE.

     (a) Each of the Subsidiary Guarantors waives notice of the issuance, sale and
purchase of any Notes and notice from the Trustee or the Holders from time to time of any of such
Notes of their acceptance and reliance on this Subsidiary Guarantee.

     (b) Notwithstanding any payment or payments made by the Subsidiary Guarantors by
reason of this Subsidiary Guarantee, the Subsidiary Guarantors shall not be subrogated to any
rights of the Trustee or any Holder against the Company until all Notes shall have been paid or
deemed to have been paid within the meaning of this Indenture. Any payment made by the Subsidiary
Guarantors by reason of this Subsidiary Guarantee shall be in all respects subordinated to the full
and complete payment or discharge under this Indenture of all Obligations guaranteed hereby, and no
payment by the Subsidiary Guarantors by reason of this Subsidiary Guarantee shall give rise to any
claim of the Subsidiary Guarantors against the Trustee or any Holder. Unless and until the
applicable Notes shall have been paid or deemed to have been paid within the meaning of this
Indenture, none of the Subsidiary Guarantors will assign or otherwise transfer any such claim
against the Company to any other Person.

-117-

 

     (c) No set-off, counterclaim, reduction or diminution of any obligation or any
defense of any kind or nature (other than performance by the Subsidiary Guarantors of their
Obligations hereunder) which any Subsidiary Guarantor may have or assert against the Trustee or any
Holder of any Note shall be available hereunder to such Subsidiary Guarantor against the Trustee.

     (d) Each Subsidiary Guarantor agrees to pay all costs, expenses and fees, including
all reasonable attorneys’ fees and expenses, which may be incurred by the Trustee in enforcing or
attempting to enforce this Guarantee or protecting the rights of the Trustee or the Holders, if
any, in accordance with this Indenture.

     SECTION 10.06 PRIMARY OBLIGATIONS.

     Each Subsidiary Guarantor agrees that it is directly liable to each Holder hereunder, that the
Obligations of each Subsidiary Guarantor hereunder are independent of the Obligations of the
Company or any other guarantor, and that a separate action may be brought against each Subsidiary
Guarantor, whether such action is brought against the Company or any other Subsidiary Guarantor or
whether the Company or any other guarantor is joined in such action. Each Subsidiary Guarantor
agrees that its liability hereunder shall be immediate and shall not be contingent upon the
exercise or enforcement by the Trustee or the Holders of whatever remedies they may have against
the Company or any other guarantor, or the enforcement of any Lien or realization upon any
Collateral. Each Subsidiary Guarantor agrees that any release which may be given by the Trustee or
the Holders of the Notes to the Company or any other guarantor shall not release such Subsidiary
Guarantor. Each Subsidiary Guarantor consents and agrees that the Trustee shall be under no
obligation to marshal any property or assets of the Company or any other guarantor in favor of such
Subsidiary Guarantor, or against or in payment of any or all of the Guaranteed Obligations.

	 	 	SECTION 10.07 WAIVERS.

     (a) Each Subsidiary Guarantor hereby waives any right to receive, or any claim or
defense based on failure to receive: (i) notice of the amount of the Guaranteed Obligations; (ii)
notice of any adverse change in the financial condition of the Company or of any other fact that
might increase such Subsidiary Guarantor’s risk hereunder; (iii) notice of a Default; and (iv) all
other notices (except if such notice is specifically required to be given to such Subsidiary
Guarantor under this Indenture to which such Subsidiary Guarantor is a party) and demands to which
such Subsidiary Guarantor might otherwise be entitled.

     (b) Each Subsidiary Guarantor hereby waives the right by statute or otherwise to
require the Trustee or the Holders to institute suit against the Company (or against any other
Person) or to exhaust any rights and remedies which the Trustee or the Holders have or may have
against the Company (or against any other Person) or against the Collateral. In this regard, each
Subsidiary Guarantor agrees that it is bound to the payment of each and all of the Guaranteed
Obligations, whether now existing or hereafter arising, as fully as if such Guaranteed Obligations
were directly owing to the guaranteed party by such Subsidiary Guarantor. Each Subsidiary
Guarantor further waives any defense arising by reason of any disability or other defense (other
than the defense that the Guaranteed Obligations shall have been fully and finally performed and
indefeasibly paid) of the Company or by reason of the cessation from any cause whatsoever of the
liability of the Company in respect thereof.

     (c) Each Subsidiary Guarantor hereby waives: (i) any claim or defense directly or
indirectly arising from or caused by any election of remedies by the Trustee or the Holders,
whether or not

-118-

 

such election of remedies directly or indirectly results in impairment or loss of
rights or claims of such
Subsidiary Guarantor against the Company or other Persons; and (ii) any defenses based on
suretyship law or impairment of Collateral.

     SECTION 10.08 RELEASES.

     Each Subsidiary Guarantor consents and agrees that, without notice to or by such Subsidiary
Guarantor and without affecting or impairing the Obligations of such Subsidiary Guarantor
hereunder, the Trustee may, by action or inaction, compromise or settle, extend the period of
duration or the time for the payment, or discharge the performance of, or may refuse to, or
otherwise not enforce, or may, by action or inaction, release all or any one or more parties to,
any one or more of the terms and provisions of this Indenture or may grant other indulgences to the
Company in respect thereof, or may, by action or inaction, release or substitute any other
guarantor, if any, of the Guaranteed Obligations, or may enforce, exchange, release, or waive, by
action or inaction, any security for the Guaranteed Obligations or any other guarantee of the
Guaranteed Obligations, or any portion thereof.

     SECTION 10.09 NO ELECTION.

     The Trustee shall have the right to seek recourse against each Subsidiary Guarantor to the
fullest extent provided for herein and no election by the Trustee to proceed in one form of action
or proceeding, or against any party, or on any Obligation, shall constitute a waiver of Trustee’s
right to proceed in any other form of action or proceeding, or against other parties unless the
Trustee has expressly waived such right in writing.

     SECTION 10.10 FINANCIAL CONDITION OF THE COMPANY.

     Each Subsidiary Guarantor represents and warrants to the Trustee and Holders that it is
currently informed of the financial condition of the Company and the other Subsidiary Guarantors
and, of all other circumstances which a diligent inquiry would reveal and which bear upon the risk
of nonpayment of the Guaranteed Obligations. Each Subsidiary Guarantor further represents and
warrants to the Trustee and Holders that it has read and understands the terms and conditions of
this Indenture and the other Transaction Documents. Each Subsidiary Guarantor hereby covenants
that it will continue to keep itself informed of the Company’s and the other Subsidiary Guarantor’s
financial condition, the financial condition of other guarantors, if any, and of all other
circumstances which bear upon the risk of nonpayment or nonperformance of the Guaranteed
Obligations.

ARTICLE XI

COLLATERAL AND SECURITY

     SECTION 11.01 COLLATERAL AND COLLATERAL DOCUMENTS; ADDITIONAL COLLATERAL.

     (a) In order to secure the Obligations of the Collateral Grantor to the Holders
under this Indenture, the Notes, the Subsidiary Guarantees and the other Transaction Documents, the
Collateral Grantor and the Collateral Agent have simultaneously with the execution of this
Indenture entered into certain Collateral Documents. The Trustee, the Company and each Subsidiary
Guarantor will comply with applicable Gaming Laws in connection with entering into any Collateral
Documents that may be executed after the Closing Date. The Trustee and the Collateral Grantor
hereby agree that the Colla-

-119-

 

teral Agent holds its interest in the Collateral in trust for the
benefit of the Holders pursuant to the terms of the Collateral Documents.

     (b) Promptly upon the acquisition by the Company or the Collateral Grantor of assets
that constitute Collateral pursuant to the Collateral Documents (including any property acquired
after the date of this Indenture that constitutes Collateral to which a perfected first priority
Lien is not established upon the Company’s acquisition of such Collateral pursuant to the
Collateral Documents) (“After-Acquired Property”), (i) the Company or such Subsidiary Guarantor and
the Collateral Agent will enter into such amendments or supplements to the Collateral Documents, or
security agreements, pledge agreements or other documents, in each case as necessary to perfect the
Lien with respect to such After-Acquired Property in a form substantially similar to the form of
the Collateral Documents entered into on the Closing Date and, if necessary, in recordable or
registrable form, (the “After-Acquired Collateral Documents”, and together with the Replacement
Collateral Documents as are necessary in order to grant to the Collateral Agent for the benefit of
the Holders a perfected first priority Lien on and security interest in such After-Acquired
Property; (ii) with respect to such After-Acquired Property, the Company shall deliver all such
documents as delivered on the Closing Date with respect to the Mortgaged Property, including,
without limitation, mortgages, deeds of trust, fixture filings, title policies, surveys, opinions
and flood determinations, in each case, in form and substance substantially similar to those
delivered on the Closing Date; and (iii) the Company shall also deliver to the Trustee the evidence
of payment of all filing fees, recording and registration charges, transfer taxes and other costs
and expenses, including reasonable legal fees and disbursements of counsel for the Trustee (and any
local counsel), that may be incurred to validly and effectively subject the After-Acquired Property
to the Lien of any applicable Collateral Document and perfect such Lien.

     (c) Each Holder, by accepting a Note, authorizes and directs the Trustee to enter
into, and agrees to all the terms and provisions of, the Collateral Documents as the same may be
amended from time to time pursuant to the provisions of the Collateral Documents and this
Indenture.

     SECTION 11.02 COLLATERAL OPINIONS.

     The Company shall furnish to the Trustee within 60 calendar days after December 31 in each
year, beginning with December 31, 2010, an Opinion of Counsel, dated as of such date, subject to
customary exceptions and assumptions, either (i)(A) stating that, in the opinion of such counsel,
all action has been taken with respect to the recording, registration, filing, re-recording,
re-registration and refiling of all mortgages, supplemental indentures, financing statements,
continuation statements and other documents as is necessary to maintain the Lien created pursuant
to the Collateral Documents and reciting with respect to the security interests in the Collateral
the details of such action or referring to prior Opinions of Counsel in which such details are
given, and (B) stating that, under the applicable Uniform Commercial Code as in effect on the date
of such Opinion of Counsel, all financing statements, continuation statements and other documents
have been executed and filed that are necessary as of such date and during the succeeding 24 months
fully to maintain the security interest of the Holders and the Collateral Agent hereunder and under
the Collateral Documents with respect to the Collateral, or (ii) stating that, in the opinion of
such counsel, no such action is necessary to maintain such Lien.

-120-

 

     SECTION 11.03 POSSESSION AND USE OF COLLATERAL; DISPOSITION OF COLLATERAL WITHOUT RELEASE
AND NOT CONSTITUTING COLLATERAL ASSET SALE.

     (a) So long as no Event of Default shall have occurred and be continuing and the
Collateral Agent has not exercised its remedies against the Collateral in accordance with the terms
of this Indenture and the Collateral Documents, the Collateral Grantor shall have the right (i) to
remain in possession and retain exclusive control of the Collateral, (ii) to sell or otherwise
dispose of inventory in the ordinary course of business, (iii) to operate, manage, develop, lease,
use, consume and enjoy the
Collateral, (iv) to alter or repair any Collateral consisting of machinery or other equipment
so long as such alterations and repairs do not diminish the value thereof or impair the Lien of the
Collateral Documents thereon, (v) to collect, receive, use, invest and dispose of the reversions,
remainders, interest, rents, lease payments, issues, profits, revenues, proceeds and other income
thereof in the ordinary course of business, (vi) to grant Permitted Liens, (vii) to dispose of
obsolete equipment or equipment that is damaged, worn out or otherwise no longer useful in the
business of the Collateral Grantor as long as such equipment is replaced with equipment of at least
equal functionality and such replacement equipment becomes Collateral pursuant to the terms of the
Collateral Documents; provided that the Collateral Grantor shall not be required to replace
immaterial equipment if replacement equipment would not be useful in any material respect to the
business of the Collateral Grantor, (viii) to abandon, terminate, cancel, release or make
alterations in or substitutions of any leases, contracts, franchises, licenses or permits subject
to the Lien of this Indenture or any of the Collateral Documents so long as such abandonment,
termination, cancellation, release, alteration or substitution does not have a materially adverse
effect on the value of the Collateral or the Holders, (ix) to grant an immaterial license of any
intellectual property, (x) to abandon any intellectual property which is no longer used or useful
in the business of the Collateral Grantor and (xi) any surrender or waiver of contract rights or a
settlement, release or surrender of contract, tort or other claims of any kind; provided, in each
case that any such sale or disposal shall not be deemed to constitute a Collateral Asset Sale;
provided, further, that any Collateral so sold or disposed of pursuant to this Section 11.03 may be
disposed of free from the Lien of this Indenture and the Collateral Documents and without any
release or consent from the Collateral Agent.

     (b) So long as no Event of Default shall have occurred and be continuing, and until
the Collateral Agent suspends such rights, the Collateral Grantor will be entitled to receive the
benefit of all cash dividends, interest and other payments made upon or with respect to the
Collateral pledged by them and to exercise any voting and other consensual rights pertaining to the
Collateral pledged by them. Upon the occurrence and during the continuance of an Event of Default,
at the election of the Collateral Agent or the Holders of a majority in aggregate principal amount
of the Outstanding Notes pursuant to Section 6.12 to suspend such rights:

     (i) all rights of the Collateral Grantor to receive all cash dividends, interest and
other payments made upon or with respect to the Collateral will cease, and upon receipt of
all required approvals from any applicable Gaming Authority, such cash dividends, interest
and other payments will be paid to the Collateral Agent;

     (ii) upon receipt of all required approvals from any applicable Gaming Authority, all
rights of the Collateral Grantor to exercise such voting or other consensual rights shall
cease, and all such rights shall become vested in the Collateral Agent which, to the extent
permitted by law, will have the sole right to exercise such rights; and

-121-

 

     (iii) the Collateral Agent may sell the Collateral or any part thereof in accordance
with the terms of the Collateral Documents.

     SECTION 11.04 SPECIFIED RELEASES OF COLLATERAL.

     (a) Satisfaction and Discharge; Defeasance. The Collateral Grantor shall be
entitled to obtain a full release of all of the Collateral from the Liens of the Collateral
Documents upon delivery by the Company to the Collateral Agent of an Officer’s Certificate and an
Opinion of Counsel, each to the effect that the conditions precedent set forth in Section 8.01 for
satisfaction and discharge of this Indenture or for Legal Defeasance or Covenant Defeasance
pursuant to Section 8.05, as applicable,
have been complied with (which Officer’s Certificate and Opinion of Counsel may be the same as
required by Section 8.05(h)).

     (b) Dispositions of Collateral Permitted by Section 4.11.

     (i) The Collateral Grantor shall be entitled to obtain a full release of, and the
Collateral Agent shall release, the Liens of the Collateral Documents on items of Collateral
subject to a Collateral Asset Sale (the “Released Property”) upon delivery by the Company to
the Trustee of (A) an Officer’s Certificate certifying that (1) such Collateral Asset Sale
covers only the Released Property, (2) all Net Proceeds from the Collateral Asset Sale of
any of the Released Property will be deposited or applied pursuant to Section 4.11, (3) all
terms and conditions of Section 4.11 have been complied with and (4) in accordance with
Section 12.03, all other conditions precedent in this Indenture and the Collateral Documents
to such release have been complied with, (B) in accordance with Section 12.03, an Opinion of
Counsel substantially to the effect that all conditions precedent herein and under the
Collateral Documents relating to the release of the Released Property have been complied
with and (C) all documents required by Section 11.08.

     (ii) The Collateral Grantor shall be entitled to obtain a full release of, and the
Collateral Agent shall release, the Liens of the Collateral Documents on items of Collateral
sold or disposed of pursuant to Section 11.03(a)(ii), (vii), (viii) and (x) upon delivery by
the Company to the Trustee of (A) an Officer’s Certificate certifying that (1) the sale and
disposal of such items of Collateral complies with the terms of Section 11.03(a) and (2) in
accordance with Section 12.03, all other conditions precedent in this Indenture and the
Collateral Documents to such release have been complied with, (B) in accordance with Section
12.03, an Opinion of Counsel substantially to the effect that all conditions precedent
herein and under the Collateral Documents relating to the release of the Collateral pursuant
to this Section 11.04(b)(ii) have been complied with and (C) all documents required by
Section 11.08.

     (c) Suspension of Covenants pursuant to Section 4.23. The Collateral Grantor shall
be entitled to obtain a full release of all of the Collateral from the Liens of the Collateral
Documents upon delivery by the Company to the Collateral Agent of an Officer’s Certificate and an
Opinion of Counsel, each to the effect that the conditions precedent set forth in Section 4.23 for
a suspension of covenants pursuant to Section 4.23 have been satisfied.

     (d) Consent pursuant to Section 9.01. The Collateral Grantor shall be entitled to
obtain a full release of all of the Collateral from the Liens of the Collateral Documents upon
consent from the Holders pursuant to Section 9.01(b).

-122-

 

     (e) Repayment in Full of Obligations. The Collateral Grantor shall be entitled to
obtain a full release of all of the Collateral from the Liens of the Collateral Documents upon
delivery by the Company to the Collateral Agent of an Officer’s Certificate certifying as to the
payment in full of the principal of, together with accrued and unpaid interest (including
Additional Interest, if any) on, the Notes and all other Obligations under this Indenture, the
Subsidiary Guarantees and the Collateral Documents that are due and payable at or prior to the time
such principal, together with accrued and unpaid interest (including Additional Interest, if any)
are paid and an Officer’s Certificate (which may be the same as the Officer’s Certificate first
referenced in this paragraph (e)) and Opinion of Counsel, each to the effect that all conditions
precedent to the discharge of such Liens have been satisfied.

     SECTION 11.05 RELEASE AND RECONVEYANCE OF COLLATERAL.

     Upon compliance with any of the conditions to release of Collateral set forth in Section
11.04, the Collateral Agent and the Trustee shall forthwith take all necessary action (at the
request of and the expense of the Company) to release and reconvey to the Collateral Grantor the
applicable portion of the Collateral, and shall deliver such Collateral in its possession to the
Collateral Grantor including, without limitation, executing and delivering releases and
satisfactions wherever required in form reasonably satisfactory to the Company, the Collateral
Agent and the Trustee.

     SECTION 11.06 PURCHASER PROTECTED.

     No purchaser or grantee of any property or rights purporting to be released herefrom shall be
bound to ascertain the authority of the Trustee to execute the release or to inquire as to the
existence of any conditions herein prescribed for the exercise of such authority.

     SECTION 11.07 AUTHORIZATION OF ACTIONS TO BE TAKEN BY THE TRUSTEE AND THE COLLATERAL AGENT
UNDER THE COLLATERAL DOCUMENTS.

     Subject to compliance with any applicable Gaming Laws and to the provisions of the Collateral
Documents, (a) the Trustee and the Collateral Agent may, each in its sole discretion and without
the consent of the Holders, take all actions as it deems necessary or appropriate in order to (i)
enforce any of the terms of the Collateral Documents and (ii) collect and receive any and all
amounts payable in respect of the Obligations of the Company hereunder and (b) the Trustee and the
Collateral Agent shall have power to institute and to maintain such suits and proceedings as it may
deem expedient to prevent any impairment of the Collateral by any act that may be unlawful or in
violation of the Collateral Documents or this Indenture, and such suits and proceedings as the
Trustee or the Collateral Agent may deem expedient to preserve or protect its interests and the
interests of the Holders in the Collateral (including the power to institute and maintain suits or
proceedings to restrain the enforcement of or compliance with any legislative or other governmental
enactment, rule or order that may be unconstitutional or otherwise invalid if the enforcement of,
or compliance with, such enactment, rule or order would impair the security interest thereunder or
be prejudicial to the interests of the Holders, the Trustee or the Collateral Agent). No duty
beyond that of a prudent Person shall rest upon the Trustee or the Collateral Agent in taking any
such action or instituting and maintaining any such suits or proceedings pursuant to this Section
11.07.

-123-

 

     SECTION 11.08 CERTAIN TIA REQUIREMENTS.

     (a) In addition to any other requirements of this Indenture, whether or not this
Indenture is required to be qualified under the TIA, the Company will cause TIA § 313(b) relating
to reports and TIA § 314(d) relating to the release of property or securities from the Lien hereof
and of the Collateral Documents to be complied with; provided that in the event that this Indenture
is not required to be qualified under the TIA, any certificate or opinion required by TIA § 314(d)
may be made by an officer or legal counsel, as applicable, of the Company.

     (b) Notwithstanding anything to the contrary in this Section 11.08, the Company
shall not be required to comply or cause the Collateral Grantor to comply with all or any portion
of TIA § 314(d) if it determines, in good faith based on the written advice of counsel, a copy of
which written advice shall be provided to the Collateral Agent, that under the terms of TIA §
314(d) or any interpretation or guidance as to the meaning thereof of the Commission and its staff,
including “no action”
letters or exemptive orders, all or any portion of TIA § 314(d) is inapplicable to any release
or series of releases of Collateral.

     SECTION 11.09 EQUAL AND RATABLE LIEN SHARING BY HOLDERS OF NOTES AND HOLDERS OF
PARI PASSU SECURED INDEBTEDNESS

     (a) Notwithstanding (1) anything to the contrary contained in the Collateral
Documents, (2) the time of incurrence of any Series of Pari Passu Secured Indebtedness, (3) the
order or method of attachment or perfection of any Liens securing any Series of Pari Passu Secured
Indebtedness, (4) the time or order of filing or recording of financing statements, mortgages or
other documents filed or recorded to perfect any Lien upon any Collateral, (5) the time of taking
possession or control over any Collateral or (6) the rules for determining priority under any law
governing relative priorities of Liens:

     (i) all Liens at any time granted by the Company or any of its Subsidiaries in the
Collateral to secure the Notes shall secure, equally and ratably, all liabilities of the
Company or such Subsidiary under or in respect of the Pari Passu Secured Indebtedness; and

     (ii) all proceeds of all Liens at any time granted by the Company or any its
Subsidiaries in the Collateral to secure the Notes shall be allocated and distributed
equally and ratably on account of all liabilities of the Company or such Subsidiary under or
in respect of the Pari Passu Secured Indebtedness as described in the Security Agreement.

     (b) The provisions of Section 11.09(a) hereof are intended for the benefit of, and
will be enforceable as a third party beneficiary by, each present and future holder of Pari Passu
Secured Indebtedness and any trustee, collateral agent or other representative in respect thereof.

     (c) It is understood that Collateral may be released pursuant to the provisions of
Section 11.05 hereof.

SECTION 11.10 RESERVED.

SECTION 11.11 ENFORCEMENT OF SECURITY INTERESTS.

     The enforcement of Liens in the Collateral shall be governed by the Collateral Documents.

-124-

 

ARTICLE XII

MISCELLANEOUS

     SECTION 12.01 NOTICES.

     Any notice or communication shall be in writing and shall be hand delivered or mailed by first
class mail (registered or certified, return receipt requested) or sent by facsimile, to the
following addresses:

if to the Company or any Subsidiary Guarantor:

MGM MIRAGE

3600 Las Vegas Boulevard South

Las Vegas, Nevada 89109

Telecopier no.: (702) 693-7628

Attention of: Treasurer

if to the Trustee or the Collateral Agent:

U.S. BANK NATIONAL ASSOCIATION

60 Livingston Avenue

St. Paul, MN 55107-1419

Telecopier no.: (651) 495-8097

Attention of: Corporate Trust Administration

     The Company, the Trustee or the Collateral Agent by notice to the other may designate
additional or different addresses for subsequent notices or communications. Any notice or
communication to the Company, any Subsidiary Guarantors, the Trustee or the Collateral Agent, shall
be deemed to have been given or made as of the date delivered if personally delivered; when
answered back, if telexed; when receipt is acknowledged, if telecopied; and five (5) calendar days
after mailing if sent by registered or certified mail, postage prepaid (except that a notice of
change of address shall not be deemed to have been given until actually received by the addressee).
Notices given by publication will be deemed given on the first date on which publication is made.
Any notice or communication mailed to a Holder shall be made in compliance with TIA § 313(c) and
mailed to the Holder at the Holder’s address as it appears on the registration books of the
Registrar and shall be sufficiently given if so mailed within the time prescribed.

     Failure to mail a notice or communication to a Holder or any defect in it shall not affect its
sufficiency with respect to other Holders. If a notice or communication is mailed in the manner
provided above, it is duly given, whether or not the addressee receives it.

     SECTION 12.02 COMMUNICATION BY HOLDERS WITH OTHER HOLDERS.

     Holders may communicate in a manner consistent with TIA § 312(b) with other Holders with
respect to their rights under this Indenture, the Notes or the Collateral Documents. The Company,
the Subsidiary Guarantors, the Trustee, the Collateral Agent, the Registrar and anyone else shall
have the protection of TIA § 312(c).

-125-

 

     SECTION 12.03 CERTIFICATE AND OPINION AS TO CONDITIONS PRECEDENT.

     Upon any request or application by the Company to the Trustee or the Collateral Agent to take
or refrain from taking any action under this Indenture or the Collateral Documents, at the request
of the Trustee or the Collateral Agent, the Company shall furnish to the Trustee:

     (1) an Officer’s Certificate in form and substance satisfactory to the Trustee or the
Collateral Agent (which shall include the statements set forth in Section 12.04) stating
that, in the opinion of the signers, all conditions precedent, if any, provided for in this
Indenture or the Collateral Documents relating to the proposed action have been complied
with, provided, however, that with respect to matters of law, an Officer’s Certificate may
be based upon an Opinion of Counsel, unless the signers know, or in the exercise of
reasonable care should know, that such Opinion of Counsel is erroneous; and

     (2) an Opinion of Counsel in form and substance satisfactory to the Trustee or the
Collateral Agent (which shall include the statements set forth in Section 12.04) stating
that, in the opinion of such counsel, all such conditions precedent have been complied with,
provided, further, that with respect to matters of fact an Opinion of Counsel may rely on an
Officer’s Certificate or certificates of public officials, unless the signer knows, or in
the exercise of reasonable care should know, that any such document is erroneous.

     SECTION 12.04 STATEMENTS REQUIRED IN CERTIFICATE OR OPINION.

     Each certificate or opinion with respect to compliance with a covenant or condition provided
for in this Indenture or the Collateral Documents shall include:

     (1) a statement that the individual making such certificate or opinion has read such
covenant or condition;

     (2) a brief statement as to the nature and scope of the examination or investigation
upon which the statements or opinions contained in such certificate or opinion are based;

     (3) a statement that, in the opinion of such individual, he has made such examination
or investigation as is necessary to enable him to express an informed opinion as to whether
or not such covenant or condition has been complied with or satisfied; and

     (4) a statement as to whether or not, in the opinion of such individual, such covenant
or condition has been complied with.

     SECTION 12.05 RULES BY TRUSTEE, PAYING AGENT AND REGISTRAR.

     The Trustee may make reasonable rules for action by or a meeting of Holders. The Registrar
and the Paying Agent may make reasonable rules for their functions.

     SECTION 12.06 BUSINESS DAYS.

     Unless otherwise specified pursuant to this Indenture or in the Notes, in any case where any
Interest Payment Date, Redemption Date, Purchase Date or Stated Maturity of the Notes shall not be
a

-126-

 

Business Day at any Place of Payment for such Notes, then (notwithstanding any other provision of
this Indenture or of such Notes) payment of principal (and premium, if any) or interest need not be
made at such Place of Payment on such date, but may be made on the next succeeding Business Day at
such Place of Payment with the same force and effect as if made on the Interest Payment Date,
Redemption Date or at the Stated Maturity, and no interest shall accrue on the amount so payable
for the period from and after such Interest Payment Date, Redemption Date, Payment Date or Stated
Maturity, as the case may be, to such Business Day if such payment is made or duly provided for on
such Business Day.

     SECTION 12.07 GOVERNING LAW.

     THIS INDENTURE, THE NOTES AND THE SUBSIDIARY GUARANTEES SHALL BE GOVERNED BY, AND CONSTRUED IN
ACCORDANCE WITH, THE LAWS OF THE STATE OF NEVADA BUT WITHOUT GIVING EFFECT TO APPLICABLE PRINCIPLES
OF CONFLICTS OF LAW TO THE EXTENT THAT THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION WOULD BE
REQUIRED THEREBY. EACH OF THE PARTIES HERETO
AGREES TO SUBMIT TO THE JURISDICTION OF THE COURTS OF THE STATE OF NEVADA IN ANY ACTION OR
PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE NOTES OR THE SUBSIDIARY GUARANTEES.

     SECTION 12.08 NO RECOURSE AGAINST OTHERS.

     No director, officer, employee, incorporator or stockholder of the Company or any Subsidiary
Guarantor or any of their parent companies shall have any liability for any Obligations of the
Company or the Subsidiary Guarantors under the Notes, the Subsidiary Guarantees, this Indenture or
the Collateral Documents or for any claim based on, in respect of, or by reason of such Obligations
or their creation. Each Holder by accepting the Notes waives and releases all such liability. The
waiver and release are part of the consideration for the issuance of the Notes. Such waiver may
not be effective to waive liabilities of directors, officers or persons controlling the Company
under the federal securities laws and it is the view of the Commission that such waiver is against
public policy and is therefore unenforceable.

     SECTION 12.09 SUCCESSORS.

     All agreements of the Company and each Subsidiary Guarantor in this Indenture, the Collateral
Documents, the Notes (including the Subsidiary Guarantee endorsements thereon) and the other
Transaction Documents shall bind their successors. All agreements of the Trustee and the
Collateral Agent in this Indenture shall bind their successors.

     SECTION 12.10 MULTIPLE ORIGINALS.

     The parties may sign any number of copies of this Indenture. Each signed copy shall be an
original, but all of them together represent the same agreement. One signed copy is enough to
prove this Indenture.

-127-

 

     SECTION 12.11 TABLE OF CONTENTS; HEADINGS.

     The table of contents, cross-reference sheet and headings of the Articles and Sections of this
Indenture have been inserted for convenience of reference only, are not intended to be considered a
part hereof and shall not modify or restrict any of the terms or provisions hereof.

	 	 	SECTION 12.12 SEVERABILITY.

     In case any one or more of the provisions in this Indenture, in the Notes or in the Subsidiary
Guarantees shall be held invalid, illegal or unenforceable, in any respect for any reason, the
validity, legality and enforceability of any such provision in every other respect and of the
remaining provisions shall not in any way be affected or impaired thereby, it being intended that
all of the provisions hereof shall be enforceable to the full extent permitted by law.

     SECTION 12.13 NO ADVERSE INTERPRETATION OF OTHER AGREEMENTS.

     This Indenture may not be used to interpret another indenture, loan or debt agreement of the
Company or any of its Subsidiaries. Any such indenture, loan or debt agreement may not be used to
interpret this Indenture.

     SECTION 12.14 NO PARENT LIABILITY.

     In the event (a) there is any Default or other default or alleged default by the Company, any
Subsidiary Guarantor or any Affiliate of any thereof under this Indenture, the Notes, any
Subsidiary Guarantee, any Collateral Document, the Registration Rights Agreement or any other
document, instrument or agreement arising out of or relating to any of the foregoing (collectively,
the “Transaction Documents”) or (b) the Trustee, the Collateral Agent any Holder or any Affiliate
of any of the foregoing has or may have any claim arising from or relating to the terms of any
Transaction Document, neither the Trustee, such Holder or such Affiliate shall commence any lawsuit
or otherwise seek to impose any liability whatsoever in respect thereof against Tracinda or its
shareholder (hereinafter for purposes of this Section 12.14 only, collectively referred to as
“Tracinda”). Tracinda shall not have any liability whatsoever with respect to any Transaction
Document or any matters relating to or arising from any Transaction Document. None of the Trustee,
the Collateral Agent, any Holder or any Affiliate of any of the foregoing shall assert or permit
any Person claiming through any of them to assert a claim or impose any liability against Tracinda
as to any matter or thing arising out of or relating to any Transaction Document or any alleged
breach or default of any Transaction Document by the Company, any Subsidiary Guarantor or any
Affiliate thereof. Tracinda is not a party to any Transaction Document and is not liable for any
alleged breach or default of any Transaction Document by the Company, any Subsidiary Guarantor or
any Affiliate of any thereof. The terms of this Section 12.14 shall control, notwithstanding
anything to the contrary appearing in any Transaction Document.

     SECTION 12.15 ADDITIONAL WAIVER.

     The Company hereby waives, to the maximum extent permitted under Nev. Rev. Stat. 40.495,
any rights arising out of Nev. Rev. Stat. 40.430.

-128-

 

     IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed and
delivered all as of the day and year first above written.

	 	 	 	 	 
	 	MGM MIRAGE

 	 
	 	By:  	/s/ John M. McManus
 	 
	 	 	Name:  	John M. McManus 	 
	 	 	Title:  	Senior Vice President, Acting General
Counsel and Secretary 	 
	 
	 	U.S. BANK NATIONAL ASSOCIATION, as Trustee

 	 
	 	By:  	/s/ Raymond S. Haverstock
 	 
	 	 	Name:  	Raymond S. Haverstock 	 
	 	 	Title:  	Vice President 	 
	 

SIGNATURE PAGE MGM MIRAGE INDENTURE

 

 

SUBSIDIARY GUARANTORS

	 	 	 
	1.

	 	350 Leasing Company I, LLC, a Nevada limited liability company
	2.

	 	350 Leasing Company II, LLC, a Nevada limited liability company
	3.

	 	550 Leasing Company I, LLC, a Nevada limited liability company
	4.

	 	AC Holding Corp., a Nevada corporation
	5.

	 	AC Holding Corp. II, a Nevada corporation
	6.

	 	Aria Resort & Casino, LLC, a Nevada limited liability company
	7.

	 	Beau Rivage Distribution Corp., a Mississippi corporation
	8.

	 	Beau Rivage Resorts, Inc., a Mississippi corporation
	9.

	 	Bellagio, LLC, a Nevada limited liability company
	10.

	 	Bungalow, Inc., a Mississippi corporation
	11.

	 	Circus Circus Casinos, Inc., a Nevada corporation
	12.

	 	Circus Circus Mississippi, Inc., a Mississippi corporation
	13.

	 	CityCenter Realty Corporation, a Nevada corporation
	14.

	 	Destron, Inc., a Nevada corporation
	15.

	 	Diamond Gold, Inc., a Nevada corporation
	16.

	 	Galleon, Inc., a Nevada corporation
	17.

	 	Gold Strike Aviation, Incorporated, a Nevada corporation
	18.

	 	Gold Strike Fuel Company, LLC, a Nevada limited liability company (successor in interest to
Gold Strike Fuel Company, a Nevada Partnership)
	19.

	 	Gold Strike L.V., a Nevada partnership

By: Diamond Gold Inc., a Nevada corporation, Partner

By: M.S.E. Investments, Incorporated, a Nevada corporation, Partner

	 	 	 
	20.

	 	Grand Laundry, Inc., a Nevada corporation
	21.

	 	IKM MGM Management, LLC, a Nevada limited liability company
	22.

	 	IKM MGM, LLC, a Nevada limited liability company
	23.

	 	Jean Development Company, LLC, a Nevada limited liability company (successor in interest to
Jean Development Company, a Nevada partnership)
	24.

	 	Jean Development North, LLC, a Nevada limited liability company (successor in interest to
Jean Development North, a Nevada partnership)
	25.

	 	Jean Development West, LLC, a Nevada limited liability company (successor in interest to
Jean Development West, a Nevada partnership)
	26.

	 	Jean Fuel Company West, LLC, a Nevada limited liability company (successor in interest to
Jean Fuel Company West, a Nevada partnership)
	27.

	 	LV Concrete Corp., a Nevada corporation
	28.

	 	MAC, Corp., a New Jersey corporation
	29.

	 	Mandalay Corp., a Nevada corporation
	30.

	 	Mandalay Employment, LLC, a Nevada limited liability company
	31.

	 	Mandalay Marketing and Events, a Nevada corporation
	32.

	 	Mandalay Place, a Nevada corporation
	33.

	 	Mandalay Resort Group, a Nevada corporation
	34.

	 	Metropolitan Marketing, LLC, a Nevada limited liability company
	35.

	 	MGM Grand Atlantic City, Inc., a New Jersey corporation
	36.

	 	MGM Grand Condominiums, LLC, a Nevada limited liability company
	37.

	 	MGM Grand Condominiums II, LLC, a Nevada limited liability company
	38.

	 	MGM Grand Condominiums III, LLC, a Nevada limited liability company
	39.

	 	MGM Grand Condominiums East — Tower 1, LLC, a Nevada limited liability company
	40.

	 	MGM Grand Detroit, Inc., a Delaware corporation

 

 

	 	 	 
	41.

	 	MGM Grand Hotel, LLC, a Nevada limited liability company
	42.

	 	MGM Grand New York, LLC, a Nevada limited liability company
	43.

	 	MGM Grand Resorts, LLC, a Nevada limited liability company
	44.

	 	MGM Grand Resorts Development, a Nevada corporation
	45.

	 	MGM MIRAGE Advertising, Inc., a Nevada corporation
	46.

	 	MGM MIRAGE Aircraft Holdings, LLC, a Nevada limited liability company
	47.

	 	MGM MIRAGE Aviation Corp., a Nevada corporation
	48.

	 	MGM MIRAGE Corporate Services, a Nevada corporation
	49.

	 	MGM MIRAGE Design Group, a Nevada corporation
	50.

	 	MGM MIRAGE Development, LLC, a Nevada limited liability company
	51.

	 	MGM MIRAGE Entertainment and Sports, a Nevada corporation
	52.

	 	MGM MIRAGE International Marketing, Inc., a Nevada corporation
	53.

	 	MGM MIRAGE Land Holdings, LLC, a Nevada limited liability company
	54.

	 	MGM MIRAGE Management and Technical Services, LLC, a Nevada limited liability company
	55.

	 	MGM MIRAGE Manufacturing Corp., a Nevada corporation
	56.

	 	MGM MIRAGE Operations, Inc., a Nevada corporation
	57.

	 	MGM MIRAGE Retail, a Nevada corporation
	58.

	 	MH, Inc., a Nevada corporation
	59.

	 	M.I.R. Travel, a Nevada corporation
	60.

	 	The Mirage Casino-Hotel, a Nevada corporation
	61.

	 	Mirage Laundry Services Corp., a Nevada corporation
	62.

	 	Mirage Leasing Corp., a Nevada corporation
	63.

	 	Mirage Resorts, Incorporated, a Nevada corporation
	64.

	 	MMNY Land Company, Inc., a New York corporation
	65.

	 	MRGS, LLC, a Nevada limited liability company (successor in interest to MRGS Corp., a Nevada
corporation)
	66.

	 	M.S.E. Investments, Incorporated, a Nevada corporation
	67.

	 	Nevada Landing Partnership, an Illinois partnership

By: Diamond Gold Inc., a Nevada corporation, Partner

By: M.S.E. Investments, Incorporated, a Nevada corporation, Partner

	 	 	 
	68.

	 	New Castle Corp., a Nevada corporation
	69.

	 	New PRMA Las Vegas, Inc., a Nevada corporation
	70.

	 	New York-New York Hotel & Casino, LLC,

a Nevada limited liability company
	71.

	 	New York-New York Tower, LLC, a Nevada limited liability company
	72.

	 	OE Pub, LLC, a Nevada limited liability company
	73.

	 	PRMA Land Development Company, a Nevada corporation
	74.

	 	PRMA, LLC, a Nevada limited liability company
	75.

	 	Project CC, LLC, a Nevada limited liability company
	76.

	 	Railroad Pass Investment Group, LLC, a Nevada limited liability company (successor in
interest to Railroad Pass Investment Group, a Nevada partnership)
	77.

	 	Ramparts, Inc., a Nevada corporation
	78.

	 	The Signature Condominiums, LLC, a Nevada limited liability company
	79.

	 	Signature Tower 2, LLC, a Nevada limited liability company
	80.

	 	Signature Tower 3, LLC, a Nevada limited liability company
	81.

	 	Signature Tower I, LLC, a Nevada limited liability company
	82.

	 	The Crystals at CityCenter Management, LLC, a Nevada limited liability company
	83.

	 	Tower B, LLC, a Nevada limited liability company

-2-

 

	 	 	 
	84.

	 	Tower C, LLC, a Nevada limited liability company
	85.

	 	Vdara Condo Hotel, LLC, a Nevada limited liability company
	86.

	 	Victoria Partners, a Nevada partnership

By: MRGS LLC, a Nevada limited liability company, Partner

By: Gold Strike L.V., a Nevada partnership, Partner

	 	 	 
	87.

	 	VidiAd, a Nevada corporation
	88.

	 	Vintage Land Holdings, LLC, a Nevada limited liability company
	89.

	 	Vintage Land Holdings II, LLC, a Nevada limited liability company

[The remainder of this page is intentionally left blank. Signature on the following page.]

-3-

 

	 	 	 	 	 
	 	 	 
	 	By:  	                                          /s/ John M. McManus
 	 
	 	 	Name:  	John M. McManus 	 
	 	 	Title:  	Secretary or Attorney-in-Fact,

as applicable, of each of the foregoing 	 
	 

-4-

 

EXHIBIT A

FORM OF 9% SENIOR SECURED NOTE DUE 2020

GLOBAL NOTE

CUSIP No.          1

     UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY
TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO MGM MIRAGE OR ITS AGENT FOR REGISTRATION OR
TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO.
OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS
MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF
DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS
WRONGFUL INASMUCH AS THE REGISTERED OWNED HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.

     THIS NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS
REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS NOTE MAY NOT BE EXCHANGED IN
WHOLE OR IN PART FOR A NOTE REGISTERED, AND NO TRANSFER OF THE NOTE IN WHOLE OR IN PART MAY BE
REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, EXCEPT IN
THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE.

     [THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN
ACCORDANCE WITH THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF OR OF A BENEFICIAL INTEREST
HEREIN, THE ACQUIRER:

     (1) REPRESENTS THAT IT, AND ANY ACCOUNT FOR WHICH IT IS ACTING, IS A “QUALIFIED
INSTITUTIONAL BUYER” (WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT) AND THAT IT
EXERCISES SOLE INVESTMENT DISCRETION WITH RESPECT TO EACH SUCH ACCOUNT, AND

     (2) AGREES FOR THE BENEFIT OF THE COMPANY THAT IT WILL NOT OFFER, SELL, PLEDGE OR
OTHERWISE TRANSFER THIS SECURITY OR ANY BENEFICIAL INTEREST HEREIN PRIOR TO THE RESALE
RESTRICTION TERMINATION DATE (AS DEFINED IN THE NEXT PARAGRAPH), EXCEPT:

 

			
	1	 	At such time as the Company notifies the
Trustee that the Private Placement Legend can be removed pursuant to the terms
of the Indenture, the CUSIP number for this Note shall be deemed to be CUSIP
No. [                    ].

A-1

 

     (A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF, OR

     (B) PURSUANT TO A REGISTRATION STATEMENT THAT HAS BECOME EFFECTIVE UNDER THE
SECURITIES ACT, OR

     (C) TO A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER THE
SECURITIES ACT, OR

     (D) PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144 UNDER THE
SECURITIES ACT OR ANY

     OTHER AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. THE
RESALE RESTRICTION TERMINATION DATE WILL BE THE DATE (1) THAT IS AT LEAST ONE YEAR AFTER THE LAST
ORIGINAL ISSUE DATE HEREOF AND (2) ON WHICH THE COMPANY INSTRUCTS THE TRUSTEE THAT THIS LEGEND
SHALL BE DEEMED REMOVED FROM THIS SECURITY, IN ACCORDANCE WITH THE PROCEDURES DESCRIBED IN THE
INDENTURE RELATING TO THIS SECURITY.

     PRIOR TO THE REGISTRATION OF ANY TRANSFER IN ACCORDANCE WITH (2)(D) ABOVE, THE COMPANY AND THE
TRUSTEE RESERVE THE RIGHT TO REQUIRE THE DELIVERY OF SUCH LEGAL OPINIONS, CERTIFICATIONS OR OTHER
EVIDENCE AS MAY REASONABLY BE REQUIRED IN ORDER TO DETERMINE THAT THE PROPOSED TRANSFER IS BEING
MADE IN COMPLIANCE WITH THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. NO REPRESENTATION
IS MADE AS TO THE AVAILABILITY OF ANY EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT.]2

     [THE RIGHTS ATTACHING TO THIS REGULATION S TEMPORARY GLOBAL NOTE, AND THE CONDITIONS AND
PROCEDURES GOVERNING ITS EXCHANGE FOR DEFINITIVE NOTES, ARE AS SPECIFIED IN THE INDENTURE. THE
HOLDER OF THIS NOTE BY ACCEPTANCE HEREOF ALSO AGREES, REPRESENTS AND WARRANTS THAT IF IT IS A
PURCHASER IN A SALE THAT OCCURS OUTSIDE THE UNITED STATES WITHIN THE MEANING OF REGULATION S OF THE
SECURITIES ACT, IT ACKNOWLEDGES THAT, UNTIL EXPIRATION OF THE “40-DAY DISTRIBUTION COMPLIANCE
PERIOD” WITHIN THE MEANING OF RULE 903 OF REGULATION S, ANY OFFER OR SALE OF THIS NOTE SHALL NOT BE
MADE BY IT TO A U.S. PERSON TO OR FOR THE ACCOUNT OR BENEFIT OF A U.S. PERSON WITHIN THE MEANING OF
RULE 902(k) UNDER THE SECURITIES ACT.]3

 

			
	2	 	Insert for Restricted Global Note.
	 
	3	 	Insert for Temporary Regulation S Global
Note.

A-2

 

MGM MIRAGE

9% Senior Secured Note Due March 15, 2020

			
	 	 	 
	No.      
	 	$[          ]

     MGM MIRAGE, a Delaware corporation (the “Company”), promises to pay to Cede & Co. or
registered assigns, or its registered assigns, the principal sum of
[________________] in U.S. Dollars
on March 15, 2020.

	 	 	 
	Interest Payment Dates:

	 	March 15 and September 15
	 
	Record Dates:

	 	March 1 and September 1

Additional provisions of this Note are set forth on the other side of this Note.

A-3

 

     IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed.

	 	 	 	 	 
	 	MGM MIRAGE

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

Attest:

 
Name:

Title:

[Authentication Page to Follow]

A-4

 

CERTIFICATE OF AUTHENTICATION

     This is one of the Notes designated therein referred to in the within-mentioned Indenture.

	 	 	 	 	 
	Dated: 	U.S. BANK NATIONAL ASSOCIATION, As Trustee

 	 
	 	By  	 	 
	 	 	Authorized Signatory 	 
	 

A-5

 

[FORM OF REVERSE SIDE OF NOTE]

9% Senior Secured Note Due March 15, 2020

	1.	 	INTEREST

     MGM MIRAGE, a Delaware corporation (the “Company”), promises to pay interest on the principal
amount of this Note at the rate per annum shown above and shall pay Additional Interest, if any,
payable pursuant to the relevant Registration Rights Agreement.

     The Company shall pay interest (including Additional Interest, if any) semi-annually in
arrears on March 15 and September 15 of each year commencing on September 15, 2010. Interest on
the Notes will accrue from the most recent date to which interest has been paid or, if no interest
has been paid, from March 15, 2010 with respect to this Note. Interest shall be computed on the
basis of a 360-day year comprised of twelve 30-day months.

	2.	 	METHOD OF PAYMENT

     The Company shall pay interest (except defaulted interest but including Additional Interest,
if any) on the Notes to the Persons who are registered Holders at the close of business on the
March 1 or September 1 immediately preceding the interest payment date even if Notes are cancelled
after the record date and on or before the interest payment date. Holders must surrender Notes to
the Paying Agent to collect principal payments. The Company shall pay principal and interest in
money of the United States that at the time of payment is legal tender for payment of public and
private debts. However, all payments in respect of this Note (including principal, premium, if
any, interest and Additional Interest, if any) must be made by wire transfer of immediately
available funds to the accounts specified by the Holder hereof.

	3.	 	PAYING AGENT AND REGISTRAR

     Initially, U.S. BANK NATIONAL ASSOCIATION (the “Trustee”) shall act as Paying Agent and
Registrar. The Company may appoint and change any Paying Agent or Registrar without notice to the
Holders. The Company or any domestically organized Subsidiary may act as Paying Agent or
Registrar.

	4.	 	INDENTURE AND SUBSIDIARY GUARANTEE

     The Company issued the Notes under an Indenture dated as of March 16, 2010 (the “Indenture”),
among the Company, the Subsidiary Guarantors and the Trustee. The terms of these Notes include
those stated in the Indenture and, if the Notes are registered under the Securities Act, those made
part of the Indenture by reference to the TIA. Terms defined in the Indenture and not defined
herein have the meanings ascribed thereto in the Indenture. These Notes are subject to all such
terms, and Holders are referred to the Indenture and, if applicable, the TIA, for a statement of
those terms.

     These Notes are secured senior obligations of the Company and is one of the Notes referred to
in the Indenture. These Notes include the Initial Notes and any Exchange Notes issued in exchange
for such Initial Notes pursuant to the Registration Rights Agreement and the Indenture. The
Initial Notes and such Exchange Notes are treated as a single class of Notes under the Indenture.

A-6

 

     The Subsidiary Guarantors have, jointly and severally, unconditionally guaranteed the
Guaranteed Obligations on a senior basis pursuant to Article X of the Indenture, with the
Subsidiary Guarantees of MGM Grand Hotel, LLC, a Nevada corporation, secured by the Collateral.

	5.	 	OPTIONAL REDEMPTION; MANDATORY DISPOSITION PURSUANT TO GAMING LAWS

     Prior to March 15, 2014, the Company may redeem all or a part of the Notes, in accordance with
the provisions of Article III of the Indenture, at a redemption price equal to 100% of the
principal amount of Notes redeemed plus the Applicable Premium as of, and accrued and unpaid
interest and Additional Interest, if any, to the date of redemption (the “Redemption Date”),
subject to the rights of Holders on the relevant Record Date prior to the Redemption Date to
receive interest due on the relevant Interest Payment Date.

     “Applicable Premium” means with respect to any Note on any Redemption Date, as determined by
the Company, the excess of:

          (a) the sum of the present values at such Redemption Date of the remaining scheduled
payments of principal and interest on the Note (excluding accrued but unpaid interest to the
Redemption Date), discounted to the Redemption Date on a semiannual basis using a discount
rate equal to the Treasury Rate as of such Redemption Date plus 50 basis points; over

          (b) the principal amount of the Note.

     The rights of each Holder or beneficial owner of these Notes are subject to the Gaming Laws
and requirements of the Gaming Authorities. Notwithstanding any other provision of the Indenture,
if any Gaming Authority requires that a Holder or beneficial owner of the Notes of a Holder must be
licensed, qualified or found suitable under any Gaming Law, such Holder or such beneficial owner
shall apply for a license, qualification or a finding of suitability, as the case may be, within
the required time period. If such person fails to apply or become licensed or qualified or is not
found suitable (in each case, a “failure of compliance”), the Company shall have the right, at its
option, (i) to require such Holder or owner to dispose of such Holder’s or beneficial owner’s Notes
within 30 days of receipt of notice of the Company’s election or such earlier date as may be
requested or prescribed by such Gaming Authority, or (ii) to redeem such Notes, which Redemption
Date may be less than 30 days following the notice of redemption if so requested or prescribed by
the Gaming Authority, at a redemption price equal to (a) the lesser of (1) the Holder’s cost, plus
accrued and unpaid interest, if any, to the earlier of the Redemption Date or the date of the
finding of unsuitability or failure to comply and (2) 100% of the principal amount thereof, plus
accrued and unpaid interest, if any, to the earlier of the Redemption Date and the date of the
finding of unsuitability or failure to comply or (b) such other amount as may be required by
applicable Gaming Laws or by order of any Gaming Authority. The Company shall notify the Trustee
in writing of any such failure of compliance or redemption as soon as practicable. The Company
shall not be responsible for any costs or expenses any such Holder or beneficial owner may incur in
connection with its application for a license, qualification or finding of suitability.
Immediately upon the imposition of a requirement to dispose of the Notes by a Gaming Authority,
such Holder or beneficial owner shall, to the extent required by applicable Gaming Laws, have no
further right (i) to exercise, directly or indirectly, through any trustee, nominee or any other
person or entity, any right conferred by the Notes, or (ii) to receive any remuneration in any form
with respect to the Notes from the Company or the Trustee, except the redemption price.

A-7

 

	6.	 	NOTICES OF REDEMPTION

     Notice of redemption shall be given by the Company, or at the Company’s written request, by
the Trustee in the name and at the expense of the Company, not less than 20 Business Days and not
more than 60 days prior to the Redemption Date to the Holders of the Notes to be redeemed upon the
terms provided in the Indenture; provided that a notice of redemption may be mailed more than 60
days prior to a Redemption Date if such notice is issued in connection with the satisfaction and
discharge of the Indenture pursuant to Section 8.01 of the Indenture or Covenant Defeasance or
Legal Defeasance pursuant to Section 8.04 of the Indenture. If the Company is purchasing or
redeeming less than all of the Notes, the Trustee will select the Notes to be purchased or redeemed
(a) if the Notes are listed on any national securities exchange, in compliance with the
requirements of the principal national securities exchange on which the Notes are listed or (b) on
a pro rata basis to the extent practicable or, to the extent that selection on a pro rata basis is
not practicable, by lot or such other similar method in accordance with the procedures of the
Depositary. On and after the Redemption Date, interest ceases to accrue on such Notes or portions
of them called for redemption.

	7.	 	PURCHASE UPON A CHANGE OF CONTROL

     If a Change of Control occurs, unless the Company has previously or concurrently mailed a
redemption notice with respect to all the Notes pursuant to Section 3.01 of the Indenture, the
Company will make an offer to purchase all of the Notes at a price equal to 101% of the aggregate
principal amount thereof plus accrued and unpaid interest, if any, to the date of purchase, in
accordance with the procedures set forth in the Indenture.

	8.	 	NON-COLLATERAL ASSET SALES

     In the event of a Non-Collateral Asset Sale, the Company may be required to make an offer to
purchase all or a portion of the Notes at an offer price in cash equal to 100% of the principal
amount of such Notes plus accrued and unpaid interest, if any, to the date of purchase, in
accordance with the procedures set forth in the Indenture.

	9.	 	COLLATERAL ASSET SALES

     In the event of a Collateral Asset Sale, the Company may be required to make an offer to
purchase all or a portion of the Notes at an offer price in cash equal to 100% of the principal
amount of such Notes plus accrued and unpaid interest to the date of purchase, in accordance with
the procedures set forth in the Indenture.

	10.	 	EVENTS OF LOSS

     In the event of an Event of Loss, the Company may be required to make an offer to purchase all
or a portion of the Notes at an offer price in cash equal to 100% of the principal amount of such
Notes plus accrued and unpaid interest, if any, to the date of purchase, in accordance with the
procedures set forth in the Indenture.

	11.	 	DENOMINATIONS; TRANSFER; EXCHANGE

     The Notes are in registered form without coupons in denominations of $2,000 and whole
multiples of $1,000. A Holder may transfer or exchange Notes in accordance with the Indenture.
Upon

A-8

 

any transfer or exchange, the Registrar and the Trustee may require a Holder, among other
things, to furnish appropriate transfer documents and to pay any taxes required by law or permitted
by the Indenture. The Registrar shall not be required (A) to issue, to register the transfer of or
to exchange any Notes during a period beginning at the opening of business 15 calendar days before
the day of any selection of Notes for redemption and ending at the close of business on the day of
selection, (B) to register the transfer of or to exchange any Note so selected for redemption in
whole or in part, except the unredeemed portion of any Note being redeemed in part or (C) to
register the transfer of or to exchange a Note between a Regular Record Date and the next
succeeding Interest Payment Date.

	12.	 	PERSONS DEEMED OWNERS

     The registered Holder of this Note may be treated as the owner of it for all purposes.

	13.	 	UNCLAIMED MONEY

     If money for the payment of principal or interest in respect of these Notes remains unclaimed
for two years, the Paying Agent shall pay the money back to the Company at its request, or if then
held by the Company or a domestic Subsidiary, shall be discharged from such trust (unless an
abandoned property law designates another Person for payment thereof). After any such payment,
Holders entitled to the money must look only to the Company for payment thereof, and all liability
of the Paying Agent with respect to such money, and all liability of the Company or such permitted
Subsidiary as trustee thereof, shall thereupon cease.

	14.	 	DISCHARGE AND DEFEASANCE

     Subject to certain conditions set forth in the Indenture, the Company at any time may
terminate some or all of its obligations under the Indenture with respect to these Notes if, among
other things, the Company deposits with the Trustee cash in Dollars, Government Securities, or a
combination thereof, in such amounts as will be sufficient, in the opinion of a nationally
recognized firm of independent public accountants, to pay the principal of, premium, if any, and
interest due on the Notes at the Stated Maturity or on the Redemption Date, as the case may be, of
such principal, premium, if any, or interest on the Notes.

	15.	 	AMENDMENT, WAIVER

     The Indenture permits, with certain exceptions as therein provided, the amendment thereof and
the modification of the rights and obligations of the Company and the rights of the Holders under
the Indenture at any time by the Company and the Trustee with the consent of the Holders of a
majority in principal amount of Outstanding Notes. The Indenture also contains provisions, with
certain exceptions as therein provided, permitting the Holders of a majority in principal amount of
the Outstanding Notes, on behalf of the Holders of all such Notes, to waive compliance by the
Company with certain provisions of the Indenture and certain past Defaults under the Indenture and
their consequences. The Indenture also permits certain other amendments, modifications or waivers
thereof only with the consent of all affected Holders, while certain other amendments or
modifications may be made without the consent of any Holders.

     A consent to a supplemental indenture or waiver by a Holder shall bind such Holder and every
subsequent Holder of the applicable Note or portion thereof that evidences the same Indebtedness as
the consenting Holder’s Note, even if notation of the consent or waiver is not made on the Note.
After

A-9

 

a supplemental indenture or waiver becomes effective, it shall bind every Holder. The Company
may, but shall not be obligated to, fix a record date for the purpose of determining the Holders
entitled to give their consent or take any other action described above or required or permitted to
be taken pursuant to this Indenture. If a record date is fixed, then notwithstanding the
immediately preceding paragraph, those Persons who were Holders at such record date (or their duly
designated proxies), and only those Persons, shall be entitled to give such consent or to revoke
any consent previously given or to take any such action, whether or not such Persons continue to be
Holders after such record date.

	16.	 	DEFAULTS AND REMEDIES

     Events of Default are set forth in the Indenture. If an Event of Default (other than certain
bankruptcy Events of Default) occurs and is continuing, then in every such case the Trustee or the
Holders of not less than 25% in principal amount of the Outstanding Notes may declare the principal
amount of all the Notes to be due and payable immediately, by a notice in writing to the Company
(and to the Trustee if given by such Holders), and upon any such declaration such principal amount
of the Notes (or specified amount) plus accrued and unpaid interest thereon (and premium, if
payable) shall become immediately due and payable.

     Holders may not enforce the Indenture, the Notes or the other Transaction Documents except as
provided in the Indenture. The Trustee may refuse to enforce the Indenture, the Notes or the other
Transaction Documents unless it receives reasonable indemnity or security. Subject to certain
limitations, the Holders of at least a majority in principal amount of the Outstanding Notes shall
have the right to direct the time, method and place of conducting any proceeding for any remedy
available to the Trustee or exercising any trust or power conferred on the Trustee with respect to
the Transaction Documents. The Trustee may withhold from the Holders notice of any continuing
Default, except a Default relating to the payment of principal, premium, if any, or interest, if it
determines that withholding notice is in their interest.

	17.	 	TRUSTEE DEALINGS WITH THE COMPANY

     Subject to certain limitations, the Trustee, any Paying Agent, the Registrar or any other
agent of the Company, in its individual or any other capacity, may become the owner or pledgee of
Notes and may otherwise deal with the Company with the same rights it would have if it were not
Trustee, Paying Agent, Registrar or such other agent.

	18.	 	NO PERSONAL LIABILITY OF DIRECTORS, OFFICERS, EMPLOYEES AND STOCKHOLDERS

     No director, officer, employee, incorporator or stockholder of the Company or any Subsidiary
Guarantor or any of their parent companies shall have any liability for any Obligations of the
Company or the Subsidiary Guarantors under the Notes, the Subsidiary Guarantees, the Indenture or
the Collateral Documents or for any claim based on, in respect of, or by reason of such Obligations
or their creation. Each Holder by accepting the Notes waives and releases all such liability. The
waiver and release are part of the consideration for issuance of the Notes. Such waiver may not be
effective to waive liabilities under the federal securities laws and it is the view of the
Commission that such waiver is against public policy and is therefore unenforceable.

A-10

 

	19.	 	GOVERNING LAW

     THE NOTES SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF
NEVADA BUT WITHOUT GIVING EFFECT TO APPLICABLE PRINCIPLES OF CONFLICTS OF LAW TO THE EXTENT THAT
THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION WOULD BE REQUIRED THEREBY.

	20.	 	AUTHENTICATION

     This Note and the Subsidiary Guarantee endorsed hereon shall not be valid until an authorized
signatory of the Trustee (or an authenticating agent) manually signs the certificate of
authentication on the other side of this Note.

	21.	 	ABBREVIATIONS

     Customary abbreviations may be used in the name of a Holder or an assignee, such as TEN COM
(=tenants in common), TEN ENT (=tenants by the entireties), JT TEN (=joint tenants with rights of
survivorship and not as tenants in common), CUST (=custodian), and U/G/M/A (=Uniform Gift to Minors
Act).

	22.	 	CUSIP NUMBERS

     Pursuant to a recommendation promulgated by the Committee on Uniform Security Identification
Procedures the Company has caused CUSIP numbers to be printed on the Notes and has directed the
Trustee to use CUSIP numbers in notices of redemption as a convenience to Holders. No
representation is made as to the accuracy of such numbers either as printed on the Notes or as
contained in any notice of redemption and reliance may be placed only on the other identification
numbers placed thereon.

     The Company shall furnish to any Holder upon written request and without charge to the Holder
a copy of the Indenture which has in it the text of this Note in larger type. Requests may be made
to:

MGM MIRAGE

3600 Las Vegas Boulevard South, Las Vegas, Nevada 89109

Attention of Secretary

A-11

 

ASSIGNMENT FORM

To assign this Note, fill in the form below:

I or we assign and transfer this Note to

(Print or type assignee’s name, address and zip code)

(Insert assignee’s soc. sec. or tax I.D. No.)

and irrevocably appoint agent to transfer this Note on the books of MGM MIRAGE. The agent may

substitute another to act for him.

Date:
                     Your Signature:
                                          

Signature Guarantee:

 
Signature must be guaranteed by a

participant in a recognized signature

guarantee medallion program)

Sign exactly as your name appears on the other side of this Note.

A-12

 

SCHEDULE OF INCREASES OR DECREASES IN GLOBAL NOTE

The following increases or decreases in this Global Note have been made:

	 	 	 	 	 	 	 	 	 
	Date of Exchange

	 	Amount of decrease in 

Principal Amount of
this 
Global Note
	 	Amount of increase
in
 Principal Amount
of this
 Global Note
	 	Principal amount of
this 

Global Note
following such 

decrease or
increase
	 	Signature of
autho-

rized
signatory of 

Trustee or Notes

Custodian

A-13

 

OPTION OF HOLDER TO ELECT PURCHASE

          If you want to elect to have this Note purchased by the Company pursuant to Section 4.09,
Section 4.10, Section 4.11 or Section 4.12 of the Indenture, check the box:

o  4.09 Change of Control

o  4.10 Non-Collateral Asset Sale

o  4.11 Collateral Asset Sale

o  4.12 Event of Loss

          If you want to elect to have only part of this Note purchased by the Company pursuant to
Section 4.09, Section 4.10, Section 4.11 or Section 4.12 of the Indenture, state the amount: $                    .

	 	 	 
	
          Date:                     

	 	Your Signature:

	 

	 	(Sign exactly as your name appears 

on the other side of the Security)

Tax I.D. number

Signature Guarantee:

 
(Signature must be guaranteed by a

participant in a recognized signature

guarantee medallion program)

A-14

 

EXHIBIT B

[FORM OF CERTIFICATE OF TRANSFER]

MGM MIRAGE

U.S. BANK NATIONAL ASSOCIATION

60 Livingston Avenue

St. Paul, Minnesota 55107-1419

Attention: Corporate Trust Trustee Administration

	 	Re: 	 	 MGM MIRAGE (the “Company”)

9% Senior Secured Notes due 2020 (CUSIP [      ]) (the “Notes”)

     Reference is hereby made to the Indenture, dated as of March 16, 2010 (the “Indenture”), among
the Company, the Subsidiary Guarantors party thereto and U.S. Bank National Association, as
Trustee. Capitalized terms used but not defined herein shall have the meanings given to them in
the Indenture.

                          (the “Transferor”) owns and proposes to transfer the Note[s] or interest in such
Note[s] specified in Annex A hereto, in the principal amount of $ in such Note[s] or interests (the
“Transfer”), to                      (the “Transferee”), as further specified in Annex A hereto. In
connection with the Transfer, the Transferor hereby certifies that:

[CHECK ALL THAT APPLY]

	1.	o 	Check if Transferee will take delivery of a beneficial interest in the 144A Global Note
or a Definitive Note Pursuant to Rule 144A. The Transfer is being effected pursuant to
and in accordance with Rule 144A under the United States Securities Act of 1933, as amended
(the “Securities Act”), and, accordingly, the Transferor hereby further certifies that the
beneficial interest or Definitive Note is being transferred to a Person that the Transferor
reasonably believed and believes is purchasing the beneficial interest or Definitive Note for
its own account, or for one or more accounts with respect to which such Person exercises sole
investment discretion, and such Person and each such account is a “qualified institutional
buyer” within the meaning of Rule 144A in a transaction meeting the requirements of Rule 144A
and such Transfer is in compliance with any applicable blue sky securities laws of any state
of the United States. Upon consummation of the proposed Transfer in accordance with the terms
of the Indenture, the transferred beneficial interest or Definitive Note will be subject to
the restrictions on transfer enumerated in the Private Placement Legend printed on the 144A
Global Note and/or the Definitive Note and in the Indenture and the Securities Act.
	 
	2.	o 	Check if Transferee will take delivery of a beneficial interest in the Regulation S
Global Note or a Definitive Note pursuant to Regulation S. The Transfer is being effected
pursuant to and in accordance with Rule 903 or Rule 904 under the Securities Act and,
accordingly, the Transferor hereby further certifies that (i) the Transfer is not being made
to a Person in the United States and (x) at the time the buy order was originated, the
Transferee was outside the United States or such Transferor and any Person acting on its
behalf reasonably believed and believes that the Transferee was out-

B-1

 

	 	 	side the United States or
(y) the transaction was executed in, on or through the facilities
of a designated offshore securities market and neither such Transferor nor
any Person acting on its behalf knows that the transaction was prearranged with a
buyer in the United States, (ii) no directed selling efforts have been made in
contravention of the requirements of Rule 903(b) or Rule 904(b) of Regulation S
under the Securities Act, (iii) the transaction is not part of a plan or scheme to
evade the registration requirements of the Securities Act and (iv) if the proposed
transfer is being made prior to the expiration of the Restricted Period, the
transfer is not being made to a U.S. Person or for the account or benefit of a U.S.
Person (other than an Initial Purchaser). Upon consummation of the proposed
transfer in accordance with the terms of the Indenture, the transferred beneficial
interest or Definitive Note will be subject to the restrictions on Transfer
enumerated in the Private Placement Legend printed on the Regulation S Global Note
and/or the Definitive Note and in the Indenture and the Securities Act.
	 
	3.	o 	Check and complete if Transferee will take delivery of a beneficial interest in a
Definitive Note pursuant to any provision of the Securities Act other than Rule 144A or
Regulation S. The Transfer is being effected in compliance with the transfer restrictions
applicable to beneficial interests in Restricted Global Notes and Restricted Definitive Notes
and pursuant to and in accordance with the Securities Act and any applicable blue sky
securities laws of any state of the United States, and accordingly the Transferor hereby
further certifies that (check one):

	 	(a)	o 	such Transfer is being effected pursuant to and in accordance
with Rule 144 under the Securities Act;

or

	 	(b)	o 	or such Transfer is being effected to the Company or a
subsidiary thereof;

or

	 	(c)	o 	such Transfer is being effected pursuant to an effective
registration statement under the Securities Act and in compliance with the
prospectus delivery requirements of the Securities Act.

	4.	o 	Check if Transferee will take delivery of a beneficial interest in an Unrestricted Global
Note or of an Unrestricted Definitive Note.

	 	(a)	o 	Check if Transfer is Pursuant to Rule 144. (i) The Transfer is
being effected pursuant to and in accordance with Rule 144 under the Securities
Act and in compliance with the transfer restrictions contained in the Indenture
and any applicable blue sky securities laws of any state of the United States
and (ii) the restrictions on transfer contained in the Indenture and the
Private Placement Legend are not required in order to maintain compliance with
the Securities Act. Upon consummation of the proposed Transfer in accordance
with the terms of the Indenture, the transferred beneficial interest or
Definitive Note

B-2

 

	 	 	 	will no longer be subject to the restrictions on transfer
enumerated in
the Private Placement Legend printed on the Restricted Global Notes,
on Restricted Definitive Notes and in the Indenture.
	 
	 	(b)	o 	Check if Transfer is Pursuant to Regulation S. (i) The
Transfer is being effected pursuant to and in accordance with Rule 903 or Rule
904 under the Securities Act and in compliance with the transfer restrictions
contained in the Indenture and any applicable blue sky securities laws of any
state of the United States and (ii) the restrictions on transfer contained in
the Indenture and the Private Placement Legend are not required in order to
maintain compliance with the Securities Act. Upon consummation of the proposed
Transfer in accordance with the terms of the Indenture, the transferred
beneficial interest or Definitive Note will no longer be subject to the
restrictions on transfer enumerated in the Private Placement Legend printed on
the Restricted Global Notes, on Restricted Definitive Notes and in the
Indenture.
	 
	 	(c)	o 	Check if Transfer is Pursuant to Other Exemption. (i) The
Transfer is being effected pursuant to and in compliance with an exemption from
the registration requirements of the Securities Act other than Rule 144, B-2
Rule 903 or Rule 904 and in compliance with the transfer restrictions contained
in the Indenture and any applicable blue sky securities laws of any State of
the United States and (ii) the restrictions on transfer contained in the
Indenture and the Private Placement Legend are not required in order to
maintain compliance with the Securities Act. Upon consummation of the proposed
Transfer in accordance with the terms of the Indenture, the transferred
beneficial interest or Definitive Note will not be subject to the restrictions
on transfer enumerated in the Private Placement Legend printed on the
Restricted Global Notes or Restricted Definitive Notes and in the Indenture.

     This certificate and the statements contained herein are made for your benefit and the benefit
of the Company.

	 	 	 	 	 
	 	[Insert Name of Transferor]

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

Dated:

B-3

 

ANNEX A TO CERTIFICATE OF TRANSFER

	1.	 	The Transferor owns and proposes to transfer the following:

[CHECK ONE OF (a) OR (b)]

	 	(a)	o 	a beneficial interest in the:

	 	(i)	o 	144A Global Note (CUSIP 552953 BP5), or
	 
	 	(ii)	o 	Regulation S Global (CUSIP U5928T AN1)), or

	 	(b)	o 	a Restricted Definitive Note.

	2.	 	After the Transfer the Transferee will hold:

[CHECK ONE]

	 	(a)	o 	a beneficial interest in the:

	 	(i)	o 	144A Global Note (CUSIP 552953 BP5), or
	 
	 	(ii)	o 	Regulation S Global Note (CUSIP U5928T AN1), or
	 
	 	(iii)	o 	Unrestricted Global Note (CUSIP U5928T AN1), or

	 	(b)	o 	a Restricted Definitive Note, or
	 
	 	(c)	o 	an Unrestricted Definitive Note,

in accordance with the terms of the Indenture.

B-4

 

EXHIBIT C

[FORM OF CERTIFICATE OF EXCHANGE]

MGM MIRAGE

U.S. BANK NATIONAL ASSOCIATION

60 Livingston Avenue

St. Paul, Minnesota 55107-1419

Attention: Corporate Trust Trustee Administration

	 	Re: 	 	 MGM MIRAGE (the “Company”)

9% Senior Secured Notes due 2020 (CUSIP [      ]) (the “Notes”)

     Reference is hereby made to the Indenture, dated as of March 16, 2010 (the “Indenture”), among
the Company, the Subsidiary Guarantors party thereto and U.S. Bank National Association, as
Trustee. Capitalized terms used but not defined herein shall have the meanings given to them in
the Indenture.

                          (the “Owner”) owns and proposes to exchange the Note[s] or interest in such
Note[s] specified herein, in the principal amount of $                     in such Note[s] or
interests (the “Exchange”). In connection with the Exchange, the Owner hereby certifies that:

     1. Exchange of Restricted Definitive Notes or Beneficial Interests in a Restricted Global
Note for Unrestricted Definitive Notes or Beneficial Interests in an Unrestricted Global Note.

     (a) o Check if Exchange is from beneficial interest in a Restricted Global Note to
beneficial interest in an Unrestricted Global Note. In connection with the Exchange of the Owner’s
beneficial interest in a Restricted Global Note for a beneficial interest in an Unrestricted Global
Note in an equal principal amount, the Owner hereby certifies (i) the beneficial interest is being
acquired for the Owner’s own account without transfer, (ii) such Exchange has been effected in
compliance with the transfer restrictions applicable to the Global Notes and pursuant to and in
accordance with the United States Securities Act of 1933, as amended (the “Securities Act”), (iii)
the restrictions on transfer contained in the Indenture and the Private Placement Legend are not
required in order to maintain compliance with the Securities Act and (iv) the beneficial interest
in an Unrestricted Global Note is being acquired in compliance with any applicable blue sky
securities laws of any state of the United States.

     (b) o Check if Exchange is from beneficial interest in a Restricted Global Note to
Unrestricted Definitive Note. In connection with the Exchange of the Owner’s beneficial interest
in a Restricted Global Note for an Unrestricted Definitive Note, the Owner hereby certifies (i) the
Definitive Note is being acquired for the Owner’s own account without transfer, (ii) such Exchange
has been effected in compliance with the transfer restrictions applicable to the Restricted Global
Notes and pursuant to and in accordance with the Securities Act, (iii) the restrictions on transfer
contained in the Indenture and the Private Placement Legend are not required in order to maintain
compliance with the Securities Act and (iv) the Definitive Note is being acquired in compliance
with any applicable blue sky securities laws of any state of the United States.

C-1

 

     (c) o Check if Exchange is from Restricted Definitive Note to beneficial interest in an
Unrestricted Global Note. In connection with the Owner’s Exchange of a Restricted Definitive Note
for a beneficial interest in an Unrestricted Global Note, the Owner hereby certifies (i) the
beneficial interest is being acquired for the Owner’s own account without transfer, (ii) such
Exchange has been effected in compliance with the transfer restrictions applicable to Restricted
Definitive Notes and pursuant to and in accordance with the Securities Act, (iii) the restrictions
on transfer contained in the Indenture and the Private Placement Legend are not required in order
to maintain compliance with the Securities Act and (iv) the beneficial interest is being acquired
in compliance with any applicable blue sky securities laws of any state of the United States.

     (d) o Check if Exchange is from Restricted Definitive Note to Unrestricted Definitive
Note. In connection with the Owner’s Exchange of a Restricted Definitive Note for an Unrestricted
Definitive Note, the Owner hereby certifies (i) the Unrestricted Definitive Note is being acquired
for the Owner’s own account without transfer, (ii) such Exchange has been effected in compliance
with the transfer restrictions applicable to Restricted Definitive Notes and pursuant to and in
accordance with the Securities Act, (iii) the restrictions on transfer contained in the Indenture
and the Private Placement Legend are not required in order to maintain compliance with the
Securities Act and (iv) the Unrestricted Definitive Note is being acquired in compliance with any
applicable blue sky securities laws of any state of the United States.

     2. Exchange of Restricted Definitive Notes or Beneficial Interests in Restricted Global
Notes for Restricted Definitive Notes or Beneficial Interests in Restricted Global Notes.

     (a) o Check if Exchange is from beneficial interest in a Restricted Global Note to
Restricted Definitive Note. In connection with the Exchange of the Owner’s beneficial interest in
a Restricted Global Note for a Restricted Definitive Note with an equal principal amount, the Owner
hereby certifies that the Restricted Definitive Note is being acquired for the Owner’s own account
without transfer. Upon consummation of the proposed Exchange in accordance with the terms of the
Indenture, the Restricted Definitive Note issued will continue to be subject to the restrictions on
transfer enumerated in the Private Placement Legend printed on the Restricted Definitive Note and
in the Indenture and the Securities Act.

     (b) o Check if Exchange is from Restricted Definitive Note to beneficial interest in a
Restricted Global Note. In connection with the Exchange of the Owner’s Restricted Definitive Note
for a beneficial interest in the [CHECK ONE]
___ 144A Global Note, ___Regulation S Global Note
with an equal principal amount, the Owner hereby certifies (i) the beneficial interest is being
acquired for the Owner’s own account without transfer and (ii) such Exchange has been effected in
compliance with the transfer restrictions applicable to the Restricted Global Notes and pursuant to
and in accordance with the Securities Act, and in compliance with any applicable blue sky
securities laws of any state of the United States. Upon consummation of the proposed Exchange in
accordance with the terms of the Indenture, the beneficial interest issued will be subject to the
restrictions on transfer enumerated in the Private Placement Legend printed on the relevant
Restricted Global Note and in the Indenture and the Securities Act.

C-2

 

     This certificate and the statements contained herein are made for your benefit and the benefit
of the Company.

	 	 	 	 	 
	 	[Insert Name of Transferor]

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

Dated:                          

C-3

 

EXHIBIT D

FORM OF INSTRUMENT OF JOINDER

(INDENTURES)

     THIS INSTRUMENT OF JOINDER (“Joinder”) is executed as of                     , by the
undersigned Subsidiaries of (“Joining Parties”), with reference to the following Subsidiary
Guarantees:

	1.	 	Guarantee of 7.25% Debentures due 2017. The Guarantee dated as of May 31, 2000, made
by MGM (under its former name MGM Grand), and certain subsidiaries of MGM in favor of First
Security Bank, National Association (the “7.25% Mirage Guarantee”), for the Holders of
Mirage’s 7.25% Debentures due 2017 issued pursuant to the Indenture dated as of August 1,
1997, between Mirage and First Security Bank, National Association, as Trustee (the “Mirage
7.25% Indenture”).
	 
	2.	 	Guarantee of 8.50% Notes Due 2010. The Guarantee dated as of September 17, 2003,
made by certain subsidiaries of MGM in favor of BNY Western Trust Company, as successor to
U.S. Trust Company, National Association (the “8.50% Guarantee”), for the Holders of MGM’s
8.50% Senior Notes due 2010 issued pursuant to the Indenture dated as of September 15, 2000,
between MGM and U.S. Trust Company, National Association, as Trustee (the “8.50% Indenture”).
	 
	3.	 	Guarantee of 5.875% Notes Due 2014. The Guarantee dated as of February 27, 2004,
made by certain subsidiaries of MGM in favor of U.S. Bank National Association (the “February
5.875% Guarantee”), for the Holders of MGM’s 5.875% Senior Notes due 2014 (including such
5.875% Senior Notes issued in the exchange offer for the 5.875% Senior Notes due 2014) issued
pursuant to the Indenture dated as of February 27, 2004, among MGM, the subsidiary guarantors
party thereto and U.S. Bank National Association, as Trustee (the “5.875% Indenture”).
	 
	4.	 	Guarantee of 5.875% Notes Due 2014. The Guarantee dated as of March 23, 2004, made
by certain subsidiaries of MGM in favor of U.S. Bank National Association (the “March 5.875%
Guarantee”), for the Holders of MGM’s 5.875% Senior Notes due 2014 (including such 5.875%
Senior Notes issued in the exchange offer for the 5.875% Senior Notes due 2014) issued
pursuant to the Indenture dated as of March 23, 2004, among MGM, the subsidiary guarantors
party thereto and U.S. Bank National Association, as Trustee (the “March 5.875% Indenture”).
	 
	5.	 	Guarantee of 6.75% Notes Due 2012. The Guarantee dated as of August 25, 2004, made
by certain subsidiaries of MGM in favor of U.S. Bank National Association (the “2004 6.75%
Guarantee”), for the Holders of MGM’s 6.75% Senior Notes due 2012 (including such 6.75% Senior
Notes issued in any exchange offer for the 6.75% Senior Notes due 2012) issued pursuant to the
Indenture dated as of August 25, 2004, among MGM, the subsidiary guarantors party thereto and
U.S. Bank National Association, as Trustee (the “2004 6.75% Indenture”).
	 
	6.	 	Guarantee of 6.375% Notes Due 2011. The Guarantee dated as of April 25, 2005, made
by MGM and certain subsidiaries of MGM in favor of The Bank of New York (the “6.375%
Guarantee”), for the Holders of Mandalay’s 6.375% Senior Notes due 2011 (including such

D-1

 

	 	 	6.375% Senior Notes issued in any exchange offer for the 6.375% Senior Notes due 2011)
issued pursuant to the Indenture dated as of November 25, 2003, between Mandalay and The
Bank of New York, as Trustee (the “6.375% Indenture”).
	 
	7.	 	Guarantee of Floating Rate Convertible Debentures Due 2033. The Guarantee dated as
of April 25, 2005, made by MGM and certain subsidiaries of MGM in favor of The Bank of New
York (the “Convertible Debentures Guarantee”), for the Holders of Mandalay’s Floating Rate
Convertible Debentures due 2033 issued pursuant to the First Supplemental Indenture dated as
of July 26, 2004 to the Indenture dated as of March 21, 2003, between Mandalay, the subsidiary
guarantors party thereto and The Bank of New York, as Trustee (the “ Floating Rate Convertible
Debentures Indenture”).
	 
	8.	 	Guarantee of 7.00% Debentures Due 2036. The Guarantee dated as of April 25, 2005,
made by MGM and certain subsidiaries of MGM in favor of Wells Fargo Bank (Colorado), N.A.
(the “7.00% Debentures Guarantee”), for the Holders of Mandalay’s 7.00% Debentures due 2036
issued pursuant to the Supplemental Indenture dated as of November 15, 1996 to the Indenture
dated as of November 15, 1996, between Mandalay and Wells Fargo Bank (Colorado), N.A., as
Trustee (the “7.00% Debentures Indenture”).
	 
	9.	 	Guarantee of 6.70% Debentures Due 2096. The Guarantee dated as of April 25, 2005,
made by MGM and certain subsidiaries of MGM in favor of Wells Fargo Bank (Colorado), N.A.
(the “6.70% Debentures Guarantee”), for the Holders of Mandalay’s 6.70% Debentures due 2096
issued pursuant to the Supplemental Indenture dated as of November 15, 1996 to the Indenture
dated as of February 1, 1996, between Mandalay and Wells Fargo Bank (Colorado), N.A., as
Trustee (the “6.70% Debentures Indenture”).
	 
	10.	 	Guarantee of 6.625% Notes Due 2015. The Guarantee dated as of June 20, 2005, made by
certain subsidiaries of MGM in favor of U.S. Bank National Association (the “June 6.625%
Guarantee”), for the Holders of MGM’s 6.625% Senior Notes due 2015 (including such 6.625%
Senior Notes issued in any exchange offer for the 6.625% Senior Notes due 2015) issued
pursuant to the Indenture dated as of June 20, 2005, among MGM, the subsidiary guarantors
party thereto and U.S. Bank National Association, as Trustee (the “6.625% Indenture”).
	 
	11.	 	Guarantee of 6.625% Notes Due 2015. The Guarantee dated as of September 9, 2005,
made by certain subsidiaries of MGM in favor of U.S. Bank National Association (the “September
6.625% Guarantee”), for the Holders of MGM’s 6.625% Senior Notes due 2015 issued pursuant to
the 6.625% Indenture, as supplemented by the First Supplement Indenture dated as of September
9, 2005, among MGM, the subsidiary guarantors party thereto and U.S. Bank National
Association, as Trustee.
	 
	12.	 	Guarantee of 6.75% Notes Due 2013. The Guarantee dated as of April 5, 2006, made by
certain subsidiaries of MGM in favor of U.S. Bank National Association (the “2006 6.75%
Guarantee”), for the Holders of MGM’s 6.75% Senior Notes due 2013 (including such 6.75% Senior
Notes due 2013 issued in any exchange offer for the 6.75% Senior Notes due 2013) issued
pursuant to the Indenture dated as of April 5, 2006, among MGM, the subsidiary guarantors
party thereto and U.S. Bank National Association, as Trustee (the “2006 6.75% and 6.875%
Indenture”).

D-2

 

	13.	 	Guarantee of 6.875% Notes Due 2016.The Guarantee dated as of April 5, 2006, made by
certain subsidiaries of MGM in favor of U.S. Bank National Association (the “6.875%
Guarantee”), for the Holders of MGM’s 6.875% Senior Notes due 2016 (including such 6.875%
Senior Notes due 2016 issued in any exchange offer for the 6.875% Senior Notes due 2016)
issued pursuant to the 2006 6.75% and 6.875% Indenture.
	 
	14.	 	Guarantee of 7.625% Notes Due 2017. The Guarantee dated as of December 21, 2006,
made by certain subsidiaries of MGM in favor of U.S. Bank National Association (the “7.625%
Guarantee”), for the Holders of MGM’s 7.625% Senior Notes due 2017 issued pursuant to the
Indenture dated as of December 21, 2006 (the “Base Indenture”), between MGM and U.S. Bank
National Association, as Trustee (the “7.625% Trustee”), as supplemented by the First
Supplemental Indenture dated as of December 21, 2006, among MGM, the subsidiary guarantors
party thereto and the 7.625% Trustee.
	 
	15.	 	Guarantee of 7.50% Notes Due 2016. The Guarantee dated as of May 17, 2007, made by
certain subsidiaries of MGM in favor of U.S. Bank National Association (the “7.50%
Guarantee”), for the Holders of MGM’s 7.50% Senior Notes due 2016 issued pursuant to the Base
Indenture, as supplemented by the Second Supplemental Indenture dated as of May 17, 2007,
among MGM, the subsidiary guarantors party thereto and the 7.625% Trustee.
	 
	16.	 	Guarantee of 13.00% Senior Secured Notes Due 2013. The Subsidiary Guarantee dated as
of November 14, 2008 made by certain subsidiaries of MGM in favor of U.S. Bank National
Association (the “13.00% Guarantee”), for the Holders of MGM’s 13.00% Senior Secured Notes due
2013 issued pursuant to the Indenture dated as of November 14, 2008 among MGM, the subsidiary
guarantors party thereto and U.S. Bank National Association, as Trustee (the “13.00% Senior
Secured Indenture”).
	 
	17.	 	Guarantee of Senior Secured Notes Due 2014 and 2017. The Subsidiary Guarantee dated
as of May 19, 2009 made by certain subsidiaries of MGM in favor of U.S. Bank National
Association (the “2014 and 2017 Guarantee”), for the Holders of MGM’s 10.375% Senior Secured
Notes due 2014 and 11.125% Senior Secured Notes due 2017 issued pursuant to the Indenture
dated as of May 19, 2009 among MGM, the subsidiary guarantors party thereto and U.S. Bank
National Association, as Trustee (the “2014 and 2017 Indenture”).
	 
	18.	 	Guarantee of Senior Secured Notes Due 2020. The Subsidiary Guarantee dated as of
March 16, 2010 made by certain subsidiaries of MGM in favor of U.S. Bank National Association
(the “9% Guarantee”), for the Holders of MGM’s 9% Senior Secured Notes due 2020 issued
pursuant to the Indenture dated as of March 16, 2010 among MGM, the subsidiary guarantors
party thereto and U.S. Bank National Association, as Trustee (the “9% Indenture”).

     (The 7.25% Mirage Guarantee, the 8.50% Guarantee, the February 5.875% Guarantee, the March
5.875% Guarantee, the 2004 6.75% Guarantee, the 6.375% Guarantee, the Convertible Debentures
Guarantee, the 7.00% Debentures Guarantee, the 6.70% Debentures Guarantee, the June 6.625%
Guarantee, the September 6.625% Guarantee, the 2006 6.75% Guarantee and the 6.875% Guarantee, the
7.625% Guarantee, the 7.50% Guarantee, the 13.00% Guarantee, the 2014 and 2017 Guarantee and the 9%
Guarantee are collectively referred to herein as the “Guarantees.”)

RECITALS

D-3

 

     Each Joining Party has Incurred Indebtedness or has guaranteed or secured Indebtedness of MGM,
and as such is required by the terms thereof to become a party to the Guarantees (capitalized terms
used by not defined herein having the meaning ascribed to such terms in the 9% Guarantee).

     NOW THEREFORE, each Joining Party jointly and severally agrees as follows:

AGREEMENT

     1. By this Joinder, each Joining Party becomes a party to each of the Guarantees as an
additional joint and several “Guarantor” or “Subsidiary Guarantor”, as the case may be. Each
Joining Party agrees that, upon its execution hereof, it will become a Guarantor or Subsidiary
Guarantor, as applicable, under each of the Guarantees and will be bound by all terms, conditions,
and duties applicable to a Guarantor or Subsidiary Guarantor, as applicable, under each of the
Guarantees.

     2. The effective date of this Joinder is                     .

     3. Notice of acceptance hereof is waived.

D-4

 

     IN WITNESS WHEREOF, each of the undersigned has executed this Joinder by its duly authorized
officer as of the date first written above.

	 	 	 	 	 
	 	“Joining Parties”

 	 
	 	By:  	 	 
	 	 	 
	 	By:  	
 	 
	 	 	 	 
	 	 	 	 
	 

D-5

 

EXHIBIT I

FORM OF TRANSFERABILITY CERTIFICATE

MGM MIRAGE

Officer’s Certificate

     I, the undersigned executive officer of MGM MIRAGE, a Delaware corporation (the “Company”), do
hereby certify, in connection with the sale of the Company’s 9% Senior Secured Notes due 2020 (the
“Notes”) pursuant to the terms of the Indenture, dated as of March 16, 2010 (as may be amended or
supplemented from time to time, the “Indenture”), by and among the Company, the Subsidiary
Guarantors party thereto and U.S. Bank National Association (the “Trustee”), that:

     1. The undersigned is permitted to sign this “Officer’s Certificate” on behalf of the
Company, as the term “Officer’s Certificate” is defined in the Indenture.

     2. The undersigned has read, and thoroughly examined, the Indenture and the definitions
therein relating thereto.

     3. In the opinion of the undersigned, the undersigned has made such examination as is
necessary to enable the undersigned to express an informed opinion as to whether or not all
conditions precedent described herein as provided for in the Indenture have been complied
with.

     4. To the best knowledge of the undersigned, all conditions precedent described herein
as provided for in the Indenture have been complied with and no Event of Default (as defined
in the Indenture) with respect to any of the Notes (as defined in the Indenture) shall have
occurred and is occurring.

     5. The Notes have become freely tradable without restrictions by non-affiliates of the
Company pursuant to Rule 144(b)(1) under the Securities Act of 1933, as amended.

     In accordance with Section 2.06 of the Indenture, the Company hereby instructs you as follows:

     1. To take those actions necessary so that the Private Placement Legend described in
Section 2.06 of the Indenture and set forth on the Global Notes shall be deemed removed from
the Global Notes in accordance with the terms and conditions of the Notes and as provided in
the Indenture, without further action on the part of the Holders.

     2. To take those actions necessary so that the restricted CUSIP for the Notes shall be
deemed removed from the Global Notes and replaced with the unrestricted CUSIP number set
forth therein, in accordance with the terms and conditions of the Global Notes and as
provided in the Indenture, without further action on the part of the Holders.

[signature page follows]

I-1

 

     IN WITNESS WHEREOF, we have signed this certificate as of [                    ], 2010.

	 	 	 	 	 
	 	MGM MIRAGE,

a Delaware corporation

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

I-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}]]